{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "bhWV8oes-wKR"
   },
   "source": [
    "# Step 1:\n",
    "---\n",
    "Download the necessary packages:\n",
    "either by running the code on your jupyter notebook:\n",
    "\n",
    "import sys\n",
    "!{sys.executable} -m pip install numpy langchain langchain-huggingface langchain-community pypdf transformers safetensors sentence-transformers datasets faiss-cpu\n",
    "\n",
    "or copy paste the following into your terminal:\n",
    "\n",
    "pip install numpy langchain langchain-huggingface langchain-community pypdf transformers safetensors sentence-transformers datasets faiss-cpu"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 2:\n",
    "Import necessary libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import numpy as np\n",
    "from langchain_community.embeddings import HuggingFaceBgeEmbeddings\n",
    "from langchain_community.llms import HuggingFaceHub\n",
    "from langchain_community.llms import HuggingFacePipeline\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "from langchain_community.document_loaders import PyPDFDirectoryLoader\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_community.vectorstores import FAISS\n",
    "from langchain.chains import RetrievalQA\n",
    "from langchain.prompts import PromptTemplate\n",
    "from huggingface_hub import hf_hub_download\n",
    "from urllib.request import urlretrieve"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 3:\n",
    "\n",
    "Choose a relevant topic, collect pdf's from the internet."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Download relevant documents\n",
    "os.makedirs(\"monkeypox\", exist_ok=True)\n",
    "files = [\n",
    "    \"https://www.binasss.sa.cr/mono/8.pdf\",\n",
    "    \"https://www.cfsph.iastate.edu/FastFacts/pdfs/monkeypox_F.pdf\",\n",
    "    \"https://www.europeanreview.org/wp/wp-content/uploads/5983-5990.pdf\",\n",
    "    \"https://centerforhealthsecurity.org/sites/default/files/2023-02/monkeypox.pdf\",\n",
    "    \"https://www.ecdc.europa.eu/sites/default/files/documents/mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf\",\n",
    "    \"https://www.ecdc.europa.eu/sites/default/files/documents/Monkeypox-multi-country-outbreak.pdf\",\n",
    "    \"https://www.nicd.ac.za/wp-content/uploads/2022/06/IPC-SOP-For-monkeypox-management.pdf\",\n",
    "    \"https://covid19.cdc.gov.sa/wp-content/uploads/2023/06/Monkeypox-Guidelines-01-June-2023-V1.4.pdf\",\n",
    "    \"https://www.cfsph.iastate.edu/Factsheets/pdfs/monkeypox.pdf\",\n",
    "    \"https://www.health.ny.gov/diseases/communicable/zoonoses/mpox/docs/mpv_college_q_and_a.pdf\"]\n",
    "for url in files:\n",
    "    file_path = os.path.join(\"monkeypox\", url.rpartition(\"/\")[2])\n",
    "    urlretrieve(url, file_path)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 4:\n",
    "Split the document into manageable chunks\n",
    "\n",
    "chunk_size = 700: Each chunk of text will have a maximum size of 700 characters.\n",
    "\n",
    "chunk_overlap = 50: This ensures that there will be a 50-character overlap between consecutive chunks to prevent loss of context between chunks."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "id": "YeuAheYyhdZw"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Ignoring wrong pointing object 8 0 (offset 0)\n",
      "Ignoring wrong pointing object 10 0 (offset 0)\n",
      "Ignoring wrong pointing object 12 0 (offset 0)\n",
      "Ignoring wrong pointing object 14 0 (offset 0)\n",
      "Ignoring wrong pointing object 16 0 (offset 0)\n",
      "Ignoring wrong pointing object 30 0 (offset 0)\n",
      "Ignoring wrong pointing object 61 0 (offset 0)\n",
      "Ignoring wrong pointing object 63 0 (offset 0)\n",
      "Ignoring wrong pointing object 65 0 (offset 0)\n",
      "Ignoring wrong pointing object 7 0 (offset 0)\n",
      "Ignoring wrong pointing object 10 0 (offset 0)\n",
      "Ignoring wrong pointing object 12 0 (offset 0)\n",
      "Ignoring wrong pointing object 14 0 (offset 0)\n",
      "Ignoring wrong pointing object 16 0 (offset 0)\n",
      "Ignoring wrong pointing object 18 0 (offset 0)\n",
      "Ignoring wrong pointing object 20 0 (offset 0)\n",
      "Ignoring wrong pointing object 28 0 (offset 0)\n",
      "Ignoring wrong pointing object 30 0 (offset 0)\n",
      "Ignoring wrong pointing object 32 0 (offset 0)\n",
      "Ignoring wrong pointing object 34 0 (offset 0)\n",
      "Ignoring wrong pointing object 39 0 (offset 0)\n",
      "Ignoring wrong pointing object 41 0 (offset 0)\n",
      "Ignoring wrong pointing object 43 0 (offset 0)\n",
      "Ignoring wrong pointing object 48 0 (offset 0)\n",
      "Ignoring wrong pointing object 56 0 (offset 0)\n",
      "Ignoring wrong pointing object 59 0 (offset 0)\n",
      "Ignoring wrong pointing object 65 0 (offset 0)\n",
      "Ignoring wrong pointing object 67 0 (offset 0)\n",
      "Ignoring wrong pointing object 69 0 (offset 0)\n",
      "Ignoring wrong pointing object 71 0 (offset 0)\n",
      "Ignoring wrong pointing object 83 0 (offset 0)\n",
      "Ignoring wrong pointing object 103 0 (offset 0)\n",
      "Ignoring wrong pointing object 105 0 (offset 0)\n",
      "Ignoring wrong pointing object 125 0 (offset 0)\n",
      "Ignoring wrong pointing object 127 0 (offset 0)\n",
      "Ignoring wrong pointing object 129 0 (offset 0)\n",
      "Ignoring wrong pointing object 131 0 (offset 0)\n",
      "Ignoring wrong pointing object 133 0 (offset 0)\n",
      "Ignoring wrong pointing object 135 0 (offset 0)\n",
      "Ignoring wrong pointing object 140 0 (offset 0)\n",
      "Ignoring wrong pointing object 142 0 (offset 0)\n",
      "Ignoring wrong pointing object 145 0 (offset 0)\n",
      "Ignoring wrong pointing object 147 0 (offset 0)\n",
      "Ignoring wrong pointing object 149 0 (offset 0)\n",
      "Ignoring wrong pointing object 151 0 (offset 0)\n",
      "Ignoring wrong pointing object 153 0 (offset 0)\n",
      "Ignoring wrong pointing object 155 0 (offset 0)\n",
      "Ignoring wrong pointing object 163 0 (offset 0)\n",
      "Ignoring wrong pointing object 169 0 (offset 0)\n",
      "Ignoring wrong pointing object 172 0 (offset 0)\n",
      "Ignoring wrong pointing object 174 0 (offset 0)\n",
      "Ignoring wrong pointing object 179 0 (offset 0)\n",
      "Ignoring wrong pointing object 181 0 (offset 0)\n",
      "Ignoring wrong pointing object 186 0 (offset 0)\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 0}, page_content='5983Abstract.  – OBJECTIVE: Recently monkeypox \\ncases have been reported from many non-en -\\ndemic countries. The objective of this article is \\nto bring out the epidemiology, mode of trans -\\nmission, clinical features, genetic clades, and \\nmolecular properties of monkeypox virus. \\nMATERIALS AND METHODS: A detailed liter -\\nature review was conducted on monkeypox, us -\\ning databases PubMed/Medline, EMBASE, PMC \\nand Cochrane Library, for the period between \\n1985 to 2022.    \\nRESULTS: Genetically monkeypox virus can \\nbe classified into Central African clade and \\nWestern African clades. The sequence simi -\\nlarity between the two strains was found to \\nbe 99.5%. However, some significant differenc -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 0}, page_content='be 99.5%. However, some significant differenc -\\nes were found in the virulent and nonvirulent \\ngenes of the strains, such as BR-203, BR-209, \\nCOP-C3L b and COP-H5R, COP-A9L, COP-A50R, \\nand COP-A36R, respectively. Human to human \\ntransmission occurs after exposure to respi -\\nratory droplets, oral secretions, contact with \\nlesions, fomites, and direct/sexual contact. \\nMonkeypox can also be transmitted from the \\ninfected mother to the fetus through the placen -\\nta leading to congenital infection. In May 2022 \\nseveral cases have been reported from Europe, \\nNorth America, and Australia, particularly from \\nhomosexual men.     \\nCONCLUSIONS: Monkeypox is a zoonotic dis -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 0}, page_content='CONCLUSIONS: Monkeypox is a zoonotic dis -\\nease which was prevalent in Central and West -\\nern African countries. Recently, human to hu -\\nman spread was noticed in developed countries \\nof Europe, North America and Australia. Despite \\nwith a close genetic similarity between the two \\nclades, the Central African strain is compara -\\ntively very virulent with high mortality. Monkey -\\npox should be considered a re-emerging, ne -\\nglected disease and proper measures like hand \\nhygiene, wearing masks and vaccination to the \\nhigh-risk groups are advised.  \\nKey Words:\\nMonkeypox, Epidemiology, Mode of transmission, \\nClinical features, Molecular properties, Virulence.Introduction'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 0}, page_content='The family Poxviridae consists of poxviruses \\nthat are complex and largest viruses affecting hu-\\nmans and animals1. Poxviruses includes variola, \\nvaccinia, buffalopox, cowpox, pseudo cowpox, \\norf, bovine popular stomatitis, tana pox, yabapox, \\nmonkeypox and molluscum contagiosum. Mon -\\nkeypox virus is subclassified under Orthopox \\nvirus genus2. The morphology of all pox viruses \\nresembles each other and possess similar nucleo -\\nprotein antigen.  Infections due to these viruses \\nare indicated by rash which is often proliferative. \\nMonkeypox is a zoonotic disease transmitted \\nto humans from primates and a variety of rodents, \\nupon direct contact. The route of entry of this'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 0}, page_content='upon direct contact. The route of entry of this \\nvirus is through cut/abrasion or mucous mem -\\nbranes. Several monkeypox outbreaks have been \\nreported through human-to-human transmission3. \\nRecent reports4 suggest that monkeypox can also \\nbe transmitted through sexual route. The clinical \\nsigns and symptoms of monkeypox resembles like \\nthat of smallpox caused by variola. But the sever -\\nity of monkeypox is mild compared to smallpox. \\nMonkeypox cases are rare and occurs usually in \\ncountries of Western and Central Africa5.  \\nMonkeypox virion consists of complex symme -\\ntry, 400 nm x 250 nm size, brick shaped with outer \\nirregular ridges, lateral bodies and a core with dou-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 0}, page_content='ble stranded (ds) DNA as genetic material (Figure \\n1)6. Monkeypox virus comprises of two prominent \\ngenetic clans depending upon its geographical dis -\\ntribution. The one distributed in Congo and adja -\\ncent countries are called the Central African clan. \\nThe other prominent in Nigeria and neighboring \\ncountries are denoted as West African clan. It was \\nobserved that Central African clan is associated \\nwith aggressive disease with high transmissibility. \\nSurprisingly in Cameroon both clades of monkey -\\npox cases have been documented7.  European Rev iew for Med ical and Pharmacol ogical Sci ences 2022; 26: 5983-5990\\nS. KANNAN, P. SHAIK SYED ALI, A. SHEEZA'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 0}, page_content='S. KANNAN, P. SHAIK SYED ALI, A. SHEEZA\\nSchool of Medicine, The Maldives National University, Male’, Maldives\\nS. Kannan and P. Shaik Syed Ali equally contributed as first authors\\nCorresponding Author: Kannan Subbaram, MSc., Ph.D; e-mail: Kannan.subbaram@mnu.edu.mvMonkeypox: epidemiology, mode \\nof transmission, clinical features, \\ngenetic clades and molecular properties'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 1}, page_content='S. Kannan, P. Shaik Syed Ali, A. Sheeza5984Materials and Methods  \\nThe detailed literature review was conducted \\non monkeypox, using databases PubMed/Med -\\nline, EMBASE, PMC, Cochrane Library and Up -\\nToDate. The search was conducted on the relevant \\naspects of monkeypox. The inclusion criteria for \\nthis review were: (a) articles written in English; \\n(b) articles published in the period 1980 to 2022. \\nArticles were excluded based on the following \\ncriteria: (a) articles with insufficient data; (b) out -\\ndated and obsolete data; (c) studies prior to 1980. \\nFurther information was also obtained from gray \\nliterature.\\nResults \\nEpidemiology and Mode of Transmission'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 1}, page_content='Results \\nEpidemiology and Mode of Transmission \\nMonkeypox virus can infect a variety of wild \\nanimals and domestic animals. Some of the nat -\\nural hosts include primates, dormice, wild squir -\\nrels, African pouched rodents and mongoose8. \\nThe exact and ideal natural reservoir for mon -\\nkeypox is not discovered yet. Smallpox caused by \\nvariola major and variola minor have been eradi -\\ncated by successful vaccination. \\nMonkeypox remains endemic in the forests \\nof Central and Western Africa. Human cases of \\nmonkeypox were reported in USA in 20039. Be-fore 2003, the cases of monkeypox were restricted \\nto Central and Western Africa. During the 1970s,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 1}, page_content='to Central and Western Africa. During the 1970s, \\nbetween 1970-1979, a total of 48 confirmed cases \\noccurred in the African subcontinent. Most num -\\nber of cases occurred in Democratic Republic of \\nCongo with at least 38 cases, 3 cases in Nigeria \\nand 1 case each in Cameroon, Côte d’Ivoire and \\nLiberia10. In the 1980s, between 1980-1989, 343 \\ncases occurred in Democratic Republic of Con -\\ngo that was a nine-fold increase compared to the \\nprevious decade11. Additionally, 8 cases reported \\nfrom Central African Republic, 4 in Gabon and \\n1 in Cameroon and Côte d’Ivoire12. In the 1990s, \\nbetween 1990-1999, 511 cases were detected in \\nDemocratic Republic of Congo that was 1.5 times'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 1}, page_content='Democratic Republic of Congo that was 1.5 times \\nhigher than the 1980s decade. Between 2000-\\n2009, the monkeypox occurrence cases were al -\\nmost 10,027 in Democratic Republic of Congo, 73 \\nin Congo, 19 in South Sudan and 47 in USA13. \\nThe sudden jump of cases from African sub -\\ncontinent to USA occurred in the year 2003. \\nNearly, 71 cases occurred in the Midwestern \\nstates of USA including Wisconsin (39), Indiana \\n(16), Illinois (12), Kansas (1), Missouri (2), and \\nOhio (1) between May - July 200314.  The source \\nof infection was prairie dogs that were housed \\nwith Gambian rodents imported from Ghana \\ninto USA. However, no mortality was reported'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 1}, page_content='into USA. However, no mortality was reported \\nin USA. Horizontal transmission was reported in \\nAfrica but not in USA. All the monkeypox cas -\\nFigure 1.  Electron micrograph of monkeypox virus – courtesy CDC.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='Monkeypox5985es reported in USA Midwest were the result of \\ndirect contact with prairie dogs4. Between 2010-\\n2019, the monkeypox cases were as follows, Dem -\\nocratic Republic of Congo (18,788), Nigeria (181), \\nCentral African Republic (61), Congo (24), Libe -\\nria (6), Sierra Leone (2), Israel (1), Singapore (1)15.  \\nAt least 3 cases were reported in UK in the year \\n2017. This was the first ever case in UK/European \\nUnion (EU). The first two cases were imported \\nfrom Nigeria as they travelled to Nigeria during \\nmonkeypox outbreak in Nigeria in 2017. The third \\ncase, health care assistant, occurred due to hori -\\nzontal transmission from the patient16.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='zontal transmission from the patient16. \\nIn Congo, first human case of monkeypox was \\ndiscovered in 1970. This was identified in a young \\nmale patient with smallpox symptoms in Congo \\nwhere smallpox was eradicated. Later many cases \\nhave been frequently reported in Congo and other \\ncountries of Western and Central Africa. Initially, \\nmonkeypox cases in human have been document -\\ned from the Republic of Congo, the Democratic \\nRepublic of Congo (DRC), Central African Re -\\npublic, Liberia, Benin, Cameroon, Gabon, Cote \\nd’Ivoire, Nigeria, Sierra Leone and Sudan. The \\ndisease burden of monkeypox virus is not yet \\nidentified. More human cases of monkeypox have'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='identified. More human cases of monkeypox have \\nbeen documented in DRC until 199717. Later in \\nNigeria hundreds of cases have been recorded \\nfrom 2017 until today with moderate to severe \\ncomplications. The case fatality ratio observed in \\nNigeria outbreak was 3%18. \\nHuman to human transfer of monkeypox vi -\\nrus can arise after very close/intimate contact, \\noral/respiratory secretions, droplets, skin lesions \\nor through contaminated fomites. Surprising -\\nly, it was observed that congenital transmission \\nthrough placenta from infected mother to the fe -\\ntus was documented. This is called ‘congenital \\nmonkeypox’ suggesting that monkeypox virus'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='monkeypox’ suggesting that monkeypox virus \\ncan surpass placental barrier. This may result in \\nthe developmental anomaly of the fetus19. \\nIn 2018 in Israel, travelers from Nigeria have \\nbeen infected with monkeypox virus20. Nigerian \\ntravelers to the UK in 2018, 2019, 2021 and May \\n2022 were affected by monkeypox virus. Passen -\\ngers from Nigeria in the year 2019 carried this vi -\\nrus to Singapore. Nigerian travelers also harbored \\nmonkeypox virus when they landed in USA in the \\nyear 202121. \\nRecently, in May 2022, several cases of mon -\\nkeypox have been registered in non-endemic \\ncountries such as, Portugal (14), Spain (7), Can -\\nada (2), Belgium (2), Italy (1), France (1), UK (9),'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='USA (1) and Australia (1). In these countries it was noticed that the infected patients were homo -\\nsexual men. Surprisingly these patients have no \\nrecent travel history to Central or Western Afri -\\ncan countries. All these patients were isolated and \\nquarantined and the May outbreak did not end \\nup in any deaths so far (Epidemiological update: \\nMonkeypox outbreak - ECDC). \\nGenetic Clades and Molecular Properties \\nof Monkeypox Virus\\nAmong the two clades of monkeypox, Central \\nAfrican clade is relatively more pathogenic than \\nthe Western African clade. A high fatality rate \\nwas associated with Central African clade with \\nlittle to no fatality in Western African clade. An -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='imal experiments with monkeys showed that the \\nanimals died when challenged with high doses \\nof Central African clade strains, whereas those \\nanimals when challenged with Western African \\nclade strains survived14. \\nCentral African strain and Western African \\nstrain showed 99.5% nucleotide sequence simi -\\nlarity and 99.4% amino acid (aa) sequence sim -\\nilarity between them. Nearly, 56 virulent genes \\nwere discovered with 53 genes present in the \\nstrains16. Comparison of genomes showed signifi -\\ncant differences between the Central African and \\nWestern African strains22. Some significant dif -\\nferences were found between the two strains in \\nthe orthologs of BR-203, BR-209, and COP-C3L'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='the orthologs of BR-203, BR-209, and COP-C3L \\nb16. BR-203 encodes a 221 aa virulence protein in \\nthe Central African strain and in Western Afri -\\ncan strain as a N-terminal 51 aa protein23. It is \\npresumed to play a role to prevent apoptosis of in -\\nfected lymphocytes24. BR-209 encodes the IL-1β-\\nbinding protein. In Central African strain BR-209 \\nencodes the two fragments of N-terminal protein \\nfragment of 210 aa and a C-terminal protein frag -\\nment of 126 aa. In Western African strain it en -\\ncodes a N-terminal 163 aa fragment and a C-ter -\\nminal 132 aa fragment. An independent study25 \\nrevealed the presence of 326 aa full-length protein \\nin Central African strain. Interleukin-1β (IL-1β)'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 2}, page_content='binding protein prevents the IL-1β from binding \\nto the IL-1 receptor. \\nCOP-C3L encodes the complement control \\nprotein. The monkeypox inhibitor of comple -\\nment enzymes (MOPICE) is not expressed by \\nviruses of the West African strains but only by \\nCentral African strains. It is encoded as a 216 aa \\nprotein. It was presumed that in Central African \\nclade, the MOPICE might be the virulence fac -\\ntor responsible for increased pathogenicity. With \\nMOPICE gene knockout the viral replication was'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 3}, page_content='S. Kannan, P. Shaik Syed Ali, A. Sheeza5986enhanced, and the adaptive immune response was \\ndampened. However, this is not the sole virulence \\nfactor responsible for pathogenesis26. The pres -\\nence of MOPICE, full length protein or a longer \\nversion of N-terminal IL-1β-binding protein and \\na longer version of N-terminal virulence protein \\nmight be responsible for enhanced pathogenesis \\nof Central African strain. Some additional differ -\\nences were found between the Western African \\nand Central African strains nonvirulent genes \\nthat influence the replication and transcription of \\nmonkeypox virus. The difference in sequence of \\ngenes were found in COP-H5R (late transcription'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 3}, page_content='genes were found in COP-H5R (late transcription \\nfactor), COP-A9L (morphogenesis factor), COP-\\nA50R (DNA ligase), and COP-A36R (role in actin \\ntail formation)15. \\nClinical Features of Monkeypox\\nThe signs and symptoms of monkeypox re -\\nsembles to an altered type of variola (smallpox) \\n(Figure 2). Cropping rash caused by monkeypox \\nvirus is similar to varicella (chickenpox), this may \\nhinder the clinical diagnosis of monkeypox pa -\\ntients (Figure 3)2. \\nThe incubation period of monkeypox virus \\nis approximately 2-3 weeks. The monkeypox in -\\nfection can be divided into two phases, the inva -\\nsion period and the skin eruption phase. Invasion'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 3}, page_content='phase is the first phase that starts in the first week \\nwith lymphadenopathy, fever, arthralgia, myal -\\ngia, and severe asthenia. In smallpox, measles \\nand chickenpox lymphadenopathy is absent. The \\nskin eruption phase starts after fever with rashes \\nfound more on face and extremities and mildly \\non the trunk. In most of the cases, face is affect -ed followed by soles, palms, oral cavity, genitals, \\ncornea and conjunctiva. The rash of monkeypox \\nemerge sequentially from macules to papules, ves -\\nicles, pustules and crusts. Single patient infected \\nby monkeypox virus may have several thousands \\nof lesions in the body (Figure 4). Normally, mon -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 3}, page_content='keypox infection will resolve on its own within \\n3-4 weeks (Figure 5). Most commonly children \\nare prone to acquire the infection. Underlying \\ndisease and immune status may determine the se -\\nverity and mortality of monkeypox13. In many pa -\\ntients infected with monkeypox virus may elicit \\nsevere and fatal complications. It may range from \\nserious lung infection (after secondary bacterial \\ninvasion) to CNS complications. Infection can \\nlead to sepsis, pneumonia and loss of vision due to \\ncorneal scarring. It can also spread to other vital \\norgans in the body leading to death. The clinical \\nsigns, disease course and complications observed'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 3}, page_content='signs, disease course and complications observed \\nin the year 1970 and later decades is similar to the \\nrecent monkeypox outbreak in 202214. This may \\nbe attributed to its stable nature of viral DNA ge -\\nnome that do not easily undergo significant muta -\\ntions over a period of time, unlike RNA viruses27. \\nDiscussion\\nThe difference observed between the old mon -\\nkeypox cases and the recent monkeypox mainly \\nlie in the mode of acquisition, all other aspects \\nremain the same. Recent monkeypox cases out -\\nbreak in Europe included sexual transmission too \\napart from other modes of transmission. Monkey -\\npox cases were observed predominantly in homo -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 3}, page_content='pox cases were observed predominantly in homo -\\nFigure 2.  African child with lesions of monkeypox – courtesy CDC.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 4}, page_content='Monkeypox5987sexual and bisexual men due to the appearance \\nof lesions in the genital and anal areas and the \\nvirus ability to transmit through intimate close \\ncontact14,28,29. \\nSince the nucleoprotein of vaccinia virus is an -\\ntigenically similar to smallpox and monkeypox, \\nvaccination against vaccinia can protect mon -\\nkeypox. It is calculated that the mortality rate of \\nmonkeypox in non-vaccinated individuals may \\ngo beyond 10%. Recent research established that \\nvaccination with vaccinia also reduces the sever -\\nity of monkeypox. But vaccination with vaccin -\\nia to prevent smallpox was already discontinued \\nthroughout the world after its eradication. This is'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 4}, page_content='the main reason that led to the surge and emer -\\ngence of human monkeypox cases in African and \\nnon-endemic countries14.   In the early times, the monkeypox diagnosis \\nwas conducted mainly by physical examination, \\nclinical signs and symptoms. Nowadays modern \\ntechniques like polymerase chain reaction (PCR), \\nreal time polymerase chain reaction (RT-PCR), \\nImmunofluorescent technique (IFT), cell culture \\nand electron microscopy with negative staining \\nare employed9.    \\nConclusions\\nMonkeypox is a zoonotic disease which was \\nprevalent in Central and Western African coun -\\ntries spread to developed countries of Europe, \\nNorth America and Australia in the last two de -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 4}, page_content='North America and Australia in the last two de -\\ncades. Monkeypox is similar to smallpox on ba -\\nFigure 3.  Scabs of monkeypox on the palms – courtesy CDC.\\nFigure 4.  Different stages of lesions of monkeypox – courtesy CDC.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 5}, page_content='S. Kannan, P. Shaik Syed Ali, A. Sheeza5988sis of genetics and antigens, so vaccination with \\nvaccinia can prevent monkeypox or reduce the \\nseverity of the disease. Monkeypox can cause se -\\nvere life-threatening disease. The mode of trans -\\nmission is by various ways such as from animals, \\ndirect/sexual contact, respiratory secretions or \\nthrough the active lesions. Despite with 99.5% ge -\\nnetic similarity between the Western African and \\nCentral African strains, the Central African strain \\nis comparatively very virulent with high mortali -\\nty.  To conclude monkeypox should be considered \\nas a remerging disease. It is necessary to prevent \\nthis disease by vaccination using vaccinia. Precau-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 5}, page_content='tionary measures like hand hygiene and the use of \\nmask are very vital to prevent the spread.\\nConflict of Interest\\nThe authors declare that there is no conflict of interest.\\nAcknowledgements\\nThe authors acknowledge the School of Medicine, The \\nMaldives National University academic staffs for their help \\nin proof reading and grammar correction. \\nInformed Consent\\nEthical guidelines are duly followed for informed consent \\nas per the declaration of Helsinki.Authors’ Contributions\\nKannan Subbaram conceptualized to the development of \\nthe article.  Shaik Syed Ali. P involved in the preparation \\nof the article. Sheeza Ali contributed to data analysis, in -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 5}, page_content='terpretation and preparation of the manuscript. \\nFunding\\nNone.\\nORCID ID\\nKannan Subbaram: 0000-0001-8547-0957\\nShaik Syed Ali. P: 0000-0002-5764-665X\\nSheeza Ali: 0000-0002-0248-6628\\nReferences\\n  1) Sklenovská N, Van Ranst M. Emergence of Mon -\\nkeypox as the Most Important Orthopoxvirus In -\\nfection in Humans. Front Public Health 2018; 6: \\n241. \\n  2) Wilson ME, Hughes JM, McCollum AM, Damon \\nIK. Human monkeypox. Clin Infect Dis 2014; 58: \\n260-267. \\n  3) Tumewu J, Wardiana M, Ervianty E, Sawitri, Rah -\\nmadewi, Astindari, Anggraeni S, Widia Y, Amin \\nM, Oktaviani Sulichah SR, Kuntaman K, Junias -\\ntuti, Lusida MI. An adult patient with suspected \\nof monkeypox infection differential diagnosed to'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 5}, page_content='of monkeypox infection differential diagnosed to \\nchickenpox. Infect Dis Rep 2020; 12: 8724. \\nFigure 5.  Monkeypox patient showing resolving lesions on the dorsal surfaces of the hands – courtesy PHIL-CDC.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='Monkeypox5989  4) Whitehouse ER, Bonwitt J, Hughes CM, Lushima \\nRS, Likafi T, Nguete B, Kabamba J, Monroe B, Doty \\nJB, Nakazawa Y, Damon I, Malekani J, Davidson \\nW, Wilkins K, Li Y, Radford KW, Schmid DS, Pukuta \\nE, Muyamuna E, Karhemere S, Tamfum JJM, Oki -\\ntolonda EW, McCollum AM, Reynolds MG. Clinical \\nand Epidemiological Findings from Enhanced Mon -\\nkeypox Surveillance in Tshuapa Province, Demo -\\ncratic Republic of the Congo during 2011-2015. J \\nInfect Dis 2021; 223: 1870-1878. \\n  5) Alakunle E, Moens U, Nchinda G, Okeke MI. \\nMonkeypox virus in nigeria: Infection biology, \\nepidemiology, and evolution. Viruses 2020; 12: \\n1257. \\n  6) Petersen E, Abubakar I, Ihekweazu C, Heymann'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='D, Ntoumi F, Blumberg L, Asogun D, Mukonka \\nV, Lule SA, Bates M, Honeyborne I, Mfinanga \\nS, Mwaba P, Dar O, Vairo F, Mukhtar M, Kock \\nR, McHugh T, Ippolito G, Zumla A. Monkeypox \\n— Enhancing public health preparedness for an \\nemerging lethal human zoonotic epidemic threat \\nin the wake of the smallpox post-eradication era. \\nInt J Infect Dis 2019; 78: 78-84. \\n  7) Harapan H, Setiawan AM, Yufika A, Anwar S, \\nWahyuni S, Asrizal FW, Sufri MR, Putra RP, Wi -\\njayanti NP, Salwiyadi S, Maulana R, Khusna A, \\nNusrina I, Shidiq M, Fitriani D, Muharrir M, Husna \\nCA, Yusri F, Maulana R, Utomo PS, Andalas M, \\nWagner AL, Mudatsir M. Confidence in managing \\nhuman monkeypox cases in Asia: A cross-sec -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='human monkeypox cases in Asia: A cross-sec -\\ntional survey among general practitioners in In -\\ndonesia. Acta Trop 2020; 206: 105450. \\n  8) Petersen BW, Kabamba J, McCollum AM, Lushima \\nRS, Wemakoy EO, Muyembe Tamfum JJ, Nguete B, \\nHughes CM, Monroe BP, Reynolds MG. Vaccinating \\nagainst monkeypox in the Democratic Republic of \\nthe Congo. Antiviral Res 2019; 162: 171-177. \\n  9) Petersen E, Kantele A, Koopmans M, Asogun \\nD, Yinka-Ogunleye A, Ihekweazu C, Zumla A. \\nHuman Monkeypox: Epidemiologic and Clinical \\nCharacteristics, Diagnosis, and Prevention. Infect \\nDis Clin North Am 2019; 33: 1027-1043. \\n 10) Brown K, Leggat PA. Human monkeypox: Current'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='state of knowledge and implications for the future. \\nTrop Med Infect Dis 2016; 1: 8. \\n 11) Reynolds MG, Doty JB, McCollum AM, Olson \\nVA, Nakazawa Y. Monkeypox re-emergence in \\nAfrica: a call to expand the concept and practice \\nof One Health. Expert Rev Anti Infect Ther 2019; \\n17: 129-139. \\n 12) Simpson K, Heymann D, Brown CS, Edmunds \\nWJ, Elsgaard J, Fine P, Hochrein H, Hoff NA, \\nGreen A, Ihekweazu C, Jones TC, Lule S, Ma -\\nclennan J, McCollum A, Mühlemann B, Night -\\ningale E, Ogoina D, Ogunleye A, Petersen B, \\nPowell J, Quantick O, Rimoin AW, Ulaeato D, \\nWapling A. Human monkeypox – After 40 years, \\nan unintended consequence of smallpox eradica -\\ntion. Vaccine 2020; 38: 5077-5081.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='tion. Vaccine 2020; 38: 5077-5081. \\n 13) Nakazawa Y, Mauldin MR, Emerson GL, Reynolds \\nMG, Lash RR, Gao J, Zhao H, Li Y, Muyembe JJ, \\nKingebeni PM, Wemakoy O, Malekani J, Karem \\nKL, Damon IK, Carroll DS. A phylogeographic \\ninvestigation of African monkeypox. Viruses 2015; \\n7: 2168-2184.  14) Bunge EM, Hoet B, Chen L, Lienert F, Weiden -\\nthaler H, Baer LR, Steffen R. The changing \\nepidemiology of human monkeypox—A potential \\nthreat? A systematic review. PLoS Negl Trop Dis \\n2022; 16: e0010141. \\n 15) Peter OJ, Kumar S, Kumari N, Oguntolu FA, \\nOshinubi K, Musa R. Transmission dynamics \\nof Monkeypox virus: a mathematical modelling \\napproach. Model Earth Syst Environ 2021; \\n1-12.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='approach. Model Earth Syst Environ 2021; \\n1-12. \\n 16) Hobson G, Adamson J, Adler H, Firth R, Gould \\nS, Houlihan C, Johnson C, Porter D, Rampling T, \\nRatcliffe L, Russell K, Shankar AG, Wingfield T. \\nFamily cluster of three cases of monkeypox im -\\nported from Nigeria to the United Kingdom, May \\n2021. Euro Surveill 2021; 26: 2100745. \\n 17) Levine RS, Peterson AT, Yorita KL, Carroll D, \\nDamon IK, Reynolds MG. Ecological niche and \\ngeographic distribution of human monkeypox in \\nAfrica. PLoS One 2007; 2: e176. \\n 18) Durski KN, McCollum AM, Nakazawa Y, Petersen \\nBW, Reynolds MG, Briand S, Harouna Djingarey \\nM, Olson V, Damon IK, Khalakdina A. Morbidity'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='M, Olson V, Damon IK, Khalakdina A. Morbidity \\nand Mortality Weekly Report Emergence of Mon -\\nkeypox — West and Central Africa, 1970-2017 \\nMonkeypox Cases in West Africa and Central \\nAfrica. MMWR Morb Mortal Wkly Rep 2018; 67: \\n306-310. \\n 19) Nalca A, Rimoin AW, Bavari S, Whitehouse CA. \\nReemergence of monkeypox: Prevalence, diag -\\nnostics, and countermeasures. Clin Infect Dis \\n2005; 41: 1765-1771. \\n 20) Yong SEF, Ng OT, Ho ZJM, Mak TM, Marimuthu \\nK, Vasoo S, Yeo TW, Ng YK, Cui L, Ferdous Z, \\nChia PY, Aw BJW, Manauis CM, Low CKK, Chan \\nG, Peh X, Lim PL, Chow LPA, Chan M, Lee VJM, \\nLin RTP, Heng MKD, Leo YS. Imported monkey-\\npox, Singapore. Emerg Infect Dis 2020; 26: 1826-\\n1830.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='1830. \\n 21) Vaughan A, Aarons E, Astbury J, Brooks T, \\nChand M, Flegg P, Hardman A, Harper N, Jarvis \\nR, Mawdsley S, McGivern M, Morgan D, Morris \\nG, Nixon G, O’Connor C, Palmer R, Phin N, Price \\nDA, Russell K, Said B, Schmid ML, Vivancos R, \\nWalsh A, Welfare W, Wilburn J, Dunning J. Hu -\\nman-to-human transmission of monkeypox virus, \\nUnited Kingdom, October 2018. Emerg Infect Dis \\n2020; 26: 782-785.\\n 22) Ye F, Song J, Zhao L, Zhang Y, Xia L, Zhu L, Ka -\\nmara IL, Ren J, Wang W, Tian H, Wu G, Tan W. \\nMolecular evidence of human monkeypox virus \\ninfection, Sierra Leone. Emerg Infect Dis 2019; \\n25: 1220-1222. \\n 23) Sood A, Sui Y, McDonough E, Santamaría-Pang'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 6}, page_content='23) Sood A, Sui Y, McDonough E, Santamaría-Pang \\nA, Al-Kofahi Y, Pang Z, Jahrling PB, Kuhn JH, \\nGinty F. Comparison of multiplexed immunoflu -\\norescence imaging to chromogenic immunohis -\\ntochemistry of skin biomarkers in response to \\nmonkeypox virus infection. Viruses 2020; 12: 787.\\n 24) Wardiana M, Rahmadewi R, Murtiastutik D, Saw -\\nitri S, Damayanti D. Chickenpox Mimicking Mon -\\nkeypox in Adult with Diabetes Mellitus and Acute \\nKidney Injury: Diagnosis and Management. Ber -\\nkala Ilmu Kesehatan Kulit Dan Kelamin 2021; 33: \\n213-223.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 7}, page_content='S. Kannan, P. Shaik Syed Ali, A. Sheeza5990 25) Ihekweazu C, Yinka-Ogunleye A, Lule S, Ibrahim \\nA. Importance of epidemiological research of \\nmonkeypox: is incidence increasing? Expert Rev \\nAnti Infect Ther 2020; 18: 389-392. \\n 26) Cohen-Gihon I, Israeli O, Shifman O, Erez N, \\nMelamed S, Paran N, Beth-Din A, Zvi A. Iden -\\ntification and Whole-Genome Sequencing of a \\nMonkeypox Virus Strain Isolated in Israel. Micro -\\nbiol Resour Announc 2020; 9: e01524-19.\\n 27)  Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina \\nD, McCollum A, Disu Y, Mamadu I, Akinpelu A, \\nAhmad A, Burga J, Ndoreraho A, Nkunzimana E, \\nManneh L, Mohammed A, Adeoye O, Tom-Aba \\nD, Silenou B, Ipadeola O, Saleh M, Adeyemo A,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 7}, page_content='D, Silenou B, Ipadeola O, Saleh M, Adeyemo A, \\nNwadiutor I, Aworabhi N, Uke P, John D, Wakama \\nP, Reynolds M, Mauldin MR, Doty J, Wilkins K, Musa J, Khalakdina A, Adedeji A, Mba N, Ojo \\nO, Krause G, Ihekweazu C, Mandra A, Davidson \\nW, Olson V, Li Y, Radford K, Zhao H, Townsend \\nM, Burgado J, Satheshkumar PS. Outbreak of \\nhuman monkeypox in Nigeria in 2017–18: a clini -\\ncal and epidemiological report. Lancet Infect Dis \\n2019; 19: 872-879. \\n 28) Pal M, Mengstie F, Kandi V. Epidemiology, Di -\\nagnosis, and Control of Monkeypox Disease: A \\ncomprehensive Review. Am J Infect Dis Microbiol \\n2017; 5: 94-99.\\n 29) Silva NIO, de Oliveira JS, Kroon EG, Trindade G'),\n",
       " Document(metadata={'source': 'monkeypox\\\\5983-5990.pdf', 'page': 7}, page_content='de S, Drumond BP. Here, there, and everywhere: \\nThe wide host range and geographic distribution \\nof zoonotic orthopoxviruses. Viruses 2021; 13: \\n43.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 0}, page_content='Human Monkeypox\\nEpidemiologic and Clinical Characteristics,\\nDiagnosis, and Prevention\\nEskild Petersen, MD, DMSc, DTMHa,b,c,*, Anu Kantele, MD, PhDd,\\nMarion Koopmans, DVM, PhDe, Danny Asogun, MBBS, FWACPf,g,\\nAdesola Yinka-Ogunleye, BDS, MPHh,\\nChikwe Ihekweazu, MBBS, MPH, FFPHh,\\nAlimuddin Zumla, MBChB, MSc, PhD, MD, FRCP(Lond), FRCP(Edin), FRCPath(UK), FAASi\\nAll authors contributed equally.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 0}, page_content='All authors contributed equally.\\nA. Zumla, D. Asogun, and C. Ihekweazu are members of the PANDORA-ID-NET Consortium.PANDORA-ID-NET (EDCTP Reg/Grant RIA2016E-1609) is funded by the European and Devel-oping Countries Clinical Trials Partnership (EDCTP2) programme, which is supported under Ho-rizon 2020, the European Union’s Framework Programme for Research and Innovation. A.Zumla is in receipt of a National Institutes of Health Research senior investigator award.Conflicts of Interest: All authors have an interest in global public health and emerging and re-emerging infections. All authors have no other conflict of interest to declare.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 0}, page_content='aInstitute of Clinical Medicine, University of Aarhus, Palle Juul-Jensens Boulevard 82, Aarhus N\\nDK-8200, Denmark;bThe Royal Hospital, Muscat, Oman;cEuropean Society for Clinical\\nMicrobiology and Infectious Diseases, Task Force for Emerging Infections, Basel, Switzerland;\\ndInflammation Center, Helsinki University Hospital and Helsinki University, Stenba ¨ckinkatu 9,\\nPO BOX 100, Helsinki FI-00029 HUS, Finland;eViroscience Department, Erasmus Medical\\nCentre, Postbus 2040, Rotterdam 3000 CA, the Netherlands;fDepartment of Public Health,\\nCollege of Medicine, Ambrose Alli University, Ekpoma, Nigeria;gDepartment of Public Health,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 0}, page_content='and Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua,Nigeria;\\nhNigeria Centre for Disease Control, Plot 801, Ebitu Ukiwe Street, Jabi, Abuja, Nigeria;\\niDivision of Infection and Immunity, Center for Clinical Microbiology, University College\\nLondon, The National Institute of Health Research Biomedical Research Centre at UCL Hospi-tals, Gower Street, London WC1E 6BT, UK* Corresponding author. Directorate General for Communicable Disease Surveillance and Con-trol, Ministry of Health, 18th November Street, 101 Muscat, Sultanate of Oman.E-mail address: eskild.petersen@gmail.com\\nKEYWORDS\\n/C15Monkeypox /C15Smallpox /C15West Africa /C15Epidemic\\nKEY POINTS'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 0}, page_content='KEY POINTS\\n/C15Human monkeypox is a zoonosis caused by the monkeypox virus (MPXV), a double-\\nstranded DNA virus of the family Poxviridae.\\n/C15The frequency and geographic distribution of human monkeypox cases across West and\\nCentral Africa have increased in recent years.\\nContinued\\nInfect Dis Clin N Am 33 (2019) 1027–1043\\nhttps://doi.org/10.1016/j.idc.2019.03.001 id.theclinics.com\\n0891-5520/19/ ª2019 Elsevier Inc. All rights reserved.\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 0}, page_content='permiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 1}, page_content='INTRODUCTION\\nHuman monkeypox virus (MPXV) is a double-stranded DNA virus of the Orthopoxvirus\\ngenus of the family Poxviridae.1–4Two genetic clades of the monkeypox virus have\\nbeen characterized: West African and Central African. MPXV is one of the 4 orthopox-virus species pathogenic for humans, the other 3 being (1) variola major virus (VARV),\\nthe causative agent of smallpox, now eradicated, (2) variola minor virus, and (3) cow-\\npox virus (CPXV). There is a range of animal poxviruses, several of which have zoo-notic potential. Infections in humans have been described for vaccinia virus,\\ncowpox virus, buffalopox virus, and sporadic cases of camelpox.\\n5,6Monkeypox in-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 1}, page_content='5,6Monkeypox in-\\nfects a wide range of mammalian species, but its natural host reservoir remainsunknown.\\nPUBLIC HEALTH IMPORTANCE\\nThought to be a rare and self-limiting disease,7monkeypox has not attracted much\\nattention since its discovery 70 years ago. The frequency and geographic distributionof human monkeypox cases have increased in recent years in a specific region of Af-\\nrica ( Fig. 1 ),\\n8and monkeypox has been recognized as an increasing public health'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 1}, page_content='threat, particularly in regions in West Africa where there is close interaction betweenhumans and wild animal reservoirs and in particular where there is evidence that theinfection attack rate is increasing. The clinical presentation of monkeypox is similar\\nto that of smallpox\\n2in terms of symptom onset, timing of rash occurrence, and rash\\ndistribution,7but generally less severe than smallpox in terms of complication rate,\\ncase fatality rate, and levels of scarification.\\nRecently, concern has been raised about the emergence of MPXV as well as the\\nresemblance of its clinical presentation to that of smallpox, a deadly disease globallyeradicated by vaccination 40 years ago.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 1}, page_content='9During outbreaks, it has been challenging to\\nclinically distinguish monkeypox from chickenpox, an unrelated herpesvirus infection.\\nHowever, sporadic zoonotic infections with other orthopoxviruses also call for vigi-lance. Outbreaks of buffalopox have occurred with multiple human cases in India.\\n10\\nSimilarly, during outbreaks of vaccinia virus infection in cattle in Brazil, there is docu-mented evidence of human infections.\\n11\\nCross-Immunity and Protection\\nVarious orthopoxvirus species share genetic and antigenic features,12–14and an infec-\\ntion by any of these species may confer substantial protection against infection by the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 1}, page_content='others.15Vaccination with vaccinia virus protects against disease caused by VARV,\\nMPXV, or CPXV.16The immunologic mechanisms underlying cross-protection by im-\\nmunization with vaccinia virus seem to be diverse, with neutralizing antibodies among\\nthe principal components.17Consistent with the ability of smallpox vaccine to provideContinued\\n/C15The clinical presentation of monkeypox is similar to that of smallpox, in terms of symptom\\nonset, timing of rash occurrence, and rash distribution, but generally less severe thansmallpox with lower fatality rate and scarification.\\n/C15Most confirmed Monkeypox cases are younger than 40 years with a median age of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 1}, page_content='31 years, a population born only after discontinuation of the smallpox vaccinationcampaign, and thus may reflect a lack of cross-protective immunity.Petersen et al 1028\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 2}, page_content='cross-protection for humans against monkeypox, monkeys can be protected against\\nmonkeypox by immunization with the human smallpox vaccine.18,19\\nEver since smallpox vaccinations were discontinued in 1978, cross-protective im-\\nmunity to various orthopoxviruses has waned, particularly in younger individuals lack-\\ning vaccinia-induced immunity, and the number of unvaccinated, susceptibleindividuals has grown worldwide. Indeed, these changes have been accompanied\\nby an increased frequency and geographic distribution of human monkeypox cases\\nin recent years.\\nEPIDEMIOLOGY\\nDiscovery and Animal Reservoirs\\nMPXV was first detected in 1958 in an outbreak of a vesicular disease among'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 2}, page_content='captive monkeys transported to Copenhagen, Denmark from Africa for research\\npurposes. Hence the name “monkeypox.”20The term is inappropriate because\\nthe largest animal reservoirs of the virus have been found in rodents, includingsquirrels and giant pouched rats, both of which are hunted for food.\\n21Rodents\\nare the largest group of mammals with more than 1500 species. The extent of\\nthe wild animal reservoir, the natural history, and pathogenesis of monkeypox in\\nFig. 1. Map of Africa showing countries reporting human Monkeypox cases (1971–2019).Human Monkeypox 1029\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 2}, page_content='Social Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 3}, page_content='both animals and humans remains unknown, requiring characterization through\\necologic and epidemiologic studies. Thus far, MPXV has been detected in diverseanimal species: squirrels (rope and tree), rats, striped mice, dormice, and monkeys.\\nIn 1985, the virus was isolated from a rope squirrel in the Democratic Republic of\\nCongo (DRC) and a dead infant mangabey monkey in Tai National Park, Coted’Ivoire.\\n22During a large monkeypox outbreak following introduction of the virus\\nthrough animals imported into an animal trading company, at least 14 species of\\nrodents were found to be infected.23\\nLike humans, monkeys are considered disease hosts. Further studies are needed'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 3}, page_content='to understand how the virus persists in nature, and to explore pathogen-host asso-\\nciations and the effect of climatic and ecologic factors influencing the shifts be-tween geographic areas and the virus as a cause of disease in humans.\\n24\\nTransmission of Monkeypox Virus to Humans\\nNot only the specific animal host reservoir of monkeypox but also the mode of trans-mission of MPXV from animals to humans remain unknown. Aerosol transmission hasbeen demonstrated in animals,\\n25,26and may explain a nosocomial outbreak in the\\nCentral African Republic.27However, indirect or direct contact with live or dead ani-\\nmals is assumed to be the driver of human monkeypox infections in humans.28,29'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 3}, page_content='Poverty and continued civil unrest force people to hunt small mammals (bushmeat)\\nto obtain protein-rich food, thus increasing exposure to wild rodents, which may carry\\nmonkeypox.30\\nIn August 1970 the first human case of monkeypox was identified in a 9-year-old\\nchild with smallpox-like vesicular skin lesions in the village of Bukenda in the Equato-\\nrial region of Zaire (now DRC).31This patient was found during a period of intensified\\nsmallpox surveillance conducted 9 months after the World Health Organization (WHO)the eradication of smallpox in the DRC had certified the eradication of smallpox in theDRC.\\nGeographic Endemicity and Increase in Number of Cases'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 3}, page_content='Ever since its discovery, the disease has been endemic to Central and West Africa withintermittent, sporadic cases of monkeypox transmitted from local wildlife reportedamong humans. Retrospective studies indicated that similar cases had occurred in\\n1970 to 1971 in the Ivory Coast, Liberia, Nigeria, and Sierra Leone.\\n32–35Subsequent\\nenhanced surveillance observed a steady increase in the rate of human monkeypoxcases. The number of cases of human monkeypox has increased exponentially over\\nthe past 20 years, and has already exceeded that accumulated during the first 45 years\\nsince its first discovery.\\n28,29,36–45\\nA comprehensive enhanced surveillance study in the DRC in 2004 to 2005'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 3}, page_content='showed a steep increase in incidence c ompared with data from a WHO enhanced\\nsurveillance program carried out from 1970 to 1986 reporting 404 cases.46The\\nincidence was highest in forested regions, and in lower age groups not vaccinatedas part of the smallpox eradication program.\\n42To date, human monkeypox cases\\nhave been reported from 10 African countries: DRC, Republic of the Congo,\\nCameroon, Central African Republic, Nigeria, Ivory Coast, Liberia, Sierra Leone,Gabon, and South Sudan.\\n1,36,47The growing incidence of human monkeypox\\ncases in Central and West Africa is considered a consequence of waning cross-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 3}, page_content='protective immunity among the population after smallpox vaccination wasdiscontinued in the early 1980s, following the eradication of smallpox.\\n28,42The\\ndeteriorating immunologic status is not only related to waning vaccine-induced\\nprotection among those initially vacci nated, but probably—and even more—toPetersen et al 1030\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 4}, page_content='the increasing proportion of those never given the vaccine, that is, nonvaccinated\\nyounger age groups. Both mechanisms lead to a growing percentage of suscepti-\\nble individuals in the endemic areas in Ce ntral and West Africa. Another central\\nfactor considered to contribute to th e incidence of monkeypox is related to\\nincreasing contact between humans and small mammals potentially carryingMPXV. Humans invade jungles and forests, t he natural environment of the reservoir\\nspecies. Civil wars, refugee displacement, farming, deforestation, climate change,\\ndemographic changes, and populati on movement may have led to a spread of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 4}, page_content='monkeypox-infected animals and increas ed their interaction with humans across\\nWest and Central Africa.\\nMonkeypox Cases in the United States\\nMonkeypox remained an ignored global public health threat and was only given inter-\\nnational attention when the first cases outside Africa were detected in the United\\nStates in 2003.48After several Midwesterners developed fever, rash, respiratory\\nsymptoms, and lymphadenopathy, outbreak investigation linked the symptoms toexposure to pet prairie dogs ( Cynomys species), and monkeypox virus was identified\\nas a causative agent.\\n48It spread rapidly. Monkeypox cases were reported from'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 4}, page_content='6 states—Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin—during the\\noutbreak.49Molecular investigations identified a monkeypox virus of the West African\\ngenetic group (clade). Epidemiologic studies concluded that the virus had been im-\\nported into the United States, more specifically to Texas, from Ghana on April 9,\\n2003, with a shipment of small mammals of 9 different species, including 6 generaof African rodents.\\n50These comprised rope squirrels ( Funiscuirus sp.), tree squirrels\\n(Heliosciurus sp.), African giant pouched rats ( Cricetomys sp.), brush-tailed porcu-\\npines ( Atherurus sp.), dormice ( Graphiurus sp.), and striped mice ( Lemniscomys'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 4}, page_content='sp.). Some of the infected animals were housed in close proximity to prairie dogs latersold as pets.\\nMonkeypox Cases in the United Kingdom and Israel\\nIn September 2018, monkeypox again drew the attention of global media, politi-cians, and scientists when 3 individual patients in the United Kingdom were diag-nosed with monkeypox.\\n51The first 2 had recently traveled in Nigeria, a country\\nwith an ongoing outbreak of the disease,52and both were symptomatic during their\\nflight home. The third case of monkeypox in the United Kingdom was diagnosed ina health care worker caring for 1 of these first 2 patients. As the clinical picture of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 4}, page_content='the 3 patients’ disease raised a concern over an exotic disease, special infection\\ncontrol measures were taken well before monkeypox was suspected. One of theprimary cases reported contact with a person with suspected rash at a family gath-\\nering, and the consumption of bushmeat.\\n52Secondary and tertiary human-to-\\nhuman transmission of monkeypox does occur in endemic areas.53,54Of note,\\ndefinitive confirmation of human-to-human transmission in endemic areas is some-what problematic, because even the secondary and tertiary cases may have been\\nexposed to infected animals. The disease contracted by the British health care'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 4}, page_content='worker provides indisputable evidence of human-to-human transmission from aninfected patient.\\nIn October 2018, Israel reported a monkeypox case imported from Nigeria.\\n55It is\\nwell known that travelers can act as sentinels of infectious disease epidemics in theregion visited. Not consistent with the reports of low levels of transmission in Nigeria,\\n3 cases imported to other countries from there within a couple of months should raise\\nthe concern of health authorities.\\n56Human Monkeypox 1031\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 4}, page_content='Social Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 5}, page_content='Ongoing Monkeypox Outbreak in West Africa\\nOn September 22, 2017, the Nigeria Center for Disease Control (NCDC) commenced\\nan outbreak investigation following the identification of a suspected case of monkey-pox in an 11-year-old child.\\n57The data available indicate that the current outbreak is\\neither a multisource outbreak or one stemming from previously undetected endemic\\ntransmission, because the cases were not epidemiologically linked.28,58–60The exact\\nzoonotic origin and role of environmental and ecologic factors in the Nigerian outbreak\\nare not yet known. New cases of monkeypox continue to be detected in the country.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 5}, page_content='Since the beginning of the outbreak on September 22, 2018, as of January 1, 2019there have been 311 suspected cases reported from 26 states (132 confirmed cases\\naffecting children and adults of all ages) and 7 deaths reported.\\n60Most of the\\nconfirmed monkeypox patients are aged between 21 and 40 years, with a medianage of 31 years, similar to the observed age range in DRC.\\n42It is noteworthy that all\\nwere born after 1978, when the global vaccination programs for smallpox were\\ndiscontinued.\\nMODES OF TRANSMISSION OF MONKEYPOX VIRUS TO HUMANS'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 5}, page_content='The exact mode of MPXV transmission to humans remains unknown. Primary animal-to-human infection is assumed to occur when handling monkeypox-infected animals,through direct (touch, bite, or scratch) or indirect contact, although the exact mecha-\\nnism(s) remains to be defined. The virus is assumed to enter the body through broken\\nskin, respiratory tract, or the mucous membranes (eyes, nose, or mouth). Secondaryhuman-to-human transmission is considered common,\\n37,53,61presumably through\\nlarge respiratory droplets or direct or indirect contact with body fluids, lesion material,\\nand contaminated surfaces or other material, such as clothing or linens. Prolonged'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 5}, page_content='contact with patients renders hospital staff and family members at greater risk of infec-tion. Nosocomial transmission has been described.\\n38There is no evidence to date that\\nhuman-to-human transmission alone can sustain monkeypox infections in the human\\npopulation.\\nThere have only been a few genomic studies of the origins of monkeypox outbreaks.\\nHuman-to-human transmission has been described from primary human cases and\\nsecondary cases,53,62,63and serial transmission across 4 cases has been observed.64\\nIn the current monkeypox outbreak in Nigeria, genomic studies of monkeypox virusisolates from humans\\n60indicate that the index case was not imported into Nigeria.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 5}, page_content='Thus, the outbreak is considered to be a spillover from multiple sources of introduction\\ninto the human population. The zoonotic source(s) of the outbreak are being investi-gated at present, and it is unclear what, if any, environmental or ecologic changes\\nmight have facilitated the sudden re-emergence of monkeypox in Nigeria. Case clus-\\ntering has been identified within the various states, but no epidemiologic linkages be-tween them have been detected thus far. Three family clusters have been identified,\\nsuggesting human-to-human transmission.\\n58–60In one family the secondary attack'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 5}, page_content='58–60In one family the secondary attack\\nrate was 71%. However, most patients had no obvious epidemiologic linkage orperson-to-person contact, indicating a probable multiple-source outbreak or,\\npossibly, an endemic disease previously unrecognized.\\nCLINICAL FEATURES\\nThe incubation period has been estimated at 5 to 21 days, and duration of symptomsand signs at 2 to 5 weeks. The illness begins with nonspecific symptoms and signs\\nthat include fever, chills, headaches, lethargy, asthenia, lymph node swellings, backPetersen et al 1032\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 5}, page_content='Social Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 6}, page_content='pain, and myalgia (muscle ache) and begins with a fever before rashes appear. Within\\n1 to 5 days after the onset of fever, rashes of varying sizes appear, first on the face(Fig. 2 ), then across the body ( Fig. 3 ), hands ( Fig. 4 A), and legs and feet ( Fig. 4 B).\\nThe rash undergoes several stages of evolution from macules, papules, vesicles\\n(fluid-filled blisters) (see Fig. 2 ), and pustules (see Fig. 3 B, D), followed by resolution\\nover time with crusts and scabs ( Fig. 5 ), which drop off on recovery. Various stages\\nof the rash may show at the same time (see Figs. 3 B and 5). Areas of erythema\\n(see Fig. 2 A) and/or skin hyperpigmentation (see Fig. 5 ) are often seen around discrete'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 6}, page_content='lesions. Detached scabs may be considerably smaller than the original lesion. Inflam-\\nmation of the pharyngeal, conjunctival, and genital mucosae may also be seen.\\nThe clinical presentation of monkeypox includes symptoms and lesions that are\\ndifficult to distinguish from smallpox.\\n37,60,65,66Although the clinical manifestations of\\nmonkeypox are milder than smallpox, the disease can prove fatal, death rates ranging\\nfrom 1% to 10%. Mortality is higher among children and young adults and the course\\nis more severe in immunocompromised individuals.67A range of complications has\\nbeen reported, such as secondary bacterial infections, respiratory distress, broncho-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 6}, page_content='pneumonia, encephalitis, corneal infection with ensuing loss of vision, gastrointestinal\\nFig. 2. (A–D) Maculo-papular-vesicular-pustular monkeypox skin lesions of varying sizes on\\nthe face. ( Courtesy of Nigeria Centre for Disease Control, Abuja, Nigeria.)Human Monkeypox 1033\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 7}, page_content='Fig. 4. (A,B) Papular-pustular monkeypox skin lesions on the hands, legs, and feet. ( Cour-\\ntesy of Nigeria Centre for Disease Control, Abuja, Nigeria.)\\nFig. 3. (A–D) Papular-vesicular-pustular monkeypox skin lesions of varying sizes across the\\nbody. ( Courtesy of Nigeria Centre for Disease Control, Abuja, Nigeria.)Petersen et al 1034\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 8}, page_content='involvement, vomiting, and diarrhea with dehydration. Case fatality rates have varied\\nbetween 1% and 10% in outbreaks, deaths occurring mostly among young adults and\\nchildren. Particularly those with immunosuppression are at risk of severe disease.Lymphadenopathy is seen in up to 90% of patients and appears to be a clinical feature\\ndistinguishing human monkeypox from smallpox.\\nPrevious smallpox vaccination confers some cross-protection against monkeypox\\nand modifies the clinical picture toward a milder disease. Between 1980 and 1990,\\nthe clinical presentation of human monkeypox seems to have changed: primary hu-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 8}, page_content='man cases have increasingly been seen among those never vaccinated against small-pox. Compared with those vaccinated, the clinical picture described for theunvaccinated was more severe, with more vigorous and pleomorphic rashes and\\nhigher mortality.\\n62,66,68–70\\nThe primary differential diagnosis is severe chickenpox with lesions in palms and\\nsoles.7,65The lesions in chickenpox are more superficial and occur in clusters of the\\nsame stage, with denser manifestations on the trunk than on the face and extremities.\\nBecause of the nonspecific nature of the symptoms and signs of monkeypox, a widevariety of differential diagnoses should be considered, ranging from chickenpox, mol-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 8}, page_content='luscum contagiosum, measles, rickettsial infections, bacterial skin infections (such as\\nthose caused by Staphylococcus aureus ), anthrax, scabies, syphilis, and drug reac-\\ntions to other noninfectious causes of rash. A clinical sign differentiating monkeypox\\nfrom smallpox and chickenpox is the presence of enlarged lymph nodes, particularly\\nsubmental, submandibular, cervical, and inguinal nodes.\\n71\\nSMALLPOX VACCINATION, MONKEYPOX PREVALENCE, AND CHANGING CLINICAL\\nPRESENTATIONS\\nIn 1980, the Global Commission for the Certification of Smallpox Eradication (GCCSE)\\ncontinued to designate monkeypox as a public health threat, recommending that the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 8}, page_content='epidemiologic, ecologic, and surveillance program on monkeypox be continued.35,72\\nFig. 5. Extensive papulo-pustular monkeypox rashes with crust and scar formation. ( Cour-\\ntesy of Nigeria Centre for Disease Control, Abuja, Nigeria.)Human Monkeypox 1035\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 9}, page_content='In response, the WHO supported an active surveillance program for human monkey-\\npox from 1970 to 1986.46It was assumed to be endemic to DRC, but other Central and\\nWest African countries also reported cases of monkeypox in humans or circulation in\\nwildlife. At the end of the smallpox eradication campaign, the GCCSE stated that\\nsmallpox vaccination to prevent monkeypox was no longer justified, even if cross-protective immunity could not be relied on for long because of the vaccinations being\\ndiscontinued. In retrospect, this resolution may have been an error.\\nExperimental studies of monkeys have shown immunization with smallpox vaccine\\nto give cross-protection against monkeypox.\\n19'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 9}, page_content='to give cross-protection against monkeypox.\\n19\\nSeveral reviews have summarized human monkeypox outbreaks over the past\\n38 years.28,29,42Between November 2005 and November 2007, population-based\\nsurveillance studies conducted in 9 health zones in central DRC identified 760laboratory-confirmed human monkeypox cases. The average annual cumulative inci-\\ndence across the zones was 5.53 per 10,000 (2.18–14.42). Factors associated with\\nincreased risk of infection included living in forested areas, male sex, age less than15 years, and absence of smallpox vaccination scar. Among those vaccinated, the\\nrisk of monkeypox was found to be 5.2-fold lower than among those unvaccinated'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 9}, page_content='(0.78 versus 4.05 per 10,000). Compared with surveillance data from the same regionrecorded in the 1980s, a 20-fold increase in human monkeypox incidence was\\nobserved. Between January 2001 and December 2004, the DRC Ministry of Health\\nsurveillance program reported 2734 cases of suspected human monkeypox in 11provinces, showing an annual upward trend: 380 cases in 2001, 545 in 2002, 783 in\\n2003, and 1026 in 2004. Most cases (94%) were observed in children and adults\\nyounger than 25 years.\\n41These patients had not been vaccinated against smallpox.\\nSurveillance activities have been halted since 2005 because of the civil war.\\nDIAGNOSIS: LABORATORY, VIROLOGIC, AND HISTOLOGIC FEATURES'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 9}, page_content='Optimal clinical specimens for laboratory analyses include specimens from skin le-sions such as swabs of vesicular lesions, exudate, or crusts stored in a dry, sterile\\ntube (no viral transport media) and kept cold. A viral culture should be obtained by\\nan oropharyngeal or nasopharyngeal swab. Skin biopsies of vesiculopustular rashor a sample of the roof of an intact skin vesicular lesion are valuable for analyses.\\nReference laboratories with high containment facilities are required to make a defini-\\ntive diagnosis using electron microscopy, culture and molecular analysis identificationby polymerase chain reaction, and sequencing. Serologic testing requires paired'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 9}, page_content='acute and convalescent sera for MPXV-specific immunoglobulin M detection within\\n5 days of presentation, or immunoglobulin G detection after 8 days.\\nHistology and immunohistochemistry of papular lesions may show acanthosis, indi-\\nvidual keratinocyte necrosis, and basal vacuolization, along with a superficial and\\ndeep perivascular lymphohistiocytic infiltrate in the dermis. Vesicular lesions show\\nspongiosis with reticular and ballooning degeneration, multinucleated epithelial giantcells with epidermal necrosis with numerous eosinophils and neutrophils, and features\\nof vasculitis and viral inclusions in keratinocytes. Intracytoplasmic, round-to-oval in-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 9}, page_content='clusions with sausage-shaped structures centrally, measuring 200 to 300 mm, may\\nbe seen on electron microscopic observation.\\nTREATMENT\\nThere is no specific treatment for monkeypox. Supportive care, symptomatic\\nmanagement, and treatment of secondary bacterial infections remain the main\\nrecommendations.Petersen et al 1036\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 10}, page_content='PREVENTION\\nPrevention of MPXV spread in endemic areas is highly challenging, and consists of\\navoiding any contact with rodents and primates as well as limiting direct exposure\\nto blood and inadequately cooked meat. Efforts to halt bushmeat trade and con-sumption of wild animals are extremely difficult both culturally and economically\\nbecause this meat may be the only protein source available for the poorest people.\\nMassive health education campaigns are needed to increase general awarenessand to advise on proper handling of potential animal reservoir species (gloves, pro-\\ntective clothing, surgical mask) as well as avoiding close contact with anyone\\ninfected.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 10}, page_content='infected.\\nInfection control measures are vital to prevention of human-to-human transmission\\nin health care. Improved nursing (gloves, protective clothing, surgical masks) and\\nisolation practices require education as well as adequate facilities and staffing.\\nNational health authorities should consider arranging immunization against small-\\npox for health care workers and those treating or exposed to patients with monkeypox\\nor their samples. Smallpox vaccination has been estimated to provide 85% cross-\\nprotection against monkeypox infection.\\n32The Centers for Disease Control and Pre-\\nvention (CDC) recommended smallpox vaccination within 2 weeks, ideally before'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 10}, page_content='4 days, after significant, unprotected exposure to a diseased animal or a confirmed\\nhuman case.\\nDuring an outbreak, the spread of monkeypox virus may be controlled by quaran-\\ntining (at least for 6 weeks from the date of last exposure) the infected animals and\\ntracing their contacts. Adherence to specific instructions from the local and globalpublic health authorities is mandatory. Increasing awareness and action (adequate de-cisions, medical staff, sampling, surveillance, education) both by local and interna-\\ntional authorities are of central importance.\\nAt hospitals in developed countries, when suspecting a case of monkeypox (eg, a'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 10}, page_content='patient with fever, skin lesions, and history of visiting endemic area or contact with pa-\\ntients), the patient should immediately be placed in a negative air pressure isolation\\nroom, or a private room if such facilities are unavailable. Standard, contact, anddroplet precautions should all be taken. Infection control personnel should be con-\\ntacted without delay. In developed countries, likewise, increasing awareness among\\nhealth care personnel about the disease and its endemic areas is an importantprecaution.\\nVACCINES AGAINST MONKEYPOX'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 10}, page_content='VACCINES AGAINST MONKEYPOX\\nAlthough new vaccines are being developed for monkeypox, there is a need for con-ducting controlled clinical trials to evaluate the impact of the use of smallpox vaccinesfor prevention of monkeypox or modifying disease severity. Studies should focus on\\nthe cost/benefit of population-level vaccination and investigation of alternative vacci-\\nnation strategies such as targeting vaccination to affected areas, contacts, and healthcare workers, and wider geographic areas. Currently the CDC recommends pre-\\nexposure smallpox vaccination for field investigators, veterinarians, animal control'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 10}, page_content='personnel, contacts of monkeypox patients, researchers, and health care workers car-ing for such patients and their contacts.\\n3\\nCan the Smallpox Vaccine Available Be Used to Protect Against Monkeypox?\\nPercutaneous inoculation with vaccinia virus elicits a broad and heterogeneous serum\\nantibody response targeting a large number of antigenic determinants of vaccinia vi-\\nrus.73,74The viral inhibitory activity of serum from immune subjects with cross-Human Monkeypox 1037\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 10}, page_content='permiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 11}, page_content='neutralizing activity to vaccinia virus, MPXV, and VARV is presumably composed of\\nantibodies with diverse specificities.75–77\\nProduction of first-generation live attenuated vaccine has been reviewed by the\\nWHO in 1988.9A considerable proportion of the population may have contraindica-\\ntions for the vaccine candidates: 15.2% to 15.8% of the United States populationhas been estimated to have potential contraindications for taking the live attenuated\\nsmallpox vaccine.\\n78\\nThe rates of side effects associated with the live attenuated vaccinia virus in the\\nUnited States in 1968 were 74 complications and 1 death per 1 million primary vacci-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 11}, page_content='nations. Morbidity and mortality rates were highest for infants, with 112 complications\\nand 5 deaths per million primary vaccinations.79In 2002, the US Department of De-\\nfense resumed a program for widespread smallpox vaccinations because of aperceived threat of biological warfare. A total of 540,824 military personnel were vacci-\\nnated with a New York City Board of Health (NYCBH) strain of vaccinia, “DryVax,” from\\nDecember 2002 through December 2003. Dryvax was produced by infecting the skinof calves using the NYCBH strain as seed virus. Of these, 67 (1 in 8000) developed\\nmyopericarditis.\\n80,81\\nThe highest rate of postvaccine encephalitis (pvE) was found with the Bern strain'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 11}, page_content='(44.9 expected cases per million vaccines), followed by the Copenhagen strain (33.3\\nper million vaccines), the Lister strain (26.2 per million vaccines), and the NYCBH strain\\nwith the lowest rate (2.9 per million vaccinations).82\\nADDRESSING GAPS IN KNOWLEDGE AND STRENGTHENING PUBLIC HEALTH\\nPREPAREDNESS\\nMost data available on monkeypox are obtained from individual case or outbreak re-\\nports, and from passive intermittent surveillance, none of which convey an accurateoverall picture. The current major gaps in monkeypox knowledge, the changing epide-\\nmiologic and clinical presentations, and the multifarious factors involved in monkey-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 11}, page_content='pox transmission argue the need to strengthen outbreak preparedness efforts.There remains an urgent need for developing public health and surveillance capacities\\nin Central and West Africa to guide appropriate surveillance, data collection, preven-\\ntion, preparedness, and response activities to monkeypox and other emerging and re-emerging infections with epidemic potential. Advancing public health preparedness\\nand aligning proactive surveillance activities to priority research will require coordi-\\nnated, locally led, multidisciplinary efforts adjusted closely to capacity developmentand training.\\nSUMMARY'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 11}, page_content='SUMMARY\\nThe spread of monkeypox across West Africa over the past decade and the ongoingoutbreak in Nigeria indicates that it is no longer “a rare viral zoonotic disease that oc-curs primarily in remote parts of Central and West Africa, near tropical rainforests.” Itspotential for further spread both regionally and internationally remains a major\\nconcern.\\n28,29The ecologic, zoonotic, epidemiologic, clinical, and public health as-\\npects of monkeypox remain inadequately characterized.33,36,44,45The first-\\ngeneration live attenuated vaccinia virus vaccines stored for emergency purposes in\\nmany countries cannot be used because of severe adverse reactions. Discontinuing'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 11}, page_content='the smallpox vaccination program has created an ecologic gap whereby an increasingproportion of the population has either waning or nonexistent immunity to MPXV. This\\ndevelopment will further increase the risk of both the animal-to-human and human-to-\\nhuman spread of the virus. Therefore, priority research and surveillance shouldPetersen et al 1038\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 12}, page_content='urgently be conducted through a joint “One-Human-Animal-Environmental Health”\\neffort across Central and West Africa.83–85\\nACKNOWLEDGMENTS\\nThe authors thank the NCDC staff for providing the clinical photographs from the\\nongoing 2019 monkeypox outbreak in Nigeria, and the patients who gave permissionto have the photos taken.\\nREFERENCES\\n1. WHO. Human monkeypox 2019. Available at: https://www.who.int/emergencies/\\ndiseases/monkeypox/en/ . Accessed February 22, 2019.\\n2. WHO. Smallpox 2019. Available at: https://www.who.int/biologicals/vaccines/\\nsmallpox/en/ . Accessed February 20, 2019.\\n3.CDC. Monkeypox. MMWR Morb Mortal Wkly Rep 2018;67:306–10 .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 12}, page_content='4.Shchelkunov SN, Totmenin AV , Babkin IV, et al. Human monkeypox and smallpox\\nviruses: genomic comparison. FEBS Lett 2001;509:66–70 .\\n5.Pauli G, Blu ¨mel J, Burger R, et al. Orthopox viruses: infections in humans. Trans-\\nfus Med Hemother 2010;37:351–64 .\\n6.Bera BC, Shanmugasundaram K, Barua S, et al. Zoonotic cases of camelpox\\ninfection in India. Vet Microbiol 2011;152:29–38 .\\n7.Cook GC, Zumla A. Chapter 47. Cutaneous viral diseases. Monkeypox. In:\\nCook GC, Zumla A, editors. Manson’s tropical diseases. 22nd edition. London:\\nHarcourt Brace Saunders, Publishing Group; 2009. p. 839–40 .\\n8.Petersen E, Abubakar I, Ihekweazu C, et al. Monkeypox—Enhancing public'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 12}, page_content='health preparedness for an emerging lethal human zoonotic epidemic threat in\\nthe wake of the smallpox post-eradication era. Int J Infect Dis 2019;78:78–84 .\\n9.Fenner F , Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva\\n(Switzerland): World Health Organisation; 1988 .\\n10.Singh RK, Hosamani M, Balamurugan V , et al. Buffalopox: an emerging and re-\\nemerging zoonosis. Anim Health Res Rev 2007;8:105–14 .\\n11.Oliveira JS, Figueiredo PO, Costa GB, et al. Vaccinia virus natural infections in\\nBrazil: the good, the bad, and the ugly. Viruses 2017;9(11) [pii:E340] .\\n12.Hughes AL, Irausquin S, Friedman R. The evolutionary biology of poxviruses.\\nInfect Genet Evol 2010;10:50–9 .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 12}, page_content='Infect Genet Evol 2010;10:50–9 .\\n13.Ichihashi Y, Oie M. Epitope mosaic on the surface proteins of orthopoxviruses.\\nVirology 1988;163:133–44 .\\n14.Stanford MM, McFadden G, Karupiah G, et al. Immunopathogenesis of poxvirus\\ninfections: forecasting the impending storm. Immunol Cell Biol 2007;85:93–102 .\\n15.McConnell S, Herman YF , Mattson DE, et al. Protection of rhesus monkeys\\nagainst monkeypox by vaccinia virus immunization. Am J Vet Res 1964;25:192–5 .\\n16.Hammarlund E, Lewis MW, Carter SV , et al. Multiple diagnostic techniques iden-\\ntify previously vaccinated individuals with protective immunity against monkey-\\npox. Nat Med 2005;11:1005–11 .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 12}, page_content='pox. Nat Med 2005;11:1005–11 .\\n17.Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev 2011;\\n239:8–26 .\\n18.Gispen R, Verlinde JD, Zwart P . Histopathological and virological studies on mon-\\nkeypox. Arch Gesamte Virusforsch 1967;21:205–16 .\\n19.McConnell S, Hickman RL, Wooding WL Jr, et al. Monkeypox: experimental infec-\\ntion in chimpanzee ( Pan satyrus ) and immunization with vaccinia virus. Am J Vet\\nRes 1968;29:1675–80 .Human Monkeypox 1039\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 12}, page_content='permiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 13}, page_content='20.von Magnus P, Anderson EK, Petersen KB, et al. A pox-like disease in cynomol-\\ngus monkeys. Acta Pathol Microbiol Scand 1959;46:156–76 .\\n21.Doty JB, Malekani JM, Kalemba LN, et al. Assessing monkeypox virus preva-\\nlence in small mammals at the human-animal interface in the democratic Repub-lic of the Congo. Viruses 2017;9(10) [pii:E283] .\\n22.Radoni /C19c A, Metzger S, Dabrowski PW, et al. Fatal monkeypox in wild-living sooty\\nmangabey, Co ˆte d’Ivoire, 2012. Emerg Infect Dis 2014;20:1009–11 .\\n23.Hutson CL, Lee KN, Abel J, et al. Monkeypox zoonotic associations: insights from\\nlaboratory evaluation of animals associated with the multi-state US outbreak. AmJ Trop Med Hyg 2007;76:757–68 .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 13}, page_content='24.Thomassen HA, Fuller T, Asefi-Najafabady S, et al. Pathogen-host associations\\nand predicted range shifts of human monkeypox in response to climate changein central Africa. PLoS One 2013;8:e66071 .\\n25.Prier JE, Sauer RM. A pox disease of monkeys. Ann N Y Acad Sci 1960;85:951–9 .\\n26.Wenner HA, Macasaet D, Kamitsuka PS, et al. Monkeypox I. Clinical, virologic\\nand immunologic studies. Am J Epidemiol 1968;87:551–66 .\\n27.Nakoune E, Lampaert E, Ndjapou SG, et al. A nosocomial outbreak of human\\nmonkeypox in the Central African Republic. Open Forum Infect Dis 2017;4:\\nofx168 .\\n28.Durski KN, McCollum AM, Nakazawa Y, et al. Emergence of monkeypox—West'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 13}, page_content='and Central Africa, 1970-2017. MMWR Morb Mortal Wkly Rep 2018;67:306–10 .\\n29.Sklenovska ´N, Van Ranst M. Emergence of monkeypox as the most important or-\\nthopoxvirus infection in humans. Front Public Health 2018;6:241 .\\n30.Quiner CA, Moses C, Monroe BP, et al. Presumptive risk factors for monkeypox in\\nrural communities in the Democratic Republic of the Congo. PLoS One 2017;12:\\ne0168664 .\\n31.Marennikova SS, Seluhina EM, Malceva NN, et al. Isolation and properties of the\\ncausal agent of a new variola-like disease (monkeypox) in man. Bull World Health\\nOrgan 1972;46:599–611 .\\n32.Fine PE, Jezek Z, Grab B, et al. The transmission potential of monkeypox virus in'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 13}, page_content='human populations. Int J Epidemiol 1988;17:643–50 .\\n33.Heymann DL, Szczeniowski M, Esteves K. Reemergence of monkeypox in Africa:\\na review of the past six years. Br Med Bull 1998;54:693–702 .\\n34.Breman JG, Kalisa R, Steniowski MV, et al. Human monkeypox, 1970-79. Bull\\nWorld Health Organ 1980;58:165–82 .\\n35.WHO. 1980 the global eradication of smallpox: final report of the Global Commis-\\nsion for the Certification of Smallpox Eradication. Geneva (Switzerland): World\\nHealth Organization; 1980 .\\n36. WHO. Human monkeypox (MPX) 2018. Available at: http://www.who.int/\\nemergencies/diseases/monkeypox/en/ . Accessed February 22, 2019.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 13}, page_content='37.Hutin YJ, Williams RJ, Malfait P , et al. Outbreak of human monkeypox, Democratic\\nRepublic of Congo, 1996 to 1997. Emerg Infect Dis 2001;7:434 .\\n38.Learned LA, Reynolds MG, Wassa DW, et al. Extended interhuman transmission\\nof monkeypox in a hospital community in the Republic of the Congo, 2003. Am J\\nTrop Med Hyg 2005;73:428–34 .\\n39.Reynolds MG, Emerson GL, Pukuta E, et al. Detection of human monkeypox in\\nthe Republic of the Congo following intensive community education. Am J Trop\\nMed Hyg 2013;88:982–5 .\\n40.Khodakevich L, Widy-Wirski R, Arita I, et al. Monkey pox virus infection in hu-\\nmans in the Central African Republic. Bull Soc Pathol Exot Filiales 1985;78:\\n311–20 .Petersen et al 1040'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 13}, page_content='311–20 .Petersen et al 1040\\nDescargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 14}, page_content='41.Rimoin AW, Kisalu N, Kebela-Ilunga B, et al. Endemic human monkeypox, Dem-\\nocratic Republic of Congo, 2001-2004. Emerg Infect Dis 2007;13:934–7 .\\n42.Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human\\nmonkeypox incidence 30 years after smallpox vaccination campaigns cease\\nin the Democratic Republic of Congo. Proc Natl Acad Sci U S A 2010;107:16262–7 .\\n43.Kantele A, Chickering K, Vapalahti O, et al. Emerging diseases—the monkeypox\\nepidemic in the Democratic Republic of the Congo. Clin Microbiol Infect 2016;22:\\n658–9 .\\n44.Hoff NA, Doshi RH, Colwell B, et al. Evolution of a disease surveillance system: an'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 14}, page_content='increase in reporting of human monkeypox disease in the Democratic Republic of\\nthe Congo, 2001-2013. Int J Trop Dis Health 2017;25 [pii:IJTDH.35885] .\\n45.Yinka-Ogunleye A, Aruna O, Ogoina D, et al. Reemergence of human Monkeypox\\nin Nigeria, 2017. Emerg Infect Dis 2018;24:1149–51 .\\n46.Jezek Z, Fenner F. Human monkeypox. Monographs in virology, vol. 17. Basel\\n(Switzerland): Karger; 1988. p. 49. Tabel 7 .\\n47.Formenty P , Muntasir MO, Damon I, et al. Human monkeypox outbreak cause by\\nnovel virus belonging to Congo Basin clade, Sudan, 2005. Emerg Infect Dis 2010;16:1539–45 .\\n48.Centers for Disease Control and Prevention (CDC). Update: multistate outbreak'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 14}, page_content='of monkeypox–Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003.\\nMMWR Morb Mortal Wkly Rep 2003;52(27):642–6 .\\n49.Centers for Disease Control and Prevention (CDC). Update: multistate outbreak\\nof monkeypox–Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003.\\nMMWR Morb Mortal Wkly Rep 2003;52(25):589–90 .\\n50. CDC, Centers for Disease Control and Prevention. Monkeypox in the United\\nStates. 2003 Outbreak. Available at: https://www.cdc.gov/poxvirus/monkeypox/\\noutbreak.html . Accessed February 22, 2019.\\n51. Public Health England. Cases of monkeypox confirmed in England. Available at:\\nhttps://www.gov.uk/government/news/monkeypox-case-in-england . Accessed\\nMarch 28, 2019.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 14}, page_content='March 28, 2019.\\n52. Vaughan A, Aarons E, Astbury J, et al. Two cases of monkeypox imported to the\\nUnited Kingdom, September 2018. Euro Surveill 2018;23(38). https://doi.org/10.\\n2807/1560-7917 .\\n53.Jezek Z, Arita I, Mutombo M, et al. Four generations of probable person-to-\\nperson transmission of human monkeypox. Am J Epidemiol 1986;123:1004–12 .\\n54.Kalthan E, Tenguere J, Ndjapou SG, et al. Investigation of an outbreak of monkey-\\npox in an area occupied by armed groups, Central African Republic. Med MalInfect 2018;48:263–8 .\\n55. Ministry of Health, State of Israel. Monkeypox patient diagnosed. Available at:\\nhttps://www.health.gov.il/English/News_and_Events/Spokespersons_Messages/'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 14}, page_content='Pages/12102018_1.aspx . Accessed February 19, 2019.\\n56. WHO. Human monkeypox in Nigeria 2018. Available at: https://www.who.int/csr/\\ndon/05-october-2018-monkeypox-nigeria/en/ . Accessed February 22, 2019.\\n57.Eteng WE, Mandra A, Doty J, et al. Notes from the field: responding to an\\noutbreak of monkeypox using the one health approach—Nigeria, 2017-2018.MMWR Morb Mortal Wkly Rep 2018;67:1040–1 .\\n58. Nigeria CDC. An update of monkeypox outbreak in Nigeria 2018. Available at:\\nhttps://ncdc.gov.ng/diseases/sitreps/?cat 58&name 5An%20Update%20of%20\\nMonkeypox%20Outbreak%20in%20Nigeria . Accessed February 22, 2019.Human Monkeypox 1041'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 14}, page_content='Descargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 15}, page_content='59. Nigeria CDC. Monkeypox 2019. Available at: https://ncdc.gov.ng/diseases/\\nsitreps/?cat 58&name 5An%20Update%20of%20Monkeypox%20Outbreak%20\\nin%20Nigeria . Accessed February 22, 2019.\\n60.Faye O, Pratt CB, Faye M, et al. Genomic characterisation of human monkeypox\\nvirus in Nigeria. Lancet Infect Dis 2018;18:246 .\\n61.Jezek Z, Grab B, Szczeniowski MV, et al. Human monkeypox: secondary attack\\nrates. Bull World Health Organ 1988;66:465–70 .\\n62.Jezek Z, Grab B, Dixon H. Stochastic model for interhuman spread of monkey-\\npox. Am J Epidemiol 1987;126:1082–92 .\\n63.Jezek Z, Szczeniowski M, Paluku KM, et al. Human monkeypox: clinical features\\nof 282 patients. J Infect Dis 1987;156:293–8 .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 15}, page_content='of 282 patients. J Infect Dis 1987;156:293–8 .\\n64.Nolen LD, Osadebe L, Katomba J, et al. Extended human-to-human transmission\\nduring a monkeypox outbreak in the Democratic Republic of the Congo. Emerg\\nInfect Dis 2016;22:1014–21 .\\n65.Jezek Z, Szczeniowski M, Paluku KM, et al. Human monkeypox: confusion with\\nchickenpox. Acta Trop 1988;45:297–307 .\\n66.Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet\\n2004;4:15–25 .\\n67.Gordon SN, Cecchinato V , Andresen V , et al. Smallpox vaccine safety is depen-\\ndent on T cells and not B cells. J Infect Dis 2011;203:1043–53 .\\n68.Huhn GD, Bauer AM, Yorita K, et al. Clinical characteristics of human monkeypox,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 15}, page_content='and risk factors for severe disease. Clin Infect Dis 2005;41:1742–51 .\\n69.Damon IK. Status of human monkeypox: clinical disease, epidemiology and\\nresearch. Vaccine 2011;29(Suppl 4):D54–9 .\\n70.McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014;58:260–7 .\\n71.Osadebe L, Hughes CM, Shongo Lushima R, et al. Enhancing case definitions for\\nsurveillance of human monkeypox in the Democratic Republic of Congo. PLoS\\nNegl Trop Dis 2017;11:e0005857 .\\n72.WHO. The current status of human monkeypox: memorandum from a WHO\\nMeeting. Bull World Health Organ 1984;62:703–13 .\\n73.Davies DH, Liang X, Hernandez JE al. Profiling the humoral immune response to'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 15}, page_content='infection by using proteome microarrays: high-throughput vaccine and diag-\\nnostic antigen discovery. Proc Natl Acad Sci U S A 2005;102:547–52 .\\n74.Davies DH, Molina DM, Wrammert, et al. Proteome-wide analysis of the serolog-\\nical response to vaccinia and smallpox. Proteomics 2007;7:1678–86 .\\n75.Hughes CM, Newman FK, Davidson WB, et al. Analysis of variola and vaccinia\\nvirus neutralization assays for smallpox vaccines. Clin Vaccine Immunol 2012;19:1116–8 .\\n76.Kennedy JS, Gurwith M, Dekker CL, et al. Safety and immunogenicity of LC16m8,\\nan attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis 2011;204:\\n1395–402 .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 15}, page_content='1395–402 .\\n77.Gilchuk I, Gilchuk P , Sapparapu G, et al. Cross-neutralizing and protective human\\nantibody specificities to poxvirus infections. Cell 2016;167:684–94 .\\n78.Carlin EP , Giller N, Katz R. Estimating the size of the U.S. population at risk of se-\\nvere adverse events from replicating smallpox vaccine. Public Health Nurs 2017;\\n34:200–9 .\\n79.Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccination, 1968.\\nN Engl J Med 1969;281:1201–8 .\\n80.Eckart RE, Love SS, Atwood JE, et al, Department of Defense Smallpox Vacci-\\nnation Clinical Evaluation Team. Incidence and follow-up of inflammatoryPetersen et al 1042'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 15}, page_content='Descargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 16}, page_content='cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004;44:\\n201–5 .\\n81.Neff J, Modlin J, Birkhead GS, et al, and the Advisory Committee on Immuniza-\\ntion. Practices; Armed Forces Epidemiological Board. Monitoring the safety of\\na smallpox vaccination program in the United States: report of the joint SmallpoxVaccine Safety Working Group of the advisory committee on immunization prac-\\ntices and the Armed Forces Epidemiological Board. Clin Infect Dis 2008;\\n46(Suppl 3):258–70 .\\n82.Kretzschmar M, Walinga J, Teunis P , et al. Frequency of adverse events after\\nvaccination with different vaccinia strains. PLoS Med 2006;3(8):e272 .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 16}, page_content='83.Bass J, Tack DM, McCollum AM, et al. Enhancing health care worker ability to\\ndetect and care for patients with monkeypox in the Democratic Republic of theCongo. Int Health 2013;5:237–43 .\\n84.Zumla A, Dar O, Kock R, et al. Taking forward a ’One Health’ approach for turning\\nthe tide against the Middle East respiratory syndrome coronavirus and other zo-onotic pathogens with epidemic potential. Int J Infect Dis 2016;47:5–9 .\\n85.Doshi RH, Guagliardo SAJ, Dzabatou-Babeaux A, et al. Strengthening of surveil-\\nlance during monkeypox outbreak, Republic of the Congo, 2017. Emerg InfectDis 2018;24:1158–60 .Human Monkeypox 1043'),\n",
       " Document(metadata={'source': 'monkeypox\\\\8.pdf', 'page': 16}, page_content='Descargado para Ismael Jesús Acevedo Canales (ijaceved@ccss.sa.cr) en National Library of Health and \\nSocial Security de ClinicalKey.es por Elsevier en junio 03, 2022. Para uso personal exclusivamente. No se \\npermiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 0}, page_content='Page 1 of 8                                                                                            INFECTION PREVENTION AND CONTROL (IPC) STANDARD OPERATING PROCEDURE (SOP) FOR HEALTHCARE MANAGEMENT OF MONKEYPOX PATIENT'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 1}, page_content='Page 2 of 8  1. INTRODUCTION Monkeypox (MPX) is a viral zoonotic disease that belongs to the Orthopoxvirus genus of the Poxviridae family. Human disease was first identified in 1970 in a 9-month-old boy in the Democratic Republic of the Congo and since then most cases have been reported across Central and West Africa.  The incubation period of monkeypox is usually 6 to 13 days following exposure but can range from 5 to 21 days. The primary infection is from animals to humans, and secondary infection is human to human, and characterized by fever and rash. The mode of transmission is via contact with monkey pox vesicles on the skin, and droplet is secondary because of skin scales being'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 1}, page_content='droplet is secondary because of skin scales being inhaled. If a patient seeking care is suspected to have monkeypox, infection prevention and control personnel should be notified immediately. A multi-country outbreak of monkeypox in humans has been reported in several regions that are not endemic for monkeypox virus. The situation is quickly evolving with cases being recorded in several European countries, the United States of America, Canada, and Australia. At present, the outbreak is linked to international travel, but community-based spread has also been noted in some areas. The source and linkage of cases are still under investigation.  2. PURPOSE The aim of this Standard Operating'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 1}, page_content='2. PURPOSE The aim of this Standard Operating Procedure (SOP) is to guide personnel in adhering to infection prevention and control (IPC) standards during healthcare or whilst providing care to the suspected, probable, or confirmed monkeypox case.   3. OBJECTIVE To give guidance and identify IPC principles to reduce all avoidable risks during care and monitoring of monkeypox cases to ensure that appropriate public health measures are instituted to contain spread.  4. CASE DEFINITIONS 4.1 Suspected case: Any person presenting with an unexplained acute rash  AND  1) one or more of the following signs and symptoms: • Headache • Acute onset of fever (>38.5°C) • Lymphadenopathy (swollen lymph'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 1}, page_content='fever (>38.5°C) • Lymphadenopathy (swollen lymph nodes) • Myalgia (muscle pain/body aches) • Backache'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 2}, page_content='Page 3 of 8  AND 2) for which the following differential diagnoses are excluded: chickenpox, measles, bacterial skin infections, syphilis, molluscum contagiosum, allergic reactions and other locally relevant common cause of popular or vesicular rash. N.B. it is not necessary to obtain negative laboratory results for differential diagnoses listed above to classify a case as suspected.  4.2 Probable case: A person meeting the suspected case definition AND one or more of the following: • An epidemiological link* to a probable or laboratory-confirmed case of monkeypox in the 21 days prior to symptom onset. • Travel history to a monkeypox endemic country** in the 21 days prior to symptom onset. •'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 2}, page_content='in the 21 days prior to symptom onset. • Had multiple or anonymous sexual partners in the 21 days prior to symptom onset. • A positive result of an orthopoxviral serological assay, in the absence of smallpox vaccination or other known exposure to orthopoxviruses.  • Hospitalised due to the illness. *Face-to-face exposure without appropriate PPE; direct physical contact with skin or skin lesions including sexual contact; contact with contaminated materials such as clothing, bedding or utensils. *Cameroon, Central African Republic, Congo, Democratic Republic of the Congo, Gabon, Ghana, Ivory Coast, Liberia, Nigeria, Sierra Leone, South Sudan.  4.3 Confirmed case:  A person meeting the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 2}, page_content='Sudan.  4.3 Confirmed case:  A person meeting the suspected or probable case definition or is laboratory-confirmed for monkeypox virus by detection of unique sequences of viral DNA either by real-time polymerase chain reaction (PCR) and/or sequencing.  5. CONTACT DEFINITION  A person who had been exposed to a suspected, probable, or laboratory-confirmed monkeypox case since onset of symptoms and has had one or more of the following exposures:  • Face-to-face contact or was in a closed environment with a case without appropriate personal protective equipment (PPE) - this includes, amongst others,  o persons living in the same household as a case,  o people working closely/in the same'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 2}, page_content='as a case,  o people working closely/in the same environment as a case (e.g. colleagues, classmates etc), o Healthcare workers or other person providing direct care.   • Direct physical contact including sexual contact.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 3}, page_content='Page 4 of 8  • Direct contact with contaminated materials such as clothing, bedding etc.  6. IPC DURING HEALTHCARE Health workers should always follow standard precautions and perform a risk assessment to evaluate the need to use additional precautions. Standard precautions include:  • hand hygiene  • respiratory hygiene and cough etiquette  • patient placement  • personal protective equipment  • aseptic technique  • safe injections and sharps injury prevention  • environmental cleaning and disinfection  • handling of laundry and linen  • decontamination and reprocessing or reusable patient care items and equipment  • waste management.  6.1 Hand hygiene The following five moments of hand'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 3}, page_content='Hand hygiene The following five moments of hand hygiene are critical:  1. Clean your hands before touching a patient when approaching him/her. 2. Clean your hands immediately before performing a clean/aseptic procedure. 3. Clean your hands immediately after an exposure risk to body fluids (and after glove removal). 4. Clean your hands after touching a patient and her/his immediate surroundings, when leaving the patient’s side. 5. Clean your hands after touching any object or furniture in the patient’s immediate surroundings, when leaving – even if the patient has not been touched. There should be an elbow-operated hand-wash basin at the entrance to the patient area of the unit  Each room'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 3}, page_content='to the patient area of the unit  Each room should be provided with at least one clinical elbow-operated hand washbasin. Laminated hand washing posters with clear instructions should be provided above or next to all elbow-operated hand washbasins. Elbow-operated hand washbasins must be appropriately positioned to prevent splashing on beds, equipment or staff. Elbow-operated hand washing basins should be placed to allow optimal workflow i.e., clean to dirty  Wall mounted antiseptic soap dispensers and clean disposable towels should be available at each elbow-operated hand washbasin.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 4}, page_content='Page 5 of 8  Alcohol-based hand rub (ABHR) should be available at each elbow-operated hand wash basin and at every occupied unit. A pedal operated refuse bin should be available at each elbow-operated hand wash basin.  6.2 Isolation room or space Health workers should perform hand hygiene according to the WHO Your 5 moments for hand hygiene, including prior to putting on and after removing PPE. Place patient in a well-ventilated, single patient room with dedicated bathroom or toilet. If single patient rooms are not available, consider cohorting confirmed cases, maintaining a distance of at least 1 m between patients. Isolation room/area should have signage posted at the entrance indicating'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 4}, page_content='have signage posted at the entrance indicating contact/droplet precautions.  Wear PPE, including gloves, gown, a respirator (e.g.N95, FFP2) and eye protection. Use dedicated footwear that can be decontaminated.  Health workers should be trained on procedures for safe donning and doffing of PPE. Cover exposed lesions when others are in the room and if the patient can tolerate.  Avoid unnecessary movement of confirmed patients. If the patient must be moved or transported within or beyond the facility, ensure transmission-based precautions are maintained, place a well-fitting medical mask on the patient and cover lesions (provided the patient is able to tolerate). The receiving'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 4}, page_content='the patient is able to tolerate). The receiving facility/ward/unit should be aware that transmission-based precautions are required and, pending arrival, the need to prepare the isolation or designated area.  Precautions should remain in place until lesions have crusted, scabs have fallen off and a fresh layer of skin has formed underneath. Severe cases (including immunosuppressed) who may experience prolonged viral shedding from the upper respiratory tract may require clinical evaluation to determine when transmission-based precautions may be discontinued.  6.3 Personal Protective Clothing (PPE) Health workers should wear the following PPE: gloves, gown, respirator (e.g.N95, FFP2) and eye'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 4}, page_content='gloves, gown, respirator (e.g.N95, FFP2) and eye protection. Health workers should be trained on procedures for safe putting on and removing PPE: Donning procedure:  1. Put on the gown: Fully cover torso from the neck to knees, arms to end of wrist, and wrap around the back; fasten behind neck and waist.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 5}, page_content='Page 6 of 8  2. Put on mask or respirator: secure ties or elastic bands at middle of head and neck; fit flexible band to nose bridge; fit snug to face and below chin 3. Put on goggles or face shield: Place over face and eyes and adjust to fit 4. Put on gloves: Extend to cover wrist of isolation gown Doffing procedure:  If your hands get contaminated at any step during the doffing procedure, immediately wash your hands or use an alcohol-based hand sanitizer. 1. Remove gloves and gown: Grasp the gown in the front and pull away from your body so that the ties break, touching outside of gown only with gloved hands; while removing the gown, fold or roll the gown inside-out into a bundle; as you'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 5}, page_content='or roll the gown inside-out into a bundle; as you are removing the gown, peel off your gloves at the same time, only touching the inside of the gloves and gown with your bare hands; place the gown and gloves into a waste container. 2. Remove googles or face shield: Remove from the back by lifting head band and without touching the front of the goggles or face shield; if the item is reusable, place in designated receptacle for reprocessing, otherwise, discard in a waste container.  3. Remove mask from behind: Grasp bottom ties or elastics of the mask/respirator, then the ones at the top, and remove without touching the front; discard in a waste container. 4. Perform hand hygiene  6.4'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 5}, page_content='a waste container. 4. Perform hand hygiene  6.4 Cleaning and disinfection of surfaces PPE (gloves [heavy duty], gown, respirator [e.g.N95, FFP2] and eye protection) should be worn by health workers while cleaning and disinfecting patient care equipment and patient care areas or isolation rooms where patients were suspected or confirmed to have monkeypox. Use dedicated footwear that can be decontaminated. Disposable shoe covers are not recommended. Wet cleaning methods are preferred. Use dedicated cleaning material. Always clean surfaces first with detergent and water followed by disinfection with an approved disinfectant with virucidal activities: Disinfect using 70% alcohol or hypochlorite'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 5}, page_content='Disinfect using 70% alcohol or hypochlorite solution (concentration of 1000ppm, usually 2 sachets to 4.5L of water) To prevent cross-contamination, cleaning must always be carried out from the cleanest area first and finish in the dirtiest area last, and always clean from top to bottom. Particular attention should be paid to toilets and frequently touched surfaces. Use disposable or dedicated patient care equipment and clean and disinfect equipment before use on other patients. Dishes can be washed with detergent in automated dishwasher or manually cleaned in hot water (>55°C) while wearing domestic gloves. 6.5 Safe handling of linen'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 6}, page_content='Page 7 of 8  Carefully lift and roll linens. Do not shake linen or laundry as this may disperse infectious particles. These items should be carefully placed into designated container or bag for transport to laundry services. Linens can be machine washed with hot water at > 60°C with laundry detergent and dried according to routine procedures, preferably at high heat. If machine washing is not possible and hot water is not available, linens can be soaked in a large drum using a stick to stir with care taken to avoid splashing. The linens should be soaked in chlorine, rinsed with clean water and allowed to fully dry. Workers in laundry area should follow standard and transmission-based'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 6}, page_content='should follow standard and transmission-based precautions including:  - minimize handling, in particular avoid shaking of linen and laundry;  - wear gloves, apron or gown, a respirator (e.g.N95, FFP2) and eye protection.  6.6 Waste management Waste should be segregated (general waste, infectious waste and sharps) and placed in appropriate bins at point of use (fill ¾ full). Management and disposal of waste (including PPE) should be done in accordance with local regulations for infectious waste. Ensure health workers wear appropriate PPE (e.g.gloves, gown, respirator [e.g.N95, FFP2], eye protection) during handling of waste. Transport to designated area and storing of waste should be done in'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 6}, page_content='area and storing of waste should be done in a controlled access area.  6.7 Management of deceased patients Handling of the deceased should be kept to a minimum. Perform hand hygiene and wear PPE according to contact and droplet precautions (gloves, gown, respirator [e.g.N95, FFP2] and eye protection) as patients with rashes that have not healed may still have infectious virus. Ensure that any leakage of body fluids is contained. The body should be wrapped in a cloth or shroud and transferred to the mortuary as soon as possible. The dignity of the dead, their cultural and religious traditions, and their families should be respected and protected. Family and friends may view the body after it'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 6}, page_content='Family and friends may view the body after it has been prepared for burial, in accordance with local customs. They should not touch or kiss the body and should clean their hands with soap and water or alcohol-based hand sanitizer after the viewing.  6.8 Management of exposed health care workers'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 7}, page_content='Page 8 of 8  Health workers should notify infection control, occupational health and public health authorities of possible exposures to receive a medical evaluation and instructions on follow up.  Health workers who have had an occupational exposure (i.e.not wearing appropriate PPE) do not need to be excluded from work if they are asymptomatic, but should undergo active surveillance for symptoms for 21 days post-exposure; and be instructed not to work with vulnerable patients. Health workers who have had an exposure to a person with confirmed monkeypox should undergo medical evaluation and consideration for possible interventions (vaccination or PEP) if available.  Other useful resources •'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 7}, page_content='or PEP) if available.  Other useful resources • Centers for Disease Control and Prevention, Infection Prevention and Control of Monkeypox in Healthcare Settings (May 2022), https://www.cdc.gov/poxvirus/monkeypox/clinicians/infection-control-healthcare.html • Centers for Disease Control and Prevention, Sequence for putting on Personal Protective Equipment (PPE), https://www.cdc.gov/hai/pdfs/ppe/ppe-sequence.pdf • Guidelines for the management of Monkeypox disease, Ministry of Health and Family Welfare, Government of India (May 2022), https://main.mohfw.gov.in/sites/default/files/Guidelines%20for%20Management%20of%20Monkeypox%20Disease.pdf • National Infection Prevention and Control Strategic'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 7}, page_content='Infection Prevention and Control Strategic Framework (March 2020), https://www.nicd.ac.za/wp-content/uploads/2020/04/National-Infection-Prevention-and-Control-Strategic-Framework-March-2020-1.pdf • World Health Organization, Health topics: Monkeypox (June 2022), https://www.who.int/health-topics/monkeypox#tab=tab_1 • World Health Organization, OpenWHO, Monkeypox: Epidemiology, preparedness and response for African outbreak contexts (June 2022), https://openwho.org/courses/monkeypox-intermediate/items/2bUkmUOjzx4a15s3sGHYeM • World Health Organization, Clinical management and infection prevention and control for monkeypox: Interim rapid response guidance (June 2022),'),\n",
       " Document(metadata={'source': 'monkeypox\\\\IPC-SOP-For-monkeypox-management.pdf', 'page': 7}, page_content='Interim rapid response guidance (June 2022), https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 0}, page_content='Interim Guidelines for Mpox (Monkeypox) V1.4  01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 1}, page_content='1   \\nV 1.4   01 June 2023 \\n          The guidelines for mpox were developed with the best available data and evidence. These guidelines will be updated as more information becomes available.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 2}, page_content='2   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 2}, page_content='Versions Update  Version 1.0 • Was written and published on May 22ed,2022  Version 1.1 • Update the surveillance case definitions and reporting   • Update the reporting and investigation forms  • Added the discontinue isolation and transmission precautions • Added the public health measures at ports of entry • Added the contact tracing  Version 1.2 • Update the discontinue isolation and transmission precautions • Added the handling of dead bodies   Version 1.3 • Update the introduction and the causative agent and natural host • Update modes of transmission. • Update the surveillance definitions of human cases of mopx  • Update the infection prevention and control • Update mpox investigation'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 2}, page_content='and control • Update mpox investigation form • Added the vaccination  Version 1.4 • Update the introduction and the causative agent and natural host  • Update modes of transmission. • Update Signs and Symptoms. • Update the surveillance definitions of human cases of mpox • Update the infection prevention and control. • Update discontinue isolation and transmission precautions • Update handling of dead bodies • Update the vaccination • Update the immediate notifiable form for a suspected case of mpox • Update mpox investigation form'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 3}, page_content='3   \\nV 1.4   01 June 2023 \\nContent:   Introduction 4 The Causative Agent and Natural Host 4 Modes of Transmission 5 Signs and Symptoms 5 Surveillance Definitions of Human cases of Mpox 6 Reporting 6 Infection Prevention and Control 7 Discontinue Isolation and Transmission Precautions 10 Laboratory Diagnosis 11 Public Health Measures at Ports of Entry (PoE) 13 Contact Tracing 13 Vaccination 14 Handling of Dead Bodies 19 Appendixes 20 References 26 Attached: Sample Collection Guide in Mpox Patients 27 Attached: Infection Prevention and Control Posters 33'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 4}, page_content='4   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 4}, page_content='Introduction:  Mpox is a viral illness first discovered in 1958 when two outbreaks of a pox-like disease occurred in colonies of monkeys in a research facility, so the name \"Monkeypox\" comes from this event. In 1970, the first human case of mpox was recorded in the Democratic Republic of the Congo (DRC). It has become endemic in parts of Central and West Africa and is most concentrated in the Democratic Republic of the Congo. In 2003, the first mpox outbreak outside Africa was in the United States of America, with over 70 cases, and was linked to contact with infected pet prairie dogs. mpox has also been reported in travelers from Nigeria to Israel and the United Kingdom in sporadic cases'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 4}, page_content=\"Israel and the United Kingdom in sporadic cases between 2018 and 2022.   On 14 May 2022, a cluster of mpox cases was reported in the United Kingdom, and these cases have no history of travel or travel-related case. Since the UK's reporting of cases, several other countries have reported cases of mpox around the world, mainly in Europe and North America. All infections characterized so far among the recent clusters have been due to the West African clade. This is the first time that chains of transmission are reported outside Africa without known epidemiological links to West or Central Africa. On 23 July 2022, the Director General of the World Health Organization (WHO) declared this\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 4}, page_content='the World Health Organization (WHO) declared this multi-country outbreak of mpox a Public Health Emergency of International Concern (PHEIC).  On May 2023, this multi-country outbreak of mpox which affected 111 countries, resulted in more than 87,000 cases and 140 deaths, according to the World Health Organization (WHO). However, there has been a significant decline in cases over the last three months compared to the previous three months, with almost 90% fewer cases reported. As a result, the committee recommended to the Director-General of WHO that the outbreak of mpox disease no longer constitutes a health emergency of international concern (PHEIC). On May 11, 2023, the Director-General'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 4}, page_content='(PHEIC). On May 11, 2023, the Director-General of WHO accepted this recommendation and declared that mpox no longer constituted a public health emergency of international concern. Coincident immunity to the Monkeypox virus was previously achieved with vaccinia vaccination; however, eradicating smallpox and subsequent lack of vaccination efforts paved the way for mpox to gain clinical relevance. The Causative Agent and Natural Host Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family, the same family of the virus that causes smallpox (eradicated in 1980). While mpox is not related to chickenpox, which is caused by the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 4}, page_content='not related to chickenpox, which is caused by the varicella virus, it is not an orthopoxvirus. Currently, two phylogenetically distinct clades have been identified: Clade I (formerly known as Central African (Congo Basin)) and Clade II (formerly known as West African clade). Additionally, the Clade II consists of two subclades. In 2022-2023 a global outbreak of mopx mainly caused by clade IIb. Mpox can infect various animal species, but the natural host is unknown. This includes rope squirrels, tree squirrels, Gambian pouched rats, sooty mangabey, and other species.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 5}, page_content='5   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 5}, page_content='Modes of Transmission Transmission of the Monkeypox virus occurs when a person comes into contact with the virus through an infected human, contaminated materials, or infected animal. Human-to-human transmission Human-to-human transmission occurs mainly through physical contact with a person having mpox symptoms or contact with contaminated surfaces or personal belongings. In 2022-2023 a global outbreak of mopx, most cases have been transmitted through close, intimate contact with symptomatic people, primarily during sexual contact. Additionally, the mopx can be transmitted through the placenta in infected pregnant women to their fetus and through percutaneous injury has also been'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 5}, page_content='and through percutaneous injury has also been documented in health workers during specimen collection as well as in the community setting in particular tattoo parlors. Animal-to-human (zoonotic) transmission It is less likely in Saudi Arabia, and it may occur through bite or scratch, direct contact or indirect contact with body fluids, or cutaneous or mucosal lesion material of infected animals. Signs and Symptoms The incubation period • Usually from 6 to 13 days but can range from 5 to 21 days.  After the incubation period, the illness typically lasts for 2−4 weeks of infection, and it can be divided into two periods:  The invasion period  • Usually lasts between 0-5 days. • Characterized'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 5}, page_content='• Usually lasts between 0-5 days. • Characterized by fever, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia (lack of energy). • However, prodromal symptoms can be absent or follow rash onset. • Lymphadenopathy is a distinctive feature of mpox compared to other diseases that may initially appear similar (chickenpox, measles, smallpox). The skin eruption period • Usually begins within 1-3 days of the appearance of fever. • Pattern: scattered or localized to a body site rather than diffuse • Rash often starts in mucosal areas (e.g., genital, perianal, oral mucosa) and may not develop simultaneously in all body areas. • The rash evolves through the following stages'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 5}, page_content='• The rash evolves through the following stages sequentially from macules (lesions with a flat base) to papules (slightly raised firm lesions), vesicles (lesions filled with clear fluid), pustules (lesions filled with yellowish fluid), and crusts which dry up and fall off.  • Proctitis: anorectal pain, tenesmus, and rectal bleeding; associated with visible perianal vesicular, pustular, or ulcerative skin lesions and proctitis • Oropharyngitis: complicated by tonsillar swelling, abscess, dysphagia.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 6}, page_content='6   \\nV 1.4   01 June 2023 \\nSurveillance Definitions of Human cases of Mpox  A suspected case is defined as: • A case that has meets clinical criteria  A confirmed case is defined as: A person who meets the suspected case definition with laboratory confirmation Monkeypox PCR positive OR Isolation of Monkeypox virus in culture.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 6}, page_content='Note: Evaluate for STIs as per current guidelines.  Reporting  Reporting of suspected cases  The mpox is an emerging incident, and suspected cases must be reported by all healthcare facilities using the notification form immediately to: - Health Electronic Surveillance Network (HESN). - Email the notification form immediately to: - Communicable diseases program at Clusters and /or Regional Health Directorates. - Coordinators at the Regional Health Directorate report to the Communicable Disease Department at MOH. Note: Failure to report reportable infectious diseases by healthcare organizations and/or professionals is punishable by law.  Clinical criteria: Unexplained rash* (macular,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 6}, page_content='Clinical criteria: Unexplained rash* (macular, popular, vesicular, pustular) AND one or more of the following: 1. high-grade fever (>38.2°C) 2. lymphadenopathy 3. intense headache 4. back pain/myalgia 5. intense asthenia (fatigue and lack of energy)  *Unexplained rash is a rash for which the following common causes of acute rash do not explain the clinical picture: drug eruption, food allergy, varicella-zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, primary or secondary syphilis; and any other locally relevant common causes of popular or vesicular rash. In addition, An Unexplained rash includes Unexplained genital, ano-genital, or oral lesion(s) (for example,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 6}, page_content='ano-genital, or oral lesion(s) (for example, ulcers, nodules) or proctitis (for example, anorectal pain, bleeding)'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 7}, page_content='7   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 7}, page_content='Infection Prevention and Control Mpox is believed to be transmitted between humans mainly via physical contact with a person having mpox symptoms or contact with contaminated surfaces or personal belongings. Transmission through respiratory droplets might occur when face-to-face contact with a person having mpox symptoms happens.  Early recognition and source control.  • Healthcare workers should be aware of the signs and symptoms of mpox and are encouraged to apply them to hospital clients for early detection and source control. • Use of signage to remind healthcare workers (HCWs) of the signs and symptoms.  • Respiratory hygiene is another important measure that should be applied to all'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 7}, page_content=\"important measure that should be applied to all HCWs, patients, and visitors.  • Whenever possible, patients identified as suspected mpox cases should be placed in a separate area from other areas of care. • If a patient seeking care is suspected to have mpox, infection prevention and control personnel should be notified immediately.  Application of standard precautions for all patients. Strict adherence to standard precautions should be followed whenever handling patients. These include:  • Proper hand hygiene.  • Use of Personal Protective Equipment's (PPEs) in a correct sequence (gowns, masks, goggles if splashes are expected, and gloves).  • Safe usage and disposal of sharps. • Aseptic\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 7}, page_content='• Safe usage and disposal of sharps. • Aseptic technique.  • Environmental cleaning and disinfection.  • Medical waste management.  Implementation of empiric additional precautions. In addition to standard precautions, suspected cases should be placed under droplet, and contact precautions.  Patient placement:  • A patient with suspected or confirmed Mpox infection should be placed in a single-person room with dedicated bathroom under droplet and contact precautions; special air handling is not required. • With the rapid influx of cases, cohorting of cases in the same room should be considered with proper signage placed indicating care of cases.  • Cohorting of cases should be considered'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 7}, page_content='cases.  • Cohorting of cases should be considered only when there is a significant shortage in single rooms and based on the infection prevention & control recommendations with the following considerations:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 8}, page_content='8   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 8}, page_content='- Cohorting only for confirmed cases. - Place the patients with distance between beds.  - Place physical separations between the beds. - Disallow any visitors or caregivers.  - Avoid performing aerosol-generating procedures inside the room. - Any aerosol-generating procedures (AGPs) should be performed in a single bed negative pressure room and if the negative pressure room is not available, the case should be placed in a single room with the use of a portable high-efficiency particulate air (HEPA) filter.  Personal Protective Equipment PPEs:  • PPEs should be donned and doffed in correct sequence whenever handing suspected or confirmed cases.  • PPEs should be donned prior to entry to the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 8}, page_content='• PPEs should be donned prior to entry to the isolation room and doffed prior to exit from the patient room. • In case of AGPs, all PPEs should be donned prior to entry to the negative pressure room or single room with portable HEPA filter and doffed prior to the exit from the patient room except for the high particulate respirator which should be removed after exit or in the ante room if available.  • Disposable gowns: use disposable gowns whenever care is provided to patients. • Surgical mask: is a loose-fitting, disposable device that creates a physical barrier between the mouth and nose of the wearer and potential contaminants in the immediate environment. • High-efficiency particulate'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 8}, page_content=\"environment. • High-efficiency particulate respirators: use fit-checked sealed masks whenever performing AGP. If the mask doesn’t match the size of the healthcare provider or the non-fitted healthcare provider' Powered Air Purifying Respirator (PAPR) should be used.   • Goggles and eye protection: whenever splashes are expected, use goggles and eye protection to minimize the risk of exposure.  • Gloves: use gloves whenever in contact with the patient, examining and contact with the patient surroundings.   Transportation of suspected and confirmed mpox patients:  • Patients’ movements should be restricted as much as possible unless indicated.  • Use portable machines such as portable x-rays\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 8}, page_content='• Use portable machines such as portable x-rays machines whenever investigations are required. If not available, transport the patient in a designated pathway that avoids crowded areas. • Notify the receiving designation about the case to allow them to take the proper precautions prior to receiving the patient. • Those who are transferring the patient should adhere to isolation precautions and wear proper PPEs, as well as placing an isolation transportation card and ask the patient to wear surgical mask. • Covering any of the patient’s exposed skin lesions with a sheet or gown.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 9}, page_content='9   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 9}, page_content='Environmental infection prevention & control measures: • Housekeepers and workers responsible for cleaning and disinfection should wear appropriate PPEs when cleaning rooms housing patients.  • In-patient rooms should be cleaned and disinfected at least daily and at the time of patient transfer or discharge or when required. • More frequent cleaning and disinfection may be indicated for high-touch surfaces and following aerosol producing procedures (e.g., tables, hard-backed chairs, doorknobs, light switches, remotes, handles, desks, toilets, sinks) • Cleaning and disinfection of the environmental surfaces should be done with approved MOH registered hospital-grade with an emerging viral'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 9}, page_content='registered hospital-grade with an emerging viral pathogen claims disinfectant, or with freshly prepared sodium hypochlorite solution 1000 ppm with consideration to the contact time in accordance with manufacturer’s instructions for environmental surface disinfection. • Activities such as dry dusting, sweeping, or vacuuming should be avoided. Wet cleaning methods are preferred. • Care should be taken when handing used patient-care equipment in a manner that prevents contamination of skin and clothing. • Ensure that used reusable equipment has been cleaned and reprocessed appropriately. • Linens and clothing should be collected and put in bags inside the room before the cleaning process'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 9}, page_content='bags inside the room before the cleaning process begins.  • Soiled laundry should be gently and promptly contained in an appropriate laundry bag and never be shaken or handled in manner that may disperse infectious material. • Adherence to standard precautions when handling contaminated laundry that generated from mpox cases and minimizing agitation of the contaminated items are considered sufficient to prevent the dispersal of potentially infectious aerosols. • Contaminated clothing and linen should be washed in high temperature washing cycle. • Transportation of food tray to the patients should be delivered from the food server’ to the nurse and accordingly the nurse delivers it to the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 9}, page_content='and accordingly the nurse delivers it to the patient. • Generated wastes from patients’ room should be handled as infectious waste and discarded accordingly.  Visitation Visitors to patients with mpox should be avoided to minimize risk of exposure and to prevent transmission of the infection. However, there is exception for those essential for the patient’s care and wellbeing (such as parents of a child) according to their age or who are unable to advocate for themselves and it permitted after providing care giver (e.g., parents) a comprehensive education & training about the required isolation precautions and infection prevention & control recommendations.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 10}, page_content='10   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 10}, page_content=\"Discontinue Isolation and Transmission Precautions Confirmed Cases: • All confirmed cases should be isolated in the healthcare facility. Based on bed capacity and if the confirmed case is clinically stable, home isolation may be considered based on the assessment of the public health team and the treating physician under the supervision of the regional command and control center (Regional CCC) with approval of the central command and control center (Central CCC) and after providing the patient' appropriate education in regard to the isolation measures. • Discontinuity of isolation should be done in consultation with the treating physician. • Patients should remain under isolation and\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 10}, page_content=\"• Patients should remain under isolation and transmission precautions until the resolution of the symptoms and the lesions have crusted, those crusts have separated, and the skin started to form a new layer underneath.   Suspected Cases: • All suspected cases must be tested and isolated in the healthcare facility. Based on bed capacity and if the suspected case is clinically stable, home isolation may be considered based on the assessment of the public health team and the treating physician under the supervision of the regional command and control center (Regional CCC) with approval of the central command and control center (Central CCC) and after providing the patient' appropriate\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 10}, page_content=\"CCC) and after providing the patient' appropriate education in regard to the isolation measures and until the result becomes available.    • If clinically unstable, the suspected case must be isolated in a hospital until the result becomes available and he/she will be managed accordingly. • If the case is clinically stable, can be discharged to home if negative result appeared. • If the result is positive, the suspected case is considered a confirmed case and managed accordingly.\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 11}, page_content='11   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 11}, page_content='Laboratory Diagnosis Nucleic acid testing (NAT) is the primary diagnostic tool for mpox. Clinical and epidemiological data should be considered, and collection of appropriate and sufficient specimens is important. Infection is confirmed by detection of Monkeypox virus using PCR. Specimen collection The best source of specimens for laboratory diagnosis of mpox infections is skin lesions. Specimens should be collected by trained staff wearing full PPE, including gowns, gloves, and masks.   Specimen Type for NAT testing Lesion material is required for persons with active lesions or rash. Lesion material, scrapings, biopsy tissue (non-formalin fixed), lesion fluid can be collected. Collect'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 11}, page_content='fixed), lesion fluid can be collected. Collect specimens from at least 3 lesions and preferably from different sites on the body.  Collection of specimens and Storage  Collect the appropriate sample type in a sealed sterile container. Sample each lesion separately. For swabs, use sterile nylon, polyester, or Dacron swabs. Swabs intended for bacterial preservation, and cotton swabs should not be used. Use of liquid transport media might cause dilution of the specimen. Label the specimen with all the essential information. If multiple specimens are collected, please indicate the site of the collection for each one. Store refrigerated at (2-8°C) within an hour after collection (for up to 7'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 11}, page_content='within an hour after collection (for up to 7 days). Freeze specimens at (-20°C or lower) for longer storage (up to 1 month).   Collection of specimens for nucleic acid testing Appropriate equipment for specimen collection: • Personal protective equipment • A small scalpel blade or 25G needle  • Leak-proof sealed tubes  • Dry swabs  • A waterproof sharps container for needles, syringes, scalpels • Waterproof plasters • A sealable plastic specimen bag. Absorbent packaging material and a strong metal outer container plus biohazard tape to seal it and appropriate disinfectant solution to clean the outside before transport to the laboratory.  Procedure for collection of specimens for nucleic'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 11}, page_content='Procedure for collection of specimens for nucleic acid testing • Wear appropriate personal protective equipment  • Gently deroof a vesicle using a syringe.   • Rub the base of the lesion firmly using a dry swab while rotating the swab to absorb fluid from the lesion onto the swab and to get the cellular material from the lesion base.  • Sample at least 3 lesions from different locations on the body or from lesions which differ in appearance.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 12}, page_content='12   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 12}, page_content='• Place the swab into a sterile, leak-proof container.  • Label the tubes with patient information and site of collection, place them in the zip-lock plastic specimen bag, and seal them.   • Use waterproof dressing(s) to cover the deroofed lesions. • After specimen collection, all protective materials (gloves, mask, gown, etc.) and all used collection materials must be placed in biohazard bags and autoclaved or incinerated prior to disposal. Use an appropriate sharps container to dispose of Needles and immediately autoclave.  Referral of samples to Public Health Laboratory: 1. In HESN Plus you can register the case and request the test Monkeypox (mpox) PCR , select the type of samples,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 12}, page_content='(mpox) PCR , select the type of samples, collection sites, and for the distention select Public Health Laboratory (PHL). 2. Label each specimen container with the patient’s ID number, HESN requisition ID, and the date the sample was collected.  3. Store the samples at 2-8°C and ship to PHL on ice pack.  4. Lab Results will be reported to HESN Plus 5. The average Turnaround time (TAT) for the lab results is 48 Hours  Specimens Packaging and Shipment to the PHL laboratory: All materials transported within and between laboratories should be placed in a secondary container to minimize the potential for breakage or a spill.  • Patient specimens from suspected or confirmed cases should be'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 12}, page_content='from suspected or confirmed cases should be transported as UN3373, “Biological. Substance, Category B. All specimens being transported as UN3373 should have appropriate packaging, labelling and documentation. • Specimens should be put in a sterile, leak-proof container screwed properly then sealed with Para film tape and placed in waterproof secondary container e.g., ziplock bags after which they should be put in a third container. Cooling agent should be outside the secondary container. • Paper sheets should be sealed in waterproof bags and kept separated from the specimens • Samples can be shipped free of charge via SMSA courier to Public Health Laboratory (PHL) as per regulations.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 12}, page_content='Health Laboratory (PHL) as per regulations.  Notify the PHL of the dispatch of the specimen and courier or airway bill number as appropriate.  •  Shipment addressed to: Public Health Laboratory,  Public health Authority,  Al Aarid, Riyadh.  phl@pha.gov.sa The courier service is available for sample transportation and pickup locations throughout the country for the collection of samples from MOH and non MOH hospitals and other Health care facilities. Courier services are provided 24 hours / 7 days a week.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 13}, page_content='13   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 13}, page_content='Public Health Measures at Ports of Entry (PoE) In response to recent outbreaks of mpox disease in multi-country, The Kingdom of Saudi Arabia has implemented procedures for all travelers arriving  (refer to the public health measures at ports of entry guideline). Contact Tracing Contact tracing is considered one of the most important public health measures to control the spread of communicable diseases. A contact is defined as a person who, in the period beginning with the onset of the source case’s first symptoms, and ending when all scabs have fallen off, has had one or more of the following exposures with a probable or confirmed case of mpox: • face-to-face exposure (including health care'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 13}, page_content='• face-to-face exposure (including health care workers without respiratory protection) • direct physical contact, including sexual contact • contact with contaminated materials such as clothing or bedding  As soon as a suspected case is identified, contact identification, and contact tracing should be initiated and fill out the List of Patient’s Contacts form. Contacts should be notified within 24 hours of identification. Contacts should be monitored at least daily for the onset of signs/symptoms for a period of 21 days from the last contact with a patient in the infectious period. The public health team at the regional health directorate is responsible for listing, tracing, and follow up'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 13}, page_content='responsible for listing, tracing, and follow up looking for symptoms of household and other contacts of patients with mpox infection in the community. Regional public health teams should keep all lists of contacts in an excellent professional format.   Note: Healthcare contacts should follow the management of exposed healthcare workers (HCWs) to a mpox case in healthcare facilities.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 14}, page_content='14   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 14}, page_content='Vaccination  Vaccination is one of the public health response measures to control the further spread of mpox infection with other public health measures, including surveillance, contact-tracing, isolation, and care of patients. As mpox is the same family of the virus that causes smallpox, the vaccines designed for smallpox will likely provide a degree of cross-protection. Previously, the vaccine used against smallpox in Africa proved to provide up to 85% effectiveness in preventing mpox infection. There are three generations of smallpox vaccines. Historically, the first and second generations are live smallpox vaccines (replication-competent) have been used for the population level. The'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 14}, page_content='have been used for the population level. The first-generation vaccines are not recommended for mpox at this time, as they do not meet current safety and manufacturing standards. The second generation of smallpox vaccine (ACAM2000) and the third generation of smallpox vaccine name JYNNEOS (also known as Imvamune or Imvanex) are both can be used to prevent mpox infection, and the JYNNEOS vaccine has been approved for the prevention of mpox.   Use of JYNNEOS vaccine (Live, Non-replicating) In the meantime, mass vaccination for the general population is not recommended for mpox disease outbreak control. However, it is recommended for a specific group of people with a high risk of mpox'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 14}, page_content='specific group of people with a high risk of mpox infection. In order to implement vaccination strategies, the JYNNEOS vaccine is used in the Kingdom of Saudi Arabia as the following: Indications and Usage of Vaccine  Pre-exposure prophylaxis (Prep) – for the certain targeted at-risk group • A vaccine is administered to people at high risk of mpox (for example, laboratory workers that handle monkeypox-contaminated specimens in laboratories dedicated for mpox diagnosis or healthcare personnel who deal with mpox cases for performing diagnostic testing).  • Currently, most clinicians and laboratories are not advised to receive mpox vaccines as preventative measures because they do not perform'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 14}, page_content='preventative measures because they do not perform the orthopoxvirus generic test. Post-exposure prophylaxis (PEP) – for close contact with a confirmed case • It is appropriate to consider this approach to be the \"standard PEP\" for mpox during the current outbreak. In order to prevent mpox virus infections, vaccination is available following exposure to mpox. Identifying contacts of confirmed mpox cases is crucial for offering PEP vaccines and monitoring early symptoms.  • For the public: The vaccine is given to anyone who has been exposed to high-risk direct contact of a confirmed case (according to the assessment of public health), including contact with skin lesions, exposure to body'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 14}, page_content='contact with skin lesions, exposure to body fluids, and sexual intercourse.  • For healthcare workers: The vaccine is given to anyone exposed to medium or high-risk unprotected contact of a confirmed or probable case (according to the assessment of infection control in the facility).  • The vaccine should be given as soon as possible, and for the best chance of preventing the onset of the disease, the vaccine should be given within four days of exposure.  • The vaccination may reduce symptoms of the disease when administered within 4 to 14 days of exposure, but it may not prevent it.  PEP, however, is a useful tool for controlling outbreaks of mpox and preventing further transmission when'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 14}, page_content='of mpox and preventing further transmission when used in conjunction with self-isolation and other prevention procedures.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 15}, page_content='15   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 15}, page_content='Vaccine Dosage and Administration  Dose and Schedule • Individuals less than 18 years of age: administer two doses by subcutaneous route (0.5 mL each) 4 weeks apart (28 days). • Individuals 18 years of age and older: administer two doses by intradermal route (0.1 mL each) 4 weeks apart (28 days).  Preparation and Administration Allow the frozen vaccine to thaw and reach room temperature before use. Which usually takes 10-15 minutes  • JYNNEOS is a milky, light yellow to pale white colored suspension when thawed. • Inspect each vail visually for particulate matter and discoloration before administration; if either of these conditions exists, the vaccine should not be administered.  • Swirl'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 15}, page_content='the vaccine should not be administered.  • Swirl the vial gently for at least 30 seconds and clean the vial stopper with a single-use antiseptic swab before each use.  Subcutaneous injection for individuals less than 18 years of age  • Withdraw a dose of 0.5 mL into a sterile (23–25 gauge, 5/8” needle) syringe for injection. • Administer by subcutaneous injection, preferably into the anterolateral thigh for infants less than one year of age or into the upper arm (deltoid) for individuals 1 through 17 years of age.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 16}, page_content='16   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 16}, page_content='Intradermal injection for individuals 18 years of age and older  • Withdraw a dose of 0.1 mL into a sterile syringe for injection. Use either a 26 gauge or 27 gauge, 3/8”, 1/4” to 1/2” needle with a short bevel. • Low-dead volume syringes and/or needles can be used to extract five doses (0.1 mL each). If standard syringes and needles are used, there may not be sufficient volume to extract five doses from a single vial.  • Administer the dose by intradermal injection, preferably into the forearm’s volar aspect (inner side). • While pulling the skin taut, position the needle bevel facing upward and insert the needle at a 5 to 15-degree angle into the dermis. Slowly inject 0.1mL intradermally.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 16}, page_content='the dermis. Slowly inject 0.1mL intradermally. This should produce a noticeable pale elevation of the skin (wheal). Warning, irrespective of the type of syringe and needle used:  • Each dose must contain 0.1 mL of vaccine.  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.1 mL, discard the vial and its contents.  • Do not pool excess vaccine from multiple vials.  • Once the vial is punctured and a dose is withdrawn, if it is not used in its entirety, it should be stored at +2°C to +8°C and discarded within 12 hours of the first puncture.  • Each dose should be drawn and given immediately, and the content of the vial should not remain at room temperature for'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 16}, page_content='vial should not remain at room temperature for more than an hour.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 17}, page_content='17   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 17}, page_content='Vaccine Contraindication and Precautions   Contraindications Based on the limited available data on the emergency uses of JYNNEOS, the vaccine should not be given to individuals who are known to have a severe (life-threatening) allergic reaction to a previous dose of JYNNEOS. Precautions  • History of a severe allergic reaction (e.g., anaphylaxis) to gentamicin, ciprofloxacin, chicken, or egg protein. The vaccine can be given if the benefits outweigh the potential risk of anaphylaxis. Vaccinated individuals should be monitored for 30 minutes post-vaccination.  • If an individual is suffering from a severe acute systemic illness, immunization may be postponed until they have fully recovered.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 17}, page_content='may be postponed until they have fully recovered. Vaccine Special Considerations Pregnancy Limited available data, which include animal studies, suggests the probable safety of the vaccine for the fetus and mother. However, it’s not routinely recommended to vaccinate pregnant women unless the potential benefits outweigh the theoretical risk. Lactations It is not known whether JYNNEOS is excreted in human milk, but this is unlikely as the vaccine virus does not replicate effectively in humans. Individuals who are breastfeeding and have significant exposure to mpox should therefore be offered vaccination after discussing the risks of mpox to themselves and the breastfed child. Individuals'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 17}, page_content='themselves and the breastfed child. Individuals with underlying medical conditions Individuals with atopic dermatitis are known to have developed more site-associated reactions and generalized symptoms following mpox vaccination. Individuals in this group, therefore, need to have a risk assessment before being offered vaccination. Individuals with a history of developing keloid scarring may be offered a 0.5mL subcutaneous dose of JYNNEOS in preference to a fractional dose intradermally.  Immunosuppression JYNNEOS is a replication-defective virus and should pose no risk to those who are immunosuppressed. The safety and immunogenicity have been demonstrated in immunocompromised. However, the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 17}, page_content='demonstrated in immunocompromised. However, the immune response to the vaccine could be reduced in severely immunosuppressed individuals. Vaccination should proceed using a 0.5mL subcutaneous dose in individuals with immunosuppression. Note: A person offered JYNNEOS vaccine due to exposure to monkeypox virus or disease should be vaccinated regardless of concurrent illnesses, pregnancy, breastfeeding, or weakened immune system.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 18}, page_content='18   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 18}, page_content='Vaccine Adverse Reactions  In smallpox vaccine-naïve healthy adults who received JYNNEOS subcutaneously, the most common (>10%) solicited injection site reactions were pain (84.9%), redness (60.8%), swelling (51.6%), induration (45.4%), and itching (43.1%); the most common solicited systemic adverse reactions were muscle pain (42.8%), headache (34.8%), fatigue (30.4%), nausea (17.3%) and chills (10.4%).   In smallpox vaccine-naïve healthy adults who received JYNNEOS intradermally, the most common (>10%) solicited reactions were erythema at the injection site (99.5%), induration at the injection site (99.5%), itchiness (89.0%), pain at the injection site (65.4%), feeling tired (51.3%),'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 18}, page_content='injection site (65.4%), feeling tired (51.3%), headache (41.4%), muscle aches (30.4%), nausea (23.0%), underarm pain (20.9%), change in appetite (20.4%), joint pain (17.8%), chills (14.7%), and underarm swelling (10.5%) Storage and Handling of Vaccine  If the vaccine is received frozen and requires storage before use, it can be stored in two ways: • Freezer storage: between -25°C and -15°C can be stored in the freezer up to the expiration date.  • Refrigerator storage: between 2°C and 8°C: after 10 minutes, it becomes thawed vaccine and must be used within eight weeks from thawing. Do NOT refreeze.  If the vaccine is received refrigerated and requires storage before use: • Maintain'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 18}, page_content='and requires storage before use: • Maintain refrigerated between 2C° and 8°C. • Refrigerated vaccine is thawed vaccine and must be used within eight weeks from thawing. • DO NOT refreeze. General Consideration.  • Store in the original package to protect from light. • Do not refreeze a vial once it has been thawed.  • Once thawed, the vaccine may be kept at +2°C to +8°C for up to eight weeks. • After the first puncture, the vial can be stored at +2°C to +8°C for up to 12 hours.  Registration and Reporting of Vaccine Adverse Events  Constant data and updates are being generated regarding the vaccine’s efficacy, safety, and usability. Therefore, it’s important that all recipients of the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 18}, page_content='it’s important that all recipients of the vaccine should be registered in the National Vaccination Registry (NVR) to allow for continuous monitoring and direct contact if necessary.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 19}, page_content='19   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 19}, page_content='Handling of Dead Bodies Strict compliance to standard precautions with appropriate use of personal protective equipments and safety features is considered a significant measure in dealing with all post-mortem procedures. If it is applicable, healthcare workers (HCWs) with an up-to-date smallpox vaccination (within three years) should participate in autopsy or mortuary care for patients with confirmed or suspected mpox.  Dealing with Dead Bodies  • Dead bodies of mpox confirmed or suspected patients could pose a risk of infection transmission. • Personnel who perform post-mortem care of remains should wear PPE as recommended for Standard, and Contact transmission-based Precautions. •'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 19}, page_content='and Contact transmission-based Precautions. • Isolation precautions should be continued for the deceased mpox confirmed or suspected case. • Cadaver bags that fulfill MOH-approved specifications should be used for transport of dead bodies of deceased mpox patients, and those handling the body at this point should use PPE (for only AGPs; fit-tested seal checked respirator or powered air-purifying respirators (PAPR) [for personnel who cannot wear respirators because of facial hair or other fit-limitations], clean gloves, surgical mask, and isolation gown). • The trolley carrying the body must be disinfected post transportation. • Only experienced morgue staff are dealing with bodies of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 19}, page_content='morgue staff are dealing with bodies of deceased mpox patients, the morgue’s staff should be well trained, and familiar with standard precautions and transmission-based precautions while handling dead bodies, especially hand hygiene, safe and proper use of PPE. • The morgue’s staff should be informed about the infectious status of the deceased, the risk of infection, and appropriate precautions required through the use of the morgue’s transportation card attached to the dead body or the bag about the disease and transmission-based precautions required.  • Prevents relatives from direct surface contact with the body, such as touching or kissing it. However, it is acceptable to open the body'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 19}, page_content='it. However, it is acceptable to open the body bag for family viewing while wearing PPE (surgical mask, isolation gown, and clean gloves) • Limit the number of morgue’s personnel dealing with the dead body to the minimum number required. • All persons performing or attending the body washing and preparation should wear PPE (fit-tested seal checked respirator or powered air-purifying respirators (PAPR) [for personnel who cannot wear respirators because of facial hair or other fit-limitations], isolation gown, and clean gloves, plastic apron and eye protection) and should perform hand hygiene after removal of the gloves and when required. • Body Washing of mpox confirmed or suspected dead'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 19}, page_content='Body Washing of mpox confirmed or suspected dead bodies should be done at hospitals and is not allowed to be transferred to home or public washing authorities.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='20   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='Appendixes:   يرﺪﺟ ضﺮﻤ) ﺔﻬﺒ ةدﺮﻘﻟا  ?@A اﻟﻤﻤﻠCﺔ اﻟﻌEFGﺔ اﻟﺴﻌﻮدIﺔ  Immediate Notifiable Form for a Suspected Case of Mpox in Saudi Arabia Date of notification: dd/mm/yyyy                Time:  Epidemiological week: Reporting person: Reporting facility: Reporting address: Reporting contact number: ﺗﺎر$ــــﺦ اﻹ*ﻼغ: ﻮﻳم1ﺷﻬﺮ1ﺳﻨﻪ             وﻗﺖ اﻹ*ﻼغ:  اﻷﺳﺒ=ع اﻟ=@ﺎABC رﻗﻢ: اﺳﻢ اﻟﻤFﻠﻎ: اﻟﺠﻬﺔ اﻟﻤFﻠﻐﺔ:  ناﻮﻨﻋ اﻟﻤFﻠﻎ1اﻟﺠﻬﺔ: رﻗﻢ اﻟﺘﻮاﺻﻞ ﻟﻠﻤFﻠﻎ1ﻟﻠﺠﻬﺔ: Suspected case information ﺔﻬﺒ  اﻻﺳﻢ: ﺗﺎر$ــــﺦ اﻟﻤXﻼد: ﻮﻳم1ﺷﻬﺮ1ﺳﻨﻪ              اﻟﻌﻤﺮ: اﻟﺠZﺴXﺔ:                                      اﻟﺠZﺲ: رﻗﻢ اﻟﻬ=$ﺔ1اﻟﺠﻮاز:                         ﻧ=ع اﻟﻬ=$ﺔ: (ﺪ  رﻗﻢ اﻟﺘﻮاﺻﻞ: اﻟﻌﻨﻮان: اﻟﻤﺪﻳﻨﺔ ............... اﻟfC'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='اﻟﺘﻮاﺻﻞ: اﻟﻌﻨﻮان: اﻟﻤﺪﻳﻨﺔ ............... اﻟfC واﻟﺸﺎرع................................... رﻗﻢ اﻟﻤghhل........... اﻟﻤﺮﻛﺰ اﻟﺼfC mhC ﻣﻨﻄﻘﺔ ﺳﻜﻦ اﻟﻤr$ﺾ: ﻋﺎﻣﻞ mhC اﻟﺮﻋﺎcﺔ اﻟﺼﺤXﺔ:      □ ﻢﻌﻧ                                           □ ﺔﻨﻬﻤﻟا ﺪ (…………………… ﻣvﺎن اﻟﻌﻤﻞ 1 اﻟﺪراﺳﺔ: Name:                       Sex: Date of birth: dd/mm/yyyy Age:  Nationality:                       ID type: (specify) ID number: Contact number(s):  Address: city......... ….. Dist&St. ….……………………......…block  ….. PHC in patient’s resident area    Healthcare worker:           □Yes                                                  □ No (specify occupation)……………….    Workplace/ study Clinical Data Signs and Symptoms ﺔ اﻻﻋﺮاض'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='study Clinical Data Signs and Symptoms ﺔ اﻻﻋﺮاض واﻟﻌﻼﻣﺎت Rash? □ Yes, onset: dd/mm/yyyy □ No □ ،ﻢﻌﻧ  اﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ                ﻻ ؟يﺪﻠﺟ ﺢﻔﻃ  Description of rash (Please provide types):       (Please provide location)           □ Macular            □ Papular   □ Vesicular           □ Pustular  □ Maculopapular □ Vesiculopustular  □ Face     □ Head      □Mouth     □Neck   □Trunk            □Arms           □Legs □Genitals         □Others…………..                                         □ ﺣﻄﺎ\\x8fC                           □ *ﻘ\\x90C □ ﺣ=$ﺼ\\x91C                          □ *ﻘ\\x90C ﺣﻄﺎ\\x8fC □ ﺣ=$ﺼ\\x91C ﺻﺪcﺪي □         ﻪﺟﻮﻟا □          سأﺮﻟا □          ﻢﻔﻟا □ ﺔ               □        عﺬﺠﻟا □     ﺔ$=ﻠﻌﻟا'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='□ ﺔ               □        عﺬﺠﻟا □     ﺔ$=ﻠﻌﻟا فاﺮﻃﻷا □    ﺔ □     ﺔ □ أﺧﺮى...............      يﺪﻠﺠﻟا ﺢﻔﻄﻟا ﻒﺻو ) ﺪ ﻪﻋﻮﻧ (  )اﻟﺮﺟﺎء ﺗﺤﺪcﺪ ﻣﻮﻗﻌﻪ(: Fever? □ Yes, onset: dd/mm/yyyy             Temperature ….. c0 □ No □ ،ﻢﻌﻧ  إﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ               ةراﺮﺤﻟا ﺔﺟرد .......         ﻻ ؟ Headache ? □ Yes, onset: dd/mm/yyyy □ No □ ،ﻢﻌﻧ  إﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ   ﻻ عاﺪﺻ ؟ Back pain? □ Yes, onset: dd/mm/yyyy □ No □ ،ﻢﻌﻧ  إﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ   ﻻ اﻟﻢ mhC اﻟﻈﻬﺮ؟ Mylagia? □ Yes, onset: dd/mm/yyyy □ No □ ،ﻢﻌﻧ  إﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ                  ﻻ آﻻم mhC اﻟﻌﻀﻼت؟ Exhaustion? □ Yes, onset: dd/mm/yyyy □ No □ ،ﻢﻌﻧ  إﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ   ﻻ قﺎ ؟ lymphadenopathy? □ Yes, onset:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='1ﺮﻬﺷ 1ﻪﻨﺳ   ﻻ قﺎ ؟ lymphadenopathy? □ Yes, onset: dd/mm/yyyy □ No □ ،ﻢﻌﻧ  إﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ   ﻻ اﻧﺘﻔﺎخ mhC اﻟﻐﺪد اﻟﻠﻤﻔﺎو$ﺔ؟ Other (Specify)?............... □ Yes, onset: dd/mm/yyyy □ No □ ،ﻢﻌﻧ  إﺑﺘﺪاءً ﻣﻦ: مﻮﻳ 1ﺮﻬﺷ 1ﻪﻨﺳ   ﻻ  ىﺮﺧأ (دﺪﺣ) ؟.............................. History of Contact with a confirmed or suspected case? □ Yes, last date:    /       /           □ No □ ،ﻢﻌﻧ   ﻟاﺘﺎر$ــــﺦ:    1     1     ﻻ    ﺔﻬﺒ  لﻼﺧ ةدﺮﻘﻟا يرﺪﺟ ضﺮﻤ* 21  مﻮﻳ ؟ﺔﻘ*ﺎﺴﻟا  History of international travel in the last 21 days? □ Yes, last date:    /       /                  From: □ No □ ،ﻢﻌﻧ   ﻟاﺘﺎر$ــــﺦ:    1     1             موﺪﻘﻟا ﺔﻟود :  ﻻ  لﻼﺧ ﺔ 21 ﺔﻘ*ﺎﺴﻟا مﻮﻳ ؟ History of any activities that contain'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='مﻮﻳ ؟ History of any activities that contain direct physical contact, such as massage or sexual activity in the last 21 days? □ Yes, last date:    /       /                  Type (place):……………… □ No □ ،ﻢﻌﻧ   ﻟاﺘﺎر$ــــﺦ:    1     1             ﺔﻌﻗﻮﻣو طﺎﺸ :.…………… ﻻ  ﻤﺗ ﻞ ﺖ  ﺎﻬﺑ نﺎ ﻣﻼﻣﺴﺔ ﺟﺴﺪcﺔ ﻣFﺎ®¯ة \\xadﺎﻟﻤﺴﺎج  وأﺔ  لﻼﺧ 21  مﻮﻳ ﺔﻘ*ﺎﺴﻟا ؟ Is the case immunosuppressed □Yes, Reason:(specify due to diseases or medication or unknown) □ No □ ﻧﻌﻢ، اﻟﺴ°ﺐ: ،ﺔ$ودا وا ضﺮﻣ ﺐ او ﻏg³ ﻣﻌﺮوف( ﻻ  ﻞ اﻟﺤﺎﻟﺔ ﺗﻌﺎAhC ﻣﻦ ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ؟ Do you currently have an STI?  □ Yes :(Please, specify) □ No □ Unknown □ ﻧﻌﻢ،:(ضﺮﻤﻟا ع=ﻧ ﺪ  ﻻ □ ﻏg³ ﻣﻌﺮوف ¡ﻞ cﻌﺎAhC اﻟﻤﺼﺎب ﻣﻦ أﺣﺪ اﻷﻣﺮاض اﻟﻤﻨﻘﻮﻟﺔ ﺟZﺴXﺎ¶؟ Has the case been isolated?'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 20}, page_content='اﻟﻤﻨﻘﻮﻟﺔ ﺟZﺴXﺎ¶؟ Has the case been isolated? □Yes, place of isolation:(specify location) □ No  □ ﻧﻌﻢ، ﻣvﺎن اﻟﻌﺰل :(نﺎ  ﻻ ؟ﺔﻟﺎﺤﻟا لﺰﻋ ﻢﺗ ﻞ  Was a sample taken? □Yes, name of a receiving lab: □ No  □ ﻧﻌﻢ، اﺳﻢ اﻟﻤﺨﺘg· اﻟﻤﺮﺳﻞ ﻟﻪ: ﻻ ؟ﺔﻨﻴﻋ ﺬﺧأ ﻢﺗ ﻞ'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 21}, page_content='21   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 21}, page_content='ﻧﻤﻮذج ﺗﻘKA ﺣﺎﻟﺔ MNOPﺔ ﻣﻦ ﺟﺪري اﻟةدﺮﻘ   Mpox Investigation Form  Notiﬁcation                                                                                                                 ﻎﻠ        جذﻮﻤﻨﻟا ﺔﺌﺒﻌﺘﺑ مﺎﻗ ﻦﻣ ﻢﺳا  Name of who completed the form  ﻒﺗﺎﻬﻟا  Contact number  ﺦــــ  Date  ﻞ Email  ﺔ Hospital Name  ﺔﻨﻳﺪﻤﻟا  City  ﻒﺻو  ﺔﻟﺎﺤﻟا  ﺖﻗو  ﺔﺌﺒﻌﺗ  اﺬ  جذﻮﻤﻨﻟا  At the time of this report, is the case? \\x00 Confirmed  ةﺪﻛﺆﻣ                                             \\x00 Suspected   ﺔﻬﺒ  \\x00 Case under investigation  ﺔﺳارﺪﻟا ﺖﺤﺗ           \\x00 Not a case ةﺪﻌ     Patient Information         ﺾ'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 21}, page_content='اﻻﺳﻢ اﻟqﺎﻣﻞ Full name  ﺔ Identification number:  ﺮﻤﻌﻟا  Age  ﺦــــ  دﻼ  Date of Birth ___dd مﻮﻳ /____mm ﺮﻬﺷ /______yyyy ﺔﻨﺳ  ﺔ Nationality  ﺔ Marital status  ﺲ Sex \\x00 Male ﺮﻛذ                          \\x00 Femaleاﻧ\\x84\\x85   اذا اﻧ\\x84\\x85ﻞﻤﺤﻟا ﺔﻟﺎﺣ ،   If a female, pregnancy status? \\x00 Positive             ﺔ \\x00 Negative  ﺔ  \\x00 Unknownﻏ\\x8e\\x8f ﻣﻌﺮوف  ﺔﻨﻬﻤﻟا  Occupation \\x00 HCWسرﺎﻤﻣ  ﺻ\\x94\\x95     \\x00 Specify : ﺔﻔ _________ ﻣ\\x99ﺎن اﻟﻌﻤﻞ \\x9b اﻟﺪراﺳﺔ Workplace / study  ﻒﺗﺎﻬﻟا  Phone Number  dﺎﺗﻒ إﺿﺎ\\x9d\\x9e\\x95 Additional No.  ﺔ Education  ناﻮﻨﻌﻟا  Address House No.ﻢﻗر  اﻟﻤ\\x8e\\x9e\\x9eل_____________ Street name ﻢﺳا  عرﺎﺸﻟا __________   District اﻟ\\x94\\x95 ___________                Cityﺔﻨﻳﺪﻤﻟا'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 21}, page_content='اﻟ\\x94\\x95 ___________                Cityﺔﻨﻳﺪﻤﻟا  _______________   Province/Regionﺔﻘﻄﻨﻤﻟا /ﺔﻈﻓﺎﺤﻤﻟا  _________________ Clinical Information                                                                                                    ﺔ Date of symptoms onsetﺗﺎرLــــﺦ ¦ﺪاQﺔ اﻻﻋﺮاض  _____dd مﻮﻳ /_____mm ﺮﻬﺷ /______yyyy ﺔﻨﺳ  Symptoms اﻻﻋﺮاض Yes No Symptoms اﻻﻋﺮاض Yes No © أ«\\x8e\\x85 ﻣﻦ 238  Fever >38.2º o o اﻟﻢ \\x9d\\x9e\\x95 اﻟﺤﻠﻖ Sore throat o o عاﺪﺻ  Headache o o ﻃﻔﺢ ﺟﻠﺪي )ﻣﺴﻄﺢ وﻏ\\x8e\\x8f ﻧﺎ¶·¸( Macular Rash (lesions with a flat base) o ﺎﻬﻌﻗﻮﻣ ________           located________ o  دﺪﻐﻟا ﻢﺨﻀﺗ ﺔ Lymphadenopathy o o ﺻﻔﺢ ﺟﻠﺪي )ﻧﺎ¶·¸ ﻋﻦ (ﺪﻠﺠﻟا ﺢﻄﺳ  PapularRash (slightly raised firm lesions) oﻗﻮﻣ ﺎﻬﻌ ________'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 21}, page_content='raised firm lesions) oﻗﻮﻣ ﺎﻬﻌ ________           located________ o اﻟﻢ \\x9d\\x9e\\x95 اﻟﻈﻬﺮ back pain o o ﺔ Vesicular Rash (lesions filled with clear fluid) oﻗﻮﻣ ﺎﻬﻌ ________           located________ o آﻻم تﻼﻀﻌﻟا  myalgia o o ءاﺮﻔﺻ ﻞﺋاﻮﺳ ﻊﻣ رﻮﺜﺑ  Pustules Rash (lesions filled with yellowish fluid) oﻗﻮﻣ ﺎﻬﻌ ________           located________ o دﺎﻬﺟا  Exhaustion o o ﺔﻓﺎﺟ رﻮﺸﻗ  Crusts which dry up and fall off. oﻗﻮﻣ ﺎﻬﻌ ________           located________ o (دﺪﺣ) ىﺮﺧأ ضاﺮﻋا  Other (specify)_______________________ Comorbid conditions (check all that apply)                   ﻷاﻣﺮاض اﻟﻤﺼﺎﺣpﺔ )اﺧ\\x8e· Èﻞ ﻣﺎ ﻳﻨﻄﺒﻖ( \\x00 None ﺪﺟﻮﻳ ﻻ       \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف     \\x00 Immunocompromised  ﺔﻋﺎﻨﻣ ﻒﻌﺿ       \\x00 HIV  (CD4 count'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 21}, page_content='ﺔﻋﺎﻨﻣ ﻒﻌﺿ       \\x00 HIV  (CD4 count ____) ﻓ\\x8e\\x8fوس ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ اﻟﻤﻜlﺴﺐ \\x00 Other STIs___________ ﻻاﻣﺮاض اﻟﻤﻨﻘﻮﻟﺔ ﺟVﺴRًﺎ ىﺮﺧﻷا        \\x00 Diabetes يﺮﻜﺳ      \\x00 Cardiac disease ﺐﻠﻗ ضاﺮﻣا       \\x00 Hypertension  مد ﻂﻐﺿ                \\x00 Chronic pulmonary disease   ﺔﺋر ضاﺮﻣا ﻟاﺔﻨﻣﺰﻤ       \\x00 Chronic kidney disease È Ñ  ﻟاﺔﻨﻣﺰﻤ     \\x00 Chronic liver diseaseﺪ ﺔﻨﻣﺰﻤﻟا  ﺰﻣ \\x00 Obesityﻟاﺔﻨﻤﺴ             \\x00 Smoking (any type) ﺗﺪﺧÒ\\x8f\\x9e ﻦﻣ يا ع      \\x00 Other  ىﺮﺧأ _______________'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 22}, page_content='22   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 22}, page_content='Hospitalization Information                                                                                           ﻢ ﻞ مﻮﻨﺗ  ﺾ \\x9d\\x9e\\x95 اﻟﻤﺴlﺸÕ\\x9e؟ Is/was the patient hospitalized?  \\x00  ﻢﻌﻧ  ,ﺦــــ  ____/_____/______      \\x00  ﻻ  \\x00  Yes, Date of admission ____/_____/______      \\x00  No ﺳØﺐ اﻟﺘsLﻢ \\x9d\\x9e\\x95 اﻟﻤﺴlﺸÕ\\x9e؟ Reason for hospitalized?   \\x00  Isolation لﺰﻌﻟا        \\x00  Patient’s medical condition  ﺾ dﻞ ﻻﻳﺰال اﻟﻤÓLﺾ ﻣﻨﻮم \\x9d\\x9e\\x95 اﻟﻤﺴlﺸÕ\\x9e؟ Still admitted in the hospital? ؟جوﺮﺧ  Discharged ? ﻣﻨﻮم \\x9d\\x9e\\x95 ؟ةﺰﻛﺮﻤﻟا ﺔ  Admitted to ICU? ﻣﺘﻮ\\x9d\\x9e\\x95؟ Patient died?   \\x00  Yes ﻢﻌﻧ        \\x00  No  ﻻ   \\x00  Yes ﻢﻌﻧ        \\x00  No  ﻻ  \\x00  Yes ﻢﻌﻧ       \\x00  No  ﻻ   \\x00  Yes ﻢﻌﻧ        \\x00  No  ﻻ Epidemiological Information  ﺔ'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 22}, page_content='Epidemiological Information  ﺔ                                                                                           ﺮﻔﺴﻟا ﺦــــ  Visiting and Travel History:  لﻼﺧ ﺔ 21 ﻳﻮم اﻟﺴﺎ¦ﻘﺔ ﻟpﺪاQﺔ اﻻﻋﺮاض ؟ Did the patient travel in the 21 days prior to illness onset?   \\x00 Yes ﻢﻌﻧ             \\x00 No  ﻻ             \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف If yes, ﻢﻌﻧ نﺎ  Trip1   ﺔﻠﺣر Dates of travel  ﺦــــ ___/___/____ toÜ  ___/___/____     Country ﺔﻟوﺪﻟا _______City ﺔﻨﻳﺪﻤﻟا _____________ Trip2   ﺔﻠﺣر Dates of travel  ﺦــــ ___/___/____ toÜ  ___/___/____     Country ﺔﻟوﺪﻟا _______City ﺔﻨﻳﺪﻤﻟا _____________  Trip3   ﺔﻠﺣر Dates of travel  ﺦــــ ___/___/____ toÜ  ___/___/____     Country ﺔﻟوﺪﻟا _______City ﺔﻨﻳﺪﻤﻟا'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 22}, page_content='Country ﺔﻟوﺪﻟا _______City ﺔﻨﻳﺪﻤﻟا _____________    ﻞ ﻤﺗﺖ ﻣﻤﺎرﺳﺔ أÝﺸﻄﺔ Èﺎن ﺑﻬﺎ ﻣﻼﻣﺴﺔ ﺟﺴﺪQﺔ ﻣpﺎÞßة Èﺎﻟﻤﺴﺎج ﺔ ﻢﺷﻮﻟا ﻊﺿو وأ  ؟ During travel, is the case did any activities that contain direct physical contact such as massage sessions, sexual activity, or tattoos? \\x00 Yes ﻢﻌﻧ                             date ﺦــــ   /       /    :                Type (place) (ﻊﻗﻮﻤﻟا) طﺎﺸ : __________________________ \\x00 No  ﻻ                      لﻼﺧ ﺾ 21 ﻳﻮم ﻗpﻞ ¦ﺪاQﺔ اﻻﻋﺮاض أي ﺷﺨﺺ ﺳﺎﻓﺮ ﺧﺎرج ﺔ؟ In the 21 days prior to illness onset, did the patient have close contact with someone who travelled outside the Country? \\x00 Yes ﻢﻌﻧ                           \\x00 No  ﻻ                    \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف Please'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 22}, page_content='ﻻ                    \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف Please describe individual (including travel location)  ﻞ      اáﻤﻞ ﻣﺎ QÑ\\x95 ،ﺢﺋﺎﺳ ﺾ  نﺎ  If the patient was tourist, please complete information bellow ﺔ Did the patient travel with?   \\x00 Airline ﻮﺠﻟا     \\x00 Ship ﺮﺤ     \\x00  Bus صﺎ     \\x00  Car ةرﺎ     \\x00 Otherىﺮﺧا ____ ﻞﻗﺎﻨﻟا تﺎﻣﻮﻠﻌﻣ  Airline Information Airline Name ﻞﻗﺎﻨﻟا ﻢﺳا  _________ Flight Number  ﺔﻠﺣﺮﻟا ﻢﻗر  ______________ Origin  ةردﺎﻐﻤﻟا ﺔﻄﺤﻣ  ______________ Date of arrival ﺔ ___/____/____ Date of departure ﺔ ____/____/____  Transit destination  رﻮﺒﻋ تﺎﻄﺤﻣ _____________ Other Trans Information رﻮﺒﻌﻟا تﺎﻄﺤﻣ ﻦﻋ ىﺮﺧأ تﺎﻧﺎ  .………………………………………  Type of transportation ﻞﻘﻨﻟا ﺔﻠ     ___________. .Date of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 22}, page_content='transportation ﻞﻘﻨﻟا ﺔﻠ     ___________. .Date of arrival  لﻮﺻﻮﻟا ﺦــــ ______/_____/________           Port of entry  لﻮﺧﺪﻟا ﺬﻔﻨﻣ __________________              Origin  ةردﺎﻐﻤﻟا ﺔﻄﺤﻣ __________________ Resident Information after arrival ﺔ  Name of resident (hotel, ,  ..etc.)  ﻢﺳا ﻣﻘﺮ اﻟﺴﻜﻦ )ﻓﻨﺪق،...( __________________    where ﻦﻜﺴﻟا ﺮﻘﻣ ﻊﻗﻮﻣ  _________________   Date of check in  لﻮﺧﺪﻟا ﺦــــ :  _____/_____/_______     Date of check out ةردﺎﻐﻤﻟا ﺦــــ ______/_____/_______ Note: (Describe the timeline of contact movement)  ﺔﻣﺎﻗﻹا ﻒﺻو'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 23}, page_content='23   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 23}, page_content='Contact Exposure and Social History ﺔﻄﻟﺎﺨﻤﻟا تﺎﻧﺎ  واﻟﺘﺎرPــــﺦ اﻻﺟﺘﻤﺎ}A                                             dﻞ ﺣﺼﻞ اﻟﻤÓLﺾ ﻋÑ\\x95 ﻟﻘﺎح اﻟﺠﺪري؟ Did the patient receive vaccination against Smallpox? o  Yes, Date (Year)  ﻢﻌﻧ ﺔﻨﺳ)   (ـــــــــــــــــــــــــــــــــ.       o No ﻻ         o Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف          لﻼﺧ ةﺪﻛﺆﻣ وأ ﺔﻬﺒ 21 ﻳﻮم اﻟ\\x84·\\x95 ﺳpﻘﺖ ﻇﻬﻮر اﻻﻋﺮاض؟ Did the patient have contact with a known or suspect case, or with any sick person before becoming ill (21 days prior to illness onset)? o Yes  ﻢﻌﻧ    Date  ﺦــــ : ـــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــ  o No ﻻ               o Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف  dﻞ dﻮ\\x9bç\\x95 Ýﺸﻂ ﺟVﺴRﺎ'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 23}, page_content='o Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف  dﻞ dﻮ\\x9bç\\x95 Ýﺸﻂ ﺟVﺴRﺎ ﺧﻼل 21 ﻳﻮم اﻟ\\x84·\\x95 ﺳpﻘﺖ ﻇﻬﻮر اﻻﻋﺮاض؟ Sexually active within ≤ 21 days prior to symptom onset? \\x00 Yes  ﻢﻌﻧ            \\x00 No  ﻻ               \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف   ﻢﻌﻧ نﺎ ﺲ If yes, select sex of sexual partner(s)   dﻞ dﻮ\\x9bç\\x95 ﻣﺎرﺳﺖ أÝﺸﻄﺔ Èﺎن ﺑﻬﺎ ﻣﻼﻣﺴﺔ ﺟﺴﺪQﺔ ﻣpﺎÞßة Èﺎﻟﻤﺴﺎج ﺧ ﻪﻓﻼﺧو  لﻼ 21 ﻳﻮم اﻟ\\x84·\\x95 ﺳpﻘﺖ ﻇﻬﻮر اﻻﻋﺮاض؟ Any activities that contain direct physical contact such as massage sessions ≤ 21 days prior to symptom onset? \\x00 Yes ﻢﻌﻧ                             date ﺦــــ  Type (place) (ﻊﻗﻮﻤﻟا) طﺎﺸ ____________________________ \\x00 No  ﻻ                     dﻞ Èﺎن dﻨﺎك أي ﻣﺨﺎﻟﻄﺔ ¦ﻤﺼﺪر ﺣﻴﻮا¶\\x9e\\x95 ﻣﺤﺘﻤﻞ ﺧﻼل 21 ﻳﻮم اﻟ\\x84·\\x95 ﺳpﻘﺖ ﻇﻬﻮر اﻻﻋﺮاض؟ Contact with'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 23}, page_content='ﺧﻼل 21 ﻳﻮم اﻟ\\x84·\\x95 ﺳpﻘﺖ ﻇﻬﻮر اﻻﻋﺮاض؟ Contact with possible animal source within ≤ 21 days prior to symptom onset? \\x00 Yes  ﻢﻌﻧ            \\x00 No  ﻻ               \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف   ﻢﻌﻧ نﺎ ﻒﺻﻮﻟا ءﺎﺟﺮﻟﺎﻓ  If yes, please describe   dﻞ ﺧﺎﻟﻂ اﻟﻤÓLﺾ اﺷﺨﺎص آﺧÓLﻦ ¦ﻌﺪ ﻇﻬﻮر اﻻﻋﺮاض ﻋﻠRﻪ؟ Did the patient have contact with anyone during illness period?  \\x00 Yes  ﻢﻌﻧ            \\x00 No  ﻻ               \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف  اذا Èﺎن ﻧﻌﻢ ﻓﻴﺘﻢ اáﻤﺎل ﻗﺎﺋﻤﺔ اﻟﻤﺨﺎﻟﻄÒ\\x8f\\x9e \\x9d\\x9e\\x95 اﻟﺼﻔﺤﺔ اﻻﺧ\\x8e\\x8fة If yes, please complete the list of patient contact in the end of report  dﻞ ﺗﻮاﺟﺪ اﻟﻤÓLﺾ \\x9d\\x9e\\x95 تﺎﻌﻤﺠﺗ يأ   لﻼﺧ ﺔﻣﺎﻋ 21 ﻳﻮم ﻗpﻞ ﻇﻬﻮر اﻻﻋﺮاض او ¦ﻌﺪ ﻇﻬﻮر اﻻﻋﺮاض )ﻣﺜﻞ اﺣﺪاث رLﺎﺿRﺔ، اﻋﺮاس، اﺣﺘﻔﺎﻻت( In the 21 days before or after becoming ill,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 23}, page_content='In the 21 days before or after becoming ill, did the patient attend a public event where a large number of people were present (i.e., a sporting event, wedding, concert)?  \\x00 Yes  ﻢﻌﻧ        \\x00 No ﻻ      \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف ﺪﺟاﻮﺘﻟا اﺬ  If yes, please describe the event (include date and location)  dﻞ ﺗﻮاﺟﺪ اﻟﻤÓLﺾ \\x9d\\x9e\\x95 أي ﻣVﺸﺄة ﺻﺤRﺔ ﺧﻼل 21 ﻳﻮم ﻗpﻞ ﻇﻬﻮر اﻻﻋﺮاض او ¦ﻌﺪ ﻇﻬﻮر اﻻﻋﺮاض  In the 21 days before or after becoming ill, did the patient visited any healthcare facility or setting? \\x00 Yes  ﻢﻌﻧ        \\x00 No ﻻ      \\x00 Unknown ﻏ\\x8e\\x8f ﻣﻌﺮوف ﺪﺟاﻮﺘﻟا  اﺬ  If yes, please describe the event (include date and location)'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 24}, page_content='24   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 24}, page_content='List of Patient’s Contacts                                                                                               ﻗﺎﺋﻤﺔ اﻟﻤﺨﺎﻟﻄ\\x81\\x82@   اﻻﺳﻢ Name of contact ﺔ Relation to patient ﺔﻄﻟﺎﺨﻣ ﺮﺧآ ﺦــــ:رﺎﺗ  Last contact date ﺔﻨﻳﺪﻤﻟا  City ﺲ Sex ﻒﺗﺎﻬﻟا  Phone  ﺔﻟﺎﺣ ﻢ Vaccination status     ____/___/____  \\x00Male ﺮﻛذ  \\x00Femaleأﻧ-.       ____/___/_____  \\x00Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/_____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 24}, page_content='____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.      ____/___/____  \\x00 Male ﺮﻛذ  \\x00 Femaleأﻧ-.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 25}, page_content='25   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 25}, page_content='V 1.4   01 June 2023 \\n  Summary of Vaccine used in Saudi Arabia Item Standard JYNNEOS Regimen Fractured Dose JYNNEOS Regimen Number of Doses 2 2 Age Group Children Less than 18 years 18 years and above Dosage 0.5 mL 0.1 mL Route of Administration Subcutaneous Intradermal Interval Between Doses 4 weeks (28 Days) Vial Type Same vial used for both regimens Number of Doses Per Vial 1 5 Preparation Needed Thawing. No dilution needed. Storage Once thawed, the vaccine may be kept refrigerated at +2°C to +8°C for 8 weeks. After first puncture, vial can be stored Continuously refrigerated at +2°C to +8°C for up to 12 hours. Special Groups history of developing keloid scars   Immunocompromised'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 26}, page_content='26   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 26}, page_content='References: 1. \"Monkeypox (mpox),\" Centers for Disease Control and Prevention, 31 July 2022. [Online]. Available: https://www.cdc.gov/poxvirus/Monkeypox (mpox)/symptoms.html. 2. \"Monkeypox (mpox),\" World Health Organization, 14 June 2022. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/Monkeypox (mpox). 3. \"Epidemiological update: Monkeypox (mpox) outbreak,\" European Centre for Disease Prevention and Control, 20 May 2022. [Online].  4. \"Monkeypox (mpox),\" UK Health Security Agency, 18 May 2022. [Online]. Available: https://www.gov.uk/guidance/Monkeypox (mpox)#transmission. 5. Sklenovská N, Van Ranst M. Emergence of Monkeypox (mpox) as the Most Important Orthopoxvirus'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 26}, page_content='(mpox) as the Most Important Orthopoxvirus Infection in Humans. Front Public Health. 2018;6:241. Published 2018 Sep 4. doi:10.3389/fpubh.2018.00241 6. Monkeypox (mpox) Autopsy and Handling of Human Remains,CDC, Autopsy and Handling of Human Remains | Monkeypox (mpox) | Poxvirus | CDC 7. National Monkeypox (mpox) Public Health Response Guidelines, - Nigeria Centre for Disease Control (2019). https://ncdc.gov.ng/themes/common/docs/protocols/96_1577798337.pdf 8. 2022. CDC JYNNEOS Vaccine. [online] Available at: <https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html#interim> [Accessed 28 August 2022]. 9. GOV.UK. 2022. Monkeypox: guidance. [online] Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 26}, page_content='2022. Monkeypox: guidance. [online] Available at: <https://www.gov.uk/government/collections/monkeypox-guidance#guidance-for-health-professionals-and-service-providers> [Accessed 28 August 2022]. 10. Fda.gov. 2022. JYNNEOS Package Insert. [online] Available at: <https://www.fda.gov/media/131078/download> [Accessed 28 August 2022]. 11. Fda.gov. 2022. FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE: EMERGENCY USE AUTHORIZATION OF JYNNEOS. [online] Available at: <https://www.fda.gov/media/160774/download> [Accessed 29 August 2022]. 12. 2022. Storage and Handling Summary. [online] Available at: <https://www.cdc.gov/poxvirus/monkeypox/pdf/Storage-and-Handling-Summary.pdf> [Accessed 29'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 26}, page_content='[Accessed 29 August 2022]. 13. 2022. Subcutaneous Vaccine Preparation and Administration Summary. [online] Available at: <https://www.cdc.gov/poxvirus/monkeypox/files/interim-considerations/guidance-Jynneos-prep-admin-stand.pdf> [Accessed 29 August 2022]. 14. 2022. Intradermal Vaccine Preparation and Administration Summary. [online] Available at: <https://www.cdc.gov/poxvirus/monkeypox/files/interim-considerations/guidance-jynneos-prep-admin-alt-dosing.pdf> [Accessed 29 August 2022].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 27}, page_content='27   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 28}, page_content='28   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 29}, page_content='29   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 30}, page_content='30   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 31}, page_content='31   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 32}, page_content='32   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 33}, page_content='33   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 34}, page_content='34   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 35}, page_content='35   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 36}, page_content='36   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 37}, page_content='37   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-Guidelines-01-June-2023-V1.4.pdf', 'page': 38}, page_content='38   \\nV 1.4   01 June 2023'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 0}, page_content='Suggested citation: European Centre for Disease Prevention and Control. Monkeypox multi -country outbreak – 23 May 2022 . \\nECDC: Stockholm; 20 22.  \\n© European Centre for Disease Prevention and Control, Stockholm, 2022  \\nall \\n \\n \\n \\n \\n \\n \\n \\n \\n RAPID RISK ASSE SSMENT  \\nMonkeypox multi -country outbreak  \\n \\n23 May 2022 \\n \\n \\nKey messages  \\nCases of monkeypox  (MPX) acquired in the EU have recently been reported in nine EU Member States  (Austria, \\nBelgium, France, Germany,  Italy, Portugal, Spain, Sweden,  and the Netherlands ). \\nMonkeypox (MPX)  does not spread easily between people.  Human -to-human t ransmission  occurs  through close'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 0}, page_content='contact with infectious material from  skin lesions  of an infected person, through respiratory droplets in \\nprolonged face -to-face contact , and through fomites . The predominance, in the current outbreak, of  diagnosed \\nhuman MPX cases among men having sex with men  (MSM), and the nature  of the presenting lesions in some \\ncases , suggest  transmission  occurred  during sexual intercourse .  \\nBased on ECDC’s epidemiological assessment, the likelihood  of MPX spreading in persons having multiple \\nsexual partners in the EU/EEA is considered high. Although most cases in  current outbreak s have presented'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 0}, page_content='with mild disease symptoms, monkeypox virus (MPXV)  may cause sever e disease in certain population groups \\n(young children, pregnant women, immunosuppressed persons) . However, t he likelihood of cases with  severe \\nmorbidity cannot be accurately estimated yet. The overall risk is assessed as moderate for persons having \\nmultiple sexual partners (including some gr oups of  MSM) and low for the broader population.   \\nTreatment is mainly symptomatic and supportiv e, including prevention and treatment of secondary bacterial \\ninfections. Smallpox vaccine can be considered  for post -exposure prophylaxis of close contacts at increased'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 0}, page_content='risk for severe disease , however careful benefit/risk assessment should be performed for the exposed \\nindividual . Important information on the use of  currently available smallpox vaccines is missing for groups at \\nincreased risk for severe disease . In addition, a ntivirals are potential treatment options for severe cases.  \\nEU/EEA countries should focus on prompt identification, management, contact tracing and  reporting of new \\nMPX cases. C ountries should update  their contact tracing mechanisms, the ir diagnostic capacity for \\northopoxviruses and review the availability of smallpox vaccines, antivirals and personal protective equipment  \\n(PPE)  for health professiona ls.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 0}, page_content='(PPE)  for health professiona ls.  \\nAn interim case definition is proposed for case reporting . Guidance for the management of MPX cases and \\nclose contacts is  also included. Cases should remain isolat ed until their rash heals completely, avoiding contact \\nwith immunosuppressed person s and pets. Abstaining from sexual activity and close physical contact is also \\nadvised until the rash heals. Most cases can remain at home with supportive care .  \\nClose contacts  of MPX cases  should self -monitor for the development of symptoms up to 21 days from the last \\nexposure to a case.  \\nHealth care workers should wear appropriate PPE (gloves, water -resistant gown, FFP2 respirator ) when'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 0}, page_content='screening suspected cases or caring for a MPX case. Laboratory personnel should also take precautions to \\navoid occupational exposure.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n2 Close contacts of a MPX case should be deferred from blood , organ or bone marrow  donations  for a minimum \\nof 21 days from the last day of exposure .  \\nProactive r isk communication and multiple community engagement activities should be carried out to increase \\nawareness, provide updates and guidance  to those at increased  risk and the wider  public . Risk communication \\nmessages should stress that MPXV  is spread through close contact between people, especially in the same \\nhousehold, potentially including the  sexual route. A balance should be kept between  informing those  most at'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='risk but also communicating that the virus does not spread easily between people  the risk to the broader  \\npopulation is low .  \\nThere is a potential risk of human -to-animal transmission in Europe, therefore clos e intersectoral collaboration \\nbetween human and veterinary public health authorities working from a ‘One Health’ perspective is needed to \\nmanage exposed pets and prevent the disease from being transmitted in wildlife.  EFSA is not aware  to date of \\nany reports on infections in animals (pets or wild animals) in the EU .   \\nSeveral unknowns still exist regarding  this outbreak  and ECDC will continue to monitor  developments closely'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='and update the risk assessment as new data and information become  available .    \\nEvent background  \\nOn 7 May  2022, the U nited Kingdom ( UK) reported an imported case o f monkeypox  (MPX) in a person travelling \\nfrom Nigeria. The case reported developing a rash -like illness on 29 April 2022 and travelled  from Lagos to London \\non 3-4 May . The diagnosis  was confirmed by monkeypox virus  (MPXV)  PCR on  a vesicular swab on 6 May by the \\nUK Health Security Agency (UKHSA ) Rare and Imported Pathogens Laboratory.    \\nOn 13 May 2022, the UK reported two  further  cases of MPX who are part of the same family  and not linked to the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='single imported case from Nigeria which was notified on 7 May . The cases were  confirmed by PCR testing on \\nvesicle  swabs . A third family member had previously developed a rash but recovered  fully. None of the  individuals \\nin this cluster  had travelled  or had contact with anyone with a relevant  travel history  [1].  \\nOn 15 May 2022, the UK reported four additional  cases of MPX, confirmed by PCR. None of the se cases  have \\nknown epidemiological links to the imported cas e from Nigeria (notified on 7 May ) or to the famil y cluster (notified \\non 13 May). The four cases were  men who have sex with men ( MSM) and presented  with a vesicular rash -like'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='illness . They were  identified through attendance at genitourinary medicine (GUM)  clinics. The cases are being \\nmanaged in high consequence infectious diseases unit s in the UK  [1].  \\nOn 18 May 2022, two additional  cases  (also MSM)  were reported , one in London and one in the South -East of \\nEngland [1].  \\nOn 20 May 2022, 11 additional cases were reported by the UKHSA, bring the total number of MPX cases confirmed \\nin England to 20  [1]. All cases reported in the UK have been confirmed as caused by the MPXV West Af rican clade.  \\nStarting from the 18 May, multiple EU/EEA Member States reported additional suspec ted or confirmed cases:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='• On 18 May, Portugal  reported  14 cases of MPXV confirmed by real -time PCR in the Lisbon and Tagus River \\nValley Region. All cases were men with a clinical presentation of rash (some  ulcerative ), fever, myalgia and \\nasthenia. None of the cases needed hospitalisation [2]. On 20 May, nine additional confirmed cases were \\nreported, bring ing the total number of confirmed cases to 23. In two cases , the west African clade was identified.  \\n• On 19 May, Spain  reported seven  confirmed and 23 suspected cases of MPX, all among men. On 20 May, 16 \\nadditional confirmed cases were reported  [3]. On 22 May, seven  more cas es were confirmed, with 39 new'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='suspected cases under investigation [4].  \\n• On 19 May, Belgium  reported a confirmed case in a man with travel history to Lisbon, Portugal . His partner \\ndeveloped similar symptoms  and was confirmed on the 20 May. As of 22 May, a total of four confirmed cases had \\nbeen reported  [5,6]. \\n• On 19 May, Germany  confirmed its first case in a man with travel history to Spain and Portugal. On 20 May, two \\nmore confirmed cases were reported.  [7]. \\n• On 20 May, France  reported its first confirmed case in a man with no travel history, with three additional cases \\nunder investigation  [8].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 1}, page_content='under investigation  [8]. \\n• On 20 May, Italy reported one confirmed case of MPX in  a man who required hospitali sation and had travel \\nhistory to Spain. On 21 May, two further confirmed cases were reported  [9]. \\n• On 18 May, Sweden  reported a confirmed case in a man [10] \\n• On 20 May, the Netherlands  reported one confirmed case , a man with travel history to Belgium  [11]. \\n• On 22 May, Austria  reported its first confirmed case  [12]. \\nAs of 23 May 2022, 67 confirmed cases had been reported in nine EU/EEA Member States and at least an \\nadditional 42 suspected cases were under investigation.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 2}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n3 Cases have also been reported o utside Europe : on 18 May 2022, Canada reported two confirmed and 20  suspected \\ncases  who were seen at sexually transmitted infection(STI) clinics , all men and  currently  undergoing laboratory \\ntesting in Montreal, Quebec [13]; one confirmed case in Boston, United States , in an adult male with recent travel \\nhistory  to Canada  [14] and one probable case in New York City [15]. On 19 May 2022, Australia reported two \\nconfirmed case s, one  was a man with travel history to the UK [16]. On 20 May 2022, Israel reported a confirmed'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 2}, page_content='case and additional suspected cases  [17]. On 22 May, Switzerland reported a confirmed case with travel history to \\nEurope [18]. \\nFigure 1.  Geographical distribution of confirmed cases of MPX  in EU/EEA  countries , as of 23 May \\n2022  (11:00)  \\n \\nFigure 2. Geographical distribution of confirmed cases of monkeypox in non -endemic countries, as of \\n23 May 2022  (11:00)'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n4 Situation  in west and central Africa in 2022  \\nGenerally, o utbrea ks of MPX continue to be reported in countries from  west and central Africa  [19]. Cameroon  \\nreported an outbreak of MPX in December 2021 and, as of 17 February 2022, three confirmed and 2 5 suspected \\ncases have been reported , including  two deaths . Cases have been reported from  countries in c entral, north -\\nwestern  and south -western regions of  the continent . Cases of  MPX are sporadically reported in Cameroon, with \\nmore than half of the geographical regions  in Africa  reporting at least one case between 2020 and 2022.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='The Central African Republic  (CAR)  reported six confirmed cases of MPX including two deaths  on 14 March 202 2.  \\nBetween 1 January and 17 April  2022, 1 152 suspected  cases of MPX including 55 deaths (case -fatality rate of \\n4.8%) were reported in 54 health zones in 14 provinces  of the Democratic Republic of the Congo (DRC) . In the \\nequivalent 2021 time period, 138 suspected cases and 1 4 deaths were reported (case-fatality rate of 10.1% ). \\nAccording to studies , the MPXV  circulating in  the DRC and CAR belong to the more virulent Congo Basin (CB) clade \\nof the virus.   \\nNigeria  reported  46 suspected (of which 15  confirmed ) cases of MPX between 1 January and 30 April  2022.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='Between 2017 -2022 Nigeria reported 241 confirmed  cases ( range 8-88 per year ) including eight deaths (case -\\nfatality ratio , CFR  3.3%)  [19,20] . \\nDisease background   \\nDisease characteristics  \\nMonkeypox  (MPX)  is a zoonotic disease and is currently the most prevalent orthopoxvirus infection in humans  after \\nthe eradication of smallpox and the cessation of universal smallpox vaccination  [21-23]. Human  MPX cases are \\nincreasingly  reported in several African countries after its first identification as a human pathogen in  the DRC in \\n1970, due to a combination of factors including both increased exposure (deforestation, conflict and displacement ),'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='as well as improved surveillance and laboratory capacity in the African region  [24-26]. \\nIn endemic areas, MPXV  is probably maintained in nature through circulation among a number of mammals , \\nincluding squirrels, Gambian  pouched  rats (Cricetomys gambianus ), striped mice, dormice and primates  [25], with \\noccasional spill -over events to humans  [27-30]. In endemic areas, MPXV is transmitted to humans through a bite \\nor direct contact with an infected animal’s b lood, meat, bodily fluids or cutaneous/mucosal lesions  [21]. \\nSequencing has identified  two distinct clades of MPXV  [31]. The West African clade is known to occur from western'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='Cameroon to Sierra Leone  and carries a <1% CFR , whereas the Congo Basin clade h as been detected from central \\nand southern Cameroon to the DRC  and is considered more virulent  with a CFR >10%  [32,33 ]. \\nThe largest West African  clade MPX outbreak identified to date was in Nigeria in 2017 , with 146 suspected and 42 \\nconfirmed cases  [20,34] . In 2018, three unlinked travel-related MPX cases were identified in Israel, the UK, and \\nSingapore  [35-37]. These exportations represent the first time that a human host was documented to transfer \\nMPXV from the African continent . However, MPX outbreaks in animals in laboratories and zoos , with no clearly'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='identified source of infection , have been reported outside the Africa n continent  [38-40]. \\nIn 2003, the US Centers for Disease Control (CDC) reported a total of 81 human MPX cases after close contact with \\npet mammals, predominantly rodents. No human -to-human transmission was identified , and none resulted in \\ndeath. The cases were connected to the importation of small mammals from Ghana to Texas as the probable \\nsource of introduction of the virus into the US. The spread of the virus between federal states was connected to \\ninfected pet prairie dogs that were -housed with rodents of African origin  [41].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='Monkeypox does not  spread easily between people.  Between humans, t he virus can be transmitted by respiratory \\ndroplets during direct and prolonged face -to-face contact. In addition, monkeypox virus can be transmitted by \\ndirect contact with body fluids of an infected person , contact of mucosa or non -intact skin with open  rash lesions \\nor with virus -contaminated objects, such as bedding or clothing  [22,25] . Sexual transmission of monkeypox has \\nbeen described , but infrequently,  in the literature. Ogoima et al . [42], in reporting the 2017 human MPX outbreak \\nin Niger ia, hypothesised  that sexual transmission was a plausible route of infection as it involved  close skin -to-skin'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='contact during sexual intercourse or transmission via genital secretions . \\nInfection of sexual partner s, both female and male , has been previously reported  for vaccinia virus , another virus \\nof the Orthopoxvirus  genus,  post smallpox vaccination  [43,44 ]. Vaginal lesions  occurred in the female partner of a \\nrecently vaccinated military man who removed bandage s covering his vaccination site , four days after unprotected \\nsexual intercourse , preceded by digital vaginal contact  [43]. A painful perianal rash and a lesion on the upper lip  \\nwere reported by a male patient  ten days after sexual intercourse with a recently vaccinated man who did not'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 3}, page_content='cover his vaccination site [45]. Further transmission from this patient, while he was experiencing perianal rash, \\noccurred in a male sexual contact who experienced general symptoms and pap ular lesions on his penis two days \\nafter sexual intercourse.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n5 The incubation period for MPX  is usually 6 to 13 days but  can range from 5 to 21 days  [25]. The illness typi cally \\nlasts for two to four weeks. Disease  usually begin s with fever , myalgia,  fatigue and headache  [36]. Within three \\ndays from the onset of the prodrome symptoms, a centrifugal maculopapular rash starts from the site of primary \\ninfection and rapidly spreads to other parts of the body. Palms and soles are involved in cases of  the disseminated \\nrash, which is a characteristic of the disease . The lesions progress , usually within 12 days, simultaneously from the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='stage of  macules  to papules, vesi cles, pustules, crusts and scab s before falling off  [46]. The lesions may be \\ncentrally depressed and can be extremely itchy and secondary bacterial infection may occur if scratching occurs. \\nLesions on oral or ophthalmic mucosa (enanthem) may also be present . Prior to and concomitant with the rash, \\nlymphadenopathy is observed in many patients, which is usually not observed in smallpox  or varicella  [22,47] . It \\nshould be noted that the clinical manifestations in travel -related cases detected in western countries w ere usually  \\nmild, sometimes with very few lesions. The onset of  the rash is considered the start of the infectious period;'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='however , it is believed that persons with prodrome symptoms can also transmit MPX V [48]. \\nThe majority of human MPX cases experience mild to moderate symptoms. Complications  in endemic countries  \\ninclude encephalitis , secondary skin bacterial infections, dehydration, conjunctivitis , keratitis, and pneumonia. T he \\ncase-fatality rat e of MPX ranges  from 0% to 1 1% in outbreaks  in endemic areas  with mortality  mostly affecting \\nyoung children  [25]. Little information is available on MPX in immunocompromised patients.  In the 2017 Nigeria \\noutbreak, patients with concurrent HIV -infection had more severe morbidity with more skin lesions and associated'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='genital ulcers as compared with HIV -negative individuals . No deaths were reported among HIV -positive patients  \\n[42]. Major disease sequela e are usually  disfiguring scars and permanent corneal lesions  [47].  \\nThe route of infection (invasive, such as animal bite, vs. exposure to fomites) play s a role , with invasive mode s of \\nexposure causing more severe disease and shorter incubation  period  [49].  \\nConsidering varicella as the most relevant differential diagnosis, electron microscopy was traditionally used in the \\npast to distinguish herpesviruses from orthopoxviruses. Currently , MPXV  real-time polymerase chain reaction ( Real'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='Time-PCR) on suspected skin lesions is used. Scabs, swabs and aspirated lesion fluid should be  preferably used for \\nPCR over blood due to limited duration of virem ia. These samples  can be transported at room temperature and \\nwithout transport media; blood and serum for serological tests can be transported at room temperature , however, \\ntissue biopsies should be shipped frozen  on dry ice. Formalin -fixed samples can be sent at room temperature  [50]. \\nResults from  scabs, swabs and aspirated lesion fluid  specimens show the best correlation with both infectivity and \\nthe clinical course of infection. Recent Real Time-PCR approaches can  also discrimin ate the two MPXV  clades'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='described above. Serology has limited value due to the immunological cross -reactivity between human -pathogenic \\northopoxviruses , but it is used to monitor antibody response in vaccinated individuals . However, for contact \\ninvestigatio ns, IgM and IgG detection is available in some laboratories. Immunohistochemistry can  potentially  be \\nused to identify antigens in biopsy samples.  \\nTreatment is primarily  symptomatic and supportive  (alleviation of fever and pruritus , hydration) , including \\nprevention and treatment of secondary bacterial infections.  Antivirals  tecovirimat , brincidofovir  and cidofovi r are'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='potential options  for severe cases  [25]. Only Tecovirimat has market authori sation in the EU  for the treatment of \\northopoxvirus infection, including MPX. Limited data on efficacy and safety exist currently, while clinical studies are \\nongoing in Africa  [51].  \\nPrevious vaccination against smallpox can confer cross -protection against monkeypox , which was estimated from \\nolder studies  to be as high as 85 % [22]. The protective effect of smallpox vaccination  wanes with time, although \\nserosurveys indicate that it can last more than 20 years . However, it is believed that despite the waning effect'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='smallpox vaccine confers , lifelong protection against sever e disease  can occur  due to memory B and T cells  \\ntherefore some degree  of protection should be expected in the population of adults in  the EU/EEA currently over \\n50 years of age  [52]. No vaccine is currently authorised in the EU against MPX, but e arly post -exposure vaccination  \\n(within four days of exposure to a MPX case)  with smallpox vaccine  may prevent the disease or make its course \\nless severe  [53,54] . A third generation, non-replicating  smallpox vaccine (I mvanexTM - Modified Vaccinia Ankara ) \\nwas authoris ed under exceptional circumstances by EMA in 2013  for use against smallpox  [55]. This vaccine has'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='indication for use in  patients with HIV infection  for smallpox , but currently  has no  authorisation for use against \\nMPX [56]. Earlier generation sma llpox vaccines have been used for years (DryvaxTM and ACAM2000TM), however \\nthey are associated with  severe side effects , including cardiac side effects , and they are  no longer  licensed  in the EU.   \\nMonkeypox  virus is not considered a biological agent of concern for biosecurity according to the  U.S. CDC list of \\nbioterrorism agents  [57], while it is considered a n ‘agent with high threat  for deliberate release ’ using the matrix'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 4}, page_content='developed by the EU task force on Bioterrorism  (BICHAT)  [58]. Although the case -fatality rate of the pathogen is \\nlow, its relative environmental stability  and persistence (see below)  and transmission pathwa ys, in addition  to the \\nlack of immunity in the population , the limited availability  of effective treatments  and vaccination , make it an agent \\nwhich could represent a bio logical threat  in case of accidental spill or intentional release.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n6 ECDC risk assessment for the EU/EEA  \\nThis assessment is based on evidence available to ECDC at the time of publication. It follows the ECDC rapid risk \\nassessment methodology, where the overall risk is determined by a combination of the probability of infec tion and \\nthe impact  of the disease on the affected population  [59]. ECDC will keep monitoring the event and will reassess \\nthe risk depending on it s evolution and the implemented response measures.  \\nWhat is the risk of further spread of monkeypox  in EU/EEA \\ncountries?  \\nRisk in persons with multiple sexual partners , including some MSM'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='Human -to-human transmission of MPX occur s through close contact with infectious material from  skin lesions of an \\ninfected person, and also  through respiratory droplets in prolonged face -to-face contact and through fomites. The  \\npredominance, in the current outbreak, of  diagnosed human MPX cas es among MSM, and the nature  of the \\npresenting lesions in some cases , suggest  that transmission occurre d during sexual inte rcourse . Transmission \\nthrough intact skin contact is less likely but cannot be excluded.  Although sequencing data are not yet available to \\nindicate that the outbreak is the result of  one introduction, the cases of MPX  within parts of the MSM community'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='whose sexual networks1 are inter -connected  could be c onsidered  a possible source of introduction . \\nParticular  sexual practices  (e.g. having multiple  casual sexual contacts  and/or multiple sex ual partners , attending \\nchemsex parties ) that may be present within some parts of the MS M community  could further facilitate  the \\ntransmission of monkeypox . Outbreaks of other sexually  transmitted infections  among MSM can be linked to travel \\nabroad  and to social and mass gathering events (e.g ., pride events)  [60-62]. Several such events are taking place \\nin Europe over the spring and summer months , which can contribute to further accelerate  the transmission of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='MPXV . In addition, smallpox vaccination , which confers cross -protection,  has been disco ntinued since the 1980s \\nand only a small percent age of military and frontline health professionals have been vaccinated in recent years . \\nTherefore , a large part of the population is vulnerable to MPXV. The probability of further spread  of MPXV among  \\npersons with multiple sexual partners in interconnected sexual networks (including some groups of MSM)  in \\nEU/EEA countries  and globally , in the coming months , is therefore assessed as high .  \\nWhile most MPX cases reported  thus far in this outbreak have been described as mild, the number of  reported'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='cases is too low to reliably estimate rates of severe morbidity and mortality , and a clear overview of the clinical \\npresentations in the reported cases is currently lacking . Severity estimates in the literature exist from endemic \\ncountries and the 2003 USA outbreak.  In Nigeria, the CFR is estimated at 3.3% for  cases diagnosed between 2017 -\\n2022, however, it is a different health care and population setting, where the disease i s endemic and is  probably  \\ntransmitted through different  routes  (e.g., more frequent contact with animals) . In the 2003 outbreak in the USA, \\nwhich was exclusively driven by contact with infected pets  (rodents), five out of 34 confirmed cases  (15%) were'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='defined as severely ill, and no deaths were reported . Patients under 18 years of age did not develop severe illness  \\nmore frequently , compared to older patients  [63]. These severity estimate s are probably biased upward s. \\nImmun ocompromised patients are believed to be more at risk for sever e disease and the prevalence of HIV among \\nMSM is higher than in the broader population  [64]. However , most people living with human immunodeficiency \\nvirus ( PLWHIV ) in EU/EEA (range  67–87%) are receiving  antiretroviral treatment , and are not severely \\nimmunocompro mised [65]. Moreover, some treatment options are available  for sever e MPX cases . Therefore , the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='impact of MPX is assessed as low, which combined  with the high probability of infection leads to an  overall \\nmoderate risk for persons with multiple sexual partners . \\nIt should be noted that the above -mentioned moderate risk may be higher for older people who have multiple \\nsexual partners or people with untreated HIV infection. ECDC will reassess the risk as more information (including \\nclinical presentation and outcomes) becomes available.   \\nRisk for the broader population  \\nBased on the evidence from the cases in this outbreak detected to date, o verall, the probability of further spread of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 5}, page_content='MPXV among the broader  population in EU/EEA countries and globally  in the coming months, is assessed as very \\nlow leading to an overall low risk for the general  population.  However, the individual risk for very young children, \\npregnant wom en, elderly  or immunocompromised individuals among close contacts of MPX cases may be high due \\nto the higher impact of the disease in these groups.  \\n \\n \\n \\n1 Sexual networks are groups of pe ople who are connected to one another sexually. The different behaviour of those within the \\ngroup can, for exa mple, affect how quickly STIs can spread through a network.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 6}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n7 Risk for h ealth  professionals  \\nHealth care workers  \\nTransmission to HCWs exposed to patients with MPX is possible, given the risk of transmission of other \\northopoxviruses, such as smallpox , and has been reported in outbreaks in endemic countries  [42,66 ]. In a study of \\n57 HCWs exposed to patients with MPX, including nursing staff, radiology technicians, emergency department staff \\nand p hysicians, no case of infection was documented  [67]. One HCW in this study had evidence of recent \\northopoxvirus seroconversion  but had also received smallpox vaccination four months before being exposed. In'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 6}, page_content='another outbreak report , monkeypox was transmitted to a HCW, whose  only identified exposure was the ch anging \\nof potentially contaminated bedding  of a hospitalised patient with MPX [35].  \\nThe probability of MPX transmission to HCWs wearing appropriate personal protective equipment  (a disposable \\ngown, disposable  gloves, disposable shoe or boots covers, respiratory  protection (Filtering Face Piece (FFP) 2 \\nrespirator), and eye splash protection (goggles or visor) is very low, with the disease having an estimated low \\nimpact, leading to an overall low risk .  \\nThe risk  to HCWs with unprotected close contact with MPX cases  (e.g. contact  face-to-face for prolonged time,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 6}, page_content='contact  with open lesions  without gloves, intubation or other invasive medical  procedure) is assessed as moderate, \\nequivalent to that of a close contact.   \\nLaboratory personnel  \\nOccupational  exposure  and infection  from orthopoxviruses have been occasionally reported among laboratory \\npersonnel  handling virus -containing specimens  [68,69 ].  \\nThe risk of occupational exposure is estimated to be low for trained laboratory personnel following appropriate \\nbiosafety procedures  [70].  \\nUnprotected occupational exposure in a laboratory, particularly involving spillage or aerosolisation with exposure of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 6}, page_content='mucosa,  carries high probability of infection and moderate risk of the disease (due to the direct exposure of \\nmucosae  to potentially significant quantity of virus ). The risk for unprotected  laboratory personnel  is assessed as \\nhigh.  \\nDue to a n expected  higher impa ct, the risk may be higher for exposed HCWs and laboratory personnel who are \\nolder or immunocompromised.  \\nTable 1.  Summary of risk assessed for the different population categories  \\n \\nPersons with \\nmultiple sexual \\npartners , including \\nsome MSM  Broader \\npopulation  Health professionals  \\n HCW s Laboratory personnel  \\n Proper \\nPPE Unprotected \\nexposure  Proper procedure and \\nPPE Unprotected \\nexposure'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 6}, page_content='PPE Unprotected \\nexposure  \\nProbability  High Very low  Very low  High Very low  High \\nImpact  Low Low Low Low Low Moderate  \\n \\nOverall risk  Moderate  Low Low Moderate  Low High  \\nThe risk may be higher for certain people  in some of the above  categories, particularly very young children, \\npregnant women, elderly , or immunocompromised persons . \\nRisk of transmission through substances of human origin   \\nNo cases of monkeypox virus transmission through  substances of human origin  have ever been documented . \\nHowever, there are reported cases of virus transmission from mother to child during pregnancy [71], and animal'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 6}, page_content='studies show  the presence of virus in blood, tissues and organs of infected animals .[72,73]  Existence of viremia \\n(i.e. blood specimens positive for viral DNA)  has been shown . The duration  of viremia  is unclear  [74], and there \\nare no data on viraemia in asymptomatic  patients (including  during the  incubation period ). Even though \\ninformation is limited , it is likely that monkeypox virus is transmissible through substances of human origin , but the \\noverall risk for recipients in the EU/EEA  is low .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n8 Risk of spill -over even t to animal species in Europe   \\nCurrently, little is known about the suitability of European peri -domestic (mammalian) animal species to serve as a \\nhost for monkeypox  virus. However, rodents, and particularly species of the family of Sciuridae  (squirrels) are likely \\nto be suitable hosts, more so than humans ( see disease background), and transmission from humans to (pet)  \\nanimals is theoretically possible.  Such a spill -over ev ent could  potentially  lead to the virus establishing in European'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='wildlife and the disease becoming an endemic zoonosis.  In the US, there is no evidence t hat the virus became \\nenzootic in wildlife , however , animal health authorities carried out systematic surveillance and an aggressive \\ncampaign for exposed animals during the 2003 outbreak  [41]. The probability of this spill -over event is very low.  \\nOptions for response  \\nThe current p riority for countries should be the identification , isolation  and contact tracing  of MPX cases. Prompt \\ndiagnosis will allow for isolation of cases and contribute to the control of this outbreak . Reportin g newly identified'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='cases to EpiPulse and the European Surveillance System ( TESSy ) is also important to allow for a better overview of \\nthe epidemiological situation and development of the outbreak. Reporting in TESSy will be implemented shortly  by \\nECDC . \\nThese priorities require significant preparedness and response activities including :  \\n• The review and strengthening of laboratory diagnostic capacity for orthopoxviruses ; \\n• The availability and stockpile of PPE for health professionals ;  \\n• The review of stockpiles o f smallpox vaccines and the development of vaccination strateg ies; \\n• The review of availability of antiviral treatments for severe cases ;'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='• The collaboration with animal health services for the managem ent of exposed pets ; \\n• Strong risk communication and engagement with the MSM communities, as well as the broader public.  \\nOverall preparedness and response  \\nLaboratory diagnostics and sequencing   \\nCountries should review their in -house molecular diagn ostic testing capacities and capabilities for orthopox viruses \\nand in particular for monkeypox virus  (including surge capacity related to reagents, consumables and available \\ntrained staff) . In case of limited experience in monkeypox testing, laboratories are encouraged to refer specimens'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='for confirmatory testing.  Countries not having national reference laboratory capacity should refer at least the first \\nsuspected case(s) for reference testing to another EU/EEA country. The European laboratory network for emerging \\nviral diseases ( EVD-LabNet ) will facilitate the sharing of protocols and can facilitate conf irmatory testing support \\nthrough their network members. The European Virus Archives ( EVAg) can provide positive control  material s [75]. \\nAccording to the EVD-LabNet  Directory , based on self-reporting of the EVD -Lab members (as of May 2022 ), MPXV \\ndiagnos is is possible in 19 laboratories in 1 3 EU/EEA countries: Denmark, Finland, France (2), Germany (4),'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='Greece, Hungary, Ireland, Italy  (2), Portugal, Romania, Slovenia, Sweden, and the Netherlands (2)  [76]. \\nSequencing of poxvirus DNA in samples can validate the specificity of the detection and  assist  in understand ing \\ntransmission chains  and patterns of spread , therefore  sharing  sequences is encouraged internationally. In addition, \\nsequencing will allow detection of potential genomic and proteomic differences  of MPXV in this outbreak . Member \\nStates who need diagnostic and/or sequencing support should contact EVD -LabNet ( chantal.reusken@rivm.nl ) and \\nECDC ( ECDC.Microbiology@ecdc.europa.eu ).'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='ECDC ( ECDC.Microbiology@ecdc.europa.eu ).  \\nCurrently , there is no commercial MPX virus assay on the European market. The GeneXpert platform  (Cepheid \\nSunnyvale, CA, USA) has been used for diagnosis of MPX in DRC  [77]. The multiplex assay includes a MPX-specific \\nassay, orthopoxvirus  generic assay, and an internal control . The methodology decreases manipulations of the \\nsamples, thereby also limiting opportunities for contamination.  \\nVaccination and antiviral s  \\nAvailability of smallpox vaccine should be reviewed  in EU/EEA countries as regards type, doses and authorisation'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 7}, page_content='status . As mentioned above (see Disease Background) smallpox vaccine can be used for post -exposure prophylaxis \\n(PEP) of close contacts at increased risk for sever e disease (see Management of MPX contacts).  The smallpox \\nvaccine, if administered within the first four days after exposure to a confirmed MPX case can have significant \\nprotective effect  [22]. In addition, countries may consider prophylactic vaccination of certain health professionals \\nresponding to this outbreak.  To date , the vast majority of cases have mild to moderate symptoms and are all \\nrecovering well . However, nu mbers are still low and the severity profile of the disease cannot be reliably estimated.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n9 No smallpox vaccine is  authorised for use against MPX in the EU, but the 3 rd generation smallpox vaccine \\nImvanexTM (Modified Vaccine Ankara -MVA) has been authorised b y EMA for the EU market against smallpox  [78]. \\nMVA has shown protection in primate models challenged with lethal doses of monkeypox virus  [79]. Older \\ngeneration smallpox vaccines have significant side effects and in addition,  are no longer authorised and  should not \\nbe used . Careful needs assessment should be carried out in each country to estimate the potential need  of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='smallpox vaccine for the management of this outbreak and collaboration between the national drug authorities and \\nEMA is nee ded to clarify the authori sation status of the MVA vaccine if it is to be used against MPX . However, it is \\nimportant to note that efficacy data  for this vaccine against MPX  in humans are missing as well as safety data for \\nthe use of this vaccine in immunocompromised persons .  \\nConsidering  the above and the limited supply of smallpox vaccine doses, National Immunization  Technical Advisory \\nGroups (NITAG)  should develop  specific guidance for the vaccination of close c ontacts  of MPX cases . The use of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='smallpox vaccination for the purpose of pre -exposure prophylaxis in the exposed communities of MSM  cannot be \\nconsidered at this point , considering the limited supply  of vacci ne and most importantly  the benefit/risk ratio of \\nsmallpox vaccination in this outbreak .  \\nAs regards antivirals used for the treatment of MPX, t ecovirimat is the only antiviral drug with an indication for the \\ntreatment of orthopoxvirus  infections, includin g MPX,  authorised by EMA  [51]. Brincidofovir is not authorised in the \\nEU but  has been authorised by FDA for treatment of MPX. However, their availability in the EU market is quite'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='limited in  the number of doses. Clinicians and infectious disease societies also need to provide guida nce for the use \\nof this medication  and ideally, follow a common treatment protocol in order to provide valuable efficacy data. \\nHealth authorities should consider p rioritisation of patient groups that could be offered treatment . Use of antivirals \\nfor post -exposure prophylaxis could be additionally investigated.  Cidofovir is active  in vitro  for smallpox, but has a \\npronounced nephro toxicity profile that makes it unsuitable as first choice  treatment .  \\nPersonal Protective Equipment'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='Personal Protective Equipment  \\nAs indicated above, human -to-human t ransmission of MPXV  can occur via droplets in prolonged close contact and \\ncontact with the infectious lesion material  [22,25] . Therefore , appropriate PPE is needed for all health professionals \\nwho will screen suspected cases, care for a MPX patient s or handl e contaminated material (clothes, bedlinen , etc.) \\nor laboratory specimens  (gowns, FFP2 respirators, goggles) . Availability of sufficient stocks of PPE at healthcare \\nfacilities and at national levels should be monitored and ensured.  \\nExposure of pets'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='Exposure of pets  \\nPublic health authorities should work together with veterinary authorities to ensure capacity  is in place for \\nquarantining  and testing  of mammalian pet animals that have been exposed or are at risk of exposure (i.e. pets of \\na close contact of a MPX case)  to MPXV . Rodent pets should ideally be isolated in  monitored facilities , complying \\nwith respiratory isolation (e.g. a laboratory) and animal welfare conditions ( e.g. government facilities , kennels or \\nanimal welfare organisations) , and tested (by PCR)  for exposure before quarantine  ends. Euthanasia should only'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='be a last resort  reserved to situations where  testing  and/or isolation are not feasible. O ther mammalian  pet species \\ncould be isolated at home if animal welfare conditions allow it (e.g. availability of an enclosed outdoo r space for \\ndogs, regular veterinary checks to assess the health status, preventing access to visitors, preventing pets from \\nleaving the home).  \\nSurveillance and EU/EEA reporting  \\nMonkeypox is currently  not listed as a disease under surveillance  [80] in the EU/EEA  , nor is the virus notifiable in \\nanimals under Commis sion Implementing Regulation 2018/1882 . Orthopox virus infection  is a mandatory notifiable'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 8}, page_content='disease in some countries , and some have now made MPX notifiable as part of the response to this outbreak . The \\nrapid evolution of the current outb reak involving multiple EU/EEA countries , the limited data available on disease \\nseverity and the previously unreported context of transmission among groups of MSM  highlight the need for setting \\nup a European surveillance system aiming to describe the epide miology and evolution of the outbreak and to \\nsupport control measures.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n10 The following interim case definition is proposed :  \\n \\n* Since EU/EEA countries are just starting to identify cases and if testing capacity is sufficient, the above mor e sensitive case \\ndefinition can be used. In countries with limited testing capacity for orthopoxviruses , the following description can be added to \\ncharacterise the rash: ‘unexplained localised or generalised maculopapular or vesiculopustular rash potentially with umbilication or \\nscabbing ’.  \\n**Fever (usually high >38.5°C), headache, back ache , fatigue, lymphadenopathy  (localised or generalised) .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='Patients  who fulfil the criteria for probable  cases should be tested with a monke ypox virus specific PCR assay or an \\northopoxvirus specific PCR assay which is then confirmed through sequencing. If negative, these patients  should \\nbe excluded.  \\nECDC in liaison with  the World Health Organization  (WHO) asks countries to report newly -identified cases in the \\nline listing document in EpiPulse  [access only to nominated users]. Reporting in TESSy will be implemented  shortly  \\nby ECDC . \\nManagement of cases  \\nNewly identified cases of MPX should undergo a medical assessment for severity and risk factors (e.g . underlying'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='conditions or medications affecting immune competence, untreated HIV infection etc.). Those at increase d risk of \\nsevere disease from  MPX may require hospitalisation and/or treatment with antivirals (see Overall preparedness \\nand response section) . People at increased risk  for severe disease include infants and young children,  pregnant \\nwomen,  elderly  and severely immunocompromised persons. A common treatment protocol  should be considered  \\nfor patients tr eated in  EU/EEA countries in order to provide much needed efficacy d ata. Tecovirimat  also has the \\npotential to cause resistance to pox viruses, therefore, careful monitoring of  treated patients should be'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='undertaken, particularly the immunosuppressed. Potential combination with brincidofovir can also be explored.  The \\nmajority of MPX cases reported so far in this outbreak have been mild  with localised disease and self -limiting  \\nsymptoms. Therefore, hospitalisation is not necessary , unless  the patient’s  clinical condition requires it. Patients \\ncan remain isolated at home with supportive care (analgesia, hydration). If isolation is not possible at home, then \\nhospitalisation or other arrangement can be considered.   \\nMPXV can be transmitted to anyone, regard less of sexual orientation or gender identity, through contact with body'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='fluids, monkeypox sores, or shared items . Therefore, c ases should be instructed to isolate until the rash scabs fall \\noff, which indicate s the end of infectiousness. Cases should remai n in their own room , when at home,  and use \\ndesignated household items ( clothes, bed linen, towels, eating utensils, plates, glasses) , which should not be \\nshared with other members of the household  (see the next section for information on cleaning and dis infection of \\nsuch materials ). Cases should also avoid contact with immunocompromised persons until their rash heals. A MPX \\ncase should be monitored daily by public health authorities (e.g. via telephone calls) and  can temporarily leave'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='their home (e.g. for medical appointments and necessary exercise for their mental health stability ), provided they \\nwear a medical face mask and their rash is covered (e.g. long sleeves and pants) . They should also be instructed Confirmed case  \\nA person with a laboratory -confirmed monkeypox infection (1) monkeypox virus specific PCR assay positive result or \\n(2) orthopoxvirus specific PCR assay positive result which is then confirmed by nucleotide sequence determination of \\nthe detected virus as MPXV) with symptom onset since 1st March 2022  \\nProbable case  \\n(1) A person with an unexplained rash* on any p art of their body'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='AND one or more other symptom(s) of monkeypox infection** with symptom onset since 1st March 2022  \\nAND one of the following:  \\n- has a positive laboratory test result on orthopoxvirus infection (e.g. orthopoxvirus specific positive PCR \\nwithout sequencing, electron microscopy, serology) ; \\n- has an epidemiological link to a confirmed or probable case of monkeypox in the 21 days before  symptom \\nonset ; \\n- reports travel to MPX endemic countries in the 21 days before symptom onset ; \\n- is a pe rson (of any sexual orientation) who had multiple or anonymous sexual partners in the 21 days before \\nsymptom onset ; \\n- is a man who has sex with men.  \\nOR'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 9}, page_content='- is a man who has sex with men.  \\nOR \\n(2) A person with an unexplained generalised or localised maculopapular or vesiculopustular rash with cen trifugal \\nspread, with lesions showing umbilication or scabbing, lymphadenopathy and one or more other MPX -compatible \\nsymptoms**.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n11 to avoid close or intimate contact (hug ging, kissing, prolonged face -to-face contact in closed spaces) with other \\npeople  until their rash heals completely.   \\nCareful hand and respiratory hygiene are recommended for the case and everyone in the household; a medical \\nface mask should be used  when in contact with other people . Cases should abstain from sexual activity  until scabs \\nfall off . While  the use of condoms is consistently  encouraged  during sex for prevention of HIV and other STIs,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='cases  should be made aware that the use of condoms alone cannot  provide full protection against MPXV  infection , \\nas contact with skin lesions is involved  for its transmission . Because transmission through dr oplets is possible, \\navoidance of close, physical  contact is recommended until the scabs fall off .   \\nHealth authorities and policy makers should consider  that s ex workers may be disproportionately affected by this \\noutbreak and may need incentives to be able to comply with the full recommendation of isolation until the rash \\nheals completely which may last up to four weeks.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='Finally, instructions  should be given to MPX cases to avoid contact with any mammal pets, and in particular pet \\nrodents  (mice, rats, hamsters, gerbils, guinea pigs , squirrels  etc), due to the possibility of  human -to-pet \\ntransmission . Any recent contact with such pets should be noted and  animal health services should be contacted  \\nfor advice . \\nEnvironmental persistence  and disinfection  \\nPoxviruses show extraordinary resistance to drying  [81], and increased temperature and pH tolerance when \\ncompared with other enveloped viruses. These characteristics strongly impact their environmental persistence:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='materials from infected patients (e.g., dermal crusts ) or fomites  (e.g., bed linens)  remain infective for months to \\nyears.   \\nDespite these characteristics, poxviruses are sensitive to  common disinfectants, although they can be less sensitive \\nto organic disinfectants compared to other enveloped viruses , due to their reduced  envelope lipid content.  \\nCleaning  of the room where a MPX case stayed should be done without stirring a lot of dust or causing the \\nformation of aerosols  and should use  regular cleaning products followed by disinfection using a 0.1 % sodium \\nhypochlorite (NaClO) (dilution 1:50, if household bleach is used, usually at an initial concentration of 5%) .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='Particular attention  should be paid to  toilets and  frequently touched sur faces. Contaminated clothing and linens \\nshould be collected and washed at 60 °C cycles . Carpets, curtains and other soft furnishings can be steam -\\ncleaned. [82].  \\nSingle-use disposable cleaning equipment (e.g . disposable towels) is recommended. If disposable cleaning \\nequipment is not available, the cleaning material (cloth, sponge etc.) should be placed in a disinfectant solution \\neffecti ve against viruses, or 0.1% sodium hypochlorite. If neither solution is available, the material should be \\ndiscarded.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='discarded.  \\nGauze s or other material soaked with lesion fluid or containing scabs from the MPX case should be preferably \\nhandled in a healthcare facility as infectious  waste , or according to instructions from the local public health \\nauthority .  \\nManagement of monke ypox  contacts  \\nClose contacts of the currently reported MPX cases include mainly sexual partners and people living in the same \\nhousehold or anyone sharing the same bedding or clothing with an MPX case. Sharing the same workspace for \\nseveral hours seated within one to two  metres or being a co -passenger in longer flights, train or bus rides may also'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='qualify as a close contact in certain situations, but this would require a case -by-case assessment. (see Table 2) . \\nFrom outbreaks in Africa, the secondary attack rate  is estimated at 9 -12% among unvaccinated contacts within \\nhouseholds, however other estimates are as high as 50%, while in the 2003 US outbreak it was 0% [34,58]. \\nAlthough some of the reported cases are epidemiologically linked, no further onward transmiss ion to close contacts \\nthat are not sexual partners has been documented yet in this outbreak.  \\nContact tracing of newly identified MPX cases should be performed carefully and exhaustively, building on long-'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='standing good practices implemented for the management of  STIs and  the HIV epide mic and the ongoing COVID -\\n19 pandemic. Partner notification should be rapidly initiated ; however , this might be challenging  in the case of \\nanonymous sexual partners.  Involvement of sexual health services, who are experienced in partner notification for \\nsexually -transmitted diseases  is recommended to ensure the best possible outcome .  \\nAwareness raising in  MSM communit ies about the ongoing MPX outbreak is extremely important and should \\nhappen with the engagement of the comm unity (see section risk communication and community engagement).'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 10}, page_content='Contact  tracing should pay particular attention to identifying MPX contacts  who are immunocompromised . Working \\nwith associations supporting people living with human immunodeficiency virus  (PLWHIV ) and immunocompromised \\npatients would be valuable.  Public health resources for these activities are very important . Although the number of \\ncontacts to be traced is not expected to be very large, the  case complexity will be high. That the public health \\nworkforce is already  affected by the continuous pressure of the response needs to the COVID -19 pandemic  should \\nalso be considered .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n12 All identified close contacts  (see Table 2)  of a MPX case should be instructed to self -monitor for fever and MPX \\nsymptoms daily for 21 days afte r their last exposure. I nstructions should be provided, if they develop any \\nsymptoms during this period,  to self -isolate except for  attending medical assessment s or testing. In general, \\nsymptomatic contacts should be isolated during th eir investigation  until MPX is excluded . Close contacts should be \\nadvised to avoid close physical contact with young children, pregnant women and immunocompromised persons \\nuntil MPX is excluded.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='until MPX is excluded.  \\nSexual contacts of MPX cases should abstain from sex for a d uration of at least 21 days or until the infection is \\nexcluded. While all persons  are encouraged to use condoms consistently during sex ual activity  for prevention of \\nHIV and other STIs, they should be made aware that the use of condoms alone cannot offer f ull protection against \\ntransmission of MPXV . Because transmission through droplets in prolonged face -to-face contact  is also possible, \\navoidance of close, physical  contact is recommended for the duration of 21 days following exposure. Sex workers'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='may be a group potentially exposed to MPX and consideration should be given to the fact that they would need \\nfinancial support to comply with the recommended dur ation of self -monitoring.  \\nClose contacts  of MPX cases  would benefit from an exposure assessment, including history of past smallpox \\nvaccination, and should be carefully evaluated for the potential need of post-exposure prophylactic (PEP) smallpox \\nvaccinat ion. Use of PEP smallpox vaccination should  only be offered  after a careful  risk/benefit  ratio assessment for \\nthe individual person, including the type and timing of last exposure, their age group, their medical history'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='particularly as regards  their immune status and other underlying conditions that would indicate that they are at \\nincreased risk  for severe MPX disease. The time from vaccination until devel oping the expected antibody pro tection \\nalso plays a role. In addition, the profile , indication  and availability  of the nationally available smallpox vaccine \\nshould be considered (which generation of vaccine is available , number of doses  etc.). Use of the smallpox vaccine \\nup to four days after exposure  to MPX  can prevent the onset of symptoms, while after that and u ntil 14 days post -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='exposure prophylactic vaccination may modify the disease course  [83]. If the currently authorised 3rd generation \\nMVA vaccine for smallpox  would be used, then two doses would be needed 28 days apart.  \\nFor pa ssengers in an aircraft , bus or train  sitting within a radius of two metres  of a symptomatic case  (i.e. seated \\none-two seats around the case) , an exposure assessment by health authorities should be carried  out and \\nmonitoring implemented accordingly . Exposure on longer flights  or rides  (more than eight hours) can be \\nconsidered  as riskier  [84]. From when  smallpox was circulating , no transmission on aircraft was documented  [85].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='Table 2 presents the overview of the advice for  the management of contacts of a MPX case.  \\nTable 2. Summary of management approach for contacts of a MPX case  \\nType of contact  Description  Management guidance  \\nClose contact  • Sexual partner  \\n• Person(s) living in same household, or similar setting  (e.g \\ncamping , overnight sleeping etc ) \\n• Person(s) sharing clothing, bedding, utensils etc , while the  \\npatient had a rash  \\n• Person(s) sharing the same closed workspace/office for  \\nlong periods of time  \\n• Caregi vers of MPX case, while symptomatic    \\n• HCW who had contact with MPX case  (lesions or \\nprolonged face-to-face contact)  without appropriate PPE'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='• HCW or other person who suffered a sharps injury  or was \\nexposed to MPX case body fluids  or aerosol generating \\nprocedure  without PPE   \\n• Laboratory staff suffering exposure to occupational \\naccident with virus -containing sample (splash, sharp or \\naerosol exposure etc)  \\n• Co-passenger seated one -two seats distance around \\ncase while they were symptomatic, in airplane, bus or train  \\n≥ 8 hours duration  • Careful benefit/risk a ssess ment for the  need \\nfor PEP smallpox vaccination  \\n• Self-monitor for fever or other MPX \\nsymptoms (headache, back ache etc)  or new \\nunexplained rash for 21 days from last \\nexposure. In that case self -isolate and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='exposure. In that case self -isolate and \\nabstain from sex ual activity  until MPX is \\nexcluded . \\n• Careful hand hygiene and respiratory \\netiquette.  \\n• Abstain from sex ual activity  and avoid close \\nphysical contact for 21  days or until MPX is \\nexcluded.  \\n• Avoid contact with mammal pets  for 21 days \\nor until MPX is excluded  \\nAll other contacts  • Brief social  interactions  \\n• Work colleagues not sharing same office  \\n• Persons sharing fitness equipment or sharing the same \\nsauna or bath , without sexual contact  \\n• Social encounters/  acquaintances  \\n• HCW contact with appropriate PPE  \\n • Depending on the certainty of contact , some \\nof these contacts  may be asked to self -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='of these contacts  may be asked to self -\\nmonitor for fever or other MPX symptoms \\n(headache, back ache etc) or new \\nunexplained rash for 21 days from last \\nexposure.  \\nHealth care settings  and diagnostic laboratories  \\nRaising awareness of health professionals is important for case identification and contact tracing in this MPX \\noutbreak. Countries are urged to provide information about the on going situation to their clinicians at various levels \\nin the health system, with a particular focus to general practitioners, sexual clinics, genito -urinary practitioners, \\nwalk-in clinics providing care to MSM and sex workers , dermatology departments and emergency departments  in'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 11}, page_content='general . Cases with localised unexplained rash with inguinal lymphadenopathy and other MPX -compatible \\nsymptoms should  be referred to specialised services  per national guidelines  for decisi on on testing.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n13 In healthcare settings, prevention of transmission is based on appropriate infection prevention and control \\nmeasures. MPX is considered to be mainly  transmitted through respiratory droplets and direct contact with body \\nfluids or lesion material [66,86] . Therefore, both  contact and airborne precautions should be applied when \\nproviding care for patients with monkeypox . Patients who need to be hospitalised should preferably  be placed in an \\nisolation room with  anteroom and  negative pressure, or if not available  in a single room.  Healthcare workers'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='entering the isolation room should wear gloves, a water -resistant gown and an FFP 2 respirator  [25]. \\nWHO suggests that national health authorities should consider immunisation against smallpox for healthcare \\nworkers treatin g or exposed to patients with MPX or their samples  [25]. Careful risk/benefit ratio assessment \\nshould also be carried out for the individual health professionals offered the smallpox vaccine as pre -exposure \\nprophylaxis in this outbreak.  \\nClinical specimens suspected to contain MPXV are considered category A (UN 2814) – Infectious Substances \\nAffecting Humans. They should be packaged and transported following the relevant regulation, unless previously'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='treated to neutralise or inactivate the pathogen  [87,88] . \\nDiagnostic specimens suspected to contain MPXV should be ideally processed using a certified Class II Biological \\nSafety Cabinet. Laboratory staff handling specimens suspected to contain MPXV  who are not vaccinated within the \\nlast 10 years should use appropriate PPE under more stringent biosafety -3 work practices to reduce the risk of \\nexposures. Vaccinated laboratory staff could work using BSL -2 practices. Centrifugation of infected materials must \\nbe carried out in closed contai ners placed in sealed safety cups, or in rotors that are loaded or unloaded in a Class'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='II biological safety cabinet. Laboratory waste containing monkeypox virus should be decontaminated before \\ndisposal (e.g ., by autoclaving). Due to the short duration of viraemia, testing specimens in clinical chemistry \\nlaboratories is probably not a high -risk activity. However, using the precautionary principle, they should be handled \\nas described above. If the appropriate safety conditions are not avai lable, referral to a certified laboratory should \\nbe considered  [89]. \\nCleaning and disinfection  in healthcare facilities  should  follow the rules a s outlined above (see environmental'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='cleaning and disinfection). In addition, s taff performing cleaning and disinfection in a MPX case ’s room should wear \\na minimum set of PPE:  \\n• a disposable water -resistant gown ;  \\n• disposable g loves; \\n• disposable shoe or boots covers ;  \\n• respiratory protection (Filtering Face Piece (FFP) 2 respirator) ;  \\n• eye splash protection (goggles or visor) .  \\nDonning and doffing of PPE should be carefully performed by trained staff, and h and hygiene should be performed \\nevery time PPE, such as gloves, are removed.  \\nWaste should be assessed depending on risk  and handled  in accordance with healthcare facility policies and local'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='regulations.  If assessed as infectious clinical waste category A (UN3549) , transport sho uld be handled according to \\nUN transport regulations  [87]. Staff engaged in waste management should wear PPE  [82]. \\nSubstances of human origin  \\nAll potential donors should be carefully interviewed regarding contacts with infected (confirmed or suspected) MPX \\ncases, infected animals or travels to affected areas. Medical history data on these risk factors should be collected in \\nthe case of deceased donors.  \\nBased on the incubation period of MPX, it is recommended to defer asymptomatic donors that have been in contact'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='with (confirmed or suspected) cases from substances of human or igin donation for  a minimum of 21 days from the \\nlast day of exposure.  \\nSince the MPX prodromal stage varies in duration (1 –4 days  [22]) and symptoms can be non-specific and mild  [88-\\n91] or absent  [49], careful examination for any possible si gns of infection should be performed even after the \\nexpiration of the deferral period  (at least 21 days from the last day of exposure) . Examination should not overlook \\nmild and non -specific signs like headache or fatigue or anogenital skin lesions.  \\nRisk communication and community engagement'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='Risk communication and community engagement  \\nIt is important that health authorities communicate risks about this MPX outbreak , referring to the specific \\ncharacteristic s of the current situation , so that people at risk can adopt appropriate preventive and treatment -\\nseeking behaviour . A balance should be kept between  informing people at risk but also communicating that the \\nvirus is not spread easily between people  and th e risk to the broader populat ion is low . However, much remains \\nunknown about the event , in particular where and how index cases have acquired their infections. Authorities'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 12}, page_content='should make clear that while the evidence  base is still quite limited, intensive work is ongoing to fill in the \\nknowledge gaps. As such, the initial prevention strategies implemented may need to be adapted as more scientific \\ninformation becomes available.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n14 In the meantime, efforts should be made t o ensure that stigmatisation does not occur  based on  sexual orientation \\nand practices . Risk communication messages should stress that monkeypox virus is spread through close contact \\nbetween people , especially in the same household,  including during sexual contact . Transmission  of vaccinia virus \\nhas been described  among heterosexual partners  [43] and similarly, it is expected that sexual transmission will \\noccur  in the broader  population.  Therefore, r isk communication messages could also state that MPX infection is not'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='indicative  of someone’s  sexual orientation  nor that the latter influences the ir susceptibility to the disease . In clear \\nand accessible language,  people  who are infected with monkeypox virus should be advise d to avoid any sort of \\nclose contact , including protected sexual contact,  with other people until their rash has ended and the last scab \\nhas fallen off, no matter how long this process takes  (may be up to four weeks) . If they are living with other \\npeople, the importance o f staying in one room  for as long as they have the rash  should be stressed,  and ideally , \\nthey should have access to  their own bathroom . Advice to  avoid sharing bedding or any household items with'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='anyone else  should be disseminated . Building on approaches that were developed  during the early COVID -19 \\npandemic  [94], if full isolation is not possible,  very good hygiene practices should be promoted:  the monkeypox \\nvirus is able to survive on surfaces  or other fomites for long periods of time (days to months  [95,96] ). \\nIf high-risk close contacts of MPX patients are offered post -exposure vaccination  in the form of  the smallpox \\nvaccine, they should be fully informed about the risk/benefits for them and potential  side effects of the vaccine  \\noffered  [95,96] .  \\nCommunity engagement approaches  should  be used to understand perceptions and concerns and to support'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='target ed risk communication messages to populations or groups more likely to be exposed to the virus . This \\nrequires  the identification of relevant community -based organisations and stakeholders  and leverag ing their \\nexisting networks so  they can communicate with community members and raise awareness using language \\nadapted to their community  and through appropriate communication channels  [97]. Public health institutions \\nshould regularly inform and exchange  ideas with these organisations and groups on specific aspects of the  risk \\ncommunication messages to be adapt ed and disseminated , as well as on their impact on the target audience .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='Three  key groups should be considered as priority  groups  for community engagement strategies  during the current \\nMPX outbreak .  \\n• Since the current event has seen several  cases in MSM, this group must be made aware of the risk  of infection as \\nwell as  prevention measures  they may take.  Applications used by MSM for meeting partners  can be explored to \\nreach those most at risk  and provide health promotion information . Various organisations exist at the regional, \\nnational, s ub-national and local level working on health for LGBTQIA+ , including  activist groups and community'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='testing organisations (i .e. checkpoints ). These  should be contacted, informed and asked to engag e with their \\nmembers , users and networks  about the situation  and hear their perceptions and concerns . Other organisations \\nworking on sexual health may also be mapped and contacted for similar purposes. Key messages should focus on \\nthe fact that MPXV  is spread through close contact with infect ious individuals, may possibly be sexually \\ntransmitted and that condoms can mitigate the risk of many sexually -transmitted infection s, but cannot  offer full \\nprotection against transmission of MPXV , since contact with lesions may be sufficient  for transmission  to occur .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='• As people who are immunocompromised have been shown to be more vulnerable to severe disease  [42], support \\norganisation s for immunocompromised people  should also be identified, kept informed, and supported in \\nconducting outrea ch to their members . Particular focus should be given to  their heightened risk  of severe \\ndisease , and the importance of seeking treatment should they develop symptoms  of MPX infection . However , it is \\nimportant to clarify that  people living with HIV  under appropriate treatment are not considered \\nimmuno compromised , and those with untreated HIV should be referred  to HIV treatment  [98].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='• Healthcare workers ’ unions  and associated professional networks  should be engaged with so they can be  \\nequipped to detect and treat cases early as well as provide health advice and disseminate messages about case \\ndefinition s and strategies for contact tracing . They should also be informed about the particular susceptibility to \\nsevere disease of p eople with untreated HIV and those who are otherwise immunocompromised so that they can \\nprovide appropriate treatment and support for such patients. Health workers should also be made aware that \\ntheir own close contact with patients may put them at increas ed risk of infection and therefor e they should'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='protect themselves accordingly.  \\nECDC is working with multiple civil society organisations to reach out to MSM groups by disseminating the following \\nmessage to all European countries:  \\n‘Monkeypox virus is spreading in Europe, in particular among men who have sex with men. It is transmitted \\nthrough close contact, like during sexual intercourse or through  contaminated bedding, sex toys.  If you or any \\nrecent (last 21 days) partner have unusual sores or rash , contact your sexual health provider (find closest site \\nhere: https://www.testfinder.info ) or your GP  or local health provider. More info can be found'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 13}, page_content='here: www.ecdc.europa.eu/en/news -events/epidemiological -update -monkeypox -outbreak ’'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 14}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n15 Limitations   \\nThis assessment is undertaken based on facts known to ECDC at the time of publication  and has several key \\nlimitations. In particular, there are many scientific uncertainties and knowledge gaps regarding  human MPX, \\nincluding :  \\n• This is the first outbreak of MPX outside Africa suggesting  transmission  during sexual contact/in tercourse  as the \\nprimary rout e of transmission  of the disease . No comprehensive  data are available on severity of illness and on \\ntransmission  dynamics as well as on effective response measures .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 14}, page_content='• A lack of clear understanding of the epidemiological situation  since countries are in the case -finding stage.  \\n• A lack of understanding of the route of introduction of MPXV in  MSM communit ies. \\n• Lack of sequencing results of MPXV to identify chains of transmission and connections among cases . Sequencing \\nmay also provide clues regarding  a possible time and mode of introduction of MPXV in  Europe. Look -back studies \\nmay also be useful in left over samples from STI clinics to study this question.  \\n• More accurate estimate s of the risk of transmission associated with different sorts of contacts with clinical cases \\nare needed in  European settings.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 14}, page_content='are needed in  European settings.  \\n• Information is needed on the current residual cross protection from smallpox vaccination in the EU/EEA \\npopulation . \\n• Efficacy  data of the currently available smallpox vaccine(s) against MPX  are lacking , and safety data for the use \\nof the smallpox vaccine in young children, pregnant women and immunocompromised are also lacking.  \\n• Efficacy data and safety profile of the available antivir al agents for the treatment of potential severe cases are \\nalso lacking. A common treatment protocol is proposed by EMA and should be adopted.  \\n• More information is needed on the clinical presentation of cases and their outcome, to establish the severity'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 14}, page_content='(morbidity and mortality) of the disease in Europe.  \\n• More information is also needed on possible contact with animals. In addition, studies are needed to assess  the \\nvulnerability of European rodent and other mammal species to MPXV . \\nSource and date of request  \\nECDC internal decision, 17 May  2022.  \\nConsulted experts  \\nECDC experts  (in alphabetic order):  Leonidas Alexakis,  Agoritsa Baka, Jon Bilbatua, Benjamin Bluemel, Olivier \\nBriet, Daniel Cauchi,  Orlando Cenciarelli, Joana Haussig, Anne I ngenbleek, John Kinsman, Favelle Lamb, Katrin \\nLeitmeyer, Otilia Mardh, Jenny Mohseni Skoglund, Vanja Nikolac Markic, Teymur Noori, Anastasia Pharris,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 14}, page_content='Diamantis Plachouras, Juliana Reyes -Urueña, Gabrielle Schittecatte, Emily Scott, Gianfranco Spiteri . \\nEuropean Food Safety Authority  (EFSA) : Ernesto Liebana  (BIOHAW Unit ). \\nEuropean Medicines Agency (EMA) : Marco Cavaleri, Eugenia Di Meco . \\nWorld Health Organization  (WHO) : Richard Pebody, Cristiana Salvi (Regional Office for Europe)  Antons \\nMozalevskis (Headquarter ). \\nPublic health experts  from EU/EEA countries : \\nBelgium:  Cécile van de Konijnenburg (SPF Santé Publique - FOD Volksgezondheid) . \\nFrance:  Emilie Chazelle , Alexandra Mailles  (Santé Publique France) . \\nPortugal:  Paula Vasconcelos, Teresa Fernandes, Ana Firme, Margarida Tavares, Mariana Perez Duque, Sofia'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 14}, page_content='Ribeiro, Pedro Ca saca, Tiago Manuel Soto , Graça Freitas , (Direção -Geral da Saúde  – Ministry of Health ), Kamal \\nMansinho (Centro Hospitalar Lisboa Ocidental/Hospital de Egas Moniz  and Institute of Hygiene and Tropical \\nMedicine/New University of Lisbon) , Jorge Machado  (National Institute of Health , Department Infectious Diseases ). \\nSweden: Britta Björkholm, Sara Bengtsson  Andreas Bråve, Erik Sturegård,  Åsa Szekely Björndal  (Public Health \\nAgency of Sweden) . \\nGermany: Christina Frank , Klaus, Jansen, Uwe Koppe , Lass Schaade, for the RKI monkeypox Team  (Robert Koch \\nInstitute, RKI) .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 14}, page_content='Institute, RKI) . \\nItaly: Flavia Riccardo , Barbara Suligoi,  Anna Teresa Palamara , Patrizio Pezzotti, Paol a Stefanelli, Giulietta V enturi, \\nSilvio Brusaffero  (Istituto Superiore di Sanit à, ISS), Francesco Ma raglino , Federica Ferraro, Giovanni Rezza, Anna \\nCaraglia  (Ministero della Salute) .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 15}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n16 Subject Matter Experts (SME) and representatives of Civil Society from EU/EEA countries and the \\nUnited Kingdom : \\nDaniel Simões (Coalition PLUS),  Christos Krasidis ( AIDS Action Europe , Freelance ), Will Nutland (The Love Tank \\nCIC and The London School of Hygiene & Tropical Medicine - LSHTM),  Helen Roberts ( UK Department for \\nEnvironment, Food and Rural Affairs, Defra  and EFSA Animal Health and Welfare Panel member ), Rajul Patel \\n(Solent NHS Trust) . \\nAll experts have submitted declarations of interest , and a  review of these declarations did not reveal any conflict of \\ninterest.  \\nDisclaimer'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 15}, page_content='interest.  \\nDisclaimer  \\nECDC issues this risk assessment document based on an internal decision and in accordance with Article 10 of \\nDecision No 1082/13/EC and Article 7(1) of Regulat ion (EC) No 851/2004 establishing a European centre for \\ndisease prevention and control (ECDC). In the framework of ECDC’s mandate, the specific purpose of an ECDC risk \\nassessment is to present different options on a certain matter. The responsibility on th e choice of which option to \\npursue and which actions to take, including the adoption of mandatory rules or guidelines, lies exclusively with the \\nEU/EEA Member States. In its activities, ECDC strives to ensure its independence, high scientific quality,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 15}, page_content='transparency and efficiency.  \\nThis report was written with the  coordination and assistance of an Internal Response Team at the European Centre \\nfor Disease Prevention and Control. All data published in this risk assessment are correct to the best of our \\nknowledg e at the time of publication . Maps and figures published do not represent a statement on the part of \\nECDC or its partners on the legal or border status of the countries and territories shown.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n17 References  \\n1. UK Health Security Agency (UKH SA). Monkeypox cases confirmed in England – latest updates. London: UKHSA; \\n2022. Available at: https://www.gov.uk/government/news/monkeypox -cases -confirmed -in-england -latest -\\nupdates  \\n2. Direção -Geral da Saúde (DGS). Casos de infeção por vírus Monkeypox em Portugal. Lisbon: DGS; 2022. \\nAvailable at: https://www.dgs.pt/em -destaque/casos -de-infecao -por-virus-monkeypox -em-portugal.aspx  \\n3. Gobierno de España - Ministerio de Sanidad - Centro de Coordinación  de Alertas y Emergencias Sanitarias.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='Informe de situación - Alerta sobre infección de viruela de los monos en España y otros países de Europa. \\nMadrid: MSCBS; 2022. Available at: \\nhttp://www.mscbs.es/profesionales/saludPublica/ccayes/alertasActual/alertaMonkeypox/docs/Informe_de_situa\\ncion_MPX.pdf  \\n4. La Razon. Virus del mono: Los casos de viruela del mono en Madrid: 30 confirmados y 39 sospechosos. La \\nRazon. 21 May 2022. Availabl e at: \\nhttps://www.larazon.es/sociedad/20220521/gid4menhqfhqzmn5ub3gyh7z74.html  \\n5. Selhorst P, Rezende AM, Block Td, Coppens S, Smet H, Mariën J, et al. Belgian case of  Monkeypox virus linked'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='to outbreak in Portugal. 2022. Available at: https://virological.org/t/belgian -case-of-monkeypox -virus-linked -to-\\noutbreak -in-portugal/801  \\n6. Emmanuel André. A l’@UZLeuven//@KU_Leuven, les laboratoires travaillent 7/7 pour offrir un diagnostic rapide \\n(PCR et séquençage) pour les patients ayant une suspicion d’infection à la variole du singe. Aujourd’hui, nous \\navons pu confirmer  un quatrième cas d’infection en Belgique. Twitter. 21 May 2022 09:22:00 PM. Available at: \\nhttps://twitter.com/Emmanuel_microb/status/1528094016230903809  \\n7. Bundeswehr Medical S ervice. Bundeswehr Institute for Microbiology detects monkeypox in Munich. Munich:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='Presseportal; 2022. Available at: https://www.presseportal.de/pm/122038/5227679  \\n8. Santé publique France (SPF).  Un premier cas confirmé de Monkeypox sur le territoire national. Saint -Maurice: \\nSPF; 2022. Available at: https://www.santepubliq uefrance.fr/presse/2022/un -premier -cas-confirme -de-\\nmonkeypox -sur-le-territoire -national  \\n9. Cigna Y. Vaiolo delle scimmie, salgono a 3 i casi confermati in Italia. La Regione Lazio: «Screening su altri 30». \\nOpenonline. 20 May 2022. Available at: https://www.open.online/2022/05/20/vaiolo -scimmie -confermati -2-casi-\\nspallanzani -roma/'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='spallanzani -roma/  \\n10. Folkhälsomyndigheten (Fohm). Ett fall av apkoppor rapporterat i Sverige. So lna: Fohm; 2022. Available at: \\nhttps://www.folkhalsomyndigheten.se/nyheter -och-press/nyhetsarkiv/2022/maj/ett -fall-av-apkoppor -\\nrapporterat -i-sverige/  \\n11. National Institute for Public Health and the Environment Ministry of Health, Welfare and Sport - The \\nNetherlands. First patient with monkeypox in the Netherlands. Bilthoven: RIVM; 2022. Available at: \\nhttps://www.rivm.nl/en/news/first -patient -with-monkeypox -in-netherlands  \\n12. Wiener Gesundheitsverbund. Verdacht auf Pockenviren bestätigt. Jener Patient, der am Sonntag in die'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='#KlinikFavorite n eingeliefert wurde, wurde positiv auf Pockenviren getestet. Die Sequenzierung steht noch aus. \\nTwitter. 22 May 05:17:00 PM. Available at: https://twitter.com/wiengesundheit/stat us/1528394719377735681  \\n13. Santé et Services sociaux - Quebec. Variole simienne - Deux premiers cas confirmés au Québec. Quebec, \\nCanada: CNW Telbec; 2022. Available at: https://www.quebec.ca/nouvelles/actualites/details/variole -simienne -\\ndeux-premiers -cas-confirmes -au-quebec -40533  \\n14. Department of Public Health - Massachusetts. Massachusetts public health officials confirm case of monkeypox.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='2022. Available at: https://www.mass.gov/news/massachusetts -public -health -officials -confirm -case-of-\\nmonkeypox  \\n15. City of New York (NYC). H ealth Department Investigating Possible Monkeypox Case in New York City. New York: \\nNYC; 2022. Available at: https://www1.nyc.gov/site/doh/about/press/pr2022/m onkeypox -possible -nyc-\\ncase.page  \\n16. Health professionals and the Victorian community. Health warning on Monkeypox. 2022. Available at: \\nhttps://www.health.vic.gov.au/hea lth-alerts/health -warning -on-monkeypox  \\n17. Ministry of Health - Israel. Update: Monkeypox. The State of Israel: Gov.il; 2022. Available at: \\nhttps://www.gov.il/en/departments/news/21052021 -02'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 16}, page_content='18. Direction de la santé, des affaires sociales et de l’intégration (DSSI) Canton de Berne. Variole du singe : \\npremier cas dans le canton de Berne. Bern: DSSI; 2022. Available at: \\nhttps://www.gsi.be.ch/fr/start/news/medienmitteilungen.html?newsID=247f41e0 -5e69-464d-9221-\\ne2d18b8e3620'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n18 19. World Health Organization - Regional Office for Africa (WHO/AFRO). Outbreaks and Emergencies Bulletin , Week \\n17: 18 - 24 April 2022. Brazzaville: WHO/AFRO; 2022. Available at: \\nhttps://apps.who.int/iris/bitstream/handle/10665/354215/OEW19 -0202052022.pdf  \\n20. Nigeria Centre For Disease Control (NCDC). Monthly Update on Monkeypox (MPX) in Nigeria, Epi -week: 17, April \\n30, 2022. Jabi Abuja: NCDC; 2022. Available at: \\nhttps://ncdc.gov.ng/themes/common/files/sitreps/ed4f642dd1b5b1f1adf277e1d48a98f8.pdf'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='21. Durski KN, McCollum AM, Nakazawa Y, Petersen BW, Reynolds MG, Briand  S, et al. Emergence of monkeypox —\\nwest and central Africa, 1970 –2017. Morbidity and mortality weekly report. 2018;67(10):306. Available at: \\nhttps://www.cdc.gov/mmwr/volumes/67/wr/mm6710a5. htm \\n22. McCollum AM, Damon IK. Human monkeypox. Clinical Infectious Diseases. 2014;58(2):260 -7. Available at: \\nhttps://academic.oup.com/cid/article -abstract/58/2/260/335791  \\n23. Simpson K, Heymann D, Brown CS, Edmunds WJ, Elsgaard J, Fine P, et al. Human monkeypox –After 40 years, \\nan unintended consequence of smallpox eradication. Vaccine. 2020;38(33):5077 -81. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='https://www.sciencedirect.com/science/article/pii/S0264410X2030579X  \\n24. Ladnyj I, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic \\nRepublic of the Congo. Bulletin of the World Health Organization. 1972;46(5):593. Available at: \\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480792/  \\n25. World Health Organization (WHO). Monkeypox fact sheet. Geneva: WHO; 2019. Available at: \\nhttps://www.who.int/news -room/fact -sheets/detail/monkeypox  \\n26. MacNeil A, Reynolds MG, Braden Z, Carroll DS, Bostik V, Karem K, et al. Transmission of atypical varicella -zoster'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='virus infections involving palm and sole manifestations in an area with monkeypox endemicity. Clinical \\nInfectious Diseases. 2009;48(1):e6 -e8. Available at: https://academic.oup.co m/cid/article -\\nabstract/48/1/e6/291721  \\n27. Doty JB, Malekani JM, Kalemba LsN, Stanley WT, Monroe BP, Nakazawa YU, et al. Assessing monkeypox virus \\nprevalence in small mammals at the human –animal interface in the Democratic Republic of the Congo. Viruses. \\n2017;9(10):283. Available at: https://www.mdpi.com/227974  \\n28. Essbauer S, Meyer H. Genus Orthopoxvirus: Monkeypox virus. In: Poxviruses. Basel, Switzerland: Birkhäuser; \\n2007.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='2007.  \\n29. Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, et al. Extended interhuman transmission of \\nmonkeypox in a hospital community in the Republic of the Congo, 2003. The American Journal of Tropical \\nMedicine and Hygiene. 2005;73(2):428 -34. Available at: \\nhttps://www.ajtmh.org/view/journals/tpmd/73/2/article -p428.xml  \\n30. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, et al. Extended human -to-human \\ntransmission during a monkeypox outbreak in t he Democratic Republic of the Congo. Emerging infectious \\ndiseases. 2016;22(6):1014. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4880088/'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='31. Likos AM, Sammons SA, Olson VA , Frace AM, Li Y, Olsen -Rasmussen M, et al. A tale of two clades: monkeypox \\nviruses. Journal of General Virology. 2005;86(10):2661 -72. Available at: \\nhttps://www. microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.81215 -0 \\n32. Nakazawa Y, Mauldin MR, Emerson GL, Reynolds MG, Lash RR, Gao J, et al. A phylogeographic investigation of \\nAfrican monkeypox. Viruses. 2015;7(4):2168 -84. Available at: https://www.mdpi.com/97118  \\n33. Sadeuh -Mba SA, Yonga MG, Els M, Batejat C, Eyangoh S, Caro V, et al. Monkeypox virus phylogenetic \\nsimilarities between a human case detected in Cameroon in 2018 and the 2017 -2018 outbreak in Nigeria.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='Infection, Genetics and Evolution. 2019;69:8 -11. Available at: \\nhttps://www.sciencedirect.com/science/article/pii/S156713481830844X  \\n34. Yinka -Ogunleye A, Aruna O, Dalhat M,  Ogoina D, McCollum A, Disu Y, et al. Outbreak of human monkeypox in \\nNigeria in 2017 –18: a clinical and epidemiological report. The Lancet Infectious Diseases. 2019;19(8):872 -9. \\nAvailable at: https://www.sciencedirect.com/science/article/pii/S1473309919302944  \\n35. Vaughan A, Aarons E, Astbury J, Brooks T, Chand M, Flegg P, et al. Human -to-human transmission of \\nmonkeypox virus, United Kingdom, October 2018. Emerging Infectious  Diseases. 2020;26(4):782. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 17}, page_content='https://wwwnc.cdc.gov/eid/article/26/4/19 -1164_article   \\n36. Yinka -Ogunleye A, Aruna O, Ogoina D, Aworabhi N, Eteng W, Badaru S, et al. Reemergen ce of human \\nmonkeypox in Nigeria, 2017. Emerging Infectious Diseases. 2018;24(6):1149. Available at: \\nhttps://wwwnc.cdc.gov/eid/article/24/6/18 -0017_article  \\n37. Yong SEF, Ng OT, Ho ZJM, Mak TM, Marimuthu K, Vasoo S, et al. Imported Monkeypox, Singapore. Emerging \\nInfectious Diseases. 2020;26(8):1826. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7392406/'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n19 38. Arita I, Henderson D. Smallpox and monkeypox in non -human primates. Bulletin of the World Health \\nOrganization. 1968;39(2):277. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/pm c2554549/  \\n39. Magnus Pv, Andersen EK, Petersen KB, Birch -Andersen A. A Pox -like Disease in Cynomolgus Monkeys. Acta \\nPathologica Microbiologica Scandinavica. 1959;46(2):156 -76. Available at: \\nhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1699 -0463.1959.tb00328.x  \\n40. Milhaud C, Klein M, Virat J. Analyse dʼun cas de variole du singe (monkeypox) chez le chimpanzé (Pan'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='troglogdytes). Exp Anim. 1969;2:121 -35.  \\n41. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. The Lancet infectious diseases. \\n2004;4(1):15 -25. Available at: https://www.thelancet.com/journals/laninf/article/PIIS1473 -3099(03)00856 -\\n9/fulltext  \\n42. Ogoina D, Izibewule JH, Ogunleye A, Ederiane E, An ebonam U, Neni A, et al. The 2017 human monkeypox \\noutbreak in Nigeria —report of outbreak experience and response in the Niger Delta University Teaching \\nHospital, Bayelsa State, Nigeria. PLoS One. 2019;14(4):e0214229. Available at: \\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214229'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='43. Shao H, McDonald EC, Ginsberg MM, Yee LM, Montgomery JR, Allan -Martinez F, et al. Vaccinia virus infection \\nafter sexual contact with a military smallpox vaccinee -Washington, 2010. MMWR Morbidity and Mortality Weekly \\nReport. 2010;59(25):773 -5. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml /mm5925a2.htm  \\n44. McLaughlin J, Schmidt T, Westcott M, Baumbach J, Lofgren J, Gerber S, et al. Vulvar vaccinia infection after \\nsexual contact with a military smallpox vaccinee --Alaska, 2006. MMWR Morbidity and mortality weekly report. \\n2007;56(17):417 -9. Available at: https://jamanetwork.com/journals/jama/fullarticle/207576'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='45. Shao H, McDonald EC, Ginsberg MM, Yee LM, Montgomery JR, Allan -Martinez F, et al. Secondary and tertiary \\ntransmission of vaccinia virus after sexual contact with a smallpox vaccinee —San Diego, California, 2012. \\nMMWR Morbidity and Mortality Weekly Report. 2013;62(8):145. Available at: \\nhttps://ww w.cdc.gov/mmwr/preview/mmwrhtml/mm6208a2.htm  \\n46. Centers for Disease Control and Prevention (CDC). Monkeypox - Signs and Symptoms. Atlanta: CDC; 2021. \\nAvailable at: https://www.cdc.gov/po xvirus/monkeypox/symptoms.html  \\n47. Damon IK. Status of human monkeypox: clinical disease, epidemiology and research. Vaccine. 2011;29:D54 -D9.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='Available at: https://www.scie ncedirect.com/science/article/pii/S0264410X1100524X  \\n48. Brown K, Leggat PA. Human monkeypox: current state of knowledge and implications for the future. Tropical \\nMedicine and Infectious Disease. 2016;1(1):8. Available at: https://www.mdpi.com/171272  \\n49. Reynolds MG, Y orita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC, et al. Clinical manifestations of \\nhuman monkeypox influenced by route of infection. The Journal of Infectious Diseases. 2006;194(6):773 -80. \\nAvailable at: https://academic.oup.com/jid/article -abstract/194/6/773/864712  \\n50. Robert Koch Institut (RKI). KL für Pockenviren - Präanalytikhandbuch. Berlin: RKI; 2020. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='https://www.rki.de/DE/Content/Infekt/NRZ/Konsiliar/Pockenviren/Praeanalytikhandbuch.pdf  \\n51. European Medicines Agency (EMA). Tecovirimat SIGA. Amsterdam: EMA; 2022. Available at: \\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat -siga \\n52. Kunasekaran MP, Chen X, Costantino V, Chughtai AA, MacIntyre CR. Evidence for residual immunity to smallpox \\nafter vaccination an d implications for re -emergence. Military Medicine. 2019;184(11 -12):e668 -e79. Available at: \\nhttps://academic.oup.com/milmed/article -abstract/184/11 -12/e668/5542515  \\n53. Centers for Disease Control and Prevention (CDC). Monkeypox - Treatment. Atlanta: CDC; 2021. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='http://www.cdc.gov/poxvirus/monkeypox/treatment.html  \\n54. European Centre for Dis ease Prevention and Control (ECDC). Factsheet for health professionals on monkeypox. \\nStockholm: ECDC; 2019. Available at: https://www.ecdc.europa.eu/en/all -topics -z/monkeypox/factsheet -health -\\nprofessionals  \\n55. European Medicines Agency (EMA). Imvanex - Smallpox vaccine (Live Modified Vaccinia Virus Ankara) - \\nAuthorisation details. London: EMA; 2013. Available at: \\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/imvanex#authorisation -details -section  \\n56. European Medicines Agency (EMA). Imvanex - EPAR - Product Information. Amsterdam: EMA; 2022. Availabl e'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 18}, page_content='at: https://www.ema.europa.eu/en/documents/product -information/imvanex -epar-product -information_en.pdf  \\n57. Centers for Disease Control and Prevention (CDC). Bioterrorism Agents/Diseases. Atlanta: CDC; 2018. Available \\nat: https://emergency.cdc.gov/agent/agentlist -category.asp  \\n58. Tegnell A, Van Loock F, Baka A, Wallyn S, He ndriks J, Werner A, et al. Biological weapons - Development of a \\nmatrix to evaluate the threat of biological agents used for bioterrorism. Cellular and Molecular Life Sciences \\nCMLS. 2006;63(19):2223 -8. Available at: https://link.springer.com/article/10.1007/s00018 -006-6310-5'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n20 59. European Centre for Disease Prevention and Control (ECDC). Operational tool on rapid risk assessment \\nmethodology - ECDC 2019. Stockholm: ECDC; 2019. Availab le at: https://www.ecdc.europa.eu/en/publications -\\ndata/operational -tool-rapid-risk-assessment -methodology -ecdc-2019 \\n60. European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease among men who \\nhave sex with men Stockholm: ECDC; 2013 . Available at: \\nhttps://www.ecdc.europa.eu/sites/default/files/media/en/publications/Public ations/rapid -risk-assessment -\\ninvasive -meningococcal -disease -among -MSM.pdf'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='61. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Hepatitis A outbreak in the \\nEU/EEA mostly affecting men who have sex with men, 3rd update, 28 Ju ne 2017. Stockholm: ECDC; 2017. \\nAvailable at: https://www.ecdc.europa.eu/en/publications -data/rapid -risk-assess ment-hepatitis -outbreak -eueea -\\nmostly -affecting -men-who-have-sex \\n62. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Increase in extensively -\\ndrug resistant Shigella sonnei infections in men who have sex with men in the EU/E EA and the UK. Stockholm:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='ECDC; 2022. Available at: https://www.ecdc.europa.eu/en/publications -data/rapid -risk-assessm ent-increase -\\nextensively -drug-resistant -shigella -sonnei  \\n63. Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A, et al. Clinical characteristics of human monkeypox, \\nand risk factors for severe disease. Clinical Infectious Diseases. 2005;41(12):1742 -51. Available at: \\nhttps://academic.oup.com/cid/article/41/12/1742/344953  \\n64. Stengaard AR, Combs L, Supervie V, Croxford S, Desai S, Sullivan AK, et al. HIV seroprevalence in five key \\npopulations in Europe: a systematic literature review, 2009 to 2019. Euro Surveill. 2021;26(47):2100044.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='Available at: https://www.eurosurveillance.org/content/1 0.2807/1560 -7917.ES.2021.26.47.2100044  \\n65. European Centre for Disease Prevention and Control (ECDC). HIV Continuum of care - Monitoring \\nimplementation of the Dublin Declaration on partnership to fight HIV/AIDS in Europe and Central Asia: 2020 \\nprogress rep ort. Stockholm: ECDC; 2021. Available at: \\nhttps://www.ecdc.europa.eu/sites/default/files/documents/hiv -continuum -of-care-dublin -declaration -2021.pdf  \\n66. Wehrle P, Posch J, Richter K, Henderson D. An airborne outbreak of smallpox in a German hospital and its \\nsignificance with respect to other recent outbreaks in Europe. Bulletin of the World Health Organization.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='1970;43(5):669. Available  at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427800  \\n67. Fleischauer AT, Kile JC, Davidson M, Fischer M, Karem KL, Teclaw R, et al. Evaluation of human -to-human \\ntransmission of monke ypox from infected patients to health care workers. Clinical Infectious Diseases. \\n2005;40(5):689 -94. Available at: https://academic.oup.com/cid/article -abstract/40/5/689/364780  \\n68. Hsu CH, Farland J, Winters T, Gunn J, Caron D, Evans J, et al. Laboratory -acquired vaccinia virus infection in a \\nrecently immunized person —Massachusetts, 2013. MMWR Morbidity and Mortality Weekly Report. \\n2015;64(16):435. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6416a2.htm'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='69. Davies E, Peake L, Woolard D, Novak C, Hall K, Leonard R, et al. Laboratory -acquired vaccinia virus infection --\\nVirginia, 2008. MMWR Morbidity an d mortality weekly report. 2009;58(29):797 -800.  \\n70. World Health Organization (WHO). Laboratory biosafety manual, 4th edition. Geneva: WHO; 2020. Available at: \\nhttps://www.who.int/publi cations/i/item/9789240011311  \\n71. Mbala PK, Huggins JW, Riu -Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, et al. Maternal and fetal outcomes \\namong pregnant women with human monkeypox infection in the Democratic Republic of Congo. The Journal of \\nInfectious D iseases. 2017;216(7):824 -8. Available at: https://academic.oup.com/jid/article -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='abstract/216/7/824/4348689  \\n72. Weiner ZP, Salzer JS, LeMasters E, Ellison JA, Kondas AV, Morgan CN, et al. Characterization of Monkeypox virus \\ndissemination in the black -tailed prairie dog (Cynomys ludovicianus) through in vivo bioluminescent imaging. \\nPLoS One. 2019;14(9):e0222612.  \\n73. Hutson CL, Carroll DS, Gallardo -Romero N, Drew C, Zaki SR, Nagy T, et al. Comparison of Monkeypox Virus \\nClade Kinetics and Pathology within the Prairie Dog Animal Model Using a Serial Sacrifice Study Design. BioMed \\nResearch International. 2015 2015/08/24; 2015:965710. Available at: https://doi.org/10.1155/2015/965710'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 19}, page_content='74. Association for the Advancement of Blood & Biotherapies (AABB). Fact Sheet Monkeypox - 130S. Bethesda: \\nAABB; 2009. Available at: https://www.aabb.org/regulatory -and-advocacy/regulatory -affairs/infectious -\\ndisease s/emerging -infectious -disease -agents/transfusion -august -2009-supplement -fact-sheets  \\n75. European Virus Archive global (EVAg). 2022. Available at: https://www.european -virus-archive.com  \\n76. European Cen tre for Disease Prevention and Control (ECDC). Directory of EVD -LabNet. Stockholm: ECDC; 2022. \\nAvailable at: https://qap.ecdc.europa.eu/public/extensions/ EVD_LabNet/EVD_LabNet.html#main -tab'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n21 77. Li D, Wilkins K, McCollum AM, Osadebe L, Kabamba J, Nguete B, et al. Evaluation of the GeneXpert for human \\nmonkeypox diagnosis. The American Journal of Tropical Medicine and Hygiene. 2017;96(2):405. Available at: \\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303045/  \\n78. European Medicines Agency (EMA). Imvanex - Smallpox vaccine (Live Modified Vaccinia Virus Ankara). \\nAmsterdam: EMA; 2022. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/imvanex   \\n79. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, et al. Modified vaccinia virus'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='Ankara protects macaques against respiratory challenge with monkeypox virus. Journal of Virology. \\n2005;79(12):7845 -51. Available at: https://journals.asm.org/doi/abs/10.1128/JV I.79.12.7845 -7851.2005  \\n80. European Commission (EC). Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the \\ncommunicable diseases and related special health issues to be covered by epidemiological surveillance as well \\nas relevant case defini tions. Brussels: Official Journal of the European Union; 2018. Available at: https://eur -\\nlex.europa.eu/legal -content/EN/TXT/PDF/?uri=CELEX:32018D0945'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='81. Rheinbaben Fv , Gebel J, Exner M, Schmidt A. Environmental resistance, disinfection, and sterilization of \\npoxviruses. In: Poxviruses. Basel: Springer; 2007. p. 397 -405. \\n82. Public Health England (PHE). Monkeypox: Guidance for environmental cleaning and decontamination. London: \\nPHE; 2018. Available at: \\nhttps://assets.publishing.service.gov.uk/government/upl oads/system/uploads/attachment_data/file/746086/Mo\\nnkeypox_Guidance__cleaning_decontamination.pdf  \\n83. Centers for Disease Control and Prevention (CDC). Monkeypox and Smallpox Vaccine Guidance. Atlanta: CDC; \\n2019. Available at: https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox -vaccine.html'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='84. American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Meningococcal infections. In: Report \\nof the Committ ee on Infectious Diseases, 31st Edition. Itasca, IL: American Academy of Pediatrics; 2018.  \\n85. European Centre for Disease Prevention and Control (ECDC). Risk assessment guidelines for infectious diseases \\ntransmitted on aircraft. Stockholm: ECDC; 2009. Ava ilable at: \\nhttps://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/0906_TER_Risk_Assessment\\n_Guidelines_for_Infectious_Diseases_Transmitted_on_Aircraft.pdf  \\n86. Centers for Disease Control and Prevention (CDC). Potential Exposure to Person wit h Confirmed Human'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='Monkeypox Infection — United States, 2021. Atlanta: CDC; 2021. Available at: \\nhttps://emergency.cdc.gov/han/2021/han00446.asp  \\n87. World Health Organization (WHO). Guidance on regulations for the transport of infectious substances 2019 – \\n2020. Geneva: WHO; 2020. Available at: https://www.who.int/publications/i/item/WHO -WHE-CPI-2019.20  \\n88. United Nations (UN). Recommendations on the transport of dangerous goods: model regulations, 21st revised \\nedition. New York, Geneva: United Nations; 2019. Available at: http://www.unece.org/trans/danger/danger .html \\n89. Centers for Disease Control and Prevention (CDC). Interim Biosafety Guidelines for Laboratory Personnel'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='Handling Human and Animal Specimens for Monkeypox Testing. Atlanta: CDC; 2003. Available at: \\nhttps://www.aphl.org/programs/preparedness/Smallpox/pdf/labbiosafetyguide.pdf  \\n90. Ježek Z, Grab B, Szczeniowski M, Paluku K, Mutombo M. Human monkeypox: secondary attack rates. Bulletin of \\nthe World Health Organ ization. 1988;66(4):465. Available at: \\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmc2491159/  \\n91. Parker S, Nuara A, Buller RML, Schultz DA. Human monkeypox: an emerging zoonotic disease.  Future \\nMicrobiology. 2007;2(1) Available at: https://www.futuremedicine.com/doi/abs/10.2217/17460913.2.1.17'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='92. Sale TA, Melski JW, Stratman EJ. Monkeypox: an epidemiologic and  clinical comparison of African and US \\ndisease. Journal of the American Academy of Dermatology. 2006;55(3):478 -81. Available at: \\nhttps://www.sciencedirect.com/science/artic le/pii/S0190962206015337  \\n93. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The detection of monkeypox in \\nhumans in the Western Hemisphere. New England Journal of Medicine. 2004;350(4):342 -50. Available at: \\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa032299  \\n94. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Outbreak of novel'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 20}, page_content='coronavirus disease 2019 (COVID -19): increased transmission  globally – fifth update. Stockholm: ECDC; 2020. \\nAvailable at: https://www.ecdc.europa.eu/en/publications -data/rapid-risk-assessment -outbreak -novel-\\ncoronavirus -disease -2019-covid-19-increased    \\n95. Centers for Disease Control and Prevention (CDC). Contraindications to Vaccination - Nonemergency Use of \\nSmallpox Vaccine. Atlanta: CDC; 2016. Available at: https://www.cdc.gov/smallpox/clinicians/vaccination -\\ncontraindications1.html  \\n96. World Health Organization (WHO). Summary Report on First, Second and Third Generation Smallpox V accines. \\nGeneva: WHO; 2013. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 21}, page_content='RAPID RISK ASSESSMENT  Monkeypox mul ti-country outbreak  – 23 May 2022  \\n \\n \\n22 http://www.who.int/immunization/sage/meetings/2013/november/2_Smallpox_vaccine_review_updat ed_11_10\\n_13.pdf  \\n97. European Centre for Disease Prevention and Control (ECDC). Guidance on community engagement for public \\nhealth events caused by communicable disease threats in the EU/EEA, 2020. Stockholm: ECDC; 2020. Available \\nat: https://www.ecdc.europa.eu/en/publications -data/guidance -community -engagement -public -health -events -\\ncaused -communicable -disease  \\n98. British HIV Association (BHIVA). BHIVA rapid statement on monkeypox virus. Letchworth, United Kingdom:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\Monkeypox-multi-country-outbreak.pdf', 'page': 21}, page_content='BHIVA; 2022. Available at: https://www.bhiva.org/BHIVA -rapid-statement -on-monk eypox -virus'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 0}, page_content='www.cfsph.iastate.ed u  © 200 4-2022 page 1 of 9 Monkeypox  \\n \\nLast Updated:  November 2020  \\n Minor Updates : December  2022 Importance  \\nMonkeypox  (also known as mpox)  is a zoonotic viral disease , endemic in western \\nand central Africa, which circulates in wild animal hosts and emerges periodically to \\naffect humans , captive or wild nonhuman primates , and other species, particularly \\nrodents . Congo Basin monkeypox viruses are particularly virulent, with human case \\nfatality rates  during outb reaks  in parts  of Africa estimated to be around 10%. West \\nAfrican viruses tend to cause milder disease; however, deaths  are seen occasionally in'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 0}, page_content='young children, individuals  with secondary bacterial sepsis or rare complications such \\nas encephalitis, and people who are immunosuppressed.  \\nMonkeypox  outbreaks have been reported  sporadically  in nonhuman primate \\nfacilities around the world , especially in the past . Human cases are almost always seen \\nin Africa , but a  large outbreak in Nigeria in 2017 -2018 resulted in a few imported cases \\namong travelers to Europe and Asia, with one case resulting in person -to-person \\ntransmission to a hospital worker. O ne outbreak occurred in the Unit ed States in 2003 , \\nassociated with virus transmission between exotic pets and from pets in humans . A'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 0}, page_content='prompt diagnosis of imported monkeypox  can help  prevent this disease from becoming \\nestablished outside Africa  in potential animal reservoirs , such as prair ie dogs or \\nreleased exotic pets .  \\nEtiology  \\nMonkeypox results from infection by monkeypox virus, a member of the genus \\nOrthopoxvirus  in the family Poxviridae (subfamily Chordopoxvirinae). Two viral \\nclades, the West African  (clade II) and Congo Basin  (clade I)  clades , have been \\nidentified. The Congo Basin viruses are more virulent. Monkeypox virus is closely \\nrelated to some other orthopoxviruses  including  variola (smallpox) virus, and it cannot \\nbe distinguished from these viruses in some laboratory te sts.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 0}, page_content='Monkeypox should not be confused with benign epidermal monkeypox (BEMP), \\na poxviral disease of primates caused by tanapox virus, an antigenically unrelated virus \\nin the genus Yatapoxvirus  of the family Poxviridae.  \\nSpecies Affected  \\nThe monkeypox vir us’s full host range is uncertain . Animals known to be \\nsusceptible to infection include diverse Old and New World monkeys and apes, and \\nvarious  rodents , shrews  and other small mammals , as well as dogs . Among nonhuman \\nprimates, c linical cases have been desc ribed in chimpanzees  (Pan troglodytes ) and  an \\ninfant  sooty mangab ey (Cercocebus atys ) in the wild, as well as  captive gorillas'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 0}, page_content='(Gorilla gorilla ), chimpanzees, Asian orangutans  (Pongo pygmaeus ), gibbons \\n(Hylobates lar ), marmosets ( Hapale jacchus ), and various monkeys  in the genera \\nCercopithecus , Macaca  and Siamiri . Antibodies have been found  in other wild or \\ncaptive nonhuman primates .  \\nDuring the 2003 o utbreak  in the U.S. associated with exotic pets, i nfected animals \\nincluded Gambian giant pouched rats (Cricetomys  spp.), North American black -tailed \\nprairie dogs ( Cynomys ludovicianus ) rope squirrels  (Funisciurus spp.) , dormice \\n(Graphiurus  sp.), a groundhog/ woodchuck ( Marmota monax ), an African hedgehog'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 0}, page_content='(Atelerix  sp.), a jerboa ( Jaculus  sp.) and two oposs ums ( Didelphis marsupialis  and \\nMonodelphis domestica ). Chinchillas ( Chinchilla lanigera ) and coatimundis ( Nasua \\nnasua ) developed antibodies after exposure, but viral DNA or infectious virus was not \\nfound. Giant a nteaters (Myrmecophaga tridactyla ) were thought to have been involved \\nin an outbreak among primates at the Rotterdam Zoo  in the Netherlands in 1964.  \\nLimited early surveillance in sheep, goats and cats in Africa found no evidence of \\nexposure, but a ntibodies were detected  in one pig. A subsequent  attempt to infect pigs \\nby rubbing virus into the skin did not result in virus recovery  except from  the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 0}, page_content='inoculation site . One case was reported in a dog during the 2022 outbreak, apparently \\nacquired during close contact with humans in the household. Experim ental infections \\nwith clinical signs have also been reported  in 13 -lined ground squirrels ( Spermophilus \\ntridecemlineatus ), the cotton rat ( Sigmodon hispidus ), forest giant squirrel ( Protexerus \\nstrangeri ), bobak marmot ( Marmota bobak ), and red squirrel s (Sciurus vulgaris ). Adult'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 2 of 9 white rabbits  (with the apparent exception of albino rabbits) , \\nguinea pigs, white rats (Rattus  spp.) and wild type  laboratory \\nmice ( Mus musculus ) are refractory to experimental \\ninfection, though newborn rats and rabbits can be infected.  \\nThe reservoir host(s) for monkey pox viruses are \\nuncertain, but are thought to be one or more African rodents \\nor small mammals. It is possible that the Congo Basin and \\nWest African clades are maintained in different species. Two \\ngenera of African squirrels, Funisciurus spp. (rope squirrel s) \\nand Heliosciurus  spp. (sun squirrels), are among the top'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='candidates for reservoir hosts, but antibodies have also been \\nfound in many other species of African rodents, shrews and \\nother small mammals including Gambian pouched rats. \\nAttempts to detect the virus directly in wild small mammals \\nor other free -living species have generally been \\nunsuccessful, though it was recovered once from a wild rope \\nsquirrel with lesions.  \\nZoonotic potential  \\nThe Congo Basin and West African clades of \\nmonkeypox virus can both  affect humans.  \\nGeographic Distribution  \\nMonkeypox is endemic in central Africa (the Congo \\nBasin) and West Africa. An outbreak of monkeypox  \\naffecting humans and exotic pets  occurred in the U.S. in'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='2003, but there is no evidence that the virus became \\nestabli shed in North America.  Isolated human cases were \\nrecently imported to other locations, including the U.K., \\nIsrael and Singapore, again without the virus becoming \\nestablished in these locations . \\nTransmission  \\nMonkeypox viruses has been  found in skin lesions and \\nmost or all secretions and excretions (e.g., urine, feces, and \\noral, nasal and conjunctival exudates ) in animals . Likely \\nroutes of transmission include inhalation , direct inoculation \\ninto breaks in the skin, and the ingestion of infected t issues. \\nThe importance of a erosol transmission might differ between'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='species or situations . Experimentally infected prairie dogs \\ncan shed monkeypox viruses until 21 days after inoculation , \\nand limited  evidence suggests that some small animals, such \\nas dormi ce and Gambian giant pouched rats, might carry this \\nvirus for a few weeks or months. Viral DNA was detected in \\nthe tissues, urine and feces of one dormouse for at least 6 \\nmonths, but no viral antigens were found when this animal \\nwas euthanized. Whether suc h animals can shed infectious \\nvirus is not known.   \\nHumans can become infected via  bites from animals, in \\naerosols during close contact, or by direct contact with \\nlesions, blood or body fluids. Sexual transmission was'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='suspected in a few cases, when there we re lesions on the \\ngenitalia, and transplacental transmission has been \\ndocumented. In Africa, clinical cases  have often been linked \\nto handling, preparing and eating wild animals , but person -\\nto-person transmission was also significant in some \\noutbreaks . In the U.S., most cases occurred among people who had close direct contact with prairie dogs; some \\ninfections were apparently acquired in scratches and bites, or \\nthrough open wounds. Monkeypox virus has been isolated \\nfrom humans for up to 18 days after the on set of the rash, and \\nscabs shed during recovery were  found to contain significant'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='amounts of infectious virus. Person -to-person transmission \\ndoes not seem to be capable of maintaining the virus in \\nhuman populations.   \\nDisinfection  \\nDisinfectants reported to be effective for \\northopoxviruses include sodium hypochlorite, chloro -\\nxylenol -based household disinfectants, glutaraldehyde, \\nformaldehyde and paraformaldehyde. During an outbreak in \\nthe U.S., t he U.S. Centers for Disease Control and Prevention \\n(CDC) recomme nded 0.5% sodium hypochlorite or other \\nEPA –approved high –level disinfectants. Incineration or \\nautoclaving is appropriate for some contaminated materials.  \\nInfections in Animals  \\nIncubation Period'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='Infections in Animals  \\nIncubation Period  \\nReported incubation periods in experimentally infected \\nanimal s range from 3  days to about 2 weeks in most cases . \\nThe incubation period was  slightly longer ( 11 to 18 days ) \\nin prairie dogs infected by exposure to fomites  than after \\ndirect exposure . \\nClinical Signs  \\nNonhuman primates  \\nThe predominant syndrome in nonhuman primates is a \\nself–limited rash, which begins as small  cutaneous papules  \\nthat develop into pustules, then crust over , and may leave \\nsmall scars  when the crusts drop off . A typical monkeypox \\nlesion has a red, necrotic, depressed center, surround ed by \\nepidermal hyperplasia . The number of lesions varies from a'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='few individual pocks to extensive, coalescing lesions. They  \\nsometimes affect  the entire body, but may be more common \\non the face, limbs, palms, soles and tail. Some animals have \\nonly skin les ions, which may be accompanied  by a fever  or \\nlymphadenopathy , but do not appear to be otherwise ill. In \\nmore severe cases, there may also be respiratory signs \\n(coughing, nasal discharge, dyspnea),  ocular discharge,  \\nanorexia, facial edema  or oral ulcers. Respiratory signs of \\nvarying severity, with minimal skin lesions (e.g., a single \\nlesion on the lip), were observed  in some wild chimpanzees \\nduring an outbreak caused by a West African virus . Other'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 1}, page_content='animals in this outbreak had more classical signs including a  \\nrash. Most naturally infected animals recover; however, \\nfatalities are sometimes seen, particularly in infant monkeys. \\nAsymptomatic infections are also possible . \\nPrairie dogs  and other species  \\nIn prairie dogs, the clinical signs may include fever, \\ndepression, anorexia, blepharoconjunctivitis (often the initial \\nsign), respiratory signs ( nasal discharge, sneezing and/or \\ncoughing, respiratory distress ), diarrhea, skin lesions  similar'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 3 of 9 to those in no nhuman primates,  and oral ulcers.  \\nLymphadenopathy was seen  in naturally infected prairie \\ndogs, but did not occur in all experimentally infected \\nanimals. Elevated serum levels of liver enzymes have also \\nbeen reported . Some  cases are fatal, and e xperimentall y \\ninfected prairie dogs sometimes died without developing \\nlesions on the skin or mucous membranes.   \\nSimilar  clinical signs have been reported in other \\nnaturally or experimentally infected rodents ; however, not all \\nanimals developed skin lesions. Intranasal ly inoculated \\ndormice, which often  died, had only nonspecific signs such as'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='lethargy, an unkempt hair coat, a hunched posture, \\nconjunctivitis and dehydration. Some  naturally infected \\nGambian giant pouched rats had asymptomatic infections or \\nmild illnesses , with no respiratory signs and limited skin \\nlesions, but other animals died, and experimentally infected \\npouched rats  sometimes became  moderate ly to severe ly ill, \\nwith skin and oral lesions, ocular lesions and nonspecific signs \\nof illness. Pox lesions wer e found in a wild Thomas’s rope \\nsquirrel ( Funisciurus anerythrus ) in Africa that was found \\ninfected with a Congo Basin strain . Some rope squirrels \\n(Funisciurus anerythrus ) inoculated with a Congo Basin strain'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='developed skin and oral lesions, respiratory si gns and , in one \\ncase, corneal lesions. However, African squirrels administered  \\na high viral dose in an earlier study died with a generalized , \\nnonspecific  illness , and skin lesions occurred only in a few \\nanimals that received a lower, nonfatal  dose.  \\nA case in a healthy greyhound dog was characterized by \\nskin and mucosal lesions that included slightly crusty, \\nerythematous pustules on the abdomen and a small erosion \\non the anus. Viral nucleic acids were also detected in oral \\nsecretions by PCR. Systemic signs were not described in this \\nanimal.  \\nPost Mortem Lesions   Click to view images'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='Post Mortem Lesions   Click to view images  \\nAt necropsy, the skin may contain one or more papules, \\numbilicated pustules (“pocks”) with central n ecrosis, or \\ncrusts over healing lesions. Ulcers, erosions or lesions with \\nnecrotic centers may be found in the mouth of some \\nanimals. Peripheral lymphadenopathy is common but not \\nalways present. C onjunctivitis or blepharoconjunctivitis \\nmay also be noted.  \\nPox lesions (white plaques or small, white, firm, deeply \\nembedded foci with umbilicated necrotic centers) are \\nsometimes detected  on internal organs  or in the stomach and \\nsmall intestine . Some animals may have other internal \\nlesio ns including lung involveme nt (e.g., pleuritis,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='consolidation of the lung , pulmonary edema, multifocal \\nnecrotizing pneumonitis  or bronchoalveolar pneumonia ), \\nenlargement and/or mottling of the liver , orchitis , and \\nmultifocal necrotizing lesions in various organs and tissues \\nincluding the spleen, liver, colon, thymus, brown fat, uterus \\nor vagina . Hemorrhages were noted in the upper \\ngastrointestinal tract, nasal cavity, gall bladder and brain  of \\nintranasally inoc ulated dormice, and in the lungs of \\nexperimentally infected ground squirrels , together with \\npulmonary edema .  Diagnostic Tests  \\nThe characteristic skin lesions and histopathology are \\nsuggestive, but can be caused by other diseases . If the animal'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='has not bee n exposed to other orthopoxviruses, monkeypox \\ncan be tentatively diagnosed by detecting orthopoxvirus \\nvirions with electron microscopy or orthopoxvirus antigens \\nby immunohistochemistry.  \\nThe diagnosis can be confirmed by virus isolation or \\nassays for genet ic material, such as PCR. Monkeypox virus \\nmay be detected  in skin lesions  or samples from affected \\norgans at necropsy, and sometimes in conjunctival swabs  or \\noral and nasal secretions (e.g., oropharyngeal swabs) . One \\nstudy found that the liver contained pa rticularly large \\namounts of virus in dormice. The viru s has also been detected \\nin the blood, urine and /or feces  of some animals . Monkeypox'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='virus can be recovered in various cell lines including Vero \\ncells, and may be specifically identified with PCR followed \\nby restriction fragment –length polymorphism (RFLP) \\nanalysis or sequencing. Monkeypox -specific PCR assays are \\navailable in some laboratories, and a DNA oligonucleotide \\nmicroarray can identify this virus rapidly and specifically. \\nPCR can also be  performed directly on clinical samples. \\nLoop -mediated isothermal amplification  (LAMP) assays for \\nthe Congo Basin  and West African strains have been \\ndeveloped.  Serology is mainly used for surveillance  in \\nanimals.  Antibodies to other orthopoxviruses can cro ss-react \\nwith monkeypox virus.  \\nTreatment'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='with monkeypox virus.  \\nTreatment  \\nTreatment is supportive, but may not be advisable or \\nallowed in some situations. During the 2003 outbreak in the \\nU.S., the CDC recommended that all animals with \\nsuspected monkeypox be euthanized , in part  to prevent  \\nzoonotic infections. Nonhuman primates are not \\nnecessarily euthanized during outbreaks in facilities.  \\nControl  \\nDisease reporting  \\nVeterinarians who encounter or suspect monkeypox \\nshould follow their national and/or local guidelines for \\ndisease reporting. I n the U.S., state or federal authorities \\nmust be notified immediately.  \\nPrevention  \\nAs a result of a monkeypox outbreak in 2003 that was'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='caused by imported exotic pets , the U.S. banned the \\nimportation of six types of African rodents – squirrels  in the \\ngenera  Heliosciurus  and Funisciurus , dormice, Gambian \\ngiant pouched rats, brush -tailed porcupines ( Atherurus  sp.), \\nand striped mice ( Hybomys  sp.). This ban applies to these \\nanimals whether they were born in Africa or on another \\ncontinent. In addition, prairie do gs can no longer be captured \\nfrom the wild for use as pets. Exceptions to the se restrictions \\nare allowed, by permit, for organizations such as zoos  and \\nscientific institutions . Similarly, some other countries and \\ngoverning bodies such as the E.U. banned th e import ation  of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 2}, page_content='prairie dogs from the U.S. and some rodents from Africa.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 4 of 9 Good infection control measures, including the isolation \\nof new animals, help prevent outbreaks in primate facilities  \\nand facilities that import exotic pets . Because infections have \\nbeen reported in Asian monkeys mixed with primates from \\nAfrica, these species should not be housed in the same area. \\nCare should be taken to avoid spreading the virus on fomites. \\nVaccination with vaccinia virus (smallpox vaccine) is \\nprotective  in nonhuman primates. Research suggests this \\nvaccine  is also protective in some other species such as \\nprairie dogs. Anyone who has been exposed to monkeypox'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='should avoid contact with animals that might be susceptible \\nto infection , particularly rodents and  nonhuman primates . \\nMorbidity and Mortality  \\nA few outbreaks have been reported among captive \\nprimates, but the only cases  observed in wild species were  in \\nan infant sooty mangabey found dead with pox lesions and an \\noutbreak in a g roup of monitored  chimpanz ees in 2017 -2018 . \\nBased on these reports, both published  recently, and a  study  \\nthat found antibodies in  8% of nonhuman primates in Africa , \\nit appears likely that some clinical cases in wild primates  are \\nmissed . The morbidity rate in nonhuman primates is usually'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='high and the mortality rate low , with most adult animals \\nrecover ing. More severe illness es may be seen in infants, \\nwhich sometimes die, and primates of all ages infected \\nexperimentally via aerosols. There also seem to be species -\\nrelated differences in susceptibility . Crab -eating macaques \\n(Macaca fascicularis ) appear  to be more susceptible than \\nrhesus macaques  (M. mulatta ), and 6 of 9 captive Asian \\norangutans ( Pongo pygmaeus ) died in an outbreak at the \\nRotterdam zoo  while  two gorillas  and most chimpan zees \\nsurvived  despite becoming ill .  \\nAs of 2020, o nly a single clinical case  has been described \\nin a wild rodent in Africa , a squirrel (Funisciurus anerythrus )'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='with poxvirus lesions. However, antibodies are reported \\nregularly in African squirrels of the genera Funisciurus  and \\nHeliosciurus , and high seroprevalence rates have  sometimes \\nbeen found in other species, such as Natal multimammate \\nmice ( Mastomys natalensi s), tiny fat mice ( Steatomys parvus ) \\nand shrews ( Crocidura  spp.) in Zambia. Prairie dogs seem to \\nbe very susceptible to monkeypox . Many of the prairie dogs \\nexposed to monkeypox became  infected during the outbreak \\nin the U.S ., and m ortality rates as high as 60% have been \\nreported after experimental inoculation. Another  study \\nreported 50 -75% mortality in rope squirrels ( Funisciurus'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='anerythrus ) inoculated with a Congo Basin strain . However, \\nsome species of rodents might be relatively r esistant  to clinical \\nsigns . During the outbreak in the U.S., monkeypox virus was \\nfound in one Gambian giant pouched rat that died soon after \\narrival , but another animal had a very mild illness, and \\northopoxvirus antibodies were found in 12 of 18 healthy \\nindividuals  after the outbreak.  Limited experimental evidence  \\nalso suggests that Gambian pouched rats are less susceptible \\nthan rope squirrels  or prairie dogs . \\nThe Congo Basin clade seems to be more virulent than \\nWest African viruses for nonhuman primates an d some'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='rodents  (e.g., prairie dogs, squirrels) , although a  West African virus was reported to be at least as virulent for Gambian \\npouched rat as the Congo Basin strain.  \\nInfections in Humans  \\nIncubation Period  \\nReported incubation period s in humans range from  7 to \\n24 days, with a mean of 12 days in Africa  and 14.5 days  \\nduring the outbreak in the U.S.  \\nClinical Signs  \\nHuman  monkeypox resembles smallpox , with a rash and \\nconstitutional signs,  but the symptoms are generally milder \\nand, unlike smallpox, the lymph nodes are usually (though \\nnot always)  enlarged. Most often, t he illness begins with \\nnonspecific, flu–like symptoms that  may include malaise,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='fever, chills, headache, sore throat, myalgia, backache, \\nfatigue , nausea, vomiting  and a nonproductive cough.  \\nLymphadenopathy can be regional or generalized, and most \\noften affects the submandibular, postauricular, cervical \\nand/or inguinal lymph nodes.  \\nMost patients develop a rash one to several days after \\nthey begin  to feel ill , though the re have been instances where \\npatients noticed a few skin lesions (e.g., at the site of an \\nanimal bite or scratch, or in the groin ) shortly before they felt \\nunwell . Skin lesions are usually concentrated on the \\nextremities (including the palms and soles), bu t they can also \\nbe seen on the head and torso, as well as the mucous'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='membranes and genitalia. They vary in number from less \\nthan 25 to more than a hundred, and may become confluent \\nin severe cases. As in animals,  skin lesions  usually begin as \\nmacules and p apules, which develop into vesicles and \\npustules (“pocks”), umbilicate, form scabs and are \\neventually shed. During the outbreak in the U.S., s ome \\npustules had prominent erythematous flares. Such flares have \\nnot been noted in African cases, possibly because  most \\naffected people have darker skin. The skin lesions usually \\nresolve within 14 to 21 days. Residual varioliform scarring, \\nwith hypopigmented and/or hyperpigmented skin lesions,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='may be a sequela in some cases. Severe scarring, as seen in \\nsmallpox, is ra re.  \\nSome patients also have ocular signs including \\nconjunctivitis, or more rarely, keratitis  or corneal ulceration . \\nRespiratory complications including bronchopneumonia , \\ncoagulation disorders, and rare cases of encephalitis or \\nmultiorgan failure have also been reported. Secondary \\nbacterial infections can occur, and may lead to sepsis. \\nPregnant women may abort or give birth to an infected fetus. \\nOne fetus infected in utero  was stillborn, with cutaneous \\nmaculopapular  skin lesions and severe hepatic invol vement; \\nanother had skin lesions and was born prematurely but alive.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 3}, page_content='At least one mildly affected pregnant woman gave birth to a \\nfull-term, healthy child.  Most patients recover in  2-4 weeks, \\nbut deaths are possible, especially in people infected with the \\nCongo Basin clade or immunosuppressed individuals \\ninfected with either clade. Subclinical and very mild cases \\nhave also been reported .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 5 of 9 Diagnostic Tests  \\nMonkeypox can be tentatively diagnosed if the \\ncharacteristic skin lesions are present and there is a his tory \\nof exposure ; however, clinical cases can resemble  \\nchickenpox  and may be difficult to distinguish clinically \\nfrom the latter disease . Tests to isolate  monkeypox  virus or \\nidentify its nucleic acids and antigens are similar to those \\nused in animals. At least one  rapid point -of-care test, a lateral \\nflow assay  for viral antigen , is commercially available. In \\nhumans, monkeypox virus can be found in skin lesions (e.g., \\nin scabs or material from vesicles) or throat and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='nasopharyngeal swabs.  \\nSerology may be he lpful  in some cases , although  cross -\\nreactions with other orthopoxviruses complicate the \\ninterpretation of serological tests . An enzyme -linked \\nimmunosorbent assay (ELISA) can be used to detect  \\northopoxvirus -specific IgM . A rising  IgG titer  in paired \\nsamples  is also sugg estive . Cross -adsorbed virus \\nneutralization, immunofluorescence or hemagglutination \\ninhibition assays, as well as immunoblotting (Western \\nblotting), can be used to distinguish reactions to monkeypox \\nvirus and smallpox virus, although some of t hese assays are \\nnot always easy to interpre t. A specific ELISA that may'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='detect monkeypox antibodies in people vaccinated for \\nsmallpox has been reported in the literature.   \\nTreatment  \\nTreatment of monkeypox is mainly supportive. \\nTecovirimat  (chemical agent ST‐246), which is also known \\nas Arestyvir , has been licensed for use in humans  infected \\nwith orthopoxvirus es, but its specific efficacy against \\nmonkeypox in people has not yet been evaluated . Other \\npossible agents , including a derivative of cidofovir \\n(CMX0 01/ Brincidofovir) are in clinical trials. Vaccinia \\nimmune globulin , which was used at one time to treat \\nsmallpox , might also be tried, especially in those who are  \\nimmunocompromised . \\nPrevention'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='immunocompromised . \\nPrevention  \\nSmallpox (vaccinia) vaccination  appears to provide \\nsome protec tion from monkeypox , and it has been \\nrecommended for some healthy people  in occupations at high \\nrisk of exposure. Post –exposure vaccination also seems to be \\nhelpful , and may be offered to people who are exposed to a \\nmonkeypox -infected person or animal . This vaccine cannot \\nbe used in those who are immunocompromised. The general \\npopulation is not currently vaccinated in endemic areas of \\nAfrica , due to the expense of the vaccine and the risk of \\nserious side effects, particularly in areas  where undiagnosed \\nsevere T cell immunodeficiencies  (e.g., untreated HIV -1'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='infection)  may be relatively common . A vaccine specifically \\nfor monkeypox is in clinical trials in Africa, as of 2020.  \\nAs a routine preventive measure, care should be taken to \\ntreat and cover breaks in the skin when working with \\nnonhuman primates or other animals that may be hosts for \\nmonkeypox virus. Infection control procedures such as good \\nhygiene, frequent hand washing , disinfection of surfaces and equipment, and the use of personal protective equipment \\n(PPE) are important during contact with animals suspected \\nto have monkeypox. Necropsies should be done in Biosafety \\nLevel 2 laboratories, using a certified Class II Biol ogical'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='Safety Cabinet. Anyone who has been in contact with a \\nmonkeypox suspect should contact a health care provider \\nimmediately. Health authorities (e.g., the local or state health \\ndepartment) must also be informed.  \\nIsolation of infected patients  and good  infection control \\nmeasures are helpful in preventing person -to-person \\ntransmission.  Ring vaccination  might also be used in some \\noutbreaks. Because the full host range of monkeypox virus is \\nuncertain, infected individuals should also limit their contact \\nwith any pet, particularly species known to be susceptible  to \\nthis virus . \\nMorbidity and Mortality  \\nIn Africa, monkeypox is usually seen in rural'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='In Africa, monkeypox is usually seen in rural \\npopulations, and is most common in children  and young \\nadults . Most cases occur among people who live in or near \\nheavily forested areas, where the virus is thought to be \\nendemic in animals , though outbreaks have bee n reported \\nelsewhere . Clinical cases often  occur after contact with wild \\nsmall mammals, which are caught for food and other \\npurposes , but person -to-person t ransmission and family \\nclusters appear  to be significant in some outbreaks . In the \\npast, monkeypox was thought to be a rare disease; however, \\noutbreaks and sporadic cases have  increasingly been \\nreported  from Africa  during  the last few decades . Waning'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='immun ity from smallpox vaccinations may be a factor,  as the \\ndisease  predominantly affect s young people born after \\nvaccination campaigns ended. Other societal factors (e.g., \\nchanges resulting from poverty or war) that increase \\nexposure to the reservoir hosts are  also plausible , as are some \\nimpacts from increased awareness and reporting .  \\nMost outbreaks have occurred in central Africa and are \\ncaused by the Congo Basin clade , which is more virulent . \\nUntil recently, c linical cases caused by the West African \\nclade we re seen only rarely. The first significant outbreak in \\nrecent years occurred in 2003 in the U.S. and was  linked to'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='imported exotic pets , which disseminated the virus to pet \\nprairie dogs  and hence to humans . Seventy -two human \\ninfections were reported, including 37 that were labo ratory \\nconfirmed. Most cases occurred  after direct contact with pet \\nprairie dogs. African rodents appeared less likely to transmit \\nthe disease to humans, possibly due to different types of \\nbehavioral interactions with these anima ls. In 2017 -2018, a \\nWest African virus caused  at least 132 confirmed and \\napproximately 300 suspected cases  in Nigeria . This event, \\nthe first significant outbreak in Nigeria since the 1970s , \\noccurred after floods that may have increased human'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 4}, page_content='exposure to ro dents . Many cases appeared to result from  \\nperson -to-person propagation of the virus . Since then,  \\nincreased  surveillance  has uncovered sporadic, ongoing \\nhuman cases  in Nigeria . Serological surveillance has also \\nrevealed antibodies to orthopoxviruses in some  healthy'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 6 of 9 young people in West Africa who report no previous illness \\nsuggestive of monkeypox .  \\nThe highest risk of death  from monkeypox  is in infants, \\nyoung children and immunocompromised individuals. \\nReported case fatality rates in outbreaks caused by  Cong o \\nBasin (Central African) strains reach 10% or more, and are  \\noccasionally as high as 20 -25% in some smaller clusters. \\nHowever, there is still uncertainty in these estimates, as milder \\ncases might be missed  and co -morbidities are common in \\naffected areas . Clinical cases caused by West African clade \\nviruses seem to be mild er. No deaths occurred during the'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='outbreaks in the U.S., while 7 deaths were seen in the recent \\noutbreak in Nigeria . Four of these fatalities occurred  in \\nimmunocompromised individuals, two of whom had \\nuncontrolled HIV -1 infections. One case of  encephalitis  and \\nbronchopneumonia  was fatal in a neonate , and two HIV -\\nnegative adults died with bronchopneumonia and sepsis. \\nAlthough secondary bacterial infectio ns were relatively \\ncommon in this outbreak, other serious complications such as \\nencephalitis, keratitis or bronchopneumonia were rare  in both \\nthis outbreak and the 2003 outbreak in the U.S . The \\navailability of advanced health care facilities and good'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='suppo rtive care, as well as the absence of poor nutrition and \\nconcurrent diseases, may contribute to high er survival rate s for \\nmonkeypox in some areas.  \\nInternet Resources  \\nCenters for Disease Control and Pr evention (CDC). \\nMonkeypox  \\nEuropean Centre for Disease Prevention and Control \\n(ECDC). Monkeypox  \\nPublic Health Agency of Canada. Pathogen Safety  \\nData Sheets  \\nThe Merck Manual  \\nThe Merck Veterinary Manual  \\nWisconsin National Primate Research Center  (WNPRC), \\nUniversity of Wisconsin  \\nWorld Health Organization. Monkeypox  \\nAcknowledgements  \\nThis factsheet was written by Anna Rovid Spickler, DVM, \\nPhD, Veterinary Specialist from the Center f or Food Security'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='and Public Health. The U.S. Department of Agriculture \\nAnimal and Plant Health Inspection Service (USDA APHIS) \\nprovided funding for this factsheet through a series of \\ncooperative agreements related to the development of \\nresources for initia l accreditation training.  \\nThe following format can be used to cite this factsheet. \\nSpickler, Anna Rovid. 2022. Monkeypox . Retrieved from \\nhttp://www.cfsph.iastate.edu/DiseaseInfo/facts heets.php .  References  \\nAcha PN, Szyfres B (Pan American Health Organization \\n[PAHO]). Zoonoses and communicable diseases common to \\nman and animals. Volume 2. Chlamydiosis, rickettsioses and \\nviroses. 3rd ed. Washington DC: PAHO; 2003. Scientific and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='Technica l Publication No. 580. Poxes of monkeys; p. 235 -45.  \\nArmed Forces Institute of Pathology [AFIP}. Case I – 952287 \\n(AFIP 2554549. AFIP Wednesday slide conference – No. 14.  \\nAFIP; 1997 Jan. Available at: \\nhttp://www.afip.org/vetpath/WSC/WSC96/96wsc14.htm.* \\nAccessed 30 Jun 2003.  \\nArmed Forces Institute of Pathology [AFIP]. Department of \\nInfectious and Parasitic Diseases. Monkeypox. AFIP; 2003 \\nJul. Available at: \\nhttp://www.afip.org/Departments/infectious/mp/index.html.* \\nAccessed 1 July 2003.  \\nBaskin GB. Pathology o f nonhuman primates [online]. Primate \\nInfo Net. Wisconsin Primate Research Center; 2002 Feb. \\nAvailable at: http://www.primate.wisc.edu/pin/pola6 –'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='99.html.* Accessed 7 Jun 2003.  \\nBaxby D. Poxviruses. In: Baron S, editor. Medical microbiology. \\n4th ed.New York:  Churchill Livingstone;1996. Available at: \\nhttp://www.gsbs.utmb.edu/microbook/ch069.htm.* Accessed \\n27 June 2003.  \\nBeer EM , Rao VB . A systematic review of the epidemiology of \\nhuman monkeypox outbreaks and  implications for outbreak \\nstrategy.  PLoS Negl  Trop Dis. 2019;13(10):e0007791.  \\nBernard SM, Anderson SA. Qualitative assessment of risk for \\nmonkeypox associated with domestic trade in certain animal \\nspecies, United States.Emerg Infect Dis. 2006;12(12):1827 -33. \\nBreman JG , Bernadou J , Nakano JH. Poxvirus  in West African'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='nonhuman primates: Serological survey  results. Bull. World \\nHealth Org. 1977 ;55:605-12. \\nBrown K , Leggat PA . Human monkeypox: Current state of \\nknowledge and implications for the future.  Trop Med Infect \\nDis. 2016;1 . pii: E8. doi: 10.3390/trop icalmed1010008.  \\nBrown University. Monkeypox . Laboratory primate newsletter. \\n1997 ;36(3) Available at: http://www.brown.edu/Research/  \\nPrimate/lpn36 –3.html#pox.* Accessed 30 Jun 2003.  \\nCenters for Disease Control and Prevention [CDC]. Considerations \\nfor select ion and prioritization of animal specimens for \\nlaboratory testing [online].   CDC; 2003 Jun. Available at: \\nhttp://www.cdc.gov/ncidod/monkeypox/labsubmissionguid.htm .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 5}, page_content='Accessed 2 Feb 20 13. \\nCenters for Disease Control and Prevention [CDC]. Interim case \\ndefinition for animal cases of monkeypox [online]. CDC; 2008 \\nSept. Available at:  http://www.cdc.gov/ncidod/  \\nmonkeypox/animalcasedefinition.htm. * Accessed 2 Feb 2013.  \\nCenters for Disease Control and Prevention [CDC]. Interim \\nguidance for necropsy and animal specimen collection for \\nlaboratory testing [online]. CDC; 2008 Sept. Available at:  \\nhttp://www.cdc.gov/ncidod/monkeypox/necropsy.htm.* . \\nAccessed 2 Feb 2013.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 7 of 9 Centers for Disease Control and Prevention [CDC]. Monkeypox \\ninfections in animals: updated interim guidance for persons \\nwho have frequent contact with animals (pet owners, pet shop \\nowners and employees, animal rescuers, animal handlers, and \\nanimal control officers [online].  CDC ; 2008 Sept. Available \\nat: http://www.cdc.gov/ncidod/monkeypox/  \\nanimalhandlers.htm * Accessed 2 Feb 2013.  \\nCenters for Disease Control and Prevention [CDC]. Monkey pox \\ninfections in animals: updated interim guidance for \\nveterinarians [online]. CDC; 2008 Sept. Available at:  \\nhttp://www.cdc.gov/ncidod/monkeypox/animalguidance.htm.*'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='Accessed 2 Feb 2013.  \\nCenters for Disease Control and Prevention [CDC]. Monkeypox in \\nanima ls: The basics for people who have contact with animals \\n[online]. CDC; 2008 Sept. Available at:  \\nhttp://www.cdc.gov/ncidod/monkeypox/animalbasics.htm .* \\nAccessed 2 Feb 2013.  \\nCenters for Disease Control and Prevention (CDC). Multistate \\noutbreak of monkeypox --Illinois, Indiana, and Wisconsin, \\n2003. Morb Mortal Wkly Rep. 2003;52(23):537 -40. \\nCenters for Disease Control and Prevention. Update: Multistate \\noutbreak of monkeypox - Illinois, Indiana, Kansas, Missouri, \\nOhio, and Wisconsin, 2003. Morb Mortal Wkly Rep. \\n2003;52(24):561 –4.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='2003;52(24):561 –4. \\nCenters for Disease Control and Prevention. Update: Multistate \\noutbreak of monkeypox - Illinois, Indiana, Kansas, Missouri, \\nOhio, and Wisconsin, 2003. Morb Mortal Wkly Rep. \\n2003;52(25):589 –90. \\nCenters for Disease Control and Prevention [C DC]. Updated interim \\nCDC guidance for use of smallpox vaccine, cidofovir, and \\nvaccinia immune globulin (VIG) for prevention and treatment in \\nthe setting of an outbreak of monkeypox infections [online].  \\nCDC; 2008 Sept. Available at: http://www.cdc.gov/ncido d/ \\nmonkeypox/treatmentguidelines.htm.* . Accessed 2 Feb 2013.  \\nChen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, Feng Z,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='Schriewer J, Buck C, Wang C, Lefkowitz EJ, Esposito JJ, \\nHarms T, Damon IK, Roper RL, Upton C, Buller RM. \\nVirulence differences betwe en monkeypox virus isolates from \\nWest Africa and the Congo basin.Virology. 2005;340(1):46 -63. \\nCho CT, Wenner HA. Monkeypox virus. Bacteriol Rev. \\n1973;37(1):1 -18.  \\nCohen J. Is an old virus up to new tricks? Science. \\n1997;277(5324): 312 –3. \\nDepartment of Heal th and Human Services (HHS), Centers for \\nDisease Control and Prevention (CDC), Food and Drug \\nAdministration (FDA). Control of communicable diseases; \\nrestrictions on African rodents, prairie dogs, and certain other \\nanimals. Interim final rule. Federal Regis ter. 2003 Nov 4; 68'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='(213): 62353 -62369. Available at: \\nhttp://edocket.access.gpo.gov/2003/03 -27557.htm . Accessed \\nJan 3 2011.  \\nDi Giulio DB, Eckburg PB. Human monkeypox: an emerging \\nzoonosis. Lan cet Infect Dis. 2004;4(1):15 -25. \\nDoshi RH, Guagliardo SAJ, Doty JB, Babeaux AD, Matheny A, et \\nal. Epidemiologic and ecologic investigations of monkeypox, \\nLikouala Department,  Republic of the Congo, 2017. Emerg \\nInfect Dis. 2019 ;25(2):281 -9.  Doty JB , Malekani JM , Kalemba LN , Stanley WT , Monroe BP , et \\nal. Assessing monkeypox virus prevalence in small mammals \\nat the human -animal  interface in the Democratic Republic of \\nthe Congo.  Viruses. 2017;9 . pii: E283. doi: \\n10.3390/v9100283.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='10.3390/v9100283.  \\nDubois ME, Slifka MK. Ret rospective analysis of monkeypox \\ninfection. Emerg Infect Dis. 2008;14(4):592 -9. \\nErez N, Achdout H, Milrot E, Schwartz Y, Wiener -Well Y, et al. \\nDiagnosis of imported monkeypox, Israel, 2018.  Emerg Infect \\nDis. 2019 ;25(5):980 -3.  \\nEuropean Commission. Monkey P ox virus: Commission bans the \\nimport prairie dogs and rodents that could carry the disease. \\nPress release Midday Express 16 June 2003. Available at: \\nhttp://europa.eu.int/comm/dgs/health_consumer/library/press/pr\\ness291_en.pdf. * Accessed 2003.  \\nFalendysz EA , Lopera JG , Doty JB , Nakazawa Y , Crill C , \\nLorenzsonn  F, Kalemba LN , Ronderos MD , Mejia A ,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='Malekani JM , Karem K , Carroll DS , Osorio JE , Rocke TE . \\nCharacterization of monkeypox virus infection in African rope \\nsquirrels  (Funisciurus  sp.). PLoS Negl  Trop Dis. \\n2017;11(8):e0005809.  \\nFalendysz EA , Lopera JG , Lore nzsonn F , Salzer JS , Hutson CL , \\nDoty J , Gallardo -Romero N , Carroll DS , Osorio JE , Rocke TE . \\nFurther assessment of monkeypox virus infection in Gambian \\npouched rats (Cricetomys gambianus ) using in vivo \\nbioluminescent imaging.   PLoS Negl Trop Dis. \\n2015;9(10):e0004130.  \\nFormenty P, Muntasir MO, Damon I, Chowdhary V, Opoka ML, et \\nal. Human monkeypox outbreak caused by novel virus \\nbelonging to Congo Basin clade, Sudan, 2005. Emerg  Infect'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='Dis. 2010;16(10):1539 -45. \\nGispen R, Verlinde JD, Zwart P. Histopathological and virological \\nstudies on monkeypox. Arch Gesamte Virusforsch. \\n1967;21(2):205 -16. \\nGuarner  J, Johnson BJ, Paddock CD, Shieh WJ, Goldsmith CS, \\nReynolds MG, Damon IK, Regnery RL, Zaki SR; Veterinary \\nMonkeypox Virus Working Group. Monkeypox transmission \\nand pathogenesis in prairie dogs. Emerg Infect Dis. \\n2004;10(3):426 -31. \\nHutin YJ , Williams RJ , Malfait P , Pebody R , Loparev VN , et al. \\nOutbreak of human monkeypox, Democratic Republic of \\nCongo, 1996 to  1997. Emerg. Infect. Dis. 2001, 7, 434 -8. \\nHutson CL, Carroll DS, Gallardo -Romero N, Weiss S, Clemmons'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='C, Hughes CM, Salzer  JS, Olson VA, Abel J, Kare m KL, \\nDamon IK. Monkeypox disease transmission in an \\nexperimental setting: prairie dog animal model. PLoS One. \\n2011;6(12):e28295.  \\nHutson CL, Lee KN, Abel J, Carroll DS, Montgomery JM, et al. \\nMonkeypox zoonotic associations: insights from laboratory \\nevaluat ion of animals associated with the multi -state US \\noutbreak.Am J Trop Med Hyg. 2007;76(4):757 -68. \\nHutson CL , Nakazawa YJ , Self J , Olson VA , Regnery RL , Braden \\nZ, Weiss S , Malekani J , Jackson E , Tate M , Karem KL , Rocke \\nTE, Osorio JE , Damon IK , Carroll DS . Laboratory \\ninvestigations of African pouched rats (Cricetomys'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 6}, page_content='gambianus ) as a  potential reservoir host species for \\nmonkeypox virus. PLoS Negl Trop Dis. 2015;9(10):e0004013.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 8 of 9 Hutson CL, Olson VA, Carroll DS, Abel JA, Hughes CM, Braden \\nZH, Weiss S, Self J, Osorio JE, Hudson PN, Dillon M, Karem \\nKL, Damon IK, Regnery RL. A prairie dog animal model of \\nsystemic orthopoxvirus disease using West African and Congo \\nBasin strains of monk eypox virus.J Gen Virol. 2009;90  (Pt \\n2):323 -33. \\nIhekweazu C , Yinka -Ogunleye A , Lule S , Ibrahim A . Importance \\nof epidemiological research of monkeypox: is incidence \\nincreasing?  Expert Rev Anti Infect Ther. 2020 ;18(5):389 -92.  \\nIizuka I , Saijo M, Shiota T, Am i Y, Suzaki Y, Nagata N, \\nHasegawa H, Sakai K,  Fukushi S, Mizutani T, Ogata M,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='Nakauchi M, Kurane I, Mizuguchi M, Morikawa S.  Loop -\\nmediated isothermal amplification -based diagnostic assay for \\nmonkeypox virus  infections.  J Med Virol. 2009 ;81(6):1102 -8.  \\nInternational Committee on Taxonomy of Viruses [ICTV]. Virus \\nTaxonomy: 2019 Release EC 51, Berlin, Germany, July 2019 \\nEmail ratification March 2020 (MSL #35).) Genus  \\nOrthopoxvirus . Available at:  \\nhttps://talk.ictvonline.org/taxonomy/.  Accessed 22 Nov 2020 . \\nKabuga AI , El Zowalaty ME . A review of the monkeypox virus \\nand a recent outbreak of skin rash disease in  Nigeria.  J Med \\nVirol. 2019 ;91(4):533 -40.  \\nKarem  KL, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='Glidewell J, Ahmed R, Amara R, Damon IK. Monkeypox -\\ninduced immunity and failure of childhood smallpox \\nvaccination to provide complete protection. Clin Vaccine \\nImmunol. 2007;14(10):1318 -27.  \\nKhodakevic h L, Ježek Z , Messinger D. Monkeypox virus: \\nEcology and public health signiﬁcance.  Bull. World Health \\nOrg. 1988 ;66:74752.  \\nKisalu NK , Mokili JL . Toward understanding the outcomes of \\nmonkeypox infection in human pregnancy.  J Infect Dis. \\n2017;216(7):795 -97. \\nKhodakevich L, Szczeniowski M, Manbu –ma–Disu JZ, \\nMarennikova S, Nakano J, Messinger D. The role of squirrels \\nin sustaining monkeypox virus transmission. Trop Geogr Med . \\n1987;39(2): 115 –22.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='1987;39(2): 115 –22.  \\nKile JC, Fleischauer AT, Beard B, Kuehnert MJ, Kanwal RS, \\nPontones P, Messersmith HJ, Teclaw R, Karem KL, Braden \\nZH, Damon I, Khan AS, Fischer M. Transmission of \\nmonkeypox among persons exposed to infected prairie dogs in \\nIndiana in 2003. Arch Pediatr Adolesc Med. \\n2005;159(11):1022 -5. \\nLangohr IM, Stevenson GW, Thacker HL,  Regnery RL. Extensive \\nlesions of monkeypox in a prairie dog ( Cynomys  sp.).Vet \\nPathol. 2004;41(6):702 -7. \\nLearned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, et al.  \\nExtended interhuman transmission of monkeypox in a hospital \\ncommunity in the Republic of the Congo, 2003. Am J Trop \\nMed Hyg. 2005;73(2):428 -34.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='Med Hyg. 2005;73(2):428 -34. \\nLewis MW, Graham MB, Hammarlund E, Hanifin J, Slifka MK. \\nMonkeypox without exanthem. N Engl J Med. \\n2007;356(20):2112 -4. \\nLikos AM, Sammons SA, Olson VA, Frace AM, Li Y, et al. A tale \\nof two clades: monkeypo x viruses.J Gen Virol. 2005;86(Pt \\n10):2661 -72. Macneil A, Abel J, Reynolds MG, Lash R, Fonnie R, Kanneh LD, \\nRobert W, Lungay VK, Goba A, Moses LM, Damon IK, \\nKarem K, Bausch DG. Serologic evidence of human \\northopoxvirus infections in Sierra Leone. BMC Res N otes. \\n2011;4:465.  \\nMbala PK , Huggins JW , Riu-Rovira T , Ahuka SM , Mulembakani \\nP, Rimoin AW , Martin JW , Muyembe JT .Maternal and fetal \\noutcomes among pregnant women with human monkeypox'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='infection  in the Democratic Republic of Congo.  J Infect Dis. \\n2017;216(7):824 -8.  \\nNakazawa Y, Emerson GL, Carroll DS, Zhao H, Li Y, et al.  \\nPhylogenetic and ecologic perspectives of a monkeypox \\noutbreak, southern Sudan, 2005. Emerg Infect Dis. \\n2013;19(2):237 -45.  \\nNalca A, Livingston VA, Garza NL, Zumbrun  EE, Frick OM, \\nChapman JL, Hartings JM. Experimental infection of \\ncynomolgus macaques ( Macaca fasciculari s) with aerosolized \\nmonkeypox virus. PLoS One. 2010;5 . pii: e12880.  \\nNalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of \\nmonkeypox: prevalence, diagnostics, and countermeasures. Clin \\nInfect Dis. 2005;41(12):1765 -71.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content=\"Infect Dis. 2005;41(12):1765 -71. \\nNolen LD , Osadebe L , Katomba J , Likofata J , Mukadi D , et al.  \\nIntroduction of monkeypox into a community and household: \\nrisk factors and  zoonotic reservoirs in the Democratic Republic \\nof the Congo.  Am J Trop Med Hyg. 2015 ;93(2):410 -5.  \\nOgoina D , Iroezindu M , James HI , Oladokun R , Yinka -Ogunleye A , \\nWakama P, Otike -Odibi B , Muhammed Usman L , Obazee E , \\nAruna O , Ihekweazu C . Clinical course and outcome of human \\nmonkeypox in Nigeria.  Clin In fect Dis. 2020 Feb 13. pii: \\nciaa143. [Epub ahead  of print]  \\nOrba Y , Sasaki M , Yamaguchi H , Ishii A , Thomas Y , Ogawa H , \\nHang'ombe BM , Mweene AS , Morikawa S , Saijo M , Sawa H .\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='Orthopoxvirus infection among wildlife in Zambia.  J Gen Virol. \\n2015 ;96(Pt 2):390 -4.  \\nParker S , Buller RM.  A review of experimental and natural \\ninfections of animals with monkeypox virus  between 1958 and \\n2012.  Future Virol. 2013;8(2):129 -57. \\nPatrono LV , Pléh K , Samuni L , Ulrich M , Röthemeier C , Sachse  A, \\nMuschter S , Nitsche A , Couacy -Hyman n E, Boesch C , Wittig  \\nRM, Calvignac -Spencer S , Leendertz FH . Monkeypox virus \\nemergence in wild chimpanzees reveals distinct clinical \\noutcomes  and viral diversity.  Nat Microbiol. 2020 ;5(7):955 -65.  \\nPetersen E , Kantele A , Koopmans M , Asogun D , Yinka -Ogunley e A,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content='Ihekweazu C , Zumla A . Human monkeypox: Epidemiologic and \\nclinical characteristics, diagnosis, and  prevention.  Infect Dis Clin \\nNorth Am. 2019 ;33(4):1027 -43. \\nPublic Health Agency of Canada (PHAC). Pathogen Safety Data \\nSheets: infectious substances - monkeypox . Pathogen Regulation \\nDirectorate, PHAC; 2010 Aug. Available at: \\nhttps://www.canada.ca/en/public -health/services/laboratory -\\nbiosafety -biosecurity/pathogen -safety -data-sheets -risk-\\nassessment/monkeypox -virus.html . Accessed 17 Nov 2020.  \\nRadonić A, Me tzger S, Dabrowski PW, Couacy -Hymann E, \\nSchuenadel L, Kurth A,  Mätz -Rensing K, Boesch C, Leendertz \\nFH, Nitsche A.  Fatal monkeypox in wild -living sooty mangabey,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 7}, page_content=\"Côte d'Ivoire, 2012.  Emerg Infect Dis. 2014 ;20(6):1009 -11.  \\nRand MS. Zoonotic diseases [online] . Institutional Animal Care \\nand Use Committee, University of California, Santa Barbara. \\nAvailable at: http://www.research.ucsb.edu/connect/pro/  \\ndisease.html.* Accessed 30 June 2003.\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 8}, page_content='Monkeypox  \\n \\nwww.cfsph.iastate.ed u  © 200 4-2022 page 9 of 9 Reynolds MG, Carroll DS, Olson VA, Hughes C, Galley J, et al. A \\nsilent enz ootic of an orthopoxvirus in Ghana, West Africa: \\nevidence for multi -species involvement in the absence of \\nwidespread human disease. Am J Trop Med Hyg. \\n2010;82(4):746 -54.  \\nReynolds MG, Cono J, Curns A, Holman RC, Likos A, Regnery \\nR, Treadwell T, Damon I. Hu man monkeypox. Lancet Infect \\nDis. 2004;4(10):604 -5. \\nReynolds MG, Damon IK. Outbreaks of human monkeypox after \\ncessation of smallpox vaccination. Trends Microbiol. \\n2012;20(2):80 -7.  \\nReynolds MG, Davidson WB, Curns AT, Conover CS, Huhn G, et'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 8}, page_content='al. Spectrum of infection and risk factors for human \\nmonkeypox, United States, 2003. Emerg Infect Dis. \\n2007;13(9):1332 -9. \\nReynolds MG , Doty JB , McCollum AM , Olson VA , Nakazawa Y . \\nMonkeypox re -emergence in Africa: a call to expand the \\nconcept and practice of One Health.  Expert Rev Anti Infect \\nTher. 2019 ;17(2):129 -39.  \\nRimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, \\nKisalu NK, et al. Major increase in human monkeypox \\nincidence 30 years after smallpox vaccination campaigns \\ncease in the Democratic Republic of Congo. Proc Natl Acad \\nSci USA. 2010;107(37):16262 -7.  \\nSaijo M, Ami Y, Suzaki Y, Nagata N, Iwata N, et al. Virulence'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 8}, page_content='and pathophysiology of the Congo Basin and West African \\nstrains of monkeypox virus in nonhuman primates. J Gen \\nVirol. 2009;90(Pt 9):2266 -71. \\nSale T A, Melski JW, Stratman EJ. Monkeypox: an epidemiologic \\nand clinical comparison of African and US disease. J Am \\nAcad Dermatol. 2006 55(3):478 -81. \\nSbrana E, Xiao SY, Newman PC, Tesh RB. Comparative \\npathology of North American and central African strains of \\nmonkeypox virus in a ground squirrel model of the \\ndisease.Am J Trop Med Hyg. 2007;76(1):155 -64. \\nSchoeb TR. Diseases of laboratory primates. Diseases of \\nlaboratory animals II. Part 1: Viral diseases [online]. \\nUniversity of Alabama at Birmingham; 1989 -1990. A vailable'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 8}, page_content='at: http://netvet.wustl.edu/species/primates/primate1.txt . \\nAccessed 27 Jul 2009.   \\nSchultz DA, Sagartz JE, Huso DL, Buller RM. Experimental \\ninfection of an African dormouse ( Grap hiurus kellen i) with \\nmonkeypox virus.Virology. 2009;383(1):86 -92.  \\nSeang S, Burrel S, Todesco E, Leducq V, Monsel G, Le Pluart D, \\nCordevant C, Pourcher V, Palich R. Evidence of human -to-\\ndog transmission of monkeypox virus . Lancet. 2022. [Online \\nahead of print. doi: :https://doi.org/10.1016/S0140 -\\n6736(22)01487 -8  \\nSergeev AA , Kabanov AS , Bulychev LE , Sergeev AA , Pyankov \\nOV, Bodnev SA , Galahova DO , Zamedyanskaya AS , Titova \\nKA, Glotova TI , Taranov OS , Omigov VV , Shishkina LN ,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 8}, page_content='Agafonov AP , Sergeev AN . Using the ground squirrel \\n(Marmota bobak ) as an animal model to assess monkeypox  \\ndrug efficacy.  Transbound Emerg Dis. 2017 ;64(1):226 -36.  \\nSimpson K , Heymann D , Brown CS , Edmunds WJ , Elsgaard J , et \\nal. Human monkeypox - After 40 years, an unintended \\nconsequence of smallpox  eradication.  Vaccine. \\n2020;38(33):5077 -81.  Tesh RB, Watts DM, Sbrana E, Siirin M, Popov VL, Xiao SY. \\nExperimental infection of ground squirrels ( Spermophilus \\ntridecemlineatus ) with monkeypox virus. Emerg Infect  Dis. \\n2004;10(9):1563 -7. \\nTownsend MB, MacNeil A, Reynolds MG, Hughes CM, Olson \\nVA, Damon IK, Karem KL.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 8}, page_content='VA, Damon IK, Karem KL.  \\nEvaluation of the Tetracore Orthopox BioThreat® antigen \\ndetection assay using laboratory grown orthopoxviruses and \\nrash illness clinical specimens. J Vir ol Methods. \\n2013;187(1):37 -42.  \\nXiao SY, Sbrana E, Watts DM, Siirin M, da Rosa AP, Tesh RB.  \\nExperimental infection of prairie dogs with monkeypox virus. \\nEmerg Infect Dis. 2005;11(4):539 -45. \\nYinka-Ogunleye A , Aruna O , Dalhat M , Ogoina D , McCollum A , \\nOutbre ak of human monkeypox in Nigeria in 2017 -18: a \\nclinical and epidemiological  report.  Lancet Infect Dis. \\n2019 ;19(8):872 -9. \\nZaucha GM. Jahrling PB, Geisbert TW, Swearengen JR, Hensley \\nL. The pathology of experimental aerosolized monkeypox'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox.pdf', 'page': 8}, page_content='virus infection in c ynomolgus monkeys ( Macaca fascicularis ). \\nLab. Invest . 2001; 81: 1581 -1600.  \\n \\n*Link defunct'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox_F.pdf', 'page': 0}, page_content='© 2013Monkeypox\\nWhat is monkeypox and \\nwhat causes it?\\nMonkeypox is a viral disease \\ndiscovered in laboratory monkeys in \\n1958. The disease most commonly \\noccurs in central and west Africa. Many \\nanimal species and humans can be \\ninfected. In 2003, monkeypox infected \\nseveral people in the United States \\nafter they had contact with infected \\nprairie dogs. The monkeypox virus is \\nclosely related to the viruses that cause \\nsmallpox and cowpox in humans.\\nWhat animals get \\nmonkeypox?\\nOld and New World monkeys and \\napes, a variety of rodents (including \\nrats, mice, squirrels, and prairie \\ndogs) and rabbits are susceptible \\nto infection. The complete range of \\nanimal species that can be infected'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox_F.pdf', 'page': 0}, page_content='animal species that can be infected \\nby the monkeypox virus is still not \\nknown; other wild and domestic \\nanimals may be susceptible.\\nHow can my animal get \\nmonkeypox?\\nMonkeypox is spread by direct \\ncontact  between infected and \\nuninfected animals. This can possibly \\nthrough skin abrasions or through the \\nair in aerosols.\\nHow does monkeypox affect \\nmy animal?\\nIn non-human primates, monkey-\\npox is usually a rash that lasts for 4 to \\n6 weeks; these sores or “pocks” can \\nbe seen over the entire body but are \\nmost common on the face, limbs, \\npalms, soles, and tails. Death is rare \\nbut can be seen in infant monkeys. \\nSome monkeys can be infected with'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox_F.pdf', 'page': 0}, page_content='Some monkeys can be infected with \\nthe virus but show no signs of illness.In rabbits and rodents, including \\nprairie dogs, the initial signs include \\nfever, reddened eyes, runny nose, \\ncough, swollen glands, depression, \\nand loss of appetite. Later, a rash \\nwith small swellings, containing pus \\n(“pocks”), and patchy hair loss can \\ndevelop. In some animals, pneumonia \\nor death can occur.\\nCan I get monkeypox?\\nYes. People can get monkeypox \\nby direct contact with an infected \\nanimal’s blood, body fluids or sores \\nas well as by a bite. Signs of illness \\nstart about 12 days after exposure. \\nSymptoms include fever, headache, \\nmuscle aches, backache, chills, sore'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox_F.pdf', 'page': 0}, page_content='muscle aches, backache, chills, sore \\nthroat, swollen glands (lymph nodes), \\nand fatigue. Usually within 1 to 3 days, \\na rash with raised bumps develops, \\non the arms and legs and possibly \\nthe face and torso. Later, these sores \\ndevelop into “pocks”, blister-like \\nlesions containing pus. In the final \\nstages, these sores crust over, form \\nscabs, and eventually fall off. Illness \\ngenerally lasts 2 to 4 weeks and most \\npeople recover fully.Who should I contact, if I \\nsuspect monkeypox?\\nIn Animals  – Contact your\\nveterinarian immediately. \\nIn Humans  – Contact your\\nphysician immediately. \\nHow can I protect my animal \\nfrom monkeypox?\\nVaccination with vaccinia virus'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox_F.pdf', 'page': 0}, page_content='from monkeypox?\\nVaccination with vaccinia virus \\n(used in smallpox vaccination) can \\nprotect non-human primates from \\nmonkeypox. For all other animals, \\nthe best method of prevention is to \\navoid exposure to animals or people \\ninfected with monkeypox. Do not \\nkeep wild animals as pets, particularly \\nprairie dogs and wild mice or rats.\\nHow can I protect myself \\nfrom monkeypox?\\nAvoid exposure to animals or \\npeople infected with the monkeypox \\nvirus. Although the smallpox vaccine \\nhas been shown to reduce the risk of \\nmonkeypox, it is only recommended \\nfor persons involved with monkeypox \\noutbreak investigations or those who \\nhave close contact with or care for'),\n",
       " Document(metadata={'source': 'monkeypox\\\\monkeypox_F.pdf', 'page': 0}, page_content='have close contact with or care for \\npeople or animals infected with the \\nvirus. Vaccination can be given up to \\n14 days after exposure. \\nFor More Information\\nCFSPH Technical Fact Sheets. Monkeypox \\nat http://www.cfsph.iastate.edu/\\nDiseaseInfo/\\nCDC website. Monkeypox at http://www.cdc.\\ngov/ncidod/monkeypox/\\nMonkeypox\\nis a viral disease  \\nthat can affect  \\nanimals and humans.  \\nIt causes  \\nblister like lesions.\\nPhotos from the CDC Public Health Image Library.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 0}, page_content='Suggested citation: European Centre for Disease Prevention and Control. Risk assessment  for the EU/EEA  of the mpox epidemic \\ncaused by monkeypox virus clade I in affected African countries  – 16 August  2024. ECDC: Stockholm; 20 24.  \\n© European Centre for Disease Prevention and Control, Stockholm, 2024  \\nCatalogue number: TQ-09-24-695-EN-N, ISBN: 978-92-9498-742-6, DOI: 10.2900/087147  \\ntem  ……………………….  \\n \\n \\n \\n \\n \\nRAPID RISK ASSE SSMENT  \\nRisk assessment  for the EU/EEA of the mpox \\nepidemic  caused by monkeypox virus  clade I in \\naffected  African countries   \\n16 August 2024  \\n \\nSummary  \\nEpidemiological situation'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 0}, page_content='Summary  \\nEpidemiological situation  \\nThe monkeypox virus  (MPXV)  clade I  epidemic that ha s been affecting the Democratic Republic of the Congo \\n(DRC) since November 2023 has recently spread to several other African countries  including Burundi, Rwanda, \\nUganda and Kenya . The size of these outbrea ks could be larger than reported due to under -ascertainment and \\nunder -reporting.  \\nOn 15 August 2024, one case of MPXV clade Ib was reported in the EU/EEA  and more imported MPXV clade I \\ncases will likely  occur. It is therefore important for European countries to be prepared to handle  such imported \\ncases and prevent secondary transmission .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 0}, page_content='cases and prevent secondary transmission . \\nIn countries reporting clade  I cases , human -to-human  transmission  through close  physical  contact  and through \\nboth sexual and non -sexual transmission has been documented.  Although a ll age groups are represented among \\ncases infected with  MPXV clade I, preliminary data show that infections by  clade Ib virus concern mostly the adult \\npopulation , whereas infections by clade Ia concern mostly children . To date, t here are still significant \\nuncertainties  about the  main transmission route s, transmissibility, severity, and natural disease history , and \\nwhether these differ between the two circulating subclades of clade I  MPXV .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 0}, page_content='Mpox symptoms usually appear 6 –13 days (up to 21 days) after infection. The clinical manifestation of the \\ndisease includes general febrile symptoms, a distinct rash (papule s) on the skin and sores on the mucosa, back \\npain and muscle aches. The rash may spread quickly throughout the body within three days of experiencing \\nthe initial symptoms . Most people experience mild to moderate symptoms that usually last two to four weeks, \\nfollowed by a full recovery.  \\nRisk assessment   \\nIn the affected areas  in the African continent : \\nThe likelihood  of infection  with MPXV clade I for EU/EEA citizens travelling to  or living in the affected areas and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 0}, page_content='having close contact  with affected communities is high, while  the likelihood of infection is low when contacts \\nwith affected communities are avoided . The sever ity of the  disease  is expected to be low. Overall, the risk for \\nthese populations is moderate  and low, respectively.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n2 In the EU/EEA : \\nThe overall risk for the EU/EEA general population is currently assessed as low, based on a very low  likelihood \\nand a low impact . \\nThe likelihood  of infection with MPXV clade I for close contacts of possible or confirmed imported cases  is high, \\nyet the severity of the  disease is expected to  be low. However, i n this same group, the sever ity of the  disease \\nis considered  moderate  amongst those with underlying conditions, particularly individuals who are'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='immunocompromis ed. Overall , the risk for these populations is moderate  and high, respectively . \\nThe likelihood  of infection  for people  with multiple sexual partners who were not previously infected with MPXV \\nclade IIb or were not vaccinated  in the 2022 outbreak  is considered moderate . This assessment is based on \\nthe difficult y of control ling the spread of infection  during the clade II ou tbreak in 2022/23 in this risk group . \\nAlthough  the severity of the  disease would in most instance s be low, people who are  immunocompromis ed and \\nthose with an untreated HIV infection  could experience  moderate  clinical severity . Overall, the risk for these'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='populations is moderate . \\nRecommendations  \\nTo contain any possible outbreak in the EU/EEA, detecting cases and preventing secondary transmission is \\nvital. This can be achieved through:  \\n• Raising awareness  among clinicians and other health professionals about possible travel -associated mpox \\ncases caused by MPXV clade I, including the possibility of different clinical presentations, transmission \\nthrough sexual and non -sexual routes and different groups affect ed than in previous outbreaks .  \\n• Ensuring effective surveillance, laboratory testing  (including molecular clade identification) , epidemiological'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='investigation and contact tracing capacities . Importation  of MPXV clade I infection s, or notable mpox \\nevents  (outbreaks related to mass gathering events or other specific settings, re -infections among cases, \\nrise in cases among women, children or other risk  groups ) should be promptly reported via EpiPulse \\nand/or EWRS. All mpox cases should be reported to the Eur opean Surveillance System ( TESSy ). \\n• Providing advice to  travellers to affected  areas on national guidance  for vaccination against mpox  prior to travelling .  \\n• Rapidly isolat ing any suspect ed cases until proven negative and, if positive , until symptom resolution .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='• Implement ing contact tracing and testing close contacts of confirmed  cases following ECDC testing protocols . \\n• Provid ing travel advice  to people visiting or returning from countries with confirmed MPXV clade I outbreaks . \\n• Continu ing risk communication activities and working with civil society organisations to engage population \\ngroups at higher risk of infection . \\nEpidemiological situation  \\nEpidemiological situation in affected African countries  \\nMpox (formerly monkeypox) is a viral disease caused by the monkeypox virus (MPXV), which is present in the \\nwildlife  in several central - and west  African countries. In 2022, an outbreak occurred in Europe and globally  where'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='the disease  was transmitted between humans  through mainly  sexual contact.   \\nThere are two genetically distinct clades for MPXV: clade I , with sub -clades Ia and Ib  [1], and clade II, with sub -\\nclades IIa and IIb  [2]. Sub-clade Ia is often referred to simply as clade I  [3]. \\nMPXV clade I has been reported in the past as associated with severe clinical symptoms and higher mortality \\ncompared to clade II  [4,5] until the 2022 global outbreak, which was instead driven by MPXV clade IIb [6]. Clade \\nIIb is characterised by  less severe illness and lower  mortality .  \\nAlthough both MPXV clades I and II are circulating in different countries in the African continent , since the end of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='2023, a large outbreak of mpox has been affecting the Democratic Republic of the Congo (DRC) , with recent \\ngeographical expansion  to other African countries. The rapid rise and spread of MPXV clade Ia and Ib has raised \\nconcerns at the global level.  \\nSince the beginning of the global mpox  outbreak  in 2022 and until the end of July 2024, 99 176 confirmed cases of \\nmpox, including 208 deaths, had been reported by 116 countries  [7]. In 2024 , 14 719 suspect ed and 2 822 \\nconfirmed  mpox cases  (total 17 541)  have been reported in the African  continent , including 517 deaths (case'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 1}, page_content='fatality  3%), according to the Africa Centres for Disease Control and Prevention (Africa CDC ) [8]. The 13 African \\nUnion Member States with reported cases  in 2024  are Burundi, Cameroon, Central African Republic, Republic of the \\nCongo  (hereafter referred to as Congo) , Côte d’Ivoire, DRC, Ghana, Liberia, Kenya, Nigeria, Rwanda, South Africa \\nand Uganda  [8].  \\nIn 2024, DRC has reported 16 789 cases (14 151 suspected and 2 638 confirmed) including 511 deaths ( case \\nfatality 3%) from all of the count ry’s provinces  [8], representing  the highest number of cases due to clade I  in Africa  [9].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n3 Confirmed mpox cases have also been reported in five of the eight neighbouring  countries to DRC  in 2024 , i.e. \\nBurundi  (61 confirmed,  165 suspected ), Central African Republic  (35 confirmed, 223 suspected) , Congo (19 \\nconfirmed, 150 suspected) , Rwanda  (four confirmed) , and Uganda  (two confirmed)  [8,10] . Additionally,  \\nsuspected cases were investigated  in South Sudan, according to med ia reports  [11]. Out of the eight neighbouring  \\ncountries  to DRC , only the Central African Republic and Congo  reported cases in 2023  [8]. Burundi , Uganda and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='Rwanda  reported their first mpox cases at the end of July 2024  with Burundi reporting  the most cases indicating \\ncommunity transmission in the country  [10]. Besides the neighbouring  countries to DRC, Kenya  reported its first  \\nconfirmed mpox case  at the  end of July 2024  [12]. MPXV clade I a has been isolated from cases in Central African \\nRepublic  and Congo  [9,13,14] . MPVX clade Ib, which was detected first in DRC and reported in April 2024, was \\nalso detected in confirmed cases in Burundi, Rwanda, Uganda  and Kenya  [10,13] .  \\nAlthough t he degree of under -ascertainment and under -reporting of cases in affected countries is unknown, it is'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='presumed to  be substantial . Thus, the number of reported cases  is likely an underestimation of the true number of \\ninfections  and the case fatality is likely overestimated . Furthermore, it can be assumed that community \\ntransmission is taking place  in several African countries due to the widespread geographical distribution of reported \\ncases and the wide age ranges represented .   \\nMultiple modes of transmission have been documented in DRC including human -to-human  transmission  through \\nclose contact (e.g. sexual transmission, household transmission) , and in some settings , zoonotic  transmission .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='Epidemiological links between confirmed cases in other countries and DRC have also been documented  [9,10,15] . \\nSustained  human -to-human transmission including through  sexual contact  has been shown to contribute to the \\nspread of MPXV  clade I b (e.g., in eastern  DRC and neighbouring  countries ), as previously  shown in the global \\noutbreak of MPXV clade II b [10,14] . An observational study conducted in  Kamituga (South Kivu province ) in April \\n2024 showed that  among cases infected with sub-clade Ib , 29%  reported  involve ment in sex work  [1]. In another \\nstudy conducted in the same area  and published in May 2024 , 88% of 371 hospital ised patients reported being'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='involved in transactional sex  [16]. Besides sexual contact, non -sexual contact, household and health care facility \\ncontacts have been reported by cases in DRC [17]. In areas where MPXV clade Ia (which is endemic in DRC ) \\ncirculates,  multiple modes of transmission have been documented [10].  \\nOverall, according to the World Health Organization External Situation Report published on 12 August 2024, adults \\nare the most affected in eastern areas of DRC  and neighbouring countries where clade Ib circulates . In areas \\nwhere clade Ia circulates (e.g. endemic MPXV  in DRC , Congo, Central Africa n Republic ) children are mostly affected [10].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='In DRC, m ost cases and deaths reported are among <15 -year-olds, representing 66% of the total cases and 82% \\nof the total deaths. Males account for 73% of the cases in DRC [8]. In Congo , based on information provided by \\nAfrica CDC, most confirmed cases (56%) were c hildren <15 -years -old and 58% were males ; similarly , in the \\nCentral African Republic , 43% of the confirmed cases were <15-year-olds and 62% males  [9]. Moreover, within \\nthe Central African Republic, u ntil 30 July 2024, cases were reported from 14  out of the 35 districts  [9,18] , \\nincluding the capital city of  Bangui  [19]. In Burundi , where cases have been reported from 22 of 48 health district s'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='(data published 9 August), 30% were in 0-5-year-olds and 52% of the confirmed cases were males  [8]. \\nWhile i nformation  from surveillance  on the clinical presentation of  cases  reported by  DRC and its neighbouring  \\ncountries is lacking [10], reports mention the presence of rash and in some cases  fever and lymphadenopathy  [1,16,17] .  \\nFurther to the countries with reports of MPXV clade I  circulation , additional African  countries have reported cases \\nof clade II including South Africa and Côte d’Ivoire  [10]. As of 5 August 2024 , South Africa  has reported 24  mpox \\ncases and three deaths. Twenty -two of the 24 cases were reported between 8 May and 6 July 2024 [20]. Cases'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='reported by South Africa have a similar epidemiological profile to those reported in the global MPXV clade II \\noutbreak i.e.  most commonly in young males [21]. Six confirmed  mpox  cases ha ve been reported in Côte  d’Ivoire  \\n[22], with t he first two confirmed cases reported in the Abidjan region [18].  \\nOn 13 August  2024, Africa CDC officially declared mpox a Public Health Emergency of Continental Security \\n(PHECS), marking the first such declaration by the agency since its inception in 2017.  The declaration will enable \\nthe mobili sation of resources across affected countries, unlocking essential funding, strengthening risk'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 2}, page_content='communication and community engagement, boosting surveillance and laboratory testing efforts, and enhancing \\nhuman resource capacities to respond effectively to the outbreak  [23]. On 14 August  2024, the Director General of \\nthe World Health Organization  declared the outbreak a public health emergency of international concern  (PHEIC ) [24].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 3}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n4 Figure 1.  Countries where monkeypox virus clade I and/or clade II have been detected  [9,10]\\n \\nCAR: Ce ntral Afri can Republic; DRC: Democ ratic Republic of Congo [9,10]  \\nEpidemiological situation in the EU/EEA  \\nOn 15 August 2024, Sweden reported one imported case of mpox due to  MPXV  clade I b [25]. The case is an adult \\nwho returned from an African country where MPXV clade Ib transmission has been reported. The mode of \\ntransmission  is under investigat ion. Contacts of the case have been informed and are being monitored.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 3}, page_content='Previously, and a s of 8 August 2024, 22 662 confirmed mpox cases ha ve been reported by 29 countries  in the \\nEU/EEA via The European Surveillance System  (TESSy ) as part of the outbreak driven by clade IIb . Most cases  \\n(93%)  were reported during an intense period of circulation in 2022 . In 2023, 860 cases were reported in 21 \\nEU/EEA countries while so far in  2024, 685 cases have been  reported by 20 EU/EEA countries . This indicates  \\ncontinued circulation of MPXV in the EU/EEA, but at very low levels . Information  on the virus clade was reported \\nfor very few  (2.1%) of all mpox cases  reported to TESSy since 2022 . All case s reported to TESSy as of 8 August'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 3}, page_content='2024 were from clade II .  \\nAs of 15 August, 29 genome sequences  from samples collected in 2024  in the EU/EEA  (from Austria, Germany, \\nNetherlands, and Portugal ) and 37 genome sequences from Africa  (from DRC, Kenya, and Uganda ) were deposited \\nin GISAID EpiPox  [26],[27]. All of the sequences from the EU/EEA belong to clade II, while all sequences from \\nAfrica belong to clade  I.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 4}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n5 Between 2022 and 2024, the profile and severity of mpox cases diagnosed in the EU/EEA has remained stable:  \\n98% of mpox cases are males  and 39% of cases are  in 31-40 years -old, while <0.1% of cases reported  are in  \\nchildren <15 years  of age . Of the 10 860  cases with data reported on sexual orientation , 95% self -identified as \\nmen who have sex with men  (MSM) . Among cases with known HIV status, 38% (4 308 /11 328 ) were HIV -positive.  \\nThe cases reported to date in the EU/EEA have been mostly mild, with 10 deaths ( 10/18 183, case fatality 0.1%)'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 4}, page_content='among all reported cases and a low proportion of hospitalised cases  (867/12 924 , 7%).  \\nECDC r isk assessment  \\nThis rapid risk assessment has been developed based on the currently available data at the time of publication and  \\nfollows the ECDC rapid risk assessment methodology, where the overall risk is determined by a combination of the  \\nlikelihood  of infection and its impac t (estimated disease  severity ) [28]. The likelihood  of infection and the impact of \\nthe disease are assessed  at the time of an emerging health threat, considering  characteristics of place (country or \\ncountries  where occurring) and person (prevalence of risk groups in EU/EEA population).'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 4}, page_content='This assessment draws on historical and emerging data from the MPXV clade I  epidemic  in DRC and other \\ncountries in Africa , and the recent global MPXV clade IIb outbreak. However, solid evidence is lacking on  \\ntransmission  routes, transmissibility , clinical outcomes , risk factors for severity , and whether these differ between \\nMPXV clade Ia and Ib.  \\nTable 1.  Summary of the risk  due to MPXV clade I  for the populations under assessment  \\n Likelihood  of \\ninfection  Impact  Overall r isk for the \\nassessed \\npopulation  \\nIn the affected countries  \\nEU/EEA citizens travelling to the affected countries  and having close'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 4}, page_content='contact  (healthcare workers, household  or other close contact and/or \\nmultiple sexual contacts ) with affected communities or living in the \\naffected countries  High Low Moderate  \\nEU/EEA citizens travelling to the affected countries , but not having \\nclose contact  with affected communities  Low Low Low \\nIn the EU/EEA  \\nClose contac ts of possible or confirmed imported cases  High Low Moderate  \\nClose contacts of possible or confirmed imported cases with \\nunderlying immunocompromising conditions and those with an \\nuntreated HIV infection  High Moderate  High \\nEU/EEA general population  Very low  Low Low  \\nWhat is the overall  risk due to MPXV clade I  circulation  for'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 4}, page_content='EU/EEA citizens travelling to or living in the affected African \\ncountries ? \\nGiven the uncertainties on the extent of community transmission in the affected areas and the lack o f conclusive \\nevidence on the relative efficiency  of different routes of transmission , EU/EEA  citizens visiting affected countries \\nand engaging in activities that involve close contact  with affected  local communities are considered at high \\nlikelihood of infection. The same applies to EU/EEA citizens living permanently  in these countries. Preliminary data \\nfrom the field show that close contacts are contributing to sustain ing the epidemic in Africa .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 4}, page_content='On the other hand, EU/EEA citizens travelling  to the affected countries who do not have  close contact  with the \\naffected communities  have a low likelihood of infection .  \\nWhile the morbidity and case fatality  for clade I has been reported in the past as higher tha n that for clade II  [29], \\ncurrent preliminary data from Africa are not showing higher clinical severity in confirmed cases . Based on this \\nassumption  and considering the relative ly few number  of EU/EEA citizens potentially affected, the impact of mpox  \\non EU/EEA citizens visiting or living in the areas affected by  the current  epidemic is considered low.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 4}, page_content='Based on these levels of likelihood and impact , the risk for EU/EEA citizens  travelling to the affected countries and \\nhaving close contact  (healthcare workers, household or other close contact and/or multiple sexual contacts) with \\naffected communities or living in the affected countries is assessed as  moderate . \\nConversely, t he risk for EU/EEA citizens travelling to  the affected countries who do not have  close contact  with the \\nlocal community  is assessed as low.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 5}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n6 What is the overall  risk due to MPXV  clade I in the EU/EEA ? \\nThe increase in  the number of mpox cases due to MPXV clade I and the geographical expansion in newly -affected \\nAfrican  countries  increases the chance of  sporadic case introduction s into the EU/EEA . On 15 A ugust 2024, one \\ncase of MPXV clade I was reported in the EU/EEA . \\nIn the event of more sporadic importation s of the MPXV clade I  in the EU/EEA , the likelihood of infection for c lose'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 5}, page_content='contacts of possible or confirmed imported cases  is assessed  high. The likelihood of infection is much lower for \\ncontacts that have been vaccinated or have a history of previous infection with MPXV clade IIb.   \\nThe likelihood of infection in the general population in the EU/EEA is assess ed as very low , provided that imported  \\ncases are diagnosed  promptly  and control measures  are implemented .  \\nSevere disease is more  likely for people with underlying immunocompromising conditions and those with an \\nuntreated HIV infection (as was the case for clade IIb).  Based on these factors , the impact of the disease is'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 5}, page_content='assessed as moderate  for this group , and low for the general population.   \\nTherefore, the level of  risk is assessed as high for close contacts with underlying immunocompromising conditions \\nand those with an untreated HIV infection , moderate  for healthy close contacts , and low for the remaining \\ngeneral EU/EEA population.  \\nIf sustained transmission of MPXV clade I is established in the EU/EEA, people with multiple sexual partners are at \\na higher likelihood of infection.  Within this group, unvaccinated , immunocompromised individuals , and those who \\ndo not have a history of previous infection  with MPXV clade IIb are at higher risk of more severe illness.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 5}, page_content='After the outbreak of MPXV clade II in the EU in 2022, Tecovirimat and Imvanex were included are part of the rescEU \\nstockpile of medical countermeasures (MCM) against CBRN events . Additionally, several EU Member States  have \\nestablished national stockpiles of Imvanex under their national preparedness plan against smallpox. Finally, in 2022, \\nthe Commission has organised joint procurements and signed framework contracts with the producers to ensure \\navailability of both pro ducts. As a result of these measures, the Health Emergency Preparedness and Response \\nAuthority  of the European Commission  expects that these medical countermeasures will be available to address'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 5}, page_content='immediate needs to respond to the first cases of infection by Clade Ib.  \\nECDC recommendations  \\nECDC issues the following recommendations targeted for specific stakeholders, which are summarised in the table \\nbelow  and detailed in the following paragraphs . \\nStakeholders  Recommendations  \\nPublic health authorities  • Follow ECDC guidelines for case detection and investigation;  \\n• Investigate every case and report any significant increases in case \\nnumbers or changes in epidemiology (increased severity, detections \\nof MPXV clade I, outbreaks related to mass gathering events, re -\\ninfections among cases, rise in cases among women, childr en or \\nother risk groups );'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 5}, page_content='other risk groups );  \\n• Implement effective surveillance, ensuring that the system is \\nsensitive enough  to ensure prompt response to possible cases;  \\n• Rapidly isolate any suspect ed cases until proven negative and, if \\npositive , until symptom resolution ; \\n• Implement contact tracing and testing of close contacts of \\nconfirmed cases following the ECDC testing protoc ols; \\n• Develop information material for clinicians;  \\n• Map laboratory capacity;  \\n• In the event of a MPXV clade I outbreak in the EU/EEA , identify and \\noffer vaccination to  eligible unvaccinated high -risk individuals  for \\nsexual transmission . If feasible, post -exposure vaccination of cases'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 5}, page_content='with the available third-generation  smallpox vaccine can be offered \\nas one of the response options.  \\nPeople planning to travel  to the affected countries  in Africa  • Consult guidance from your national health authorities , ECDC \\nguidance  and epidemiological information;  \\n• Avoid contact with wild animals;  \\n• Refrain from sexual or other close contact with individuals with \\npossible or known mpox infection and those with visible lesions or \\nother mpox compatible symptoms.  \\n• Consult national guidelines on vaccination against mpox  before \\ntravel  \\nPeople  living in the EU/EEA  • No special  recommendations  are issued at this stage for the \\ngeneral public'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n7 Surveillance   \\nNational mpox surveillance  \\nEU/EEA countries should maintain  their mpox event -based and indicator -based surveillance and testing capacit y to \\nenable prompt identification of  cases and clusters, monitor the ir epidemiological characteristics , including  affected \\npopulation sub -groups, and rapidly detect changes in disease  trends. In this regard, EU/EEA countries are also \\nencouraged to define mpox as a nationally notifiable disease.  \\nTo meet these objectives , surveillance systems should be sensitive enough to  prompt a thorough investigation of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='each suspect ed case as recommended by ECDC.  \\nThe ECDC interim indications for testing  are: \\n• Individuals  returning from an affected area and reporting any of the symptoms (including prodromal \\nsymptoms  or lymphadenopathy)  described in this document ; \\n• Close contacts  of confirmed cases  in the EU/EEA reporting any of the symptoms (including prodromal \\nsymptoms or lymphadenopathy) described in this document (regardless of type of contact ); \\n• Individuals presenting with mpox compatible lesions or any other typical symptom s, including isolated genital lesions.   \\nEU/EEA mpox surveillance'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='EU/EEA mpox surveillance  \\nEU/EEA level surveillance by ECDC is based on  indicator -based data collection through TESSy, complemented by \\nevent -based surveillance with reporting through EpiPulse (and/or  ECDC’s Early Warning Response System  (EWRS)  \\ndepending on the event).  \\nNational EU/EEA public health authorities should report all mpox cases every month  to TESSy. Information about \\nthe clade  should be included . Case records can be reported in TESSy  as soon as information becomes available .  \\nAny significant increases in case numbers or changes in epidemiology, such as increase d severity, detections of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='MPXV clade I , outbreaks related to mass gathering events or other specific settings, re -infections among cases, rise \\nin cases among women, children or other risk  groups ( e.g., sex workers ) should be reported through event -based \\nsurveillance  as a new event on EpiPulse and/or EWRS . \\nAccording to a survey by the European Commission Joint Research Centre  in August 2024, MPXV  is not \\nsystematically included in the list of pathogens monitored in wastewater in EU Member States. Of the 16 countries \\nwho respond ed, only four monito r MPXV  in wastewater ( two in both community and airport wastewater, and two'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='only in community wastewater  This exercise, supported by  DG HERA in collaboration with the JRC, will take place \\nin the week of 23 September 2024 and is dedicated to the synchronised collection and coordinated examination of \\nwastewater samples originating from aircraft at a variety of global airports, including in Africa.  \\nGenomic surveillance  \\nSequencing  MPXV contributes to  understanding viral evolution, transmission chains and patterns of spread. \\nCountries are encouraged to comprehensively sequence all positive  mpox specimens and share sequences in \\npublicly  available sequence repositories . Sequencing would be of even greater relevance  when sudden clinical'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='and/or epidemiological changes are observed. Such changes may include, but are not limited to, increase s in \\nvirulence,  change s in clinical disease presentation, and change s in the performance of laboratory diagnostics  \\nLaboratory testing  \\nThe laboratory diagnosis of mpox is predominantly based on the direct demonstration of the Orthopoxvirus \\nmonkeypox  (MPXV) in a clinical specimen. Real-time polymerase chain reaction (real -time PCR) on skin lesion \\nmaterials (e.g. swabs, exudate, or lesion crusts) are used most frequently . Viral throat swabs can be used for high-\\nrisk contacts  of confirmed or high -probable cases  who have developed systemic symptoms but do not have  a rash'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='or lesions that can be sampled [30]. Several real -time PCR assays for the specific detection of MPXV, or for generic \\northopoxvirus detection are available  [31-36]. Over 80 MPXV  laboratory  tests are CE -validated, mostly based on \\nPCR [31-36]. Mpox laboratory diagnostics are well established in several laboratories in Europe (see Emerging Viral \\nDiseases -Expert Laboratory Network – EVD-LabNet  [37]).  \\nIdentification of the genetic clade of MPXV is mainly based on the determination and analysis of the partial genome \\nsequence s of the detected virus; however, clade -specific real -time PCR assays are also used for this purpose in'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 6}, page_content='some laboratories. Recent studies revealed that a novel clade I MPXV which was detected in the current mpox \\noutbreak in  DRC has a deletion in and surrounding the OPG032 gene. This mutation may result in false negative \\ntest results  for certain  real-time PCR assays to discriminate between clade I and clade II MPXV strains  [38,39] . \\nHowever, validated assays are available for the detection of the new clade Ib variant  [40].'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n8 Mpox diagnostic laboratories in the EU/EEA have been alerted through the EVD -LabNet about this finding and were \\nadvised to use molecular assays which are able to detect this mutant strain. The timely detection of the potential \\nemergence of clade I MPXV in the EU/EEA requires molecular identification of viruses detected in diagnostic \\nspecimens. Therefore, nucleotide  sequencing and sharing sequence information through public databases (e.g., \\nGISAID) remains an essential component to monitor  the mpox epidemiol ogical situation in Europe and globally.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='Raising awareness among clinicians and laboratories  \\nGiven that case numbers of mpox have declined substantially since the summer 2022, there might be a need to \\nremind clinicians – especially those who do not work directly in STI clinics or with MSM – of mpox symptoms and \\nthe possibility that cases may reappear.   \\nClinicians and laboratories should be aware of how to rapidly report cases of mpox to public health authorities to \\nensure that a potential increase in transmission is rapidly detected. Similarly, rapid reporting to partner notification \\nor contact tracing services can ensure that potential contacts are notified as quickly as possibl e.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='Awareness should  be maintained or raised among clinicians and other health professionals in EU/EEA countries of \\nthe ongoing possibility of introduction of clade I or increased circulation of clade II  in new risk groups,  and the \\nrecommendation to promptly test all suspect ed cases and inform public health authorities even before test results \\nare available. This includes clinicians at sexual health clinics serving MSM and other populations with multiple \\nsexual partners, but also clinicians serving the general population (dermatologists, paediatricians, primary care \\nproviders).  Clinicians  should also be made aware of the possibility of seeing more severe cases due to infection'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='with MPXV clade I. Such patients, as was observed in the outbreak of MPXV clade II, require prompt initiation of \\nsupportive and antiviral treatment and/or post -exposure vaccination.  \\nIn case of emergence of MPXV clade I in Europe, public health authorities should be ready to perform \\ncomprehensive contact tracing with thorough interview of cases to collect essential epidemiological data, such as \\ntravel history, list of contacts and type of contact, behavioural risk factors, underlying conditions, vaccination status \\nfor previous mpox and /or smallpox vaccination and date of last vaccination.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='Travel lers to areas where MPXV  clade I outbreak s are ongoing should receive pre - and post -travel advice . Hence, \\ntravel medicine clinics should be aware of the ongoing outbreak s and familiar with the available preventive and \\ncontrol  method s.  \\nVaccination  \\nECDC recommends travellers to epidemic areas consult their  national guidance on vaccination against mpox  before \\ntravel . The US CDC has issued recommendations for vaccination which may be useful for Member States to \\nconsider  until specific guidance from ECDC is available [41,42] .  \\nSince people with multiple sexual partners remains at higher risk if infection also with MPVX clade I , ECDC'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='recommends  EU/EEA countries to identify and offer vaccination to  eligible unvaccinated high -risk individuals. If \\nfeasible, post -exposure vaccination of cases with the available third -generation smallpox vaccine can be offered as \\none of the response options , considering that MPXV clade II is still circulating, albeit at low level . This can be \\ncomplemented by the vaccination programmes (pre -exposure vaccination for at -risk groups) that have been in \\nplace in the EU/EEA since the MPXV clade II outbreak in 2022.   \\nVaccination campaigns in the EU/EEA and other countries were implemented to control the outbreak of clade IIb'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='MPXV in 2022, with a third -generation non -replicating smallpox vaccine authorised by the European Medicines \\nAgency (EMA) for protection against mp ox in adults [43,44] . The vaccine effectiveness of two pre -exposure vaccine \\n(PPV) doses is estimated as 82% (95% CI: 72 -92), while even one PPV dose provides effectiveness of 76% (95% \\nCI: 64 -88) [45]. For post -exposure vaccination (PEPV) the vaccine effectiveness was estimated a t 20% (95%CI: -\\n24-65) [45]. In individuals who experienced infection after being  vaccinated , the disease was less severe compared \\nto unvaccinated individuals  [46]. The third-generation  smallpox vaccine is expected to have similar vaccine'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 7}, page_content='effectiveness against MPXV clade I, although clade-specific vaccine effectiveness evidence is currently lacking [47,48] . \\nReaching the target population for vaccination also presents challenges, although in the first months of the multi -\\ncountry mpox outbreak in 2022, the number of countries administering this vaccine, and the number of doses \\nadministered, increased rapidly. Pop -up vaccination clinics with extended working hours, as well as vaccination in \\nthe context of mass gathering even ts frequented by groups at high risk was effective  [49,50] .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n9 A survey based on a convenience sample of more than 15 000 MSM  at higher  risk of HIV infection  conducted from \\nOctober 2023 to April 2024 in 20 countries in Europe found self -reported receipt of at least one dose of the mpox \\nvaccine to be 39%, with wide variation between countries ranging from 51% of the sample in France to <10% of \\nthe sample in Poland and Greece [51]. In another exercise to estimate mpox vaccination coverage among  MSM \\nwith multiple sexual partners using general population data, EMIS-2017 data , and mpox doses reported to ECDC'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content='by European countries (as of March 2023) , receipt of two doses of the mpox vaccine was estimated to be much \\nlower, ranging from <1% to 12% in EU/EEA countries [52].  \\nTailored interventions are needed to increase  confidence in the vaccine, maximi se uptake, and increase vaccine \\naccess , especially among key populations residing in regions with low rates of acceptance and uptake  [53]. \\nRisk communication and community engagement  \\nClose collaboration with community -based organisations that work with MSM or other groups at high risk is \\nessential to reach target groups. Public health authorities can use guidance and good examples of risk'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content='communication and community engagement developed during the 202 2-23 mpox outbreak which is  available on \\nthe ECDC website  [54]. Key messages include awareness of symptoms, seeking testing and avoiding sex and close \\ncontacts until symptoms resolve , and to seek vaccination if available. Risk communication in the general population \\nif there is increased community circulation in the EU/EEA, should include the risk of exposure to mpox through sex. \\nAnyone presenting with symptoms compatible with mpox should be advised to seek medical care and abstain from \\nsex and close contact  with others  until a diagnosis is made or until symptoms resolve if infected.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content='Infection prevention and control  \\nAs there is uncertainty ar ound the  different routes  of transmission  in the  current outbreak of  MPXV clade I, \\nincluding the role played by respiratory droplets and aerosols, and the possible increased risk to healthcare workers  \\nposed by this clade , it is best to apply the  precautionary principle  when performing at -risk activities (i.e., any \\nprocedures likely to spread oral secretions ). Further information can be found on the CDC webpage  on Infection \\nPrevention and Control of Mpox in Healthcare Settings . \\nGlobal efforts to control the outbreak in the affected  African \\ncountries could reduce geographical spread'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content=\"countries could reduce geographical spread  \\nThe control of the ongoing outbreak in DRC and other affected countries on the African continent would, apart \\nfrom directly benefiting the  affected population, also reduce the likelihood of geographical spread of MPXV clade I \\nwithin Africa and to the EU/EEA  and globally . Building capacity for contact tracing, diagnosis and sequencing, and \\nthe provision of vaccines to affected communities  are essential  to support public health authorities' control efforts.  \\nTo this end,  the Health Emergency Preparedness and Response Authority , Africa CDC  and Bavarian Nordic (BN)\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content='signed a tripartite agreement  on 14 August 2024  to secure 215 000 doses of mpox vaccines  for delivery in \\nSeptember 2024  to the most affected African countries where the BN vaccine is authori sed[55]. \\nWHO has issued  on 21 august 2023 Standing recommendations against mpox , now prolonged by the Director \\nGeneral until 20 August 2025. They are directed to all WHO Member States and cover several aspects , including \\nnational action plans, diagnostic capacity, surveillance, risk communication, research, international travel, clinical \\ncare and access to vaccines.  \\nECDC is supporting the G OARN  efforts in response to the mpox outbreak in DRC by deploying ECDC experts .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content='Further deployments are planned if needed.   \\nLimitations  \\nThis assessment is based on historical data on MPXV clade I, on data from the ongoing epidemic in DRC, and on \\ndata from the recent MPXV clade IIb outbreak. Many elements on which this assessment is based  on contain a \\nsignificant level of uncertainty.  \\nThe number of reported outbreaks of mpox and the number of cases in Africa within the past  year are \\nunprecedented , and the ecological and epidemiological drivers are poorly identified. The sustained transmission \\nchains in the communities and household transmissions may indicate changes in mpox epidemiology, but detailed'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 8}, page_content='data on secondary attack rates, basic reproduction numbers and transmission routes , particula rly when stratified \\nby clade Ia, Ib and II  are not currently available. Altered transmission modes (e.g., through direct vs. indirect \\ncontact) may influence the probability of infection of EU/EEA travellers to affected areas in Africa.  \\nUntil 15 August 2024, mpox outbreaks reported outside of Africa have been caused by MPXV clade IIb exclusively.  \\nThese outbreaks predominantly affected MSM in the EU/EEA, with transmission mainly attributed to sexual contact, \\nand the resulting symptoms in those infected  were typically mild .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 9}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n10 On 15 August 2024, one case of MPXV clade I was reported in the EU/EEA . It is unknown whether the same risk \\ngroups will be affected, and whether the severity of the disease will be similar to or higher than observed in mpox \\ncases caused by  MPXV  clade II b. \\nAlthough vaccines and antivirals used against MPXV clade II should also work for  MPXV clade I , there is limited  \\nscientific  data from real -world settings to confirm this.  \\nWhen there is relevant new information about transmission modes, disease severity and the effectiveness of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 9}, page_content='preventive and treatment methods , this risk assessment will be updated . \\nECDC contributors (in alphabetical order)  \\nMohammed Afzal, Luis Alves de Sousa, Erik Alm, Angela Ancona, Leonidas Alexakis, Xanthi Andrianou , Tamás  \\nBakonyi, Jon Bilbatua, Olivier Cecchi, Orlando Cenciarelli,  Silvia Funke, C éline Gossner, Konstantinos Koutentakis, \\nAnastasia Pharris, Maryoli Veloso  Fraigola . \\nExternal reviewers  \\nEmerging Viral Diseases -Expert Laboratory Network (EVD -LabNet) : Chantal Reusken , Harry Vennema (National \\nInstitute for Public Health and the Environment , the Netherlands ), Klara Sond én (The Public Health Agency of Sweden) . \\nPublic Health Agency, Sweden : Erik Sturegård .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 9}, page_content='Public Health Agency, Sweden : Erik Sturegård . \\nDG HERA: Experts from D G HERA were consulted and provided comments  to this document.  \\nWHO Regional Office for Europe: Kareena Hundal , Ioannis K aragiannis,  Tran Minh Nhu Nguyen , Marc-Alain Widdowson .  \\nAfrica CDC: Kyeng Mercy . \\nAll experts have submitted declarations of interest. A review of these declarations did not reveal any conflict of \\ninterest except for two reviewers for which mitigations measures were put in place, i.e. disregarding comments \\nrelated to a specific product and/or area of interest.  \\nDisclaimer  \\nECDC issues this risk assessment document based on an internal decision and in accordance with Article 10 of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 9}, page_content='Decision No 1082/13/EC and Article 7(1) of Regulation (EC) No 851/2004 establishing a European centre for \\ndisease prevention and control (ECDC). In  the framework of ECDC’s mandate, the specific purpose of an ECDC risk \\nassessment is to present different options on a certain matter. The responsibility on the choice of which option to \\npursue and which actions to take, including the adoption of mandatory  rules or guidelines, lies exclusively with the \\nEU/EEA Member States. In its activities, ECDC strives to ensure its independence, high scientific quality, \\ntransparency and efficiency.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 9}, page_content='transparency and efficiency.  \\nThis report was written with the coordination and assistance of an internal response team at the European Centre \\nfor Disease Prevention and Control. All data published in this risk assessment are correct to the best of our \\nknowledge at the time of publication. Maps and figures published do not represent a statement on the part of \\nECDC or it s partners on the legal or border status of the countries and territories shown.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n11 References  \\n1. Vakaniaki EH, Kacita C, Kinganda -Lusamaki E, O’Toole Á, Wawina -Bokalanga T, Mukadi -Bamuleka D, et al. \\nSustained Human Outbreak of a New MPXV Clade I Lineage in the Eastern Democratic Republic of the Congo. \\nNature Medicine. 2024:1 -11. Available at: https://www.nature.com/articles/s41591 -024-03130 -3 \\n2. Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen -Rasmussen M, et al. A tale of two clades: monkeypox \\nviruses. Journal of General Virology. 2005;86(10):2661 -72. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content='https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.81215 -0 \\n3. Nextstrain.org. Genomic epidemiology of mpox viruses across clades. 2024. Available at: \\nhttps://nextstrain.org/mpox/all -clades   \\n4. Van Dijck C, Hoff NA, Mbala -Kingebeni P, Low N, Cevik M, Rimoin AW, et al. Emergence of mpox in the post -\\nsmallpox era -a narrative review on mpox epidemiology. Clinical Microbiology and Infection. 2023;29(12):1487 -\\n92. Available at: https://www.sciencedirect.com/science/article/pii/S1198743X23003890  \\n5. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content='monkeypox —A potential threat? A systematic review. PLoS Neglected Tropical Diseases. 2022;16(2):e0010141. \\nAvailable at: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010141  \\n6. World Health Organization (WHO). Mpox (monkeypox) - Democratic Republic of the Congo. Geneva: WHO; \\n2023. Available at: https://www.who.int/emergencies/disease -outbreak -news/item/2023 -DON493  \\n7. World Health Organization (WHO). 2022 -24 Mpox (Monkeypox) Outbreak: Global Trends. Geneva: WHO; 2024. \\nAvailable at: https://worldhealthorg.shinyapps.io/mpx_global/  \\n8. Africa Centres for Disease Control and Prevention (AfricaCDC). Africa CDC Epidemic Intelligence Weekly Report,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content='9 August 2024. Addis Ababa: AfricaCDC; 2024. Available at: https://africacdc.org/download/africa -cdc-weekly -\\nevent -based -surveillance -report -august -2024/  \\n9. Africa Centres for Disease Control and Prevention (AfricaCDC). Mpox Situation in Africa. Addis Ababa: \\nAfricaCDC; 2024. Available at: https://africacdc.org/disease -outbreak/mpox -situation -in-africa/  \\n10. World Health Organization (WHO). Multi -country outbreak of mpox, External situation report#35 - 12 August \\n2024. Geneva: WHO; 2024. Available at: https://www.who.int/publications/m/item/multi -country -outbreak -of-\\nmpox --external -situation -report -35--12-august -2024'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content=\"11. Radio Tamazuj. South Sudan detects two suspected monkeypox cases in Aweil. 2024. Available at: \\nhttps://www.radiotamazuj.org/en/news/article/south -sudan -detects -two-suspected -monkeypox -cases -in-aweil \\n12. The Ministry of Health - Kenya. Ministry of Health Confirms Mpox Outbreak at Taita -Taveta Border Point. \\nFacebook. 31 July 2024, 05:21. Available at: \\nhttps://www.facebook.com/MinstryofHealthKE/posts/pfbid023nGb8hu34UHAoyzRhNfzZcRd33Be2TSFF8ee9MUm\\nmwhEKMCj3cxZxgw99p4q8P3Ml  \\n13. World Health Organization (WHO). WHO Director -General's opening remarks at the media briefing – 7 August\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content=\"2024. Geneva: WHO; 2024. Available at: https://www.who.int/director -general/speeches/detail/who -director -\\ngeneral -s-opening -remarks -at-the-media -briefing ---7-august -2024 \\n14. World Health Organization (WHO). African region faces an unprecedent surge in mpox cases. Geneva: WHO; \\n2024. Available at: https://www.afro.who.int/news/african -region -faces-unprecedent -surge -mpox -cases  \\n15. Uganda Medical Association Central Branch. Uganda reports an outbreak of the Mpox virus. Let's act swiftly to \\ncontain its spread! X. 5 August 2024, 13.36. Available at: \\nhttps://x.com/UMACentralb_Off/status/1820423714338488477\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content='16. Masirika LM, Nieuwenhuijse DF, Ndishimye P, Udahemuka JC, Steeven BK, Gisèle NB, et al. Mapping the \\ndistribution and describing the first cases from an ongoing outbreak of a New Strain of mpox in South Kivu, \\nEastern Democratic Republic of Congo between  September 2023 to April 2024. medRxiv [Preprint]. 2024. DOI: \\n10.1101/2024.05.10.24307057. Available at: \\nhttps://www.medrxiv.org/content/10.1101/2024.05.10.24307057v1  \\n17. World Health Organization (WHO). Mpox - Democratic Republic of the Congo. Geneva: WHO; 2024. Available \\nat: https://www.who.int/emergencies/disease -outbreak -news/item/2024 -DON522'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 10}, page_content='18. Africa Centres for Disease Control and Prevention (AfricaCDC). Africa CDC Epidemic Intelligence Weekly Report, \\n2 August 2024. Addis Ababa: AfricaCDC; 2024. Available at: https://africacdc.org/download/africa -cdc-weekly -\\nevent -based -surveillance -report -august -2024/  \\n19. Ministère de la Santé et de la Population - RCA. Épidémie de Monkeypox à Bangui!!! Facebook. 29 July 2024, \\n04:32. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n12 https://www.facebook.com/RCAMSP/posts/pfbid02J8Z9hehMvvQMz89YFAwYv7JQ17YDLVpbwF7XG4wceQWAiW\\nzhMKXRZUgkNoqnLazRl  \\n20. National Department of Health - South Africa. Health Department calls for vigilance as mpox cases re -emerge. \\nCape Town: National Department of Health; 2024. Available at: https://www.nicd.ac.za/wp -\\ncontent/uploads/2024/08/Health -Department -calls-for-vigilance -as-mpox -cases -re-emerge.pdf  \\n21. National Department of Health - South Africa. Update on mpox outbreak and response efforts. Cape Town:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content=\"National Department of Health; 2024. Available at: https://www.nicd.ac.za/wp -\\ncontent/uploads/2024/06/Update -on-mpox -outbreak -and-response -efforts.pdf  \\n22. Ministère de la Santé et de l'Hygiène Publique. Variole du Singe/ 6 cas détectés en Côte d'Ivoire. Facebook. 1 \\nAugust 2024, 12:38. Available at: \\nhttps://www.facebook.com/mshpcmu/posts/pfbid0Yq498V6NTA6Lw8j9kchhY9v2opSvpEiK9UDuZmLvGSa59o84E\\nkih99eHTnmPs9Bml  \\n23. Africa Centres for Disease Control and Prevention (AfricaCDC). Africa CDC Declares Mpox A Public Health \\nEmergency of Continental Security, Mobilizing Resources Across the Continent. Addis Ababa: AfricaCDC; 2024.\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content='Available at: https://africacdc.org/news -item/africa -cdc-declares -mpox -a-public -health -emergency -of-\\ncontinental -security -mobilizing -resources -across -the-continent/  \\n24. World Health Organization (WHO). WHO Director -General declares mpox outbreak a public health emergency of \\ninternational concern. Geneva: WHO; 2024. Available at: https://www.who.int/news/item/14 -08-2024-who-\\ndirector -general -declares -mpox -outbreak -a-public -health -emergency -of-international -concern  \\n25. Public Healht Agency of Sweden (PHAS). Ett fall av mpox klad I rapporterat i Sverige. Stockholm: ECDC; 2024.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content='Available at: https://www.folkhalsomyndigheten.se/nyheter -och-press/nyhetsarkiv/2024/augusti/ett -fall-av-\\nmpox -klad-i-rapporterat -i-sverige/  \\n26. Global Initiative on Sharing All Influenza Data (GISAID). EpiPox. Munich: Freunde von GISAID e.V.; 2024. \\nAvailable at: https://gisaid.org/  \\n27. National Library of Medicine. GenBank Overview. Bethesda: National Institutes of Health (NIH); 2024. Available \\nat: https://www.ncbi.nlm.nih.gov/genbank/  \\n28. European Centre for Disease Prevention and Control (ECDC). Operational tool on rapid risk assessment \\nmethodology - ECDC 2019. Stockholm: ECDC; 2019. Available at: https://www.ecdc.europa.eu/en/publications -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content='data/operational -tool-rapid-risk-assessment -methodology -ecdc-2019 \\n29. European Centre for Disease Prevention and Control (ECDC). Factsheet for health professionals on mpox \\n(monkeypox). Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/all -topics -\\nz/monkeypox/factsheet -health -professionals  \\n30. UK Health Security Agency (UKHSA). Mpox (monkeypox): diagnostic testing. London: UKHSA; 2024. Available \\nat: https://www.gov.uk/guidance/monkeypox -diagnostic -testing  \\n31. Maksyutov RA, Gavrilova EV, Shchelkunov SN. Species -specific differentiation of variola, monkeypox, and'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content='varicella -zoster viruses by multiplex real -time PCR assay. Journal of Virological Methods. 2016;236:215 -20. \\nAvailable at: https://www.sciencedirect.com/science/article/pii/S0166093416300672  \\n32. Li Y, Zhao H, Wilkins K, Hughes C, Damon IK. Real -time PCR assays for the specific detection of monkeypox \\nvirus West African and Congo Basin strain DNA. Journal of Virological Methods. 2010;169(1):223 -7. Available at: \\nhttps://www.sciencedirect.com/science/article/pii/S0166093410002545  \\n33. Li Y, Olson VA, Laue T, Laker MT, Damon IK. Detection of monkeypox virus with real -time PCR assays. Journal \\nof Clinical Virology. 2006;36(3):194 -203. Available at:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content='https://www.sciencedirect.com/science/article/pii/S1386653206001223  \\n34. Schroeder K, Nitsche A. Multicolour, multiplex real -time PCR assay for the detection of human -pathogenic \\npoxviruses. Molecular and Cellular Probes. 2010;24(2):110 -3. Available at: \\nhttps://www.sciencedirect.com/science/article/pii/S0890850809000772  \\n35. Luciani L, Inchauste L, Ferraris O, Charrel R, Nougairède A, Piorkowski G, et al. A novel and sensitive real -time \\nPCR system for universal detection of poxviruses. Scientific Reports. 2021;11(1):1798. Available at: \\nhttps://www.nature.com/articles/s41598 -021-81376 -4'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 11}, page_content='36. Li D, Wilkins K, McCollum AM, Osadebe L, Kabamba J, Nguete B, et al. Evaluation of the GeneXpert for human \\nmonkeypox diagnosis. The American Journal of Tropical Medicine and Hygiene. 2017;96(2):405. Available at: \\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303045/  \\n37. European Centre for Disease Prevention and Control (ECDC). Directory of EVD -LabNet. Stockholm: ECDC; 2024. \\nAvailable at: https://qap.ecdc.europa.eu/public/extensions/EVD_LabNet/EVD_LabNet.html#main -tab'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content='RAPID RISK ASSESSMENT  Monkeypox virus clade I  circulation in Africa: risk for the EU /EEA– 16 August 2024  \\n \\n \\n13 38. Masirika LM, Udahemuka JC, Schuele L, Ndishimye P, Otani S, Mbiribindi JB, et al. Ongoing mpox outbreak in \\nKamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub -lineage, Democratic \\nRepublic of the Congo, 2024. Euro Surve ill. 2024;29(11):2400106. Available at: \\nhttps://www.eurosurveillance.org/content/10.2807/1560 -7917.ES.2024.29.11.2400106  \\n39. Masirika LM, Udaheuka J, Schuele L, Ndishimye P, Otani S, Mbiribindi JB, et al. Novel Clade I genome sequences'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content='from the ongoing mpox virus outbreak of Kamituga in South Kivu province, Democratic Republic of Congo. \\nVirological [Preprint]. 2024. Availabl e at: https://virological.org/t/novel -clade-i-genome -sequences -from-the-\\nongoing -mpox -virus-outbreak -of-kamituga -in-south -kivu-province -democratic -republic -of-congo/956  \\n40. Schuele L, Masirika LM, Udahemuka JC, Siangoli FB, Mbiribindi JB, Ndishimye P, et al. Real -time PCR assay to \\ndetect the novel Clade Ib monkeypox virus, September 2023 to May 2024. Euro Surveill. 2024;29(32):2400486. \\nAvailable at: https://www.eurosurveillance.org/content/10.2807/1560 -7917.ES.2024.29.32.2400486'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content='41. Centers for Disease Control and Prevention (CDC). Mpox Caused by Human -to-Human Transmission of \\nMonkeypox Virus in the Democratic Republic of the Congo with Spread to Neighboring Countries. Atlanta: CDC; \\n2024. Available at: https://emergency.cdc.gov/han/2024/han00513.asp  \\n42. Centers for Disease Control and Prevention (CDC). Mpox Vaccine Recommendations. Atlanta: CDC; 2024. \\nAvailable at: https://www.cdc.gov/poxvirus/mpox/vaccines/vaccine -recommendations.html  \\n43. European Medicines Agency (EMA). Imvanex -Smallpox vaccine (Live Modified Vaccinia Virus Ankara). \\nAmsterdam: EMA; 2022. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/imvanex'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content='44. European Medicines Agency (EMA). EMA recommends approval of Imvanex for the prevention of monkeypox \\ndisease. Amsterdam: EMA; 2022. Available at: https://www.ema.europa.eu/en/news/ema -recommends -\\napproval -imvanex -prevention -monkeypox -disease  \\n45. Pischel L, Martini BA, Yu N, Cacesse D, Tracy M, Kharbanda K, et al. Vaccine effectiveness of 3rd generation \\nmpox vaccines against mpox and disease severity: A systematic review and meta -analysis. Vaccine [Preprint]. \\n2024. DOI: 10.1016/j.vaccine.2024.0 6.021. Available at: \\nhttps://www.sciencedirect.com/science/article/pii/S0264410X24006947'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content='46. Guagliardo SAJ, Kracalik I, Carter RJ, Braden C, Free R, Hamal M, et al. Monkeypox Virus Infections After 2 \\nPreexposure Doses of JYNNEOS Vaccine - United States, May 2022 - May 2024. Morbidity and Mortality Weekly \\nReport. 2024;73(20):460 -6. Available a t: https://www.cdc.gov/mmwr/volumes/73/wr/mm7320a3.htm  \\n47. Palich R, Jedrzejewski T, Schneider L, Qatib N, Orriere T, Gosset D, et al. High uptake of vaccination against \\nmpox in men who have sex with men (MSM) on HIV pre -exposure prophylaxis (PrEP) in Paris, France. Sexually \\nTransmitted Infections. 2023;99(8): 552-3. Available at: https://sti.bmj.com/content/99/8/552'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content='48. Svartstein AW, Knudsen AD, Heidari SL, Heftdal LD, Gelpi M, Benfield T, et al. Mpox Incidence and Vaccine \\nUptake in Men Who Have Sex with Men and Are Living with HIV in Denmark. Vaccines (Basel). \\n2023;11(7):1167. Available at: https://www.mdpi.com/2076 -393X/11/7/1167  \\n49. Dukers -Muijrers NH, Evers Y, Widdershoven V, Davidovich U, Adam PC, Op de Coul EL, et al. Mpox vaccination \\nwillingness, determinants, and communication needs in gay, bisexual, and other men who have sex with men, \\nin the context of limited vaccine avail ability in the Netherlands (Dutch Mpox -survey). Frontiers in Public Health. \\n2023;10:1058807. Available at: https://www.frontiersin.org/journals/public -'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content=\"health/articles/10.3389/fpubh.2022.1058807/full  \\n50. Reyes -Urueña J, D'Ambrosio A, Croci R, Bluemel B, Cenciarelli O, Pharris A, et al. High monkeypox vaccine \\nacceptance among male users of smartphone -based online gay -dating apps in Europe, 30 July to 12 August \\n2022. Euro Surveill. 2022;27(42):2200757. A vailable at: \\nhttps://www.eurosurveillance.org/content/10.2807/1560 -7917.ES.2022.27.42.2200757  \\n51. Jonas K. PROTECT study www.protect -study.eu . Message to: Pharris A. 8 August 2024.  \\n52. Schmidt AJ. Unpublished data. Message to: Pharris A. 8 August 2024.  \\n53. Sulaiman SK, Isma’il Tsiga -Ahmed F, Musa MS, Makama BT, Sulaiman AK, Abdulaziz TB. Global prevalence and\"),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpox-risk-assessment-monkeypox-virus-africa-august-2024.pdf', 'page': 12}, page_content='correlates of mpox vaccine acceptance and uptake: a systematic review and meta -analysis. Communications \\nMedicine. 2024;4(1):136. Available at: https://www.nature.com/articles/s43856 -024-00564 -1 \\n54. European Centre for Disease Prevention and Control (ECDC). Mpox (Monkeypox). Stockholm: ECDC; 2024. \\nAvailable at: https://www.ecdc.europa.eu/en/mpox -monkeypox  \\n55. European Commission (EC). European Commission coordinates procurement and donation of 215,000 vaccine \\ndoses from Bavarian Nordic to support Africa CDC in addressing the Mpox outbreak in affected countries in \\nAfrica. Brussels: EC; 2024. Available at: https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4244'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 0}, page_content='Questions and Answers Regarding M onkeypox  \\nFor Administrators  and Staff of Institutions of Higher Education (IHEs)  \\nsuch as Colleges and Universities  \\n \\nUPDATED: September 12, 2022  \\n \\nSummary of Recent Changes  \\n• Statewide eligibility has now been expanded to include immunization of all individuals at risk of \\nbecoming infected with Monkeypox.  \\n \\nWhere can I find the latest information on monkeypox?  \\nInformation can be found on the Center s for Disease Control and Prevention (CDC) monkeypox website , \\nspecifically the  page for Institutions of Higher Education  or the  New York State Department of Health'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 0}, page_content='(NYSDOH)  monkeypox website . New York City based institutions can find more information  on the  New \\nYork City Department of Health and Mental Hygiene  (NYCDOHMH ) website , as well.  \\n \\nHow can we protect our campus community while avoiding stigma?  \\nIHEs can help by providing mo nkeypox information to different communities and various channels. Be \\ncareful to avoid marginalizing groups who may be at increased risk for monkeypox. Keep messages fact -\\nbased to help prevent stigmatizing populations most affected.  CDC communication resources  including a \\ntip sheet for reducing stigma  and NYSDOH downloadable materials  are available .  \\n \\nWhat are the signs and  symptoms of monkeypox?'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 0}, page_content='What are the signs and  symptoms of monkeypox?  \\nSigns and s ymptoms of monkeypox can include:  \\n• Rashes, bumps, or blisters on or around the genitals or in other areas like hands, feet, chest, or \\nface  (prolonged phase) . \\n• Flu-like symptoms, such as fever, headache, muscle aches, chills, and fatigue. These signs and  \\nsymptoms may occur before or after the  rash appears, or not at all  (prodromal  phase) . \\n• There can be significant pain associated with this disease , which m ay interfere with basic \\nfunctions such as eating, urination, and defecation . \\n \\nHow is monkeypox spread?  \\nThe most  common way monkeypox  spreads is  through close, physical contact  such as during  sex,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 0}, page_content='hugging, and kissing . Spread can also happen by touching clothing or linens that have been \\ncontaminated with body fluids. This means anyone can get monkeypox  regardless of gender identity, \\nbirth sex, or sex of sex partner(s) . However, based on the current outbreak, certain populations are \\nbeing affected by monkeypox more than others, including gay, bisexual, transgender, and  gender \\nnonconforming community and other communities of men who have sex with men (MSM). Based on \\nprev ious outbreaks of monkeypox around the world, some groups might also be at heightened risk for \\nsevere outcomes if they contract monkeypox. This includes people with weakened immune systems,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 0}, page_content='older adults , children under 8 years of age, and  people who are  pregnant.  It does NOT include attending \\nclass, or walking to class, or hanging out in a dorm room .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 1}, page_content='September 12 , 2022  2 Why is this important to institut ions of higher education  (IHEs) ? \\nThe fluid  social networks on a college /university  campus could aid the spread  of monkeypox . Awareness \\nof risk and prevention strategies are key to  avoiding outbreaks.   \\n \\nHow can students  and staff  protect themselves ? \\nIndividuals  can protect themselves by taking 4 simple steps, which  are especially important for those \\nwho may be at higher risk for severe disease, including people with weakened immune systems:  \\n• Ask your sexual partner (s) whether they have a rash or other signs or symptoms consistent with \\nmonkeypox.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 1}, page_content='monkeypox.  \\n• Avoid skin -to-skin contact  with someone who has a rash or other monkeypox -related signs or \\nsymptoms.  \\n• If you are exposed or experience symptoms, make sure to contact  a health care provider.  \\n• Follow reputable sources of health information, including NYSDOH, CDC, and your local health \\ndepartment.  \\n \\nIs there a vaccine to prevent monkeypox?  \\nJYNNEOS is licensed by the US FDA as a 2 -dose series for the prevention of monkeypox , including  people \\nunder 18 years of age . If given within four (4) days of exposure, this vaccine can reduce the likelihood of \\ninfection, and within 14 days might reduce severity of symptoms. There is currently a limited supply of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 1}, page_content='JYNNEOS vaccine, although more vaccine is expected in the coming months. NYSDOH is rolling out \\nvaccine in a phased approach, as it becomes available, in accordance with CDC guidance  and in \\npartnership with local health departments and health care providers.  \\n \\nWho is eligible for vaccination?  \\nStatewide eligibility current ly includes the following New Yorkers:  \\n• Pre-exposure Prophylaxis (PREP) . Any individual that may be at risk of future exposure to \\ninfection with monkeypox, even though they are not at high risk of recent exposure to \\nmonkeypox (PrEP).  \\n• Post -Exposure Prophylaxis (PEP) . Individuals with recent exposure to a suspected or confirmed'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 1}, page_content='case of monkeypox within the past 14 days (PEP).  \\n• Post -Exposure Prophylaxis Plus Plus (PEP++) . Those at high risk of a recent exposure to \\nmonkeypox, including gay men and members of the bisexual, transgender, and gender non -\\nconforming community and other communities of men who have sex with men and who have \\nengaged in intimate or skin -to-skin contact with others in the past 14 days areas where \\nmonkeypox is spreading  ) OR individuals who have had skin -to-skin contact with someone in a \\nsocial network experiencing monkeypox activity, including men who have sex with men who \\nmeet partners through an online website, digital application (\"app\"), or social event, such as a'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 1}, page_content='bar or party  \\n \\nWhere to go to receive vaccination  \\nPeople identified by a local health department as exposed to a suspected or confirmed case of \\nmonkeypox in the past 14 days should work directly with their local health department and health  care \\nprovider to  discuss obtaining the JYNNEOS vaccine. There is currently a limited federal supply of \\nJYNNEOS vaccine, although more vaccine is expected in the coming weeks and months. The New York \\nState Department of Health is distributing vaccine to local health departments for targeted distribution , \\nin accordance with CDC guidance.'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 2}, page_content='September 12 , 2022  3 What should individuals  do if they have been exposed  or have signs or symptoms consistent \\nwith monkeypox?  \\nThose  who experience  signs or  symptoms consistent with monkeypox, such as characteristic rashes or \\nlesions, should contact their health care provider for a risk assessment. This includes anyone who \\ntraveled to countries where monkeypox cases have been reported or has had contact with someone \\nwho has a similar rash, or who received a diagnosis of suspected or confirmed monkeypox.  If a rash is \\npresent, individuals  should cover their rashes and avoid close contact with anyone. If there is fever,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 2}, page_content='chills,  or respiratory symptoms, they shoul d isolate in their  residence hall or home.   \\n \\nIndividuals who have been exposed to monkeypox  but have no signs or symptoms  do not need to be \\nexcluded from school or work duty, but should undergo active surveillance for signs and symptoms, \\nwhich includes mea surement of temperature at least twice daily for 21 days following the exposure.  \\nBefore reporting for school or work each day, the individual should be self -screening for evidence of \\nfever or rash . If an individual has  a temperature of 100.4 and above , then they should not report to \\nschool or work duty.   \\n \\nAre there treatments available?'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 2}, page_content='Are there treatments available?  \\nAntiviral medications exist to treat monkeypox, which may be appropriate for some people. Those  who \\ndevelop a rash or skin lesions should be sure to:  \\n• Keep rash areas clean and dry to protect against secondary infections  \\n• Be conscious of sun exposure to avoid discoloring exposed lesions  \\n• Talk to a health  care provider about over -the-counter medications, which might be helpful, such \\nas oral antihistamines and topical agents such as calamine lotion, hydrocortisone,  petroleum \\njelly, and lidocaine cream  or gels  \\n• If there is constipation, over -the-counter stool softeners (docusate sodium) or laxatives (e.g.,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 2}, page_content='MiraLAX ) might be helpful  to reduce peri -anal discomfort  \\n \\nAnyone  experienc ing a painful rash or skin lesion should contact a health  care  provider about \\nmedication to help with pain management. Prescription medicated mouthwashes and topical gels can \\nprovide pain relief and keep rashes and lesions clean and are widely available.  \\n \\nWhere to go for testing  \\nIf you have been exposed or have s igns or symptoms consistent with monkeypox contact  your health \\ncare provider  or campus health center. Testing can be done at any outpatient clinic. If you reside on \\ncampus and signs or symptoms worsen after hours, coordinate with your resident advisor to seek'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 2}, page_content='needed care. If your campus offers a 24 -hr telehealth consultation number, please use that , as well.  \\n \\nWhat is the role of the campus health center?  \\nThe campus health center should be the primary place students seek care. Providers should be informed \\non current monkeypox testing and treatment instructions, use standard precautions when caring for \\npotential cases, and never  turn away a student who has symptoms consistent with monkeypox who  \\nrequests testing.  \\n \\nWhat is the role of the Resident Advisor/Resident Director?  \\nStudents who reside on campus may look to their Resident Advisors (RA) or Resident Directors (RD) for'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 2}, page_content='advice outside of the Campus Health Center hours. If a student asks a Resident Advisor or Residence \\nDirector about monkeypox, i t is an important opportunity to be helpful . It is common for people who'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 3}, page_content='September 12 , 2022  4 think they have monkeypox to be uncertain and maybe even anxious. The RAs/RDs should know the \\nprocedure for their campus regarding medical attention after hours, inform appropriate Re sidence Life \\nstaff of a potential case, and provide roommates with information on how to protect against monkeypox \\npost exposure (i.e. , watch for symptoms).  \\n \\nWhen is someone with monkeypox contagious ? \\nDuring the incubation period, 1 -2 weeks after exposure, a person is not believed to be contagious. At  \\nthe onset of signs or symptoms , one might be contagious and should isolate. Once there is a rash'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 3}, page_content='present, a person is contagious until all the scabs have fallen off and a fresh layer of intact skin has \\nformed  underneath . \\n \\nWhat to do if a roommate tests positive?  \\nIf a roommate tests positive for monkeypox, the other roommate/roommates should avoid close \\ncontact with the positive person, watch for symptoms, don’t share clothes or linens, and get tested if a \\nrash develops.  \\n \\nDo students  go to class if exposed  to monkeypox?  \\nIndividuals  who have been exposed to monkeypox do not need to quarantine or  be excluded from \\nschool or work . It is important to self -monitor  for signs and  symptoms, which includes measurement of'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 3}, page_content='temperature at least twice daily for 21 days  following the exposure.  If an individual has  a temperature of \\n100.4 and above , then they should not report to school or work duty.   \\n \\nHow  to handle  cleaning and disinfection of  laundry or common area furniture that was \\nexposed to monkeypox  \\nRemind students living  in a residence hall to report any cases of monkeypox to the Resident  Director or \\nthe Residence Life office . This will ensure that  proper cleaning and disinfection of common areas such as \\nbathroom s and lounges  can be completed . The following guidance  should be followed by both on and \\noff campus students:  \\n• Personal Protective Equipment (PPE)'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 3}, page_content='• Personal Protective Equipment (PPE)  \\nIf cleaning and disinfection is done by someone other than the individual with monkeypox,  the \\nperson should wear clothing that fully covers the skin, disposable medical gloves, eye protection \\nand a  respirator or well -fitting mask.  Additional PPE may be needed depending on the  cleaning  \\nand disinfection products used. Follow product label instruc tions for proper use an d handling \\nincluding use of PPE.   \\n• Laundry  \\nSoiled laundry should not be mixed with laundry from other individuals. Used bed linens and \\ntowels should be folded inward during removal and not shaken. Shaking laundry can cause'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 3}, page_content='infectious particles to become airborne. Used laundry should be contained within a washable, \\nnon-mesh or plastic laundry bag for transport to the laundry facilities. Washable laundry bags \\ncan be washed with the soiled laundry. Care should be taken to keep bed linens and towels \\nfolded inward as they are placed into the washing machine. Staff handling soiled laundry should \\nwear, at a minimum, disposable medical gloves and a well -fitting mask or N95. After placing the \\nlaundry into the washing machine, dispose of the glov es and perform hand hygiene using soap \\nand water or an alcohol -based hand sanitizer. All laundry should be washed at warmest'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 3}, page_content='temperatures recommended on the fabric label and follow detergent label and instructions for \\nuse. Bleach is not necessary to remove  infectious particles. Clean, wet laundry should be dried'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 4}, page_content='September 12 , 2022  5 at the highest temperature allowed. No personal protective equipment (PPE) or special handling \\nis necessary after drying the clean laundry.  \\n• Disinfecting n on-porous  (hard) and porous  (soft) surface s \\nBe sure to clean areas before disinfecting . Avoid sweeping and vacuuming and use wet methods \\nsuch as disinfection wi pes and wet mopping. For soft surfaces,  a removable  cover can be placed \\nover  the soft surface that can be laundered or discarded.  Steam cleaning may be considered if \\nexcessive contamination of porous surfaces has  occurred . \\n \\nFurther guidance is listed here:'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 4}, page_content='Further guidance is listed here: \\nhttps://www.health.ny.gov/diseases/communicable/zoonoses/monkeypox/docs/cleaning_and_disinfect\\nion_guidance.pdf . \\n \\nWhen to isolate?  \\nWe recognize that the college environment is different than others, and isolation can be more \\nchallenging . Students who have active symptoms  (prodromal phase) of monkey pox, such as , fever , chills  \\nand cough or other respiratory illness should isolate  at home .  \\n \\nWhen the prodrome has concluded; fever is gone, chills are absent , and the cough has gone yet  the rash \\npersists , the individual has entered the prolonged phase of the illness. It will take 2 -4 weeks for the rash'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 4}, page_content='to scab over and be covered by new skin.   \\n \\nThose who have a rash but not those other symptoms may leave isolation if lesions are covered, and \\nthey can wear a well -fitting mask .  \\n \\nRemember, w hile a rash persists, but in the absence of a fever or respiratory symptoms : \\n• Cover all parts of the r ash with clothing, gloves, and/or bandages . \\n• Wear a well -fitting mask to prevent spreading oral and respiratory secretions when interacting \\nwith others until the rash and all other symptoms have resolved . \\n• Masks should fit closely on the face without any gap s along the edges or around the nose and be \\ncomfortable when worn properly over the nose and mouth .'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 4}, page_content='• Limit activity to essential activities, e.g., attending class, dining, laundry. (Participation in contact \\nsports, social outings , work , etc.,  are best deferred until lesions have scabbed over,  and new skin \\ncovers them , which take s approximately  2-4 weeks ) \\n \\nSomeone  has tested  positive and  is in isolation . What  should they do? \\nIndividuals  with a confirmed  case of monkeypox should isolate until all active symptoms, besides the \\nrash, are gone.  While in isolation students should follow these recommendations:  \\n• Do not leave your room or home  except as required for emergencies or follow -up medical care'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 4}, page_content='• Persons without an essential need to be in the room or home should not visit  \\n• Avoid close contact with others  \\n• Avoid close contact with pets in the home  \\n• Abstain from all sexual activity  \\n• Do not share items that could be contaminated by the lesions (e.g., bed linens, clothing, towels, \\nwash cloths).\\u202fDo not share drinking glasses or eating utensils  \\n• Routinely clean and disinfect commonly touched surfaces and items (e.g., counters, light \\nswitches) using an Environmental Protection Agency ( EPA)-registered disinfectant in accordance \\nwith the manufacturer’s instructions'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 5}, page_content='September 12 , 2022  6 • Wear a well -fitting mask or respirator for source control when in close contact with others at \\nhome  or in your room  \\n• Avoid use of contact lenses to prevent inadvertent infection of the eye  \\n• Avoid shaving areas of the body with lesions , as this can lead to spread of the virus  \\n• If possible, use a separate bathroom if there are others who live in the same household  \\no If there is not a separate bathroom in the home, the patient should clean and disinfect \\nsurfaces (e.g., count ers, toilet seats, faucets) using an EPA-registered household \\ncleaning product (List Q)  after using a shared space if the lesions are exposed (e.g.,'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 5}, page_content='showering, toileting, changing bandages covering the lesions). Consider disposable glove \\nuse for cleaning and disinfection if lesions are present on the hands  \\n \\nRemember to limit your exposure to others  and limit use of spaces, items, and foo d that are shared with \\nother household/residence hall members . \\n \\nShould you be concerned about your  pets?  \\nPeople with monkeypox should avoid contact with animals (specifically mammals), including pets.  \\n• If possible, friends or family members should care for healthy animals until the owner has fully \\nrecovered.  \\n• Keep any potentially infectious bandages, textiles (e.g., clothes, bedding) and other items away'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 5}, page_content='from pets, other domestic animals, and wildlife.  \\n• There is currently no evidence that animals apart from mammals can become infected and \\ntransmit monkeypox.  \\n \\nIf you notice an animal that had contact with an infected person appearing sick (e.g., lethargy, lack of \\nappetite, coughing, bloating, nasal or eye secretions or crust, fever, pox lesions) contact the owner’s \\nveterinarian, state public health veterinarian,  or state animal health official.  \\n \\nWhat student focused information is available?  \\nThe following CDC materials are available:  \\n• Infographic: What You Need to Know about Monkeypox if You are a Teen or Young Adult  \\n• Infographic: Monkeypox and Safer Sex'),\n",
       " Document(metadata={'source': 'monkeypox\\\\mpv_college_q_and_a.pdf', 'page': 5}, page_content='• Infographic: Monkeypox and Safer Sex  \\n• Safer Sex, Social Gatherings, and Monkeypox  \\n• Preventin g Spread to Others')]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Load pdf files in the local directory\n",
    "loader = PyPDFDirectoryLoader(\"./monkeypox/\")\n",
    "\n",
    "docs_before_split = loader.load()\n",
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    chunk_size = 700,\n",
    "    chunk_overlap  = 50,\n",
    ")\n",
    "docs_after_split = text_splitter.split_documents(docs_before_split)\n",
    "\n",
    "docs_after_split"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# What's happening?\n",
    "\n",
    "The error or message you are seeing, such as \"Ignoring wrong pointing object,\" is typically encountered when dealing with corrupted or improperly formatted files—often in the context of PDF parsing or rendering.\n",
    "\n",
    "What it means:\n",
    "- Pointing Object: This refers to a reference or pointer in the PDF structure that should point to a valid object (such as text, images, or other resources).\n",
    "- Wrong Pointing Object: This message is likely triggered when a PDF processing library (e.g., PyPDF or other PDF libraries) tries to access objects in the PDF that are either corrupt, missing, or incorrectly defined.\n",
    "- Offset 0: The offset refers to the location in the PDF file where the object is expected. Offset 0 suggests that the pointer is not pointing to a valid location, which is a sign of a problem in the PDF structure."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Before split, there were 123 documents loaded, with average characters equal to 3098.\n",
      "After split, there were 666 documents (chunks), with average characters equal to 580 (average chunk length).\n"
     ]
    }
   ],
   "source": [
    "avg_doc_length = lambda docs: sum([len(doc.page_content) for doc in docs])//len(docs)\n",
    "avg_char_before_split = avg_doc_length(docs_before_split)\n",
    "avg_char_after_split = avg_doc_length(docs_after_split)\n",
    "\n",
    "print(f'Before split, there were {len(docs_before_split)} documents loaded, with average characters equal to {avg_char_before_split}.')\n",
    "print(f'After split, there were {len(docs_after_split)} documents (chunks), with average characters equal to {avg_char_after_split} (average chunk length).')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 5:\n",
    "\n",
    "Text Embeddings with Hugging Face models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "id": "MU7rvmWuhjud"
   },
   "outputs": [],
   "source": [
    "huggingface_embeddings = HuggingFaceBgeEmbeddings(\n",
    "    model_name=\"BAAI/bge-small-en-v1.5\",  # alternatively use \"sentence-transformers/all-MiniLM-l6-v2\" for a light and faster experience.\n",
    "    model_kwargs={'device':'cpu'}, \n",
    "    encode_kwargs={'normalize_embeddings': True}\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sample embedding of a document chunk:  [ 1.42315803e-02  3.02480124e-02 -1.94063038e-03 -2.37165466e-02\n",
      "  8.72085914e-02  2.57493537e-02  2.55865939e-02  5.37119582e-02\n",
      " -5.97317778e-02  2.79164035e-02  2.28543319e-02 -7.57816732e-02\n",
      "  5.22226617e-02 -1.95315983e-02 -8.61759856e-03 -2.61693522e-02\n",
      " -4.99382950e-02 -4.07498740e-02  2.17050873e-02  2.44464409e-02\n",
      "  8.82618502e-03 -2.49396618e-02  3.78644913e-02  1.27089745e-03\n",
      "  4.96838614e-02  2.95210909e-02 -1.56822111e-02  6.39245734e-02\n",
      "  3.11577711e-02 -2.05213994e-01 -1.40936263e-02 -2.44428348e-02\n",
      " -3.63206565e-02 -7.12227961e-03  8.26122519e-03 -6.49903668e-03\n",
      " -2.70382725e-02 -2.29580533e-02 -6.96670124e-03 -1.51532385e-02\n",
      "  5.99912219e-02  1.34736598e-02  3.46205942e-02 -3.77883688e-02\n",
      "  1.17250672e-02 -6.19833805e-02 -4.93516140e-02  1.16232866e-02\n",
      "  2.27204431e-02 -9.13899299e-03  1.77481268e-02 -6.35470971e-02\n",
      "  1.81622040e-02  1.09002486e-01 -2.58362796e-02 -2.35719346e-02\n",
      "  3.58781144e-02 -5.86627461e-02 -3.13700251e-02 -4.27615829e-03\n",
      "  6.20722473e-02 -6.29784563e-06 -1.19539946e-01  6.80314973e-02\n",
      "  5.51509112e-02  3.69103141e-02 -3.34670916e-02 -4.06635925e-02\n",
      "  4.85933200e-03 -2.49172505e-02 -7.26471394e-02  3.25170457e-02\n",
      " -5.78328706e-02  5.05393408e-02 -4.87167947e-02  5.13198376e-02\n",
      "  1.75125711e-02 -2.74594165e-02  6.48789434e-03 -2.41686143e-02\n",
      "  1.80465616e-02 -1.16772382e-02  3.79986204e-02 -4.79053259e-02\n",
      "  5.70444902e-03  1.77071076e-02  3.54030244e-02 -3.86725157e-03\n",
      " -6.54762760e-02  5.66425882e-02  4.08484526e-02  4.10767086e-02\n",
      "  8.09281319e-02 -2.26680730e-02 -6.57129213e-02  1.48193156e-02\n",
      "  3.70589793e-02 -1.69924572e-02  3.05922851e-02  3.76474708e-01\n",
      " -2.99996845e-02  1.35218650e-02  1.38018914e-02  3.97069529e-02\n",
      "  4.12172601e-02 -5.22082672e-03 -1.49392243e-02 -1.16089936e-02\n",
      " -7.79703306e-03  4.94171493e-02  1.87400002e-02 -1.55970110e-02\n",
      "  1.82441399e-02  2.49874145e-02 -3.80516276e-02 -5.40139601e-02\n",
      "  2.39609983e-02  4.11234982e-02  1.54742878e-02  3.72468494e-02\n",
      " -3.83062288e-02 -4.96089906e-02 -4.80424538e-02 -4.42628600e-02\n",
      "  4.70636599e-02  1.09400218e-02  1.96723044e-02  6.26096055e-02\n",
      "  4.87049706e-02 -2.55117361e-02  7.16852173e-02  7.14855120e-02\n",
      " -3.79978158e-02  6.77403854e-03  3.64113301e-02 -4.26310487e-02\n",
      " -2.95723905e-04 -8.78837984e-03 -4.54323031e-02 -5.73607534e-02\n",
      "  3.30188335e-03 -6.12631850e-02 -8.35201424e-03 -4.46571335e-02\n",
      " -7.07885250e-02  7.40186349e-02 -4.95807230e-02  5.56489918e-03\n",
      " -9.99936368e-03 -4.16803844e-02  3.72691546e-03  8.84806514e-02\n",
      " -1.16814980e-02  7.75093387e-04 -3.14358547e-02  2.31602769e-02\n",
      "  3.68213058e-02  1.30699761e-02 -4.76494208e-02 -2.39067525e-02\n",
      " -4.04612310e-02 -5.05102798e-02 -3.89816836e-02  8.36172327e-02\n",
      "  7.64371976e-02 -1.28309086e-01 -4.26636934e-02  7.24456226e-03\n",
      "  6.76163584e-02 -1.05139082e-02  3.89582776e-02  2.10505128e-02\n",
      " -2.36068945e-02  1.47093898e-02 -4.48917374e-02 -2.37642396e-02\n",
      " -8.65493640e-02 -3.47596854e-02  1.53733725e-02  1.18563313e-03\n",
      "  9.17449011e-04 -1.20580918e-03  5.63372895e-02  2.34539863e-02\n",
      "  3.14572081e-02 -2.15889569e-02 -5.31351157e-02  4.32066135e-02\n",
      "  5.19404523e-02 -2.83110924e-02  3.10977418e-02 -5.76952472e-02\n",
      "  7.93467462e-03  3.25973518e-02  6.56949803e-02  1.14005627e-02\n",
      " -3.01716849e-02  5.88852260e-03  2.35728063e-02 -2.35373452e-02\n",
      "  3.23644839e-02 -1.63792726e-02  5.97451441e-02 -1.95255643e-03\n",
      " -4.94380593e-02 -2.84101311e-02  3.86161618e-02 -5.05897477e-02\n",
      "  3.37621272e-02  2.24214364e-02 -1.98947452e-02  3.24383415e-02\n",
      " -4.87601757e-02  1.98301524e-02 -1.09705009e-01  7.52398148e-02\n",
      " -1.16950553e-02  3.08568012e-02  5.56013100e-02  9.55485925e-03\n",
      " -4.12731282e-02 -4.17860039e-02  2.30040364e-02 -2.81044960e-01\n",
      " -1.86325293e-02 -4.77124043e-02  9.33502242e-03 -4.05063219e-02\n",
      " -1.56961475e-02  1.91913918e-02 -1.44879548e-02  5.25812022e-02\n",
      "  4.95399199e-02  2.13575028e-02  1.02370657e-01 -2.26965845e-02\n",
      " -2.70731840e-03 -9.84362438e-02  3.75358425e-02  8.40767194e-03\n",
      " -4.99194190e-02 -1.18763950e-02 -3.75490077e-02 -1.47618763e-02\n",
      " -3.74073498e-02 -4.94152419e-02  2.07163468e-02  6.97570341e-03\n",
      " -4.79456633e-02  1.04259640e-01  1.47629697e-02  1.48807969e-02\n",
      "  2.75595430e-02 -2.97758747e-02 -1.95902679e-02 -4.87752445e-03\n",
      " -8.39570686e-02  7.26914778e-03  6.17440650e-03 -2.07671281e-02\n",
      " -4.36670966e-02 -4.35498208e-02  8.15863535e-03 -9.03028902e-03\n",
      "  2.02292185e-02  2.21176911e-02  2.21021026e-02 -7.22249853e-04\n",
      " -1.78103689e-02  3.75639535e-02  4.98867482e-02  1.30476328e-02\n",
      "  2.75528487e-02  2.38641209e-04  2.62524746e-02 -4.64400975e-03\n",
      "  2.29789000e-02 -2.23913435e-02 -7.04629300e-03 -4.53977361e-02\n",
      " -1.33993626e-02  1.95846148e-02 -5.40862903e-02  2.37610992e-02\n",
      " -1.66894365e-02  3.90145108e-02 -3.46676782e-02 -5.68325371e-02\n",
      " -6.83365613e-02  9.73605290e-02 -2.81209107e-02  6.96969703e-02\n",
      " -8.36266484e-03 -5.93519025e-03  1.25051752e-01 -3.88541035e-02\n",
      "  1.30860899e-02  5.56034641e-03  2.43298523e-02  3.49046439e-02\n",
      " -3.26906778e-02 -5.95589653e-02 -3.75937559e-02  4.31931540e-02\n",
      " -3.36574651e-02 -3.61398049e-02  3.36759351e-02  5.06180041e-02\n",
      " -6.37441082e-03  2.20397115e-02 -2.07289997e-02  2.91038565e-02\n",
      "  5.11775836e-02  7.28717446e-02 -8.62167627e-02  1.61798988e-02\n",
      " -3.96870375e-02 -2.44954620e-02  7.77859986e-02 -2.31951430e-01\n",
      " -4.76699471e-02  2.11537387e-02  5.34071214e-02  2.51308605e-02\n",
      " -2.40729544e-02  6.07675388e-02 -9.12215933e-02  2.11002794e-03\n",
      "  2.35580392e-02  7.11393207e-02  1.09548792e-02  6.38290793e-02\n",
      " -2.74414551e-02  2.43739113e-02  2.34995019e-02  5.87570183e-02\n",
      " -3.43764648e-02  3.54648381e-02 -6.56691566e-02  2.03684624e-03\n",
      " -4.20243926e-02  1.58042580e-01 -8.19179520e-04 -2.27740053e-02\n",
      "  4.83786054e-02 -2.20522545e-02  6.44511431e-02 -4.68702503e-02\n",
      " -2.68418603e-02  7.21015930e-02 -1.50779006e-03  6.64610341e-02\n",
      " -2.51497440e-02  1.66741572e-02  2.19329074e-02  2.13149376e-03\n",
      "  6.91898866e-03  6.87673781e-03  5.70479874e-03 -4.37150188e-02\n",
      "  3.96162942e-02 -4.91840430e-02 -2.68745329e-03  5.40948920e-02\n",
      " -4.34038788e-02 -1.24251470e-02 -5.94550371e-02 -1.39669888e-02\n",
      "  1.62608847e-02 -5.42322397e-02 -4.82991189e-02 -3.36341076e-02\n",
      " -1.00613618e-02 -7.96435308e-03 -3.71193886e-02  5.15522771e-02\n",
      " -6.81333765e-02  3.91670577e-02 -2.79219206e-02  3.13797295e-02\n",
      " -1.65992518e-04 -3.76311317e-02  1.04597934e-01  9.08733532e-03]\n",
      "Size of the embedding:  (384,)\n"
     ]
    }
   ],
   "source": [
    "sample_embedding = np.array(huggingface_embeddings.embed_query(docs_after_split[0].page_content))\n",
    "print(\"Sample embedding of a document chunk: \", sample_embedding)\n",
    "print(\"Size of the embedding: \", sample_embedding.shape)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 6:\n",
    "\n",
    "Retrieval System for vector embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "vectorstore = FAISS.from_documents(docs_after_split, huggingface_embeddings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are 4 documents retrieved which are relevant to the query. Display the first one:\n",
      "\n",
      "© 2013Monkeypox\n",
      "What is monkeypox and \n",
      "what causes it?\n",
      "Monkeypox is a viral disease \n",
      "discovered in laboratory monkeys in \n",
      "1958. The disease most commonly \n",
      "occurs in central and west Africa. Many \n",
      "animal species and humans can be \n",
      "infected. In 2003, monkeypox infected \n",
      "several people in the United States \n",
      "after they had contact with infected \n",
      "prairie dogs. The monkeypox virus is \n",
      "closely related to the viruses that cause \n",
      "smallpox and cowpox in humans.\n",
      "What animals get \n",
      "monkeypox?\n",
      "Old and New World monkeys and \n",
      "apes, a variety of rodents (including \n",
      "rats, mice, squirrels, and prairie \n",
      "dogs) and rabbits are susceptible \n",
      "to infection. The complete range of \n",
      "animal species that can be infected\n"
     ]
    }
   ],
   "source": [
    "query = \"\"\"What is monkeypox?\"\"\"  \n",
    "         # Sample question, change to other questions you are interested in.\n",
    "relevant_documents = vectorstore.similarity_search(query)\n",
    "print(f'There are {len(relevant_documents)} documents retrieved which are relevant to the query. Display the first one:\\n')\n",
    "print(relevant_documents[0].page_content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 7:\n",
    "\n",
    "Create a retriever interface using vector store.\n",
    "- Since we are using FAISS, it defaults into cosine similarity:\n",
    "\\begin{align}\n",
    "\\text{Cosine Similarity} = \\frac{A \\cdotp B}{\\|A\\|\\|B\\|}\n",
    "\\end{align}\n",
    "- mmr (maximum marginal relevance) can also be used:\n",
    "\\begin{align}\n",
    "\\text{MMR} = \\arg \\max_{D_{i} \\in S \\setminus R} \\left [\\lambda \\cdotp sim \\left( D_{i}, Q \\right)  - (1 - \\lambda) \\cdotp \\max_{D_{j} \\in R} sim(D_{i}, D_{j})\\right]\n",
    "\\end{align}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Use similarity searching algorithm and return 3 most relevant documents.\n",
    "retriever = vectorstore.as_retriever(search_type=\"similarity\", search_kwargs={\"k\": 3})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\isabe\\AppData\\Local\\Temp\\ipykernel_6604\\1080189355.py:1: LangChainDeprecationWarning: The class `HuggingFaceHub` was deprecated in LangChain 0.0.21 and will be removed in 1.0. An updated version of the class exists in the langchain-huggingface package and should be used instead. To use it run `pip install -U langchain-huggingface` and import as `from langchain_huggingface import HuggingFaceEndpoint`.\n",
      "  hf = HuggingFaceHub(\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'What were the trends in monkeypox for  the last quarter of 2024.\\n\\n## Monkeypox\\n\\nMonkeypox is a viral disease that is caused by the monkeypox virus. The virus is related to the virus that causes smallpox. Monkeypox is found in parts of Africa.\\n\\nMonkeypox can cause a rash that looks like pimples or blisters. The rash can be on the face, inside the mouth, and on other parts of the body. The rash can'"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "hf = HuggingFaceHub(\n",
    "    repo_id=\"mistralai/Mistral-7B-v0.1\",\n",
    "    huggingfacehub_api_token=\"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\",\n",
    "    model_kwargs={\"temperature\":0.1, \"max_length\":1000})\n",
    "\n",
    "query = \"\"\"What were the trends in monkeypox for  the last quarter of 2024.\"\"\"  # Sample question, change to other questions you are interested in.\n",
    "hf.invoke(query)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 8:\n",
    "\n",
    "Create a Hugging Face Local Pipelines"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The token has not been saved to the git credentials helper. Pass `add_to_git_credential=True` in this function directly or `--add-to-git-credential` if using via `huggingface-cli` if you want to set the git credential as well.\n",
      "Token is valid (permission: fineGrained).\n",
      "Your token has been saved to C:\\Users\\isabe\\.cache\\huggingface\\token\n",
      "Login successful\n"
     ]
    }
   ],
   "source": [
    "# need to login to use mistralai/Mistral-7B-v0.1\n",
    "from huggingface_hub import login\n",
    "login(token=\"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\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "55f046d720df41d99453f9d6728f368c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "tokenizer_config.json:   0%|          | 0.00/26.0 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\isabe\\anaconda3\\envs\\rag-workshop\\lib\\site-packages\\huggingface_hub\\file_download.py:147: UserWarning: `huggingface_hub` cache-system uses symlinks by default to efficiently store duplicated files but your machine does not support them in C:\\Users\\isabe\\.cache\\huggingface\\hub\\models--distilgpt2. Caching files will still work but in a degraded version that might require more space on your disk. This warning can be disabled by setting the `HF_HUB_DISABLE_SYMLINKS_WARNING` environment variable. For more details, see https://huggingface.co/docs/huggingface_hub/how-to-cache#limitations.\n",
      "To support symlinks on Windows, you either need to activate Developer Mode or to run Python as an administrator. In order to activate developer mode, see this article: https://docs.microsoft.com/en-us/windows/apps/get-started/enable-your-device-for-development\n",
      "  warnings.warn(message)\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "07a1a3602c604354bf022e13d7961c26",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "config.json:   0%|          | 0.00/762 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "87a9e70125dc46f5b2b674fa244f1971",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "vocab.json:   0%|          | 0.00/1.04M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f4c7bbc96c634f1299edc75fe255d4f4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "merges.txt:   0%|          | 0.00/456k [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cdbddb84eeac4b6aaeaff77b5cbc5e28",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "tokenizer.json:   0%|          | 0.00/1.36M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\isabe\\anaconda3\\envs\\rag-workshop\\lib\\site-packages\\transformers\\tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "dd3a84be631d4fc19192ba9b04ec4fb4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "model.safetensors:   0%|          | 0.00/353M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "223486d555404188b030f72b4b9dc2e8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "generation_config.json:   0%|          | 0.00/124 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "\"What were the trends in monkeypox for  the last quarter of 2024. When compared with the other five pandemic pandemics in 2009, all in 2009 were at this stage of their pandemics, with only one case occurring in 2000. As with HIV, they have a history of using their virus to treat a disease. Now, for example, it's clear from this study of influenza by researchers at Harvard Medical School, that the viral burden of the disease rose significantly between 2006-2014. This increase was large enough, and the fact that there were no studies focusing on it, suggests some of the research on this pandemic may have also played an important role in influencing the future of pandemics.\\n\\n\\nThe present research has been criticized for some of the ways the new findings indicate pandemics have changed from the original one to the present. In other words, new research is increasingly making up some of the best estimates that have been available of these types of epidemics in the past five years based on the current evidence.\\nWhile the new research is very different from previous study, its new findings suggest the important thing here is that our research is being published from earlier years. We have a few things to be thankful for: first, the new evidence that we have come to believe is highly reliable -- the new data shows that the same numbers are still correct. Second, the new evidence suggests that the rates at which virus infection is increased with respect to the disease could have been better understood if the epidemic had continued for at least some time.\""
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from langchain_community.llms.huggingface_pipeline import HuggingFacePipeline\n",
    "\n",
    "hf = HuggingFacePipeline.from_model_id(\n",
    "    model_id=\"distilgpt2\",\n",
    "    task=\"text-generation\",\n",
    "    pipeline_kwargs={\"temperature\": 1, \"max_new_tokens\": 300}\n",
    ")\n",
    "\n",
    "llm = hf \n",
    "llm.invoke(query)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 9: \n",
    "\n",
    "Develop a Q & A chain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt_template = \"\"\"Use the following pieces of context to answer the question at the end. Please follow the following rules:\n",
    "1. If you don't know the answer, don't try to make up an answer. Just say \"I can't find the final answer but you may want to check the following links\".\n",
    "2. If you find the answer, write the answer in a concise way with five sentences maximum.\n",
    "\n",
    "{context}\n",
    "\n",
    "Question: {question}\n",
    "\n",
    "Helpful Answer:\n",
    "\"\"\"\n",
    "\n",
    "PROMPT = PromptTemplate(\n",
    " template=prompt_template, input_variables=[\"context\", \"question\"]\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "retrievalQA = RetrievalQA.from_chain_type(\n",
    "    llm=llm,\n",
    "    chain_type=\"stuff\",\n",
    "    retriever=retriever,\n",
    "    return_source_documents=True,\n",
    "    chain_type_kwargs={\"prompt\": PROMPT}\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Step 10:\n",
    "\n",
    "Use RetrievalQA invoke method to execute the chain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Use the following pieces of context to answer the question at the end. Please follow the following rules:\n",
      "1. If you don't know the answer, don't try to make up an answer. Just say \"I can't find the final answer but you may want to check the following links\".\n",
      "2. If you find the answer, write the answer in a concise way with five sentences maximum.\n",
      "\n",
      "signs, disease course and complications observed \n",
      "in the year 1970 and later decades is similar to the \n",
      "recent monkeypox outbreak in 202214. This may \n",
      "be attributed to its stable nature of viral DNA ge -\n",
      "nome that do not easily undergo significant muta -\n",
      "tions over a period of time, unlike RNA viruses27. \n",
      "Discussion\n",
      "The difference observed between the old mon -\n",
      "keypox cases and the recent monkeypox mainly \n",
      "lie in the mode of acquisition, all other aspects \n",
      "remain the same. Recent monkeypox cases out -\n",
      "break in Europe included sexual transmission too \n",
      "apart from other modes of transmission. Monkey -\n",
      "pox cases were observed predominantly in homo -\n",
      "\n",
      "S. Kannan, P. Shaik Syed Ali, A. Sheeza5984Materials and Methods  \n",
      "The detailed literature review was conducted \n",
      "on monkeypox, using databases PubMed/Med -\n",
      "line, EMBASE, PMC, Cochrane Library and Up -\n",
      "ToDate. The search was conducted on the relevant \n",
      "aspects of monkeypox. The inclusion criteria for \n",
      "this review were: (a) articles written in English; \n",
      "(b) articles published in the period 1980 to 2022. \n",
      "Articles were excluded based on the following \n",
      "criteria: (a) articles with insufficient data; (b) out -\n",
      "dated and obsolete data; (c) studies prior to 1980. \n",
      "Further information was also obtained from gray \n",
      "literature.\n",
      "Results \n",
      "Epidemiology and Mode of Transmission\n",
      "\n",
      "CONCLUSIONS: Monkeypox is a zoonotic dis -\n",
      "ease which was prevalent in Central and West -\n",
      "ern African countries. Recently, human to hu -\n",
      "man spread was noticed in developed countries \n",
      "of Europe, North America and Australia. Despite \n",
      "with a close genetic similarity between the two \n",
      "clades, the Central African strain is compara -\n",
      "tively very virulent with high mortality. Monkey -\n",
      "pox should be considered a re-emerging, ne -\n",
      "glected disease and proper measures like hand \n",
      "hygiene, wearing masks and vaccination to the \n",
      "high-risk groups are advised.  \n",
      "Key Words:\n",
      "Monkeypox, Epidemiology, Mode of transmission, \n",
      "Clinical features, Molecular properties, Virulence.Introduction\n",
      "\n",
      "Question: What were the trends in monkeypox for  the last quarter of 2024.\n",
      "\n",
      "Helpful Answer:\n",
      "Monkeypox is the single most contagious disease, for \n",
      "disease, a direct consequence of \n",
      "in the late 1900's, and the\n",
      "most common \n",
      "epidemiology, the first in most recent centuries. \n",
      "Crisis -\n",
      "On March 4, 1920, the\n",
      "N.C. Department of Health said they had\n",
      "not been able to determine the precise cause or cause of \n",
      "the outbreak. It has been stated that the\n",
      "\"cause of the outbreak\" was not the cause of the recent monkeypox outbreak and that the\n",
      "\"cause of the outbreak was not the cause of the latest monkeypox outbreak\".  \n",
      "Further Information\n",
      "This article was prepared by the Department of Health in collaboration with the United Nations Department of Health.\n"
     ]
    }
   ],
   "source": [
    "# Call the QA chain with our query.\n",
    "result = retrievalQA.invoke({\"query\": query})\n",
    "print(result['result'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "There are 3 documents retrieved which are relevant to the query.\n",
      "****************************************************************************************************\n",
      "Relevant Document #1:\n",
      "Source file: monkeypox\\5983-5990.pdf, Page: 3\n",
      "Content: signs, disease course and complications observed \n",
      "in the year 1970 and later decades is similar to the \n",
      "recent monkeypox outbreak in 202214. This may \n",
      "be attributed to its stable nature of viral DNA ge -\n",
      "nome that do not easily undergo significant muta -\n",
      "tions over a period of time, unlike RNA viruses27. \n",
      "Discussion\n",
      "The difference observed between the old mon -\n",
      "keypox cases and the recent monkeypox mainly \n",
      "lie in the mode of acquisition, all other aspects \n",
      "remain the same. Recent monkeypox cases out -\n",
      "break in Europe included sexual transmission too \n",
      "apart from other modes of transmission. Monkey -\n",
      "pox cases were observed predominantly in homo -\n",
      "----------------------------------------------------------------------------------------------------\n",
      "There are 3 documents retrieved which are relevant to the query.\n",
      "Relevant Document #2:\n",
      "Source file: monkeypox\\5983-5990.pdf, Page: 1\n",
      "Content: S. Kannan, P. Shaik Syed Ali, A. Sheeza5984Materials and Methods  \n",
      "The detailed literature review was conducted \n",
      "on monkeypox, using databases PubMed/Med -\n",
      "line, EMBASE, PMC, Cochrane Library and Up -\n",
      "ToDate. The search was conducted on the relevant \n",
      "aspects of monkeypox. The inclusion criteria for \n",
      "this review were: (a) articles written in English; \n",
      "(b) articles published in the period 1980 to 2022. \n",
      "Articles were excluded based on the following \n",
      "criteria: (a) articles with insufficient data; (b) out -\n",
      "dated and obsolete data; (c) studies prior to 1980. \n",
      "Further information was also obtained from gray \n",
      "literature.\n",
      "Results \n",
      "Epidemiology and Mode of Transmission\n",
      "----------------------------------------------------------------------------------------------------\n",
      "There are 3 documents retrieved which are relevant to the query.\n",
      "Relevant Document #3:\n",
      "Source file: monkeypox\\5983-5990.pdf, Page: 0\n",
      "Content: CONCLUSIONS: Monkeypox is a zoonotic dis -\n",
      "ease which was prevalent in Central and West -\n",
      "ern African countries. Recently, human to hu -\n",
      "man spread was noticed in developed countries \n",
      "of Europe, North America and Australia. Despite \n",
      "with a close genetic similarity between the two \n",
      "clades, the Central African strain is compara -\n",
      "tively very virulent with high mortality. Monkey -\n",
      "pox should be considered a re-emerging, ne -\n",
      "glected disease and proper measures like hand \n",
      "hygiene, wearing masks and vaccination to the \n",
      "high-risk groups are advised.  \n",
      "Key Words:\n",
      "Monkeypox, Epidemiology, Mode of transmission, \n",
      "Clinical features, Molecular properties, Virulence.Introduction\n",
      "----------------------------------------------------------------------------------------------------\n",
      "There are 3 documents retrieved which are relevant to the query.\n"
     ]
    }
   ],
   "source": [
    "relevant_docs = result['source_documents']\n",
    "print(f'There are {len(relevant_docs)} documents retrieved which are relevant to the query.')\n",
    "print(\"*\" * 100)\n",
    "for i, doc in enumerate(relevant_docs):\n",
    "    print(f\"Relevant Document #{i+1}:\\nSource file: {doc.metadata['source']}, Page: {doc.metadata['page']}\\nContent: {doc.page_content}\")\n",
    "    print(\"-\"*100)\n",
    "    print(f'There are {len(relevant_docs)} documents retrieved which are relevant to the query.')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "colab": {
   "provenance": [
    {
     "file_id": "1YpHocGI4rApOxIBb1ZghCU5L-hFnv4CK",
     "timestamp": 1615925514977
    }
   ]
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
